{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0001","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"Abbreviations and acronyms","content_type":"text","pages":"1","tokens_est":226,"char_count":901,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0002","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"Abbreviations and acronyms","content_type":"text","pages":"1-4","tokens_est":212,"char_count":847,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0003","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"Abbreviations and acronyms","content_type":"text","pages":"4","tokens_est":223,"char_count":890,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0004","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"Abbreviations and acronyms","content_type":"text","pages":"4","tokens_est":239,"char_count":953,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0005","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"Abbreviations and acronyms","content_type":"text","pages":"4","tokens_est":241,"char_count":963,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0006","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"Abbreviations and acronyms","content_type":"text","pages":"4-5","tokens_est":231,"char_count":922,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0007","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"Abbreviations and acronyms","content_type":"text","pages":"5","tokens_est":195,"char_count":778,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0008","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"Abbreviations and acronyms","content_type":"text","pages":"5","tokens_est":128,"char_count":510,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0009","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"Abbreviations and acronyms","content_type":"text","pages":"5","tokens_est":170,"char_count":678,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0010","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction","content_type":"text","pages":"5","tokens_est":244,"char_count":975,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0011","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction","content_type":"text","pages":"5","tokens_est":121,"char_count":483,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0012","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.1 Background","content_type":"text","pages":"5-6","tokens_est":194,"char_count":775,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0013","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.1 Background","content_type":"text","pages":"5-6","tokens_est":215,"char_count":857,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0014","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.1 Background","content_type":"text","pages":"6","tokens_est":228,"char_count":909,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0015","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.1 Background","content_type":"text","pages":"6","tokens_est":107,"char_count":426,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0016","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.1 Background","content_type":"text","pages":"6","tokens_est":213,"char_count":851,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0017","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.1 Background","content_type":"text","pages":"6","tokens_est":80,"char_count":319,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0018","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.1 Background","content_type":"text","pages":"6","tokens_est":179,"char_count":713,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0019","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.1 Background","content_type":"text","pages":"6","tokens_est":112,"char_count":445,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0020","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.1 Background","content_type":"text","pages":"6-7","tokens_est":213,"char_count":849,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0021","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.1 Background | Recommendations in the WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment (13) | 1.1. Identifying populations for TB preventive treatment | People with HIV","content_type":"text","pages":"8","tokens_est":185,"char_count":737,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0022","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.1 Background | Recommendations in the WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment (13) | 1.1. Identifying populations for TB preventive treatment | People with HIV","content_type":"text","pages":"8","tokens_est":126,"char_count":504,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0023","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.1 Background | Recommendations in the WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment (13) | 1.1. Identifying populations for TB preventive treatment | Household contacts of people with TB (regardless of HIV status)","content_type":"text","pages":"8","tokens_est":166,"char_count":662,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0024","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.1 Background | Recommendations in the WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment (13) | 1.1. Identifying populations for TB preventive treatment | Other people at risk","content_type":"text","pages":"8","tokens_est":110,"char_count":437,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0025","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.1 Background | Recommendations in the WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment (13) | 1.2. TB screening and ruling out TB disease","content_type":"text","pages":"8-9","tokens_est":229,"char_count":915,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0026","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.1 Background | Recommendations in the WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment (13) | 1.2. TB screening and ruling out TB disease","content_type":"text","pages":"9","tokens_est":230,"char_count":920,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0027","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.1 Background | Recommendations in the WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment (13) | 1.2. TB screening and ruling out TB disease","content_type":"text","pages":"9","tokens_est":72,"char_count":285,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0028","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.1 Background | Recommendations in the WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment (13) | 1.3. Testing for TB infection","content_type":"text","pages":"9","tokens_est":62,"char_count":247,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0029","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.1 Background | Recommendations in the WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment (13) | 1.4. TB preventive treatment options | TB preventive treatment with isoniazid or rifamycins","content_type":"text","pages":"9","tokens_est":121,"char_count":483,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0030","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.1 Background | Recommendations in the WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment (13) | 1.4. TB preventive treatment options | TB preventive treatment with levofloxacin","content_type":"text","pages":"9","tokens_est":48,"char_count":192,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0031","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.2 Cascade of care approach","content_type":"text","pages":"9-10","tokens_est":209,"char_count":836,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0032","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.2 Cascade of care approach | Fig. 1. Cascade of care approach to scaling TB, tuberculosis; TPT, TB preventive treatment","content_type":"figure","pages":"10","caption":"Fig. 1. Cascade of care approach to scaling TB, tuberculosis; TPT, TB preventive treatment","tokens_est":75,"char_count":298,"has_attachment":true,"attachment_id":"Fig. 1.","attachment_path":"figures/WHO_TB_handbook_module1_TPT_2024/Fig. 1..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0033","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.2 Cascade of care approach","content_type":"text","pages":"10","tokens_est":244,"char_count":975,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0034","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.2 Cascade of care approach","content_type":"text","pages":"10","tokens_est":55,"char_count":219,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0035","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.2 Cascade of care approach","content_type":"text","pages":"10","tokens_est":172,"char_count":685,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0036","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.2 Cascade of care approach","content_type":"text","pages":"10","tokens_est":158,"char_count":631,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0037","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.3 Components of a system for delivering TPT","content_type":"text","pages":"11","tokens_est":206,"char_count":821,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0038","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.3 Components of a system for delivering TPT","content_type":"text","pages":"11","tokens_est":230,"char_count":919,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0039","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.3 Components of a system for delivering TPT","content_type":"text","pages":"11","tokens_est":110,"char_count":437,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0040","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.3 Components of a system for delivering TPT","content_type":"text","pages":"11","tokens_est":156,"char_count":622,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0041","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.3 Components of a system for delivering TPT | Fig. 2. Considerations in implementing PMTPT","content_type":"figure","pages":"11","caption":"Fig. 2. Considerations in implementing PMTPT","tokens_est":14,"char_count":54,"has_attachment":true,"attachment_id":"Fig. 2.","attachment_path":"figures/WHO_TB_handbook_module1_TPT_2024/Fig. 2..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0042","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.4 Objectives and structure of the operational handbook","content_type":"text","pages":"12","tokens_est":221,"char_count":884,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0043","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.4 Objectives and structure of the operational handbook","content_type":"text","pages":"12","tokens_est":240,"char_count":959,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0044","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.4 Objectives and structure of the operational handbook","content_type":"text","pages":"12","tokens_est":247,"char_count":988,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0045","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.4 Objectives and structure of the operational handbook","content_type":"text","pages":"12","tokens_est":248,"char_count":992,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0046","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"1. Introduction | 1.4 Objectives and structure of the operational handbook","content_type":"text","pages":"12-13","tokens_est":57,"char_count":225,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0047","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment","content_type":"text","pages":"14","tokens_est":222,"char_count":887,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0048","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment","content_type":"text","pages":"14","tokens_est":226,"char_count":903,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0049","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment","content_type":"text","pages":"14-15","tokens_est":190,"char_count":758,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0050","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.1 Populations eligible for TPT | 2.1.1 People with HIV","content_type":"text","pages":"15","tokens_est":178,"char_count":710,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0051","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.1 Populations eligible for TPT | 2.1.1 People with HIV","content_type":"text","pages":"15","tokens_est":184,"char_count":735,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0052","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.1 Populations eligible for TPT | 2.1.1 People with HIV","content_type":"text","pages":"15","tokens_est":168,"char_count":671,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0053","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.1 Populations eligible for TPT | 2.1.1 People with HIV","content_type":"text","pages":"15","tokens_est":199,"char_count":795,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0054","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.1 Populations eligible for TPT | 2.1.1 People with HIV","content_type":"text","pages":"15","tokens_est":82,"char_count":327,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0055","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.1 Populations eligible for TPT | 2.1.2 Household contacts (regardless of HIV status)","content_type":"text","pages":"16","tokens_est":237,"char_count":946,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0056","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.1 Populations eligible for TPT | 2.1.2 Household contacts (regardless of HIV status)","content_type":"text","pages":"16","tokens_est":209,"char_count":836,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0057","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.1 Populations eligible for TPT | 2.1.2 Household contacts (regardless of HIV status)","content_type":"text","pages":"16","tokens_est":67,"char_count":266,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0058","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.1 Populations eligible for TPT | 2.1.2 Household contacts (regardless of HIV status)","content_type":"text","pages":"16","tokens_est":116,"char_count":464,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0059","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.1 Populations eligible for TPT | 2.1.2 Household contacts (regardless of HIV status)","content_type":"text","pages":"16","tokens_est":194,"char_count":775,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0060","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.1 Populations eligible for TPT | 2.1.2 Household contacts (regardless of HIV status)","content_type":"text","pages":"16","tokens_est":108,"char_count":430,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0061","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.2 Integrating systematic screening for TB disease","content_type":"text","pages":"17","tokens_est":221,"char_count":882,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0062","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.2 Integrating systematic screening for TB disease","content_type":"text","pages":"17","tokens_est":217,"char_count":868,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0063","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.2 Integrating systematic screening for TB disease | Fig. 3. Populations for which PMTPT and screening for TB disease are recommended","content_type":"figure","pages":"17","caption":"Fig. 3. Populations for which PMTPT and screening for TB disease are recommended","tokens_est":42,"char_count":166,"has_attachment":true,"attachment_id":"Fig. 3.","attachment_path":"figures/WHO_TB_handbook_module1_TPT_2024/Fig. 3..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0064","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.3 National policy for identifying TPT target populations","content_type":"text","pages":"18","tokens_est":164,"char_count":655,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0065","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.3 National policy for identifying TPT target populations","content_type":"text","pages":"18","tokens_est":243,"char_count":970,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0066","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.3 National policy for identifying TPT target populations","content_type":"text","pages":"18","tokens_est":219,"char_count":875,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0067","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.3 National policy for identifying TPT target populations","content_type":"text","pages":"18","tokens_est":242,"char_count":966,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0068","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.4 Reaching TPT target populations | 2.4.1 Reaching people with HIV and other target populations","content_type":"text","pages":"19","tokens_est":212,"char_count":845,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0069","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.4 Reaching TPT target populations | 2.4.1 Reaching people with HIV and other target populations","content_type":"text","pages":"19","tokens_est":179,"char_count":714,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0070","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.4 Reaching TPT target populations | 2.4.1 Reaching people with HIV and other target populations","content_type":"text","pages":"19","tokens_est":118,"char_count":472,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0071","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.4 Reaching TPT target populations | 2.4.2 Strengthening investigation of household contacts","content_type":"text","pages":"19-20","tokens_est":231,"char_count":922,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0072","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.4 Reaching TPT target populations | 2.4.2 Strengthening investigation of household contacts","content_type":"text","pages":"19-20","tokens_est":126,"char_count":504,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0073","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.4 Reaching TPT target populations | 2.4.2 Strengthening investigation of household contacts | Fig. 4. Building blocks for strong contact investigation","content_type":"figure","pages":"20-21","caption":"Fig. 4. Building blocks for strong contact investigation","tokens_est":17,"char_count":66,"has_attachment":true,"attachment_id":"Fig. 4.","attachment_path":"figures/WHO_TB_handbook_module1_TPT_2024/Fig. 4..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0074","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.4 Reaching TPT target populations | 2.4.2 Strengthening investigation of household contacts","content_type":"text","pages":"21-22","tokens_est":230,"char_count":917,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0075","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.4 Reaching TPT target populations | 2.4.2 Strengthening investigation of household contacts","content_type":"text","pages":"22","tokens_est":200,"char_count":799,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0076","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.4 Reaching TPT target populations | 2.4.2 Strengthening investigation of household contacts","content_type":"text","pages":"22","tokens_est":149,"char_count":595,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0077","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.4 Reaching TPT target populations | 2.4.2 Strengthening investigation of household contacts","content_type":"text","pages":"22","tokens_est":194,"char_count":776,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0078","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.4 Reaching TPT target populations | 2.4.2 Strengthening investigation of household contacts","content_type":"text","pages":"22","tokens_est":175,"char_count":699,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0079","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.4 Reaching TPT target populations | 2.4.2 Strengthening investigation of household contacts","content_type":"text","pages":"22-23","tokens_est":248,"char_count":989,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0080","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.4 Reaching TPT target populations | 2.4.2 Strengthening investigation of household contacts","content_type":"text","pages":"23","tokens_est":249,"char_count":994,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0081","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.4 Reaching TPT target populations | 2.4.2 Strengthening investigation of household contacts","content_type":"text","pages":"23","tokens_est":44,"char_count":176,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0082","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.4 Reaching TPT target populations | 2.4.2 Strengthening investigation of household contacts","content_type":"text","pages":"23","tokens_est":227,"char_count":907,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0083","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.4 Reaching TPT target populations | 2.4.2 Strengthening investigation of household contacts","content_type":"text","pages":"23","tokens_est":179,"char_count":713,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0084","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.4 Reaching TPT target populations | 2.4.2 Strengthening investigation of household contacts","content_type":"text","pages":"23","tokens_est":199,"char_count":793,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0085","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.4 Reaching TPT target populations | 2.4.2 Strengthening investigation of household contacts | Box 1. Use of measures of timeliness for screening and implementing TPT for household contacts of index patients with pulmonary TB (42) .","content_type":"box","pages":"24","caption":"Box 1. Use of measures of timeliness for screening and implementing TPT for household contacts of index patients with pulmonary TB (42) .","tokens_est":107,"char_count":426,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0086","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.4 Reaching TPT target populations | 2.4.2 Strengthening investigation of household contacts | Box 1. Use of measures of timeliness for screening and implementing TPT for household contacts of index patients with pulmonary TB (42) .","content_type":"box","pages":"24","caption":"Box 1. Use of measures of timeliness for screening and implementing TPT for household contacts of index patients with pulmonary TB (42) .","tokens_est":246,"char_count":982,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0087","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.4 Reaching TPT target populations | 2.4.2 Strengthening investigation of household contacts | Box 1. Use of measures of timeliness for screening and implementing TPT for household contacts of index patients with pulmonary TB (42) .","content_type":"box","pages":"24","caption":"Box 1. Use of measures of timeliness for screening and implementing TPT for household contacts of index patients with pulmonary TB (42) .","tokens_est":121,"char_count":484,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0088","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.4 Reaching TPT target populations | 2.4.2 Strengthening investigation of household contacts | Box 1. Use of measures of timeliness for screening and implementing TPT for household contacts of index patients with pulmonary TB (42) .","content_type":"box","pages":"24","caption":"Box 1. Use of measures of timeliness for screening and implementing TPT for household contacts of index patients with pulmonary TB (42) .","tokens_est":218,"char_count":869,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0089","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.4 Reaching TPT target populations | 2.4.2 Strengthening investigation of household contacts | Box 1. Use of measures of timeliness for screening and implementing TPT for household contacts of index patients with pulmonary TB (42) .","content_type":"box","pages":"24","caption":"Box 1. Use of measures of timeliness for screening and implementing TPT for household contacts of index patients with pulmonary TB (42) .","tokens_est":244,"char_count":974,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0090","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.4 Reaching TPT target populations | 2.4.2 Strengthening investigation of household contacts | Fig. 5. Time to initiation of TPT in household contacts","content_type":"figure","pages":"24","caption":"Fig. 5. Time to initiation of TPT in household contacts","tokens_est":77,"char_count":306,"has_attachment":true,"attachment_id":"Fig. 5.","attachment_path":"figures/WHO_TB_handbook_module1_TPT_2024/Fig. 5..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0091","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.4 Reaching TPT target populations | 2.4.2 Strengthening investigation of household contacts","content_type":"text","pages":"24","tokens_est":15,"char_count":59,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0092","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.4 Reaching TPT target populations | 2.4.2 Strengthening investigation of household contacts | Box 2. 10 steps in conducting a contact investigation (46)","content_type":"box","pages":"24-25","caption":"Box 2. 10 steps in conducting a contact investigation (46)","tokens_est":206,"char_count":822,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0093","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.4 Reaching TPT target populations | 2.4.2 Strengthening investigation of household contacts | Box 3. Nurse-led outreach for contact investigation in Mozambique (47)","content_type":"box","pages":"25","caption":"Box 3. Nurse-led outreach for contact investigation in Mozambique (47)","tokens_est":218,"char_count":869,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0094","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"2. Identifying populations for TB preventive treatment | 2.4 Reaching TPT target populations | 2.4.2 Strengthening investigation of household contacts | Box 3. Nurse-led outreach for contact investigation in Mozambique (47)","content_type":"box","pages":"25","caption":"Box 3. Nurse-led outreach for contact investigation in Mozambique (47)","tokens_est":156,"char_count":623,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0095","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"3. Screening for TB and ruling out TB disease before TB preventive treatment","content_type":"text","pages":"27","tokens_est":245,"char_count":977,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0096","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"3. Screening for TB and ruling out TB disease before TB preventive treatment","content_type":"text","pages":"27","tokens_est":248,"char_count":989,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0097","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"3. Screening for TB and ruling out TB disease before TB preventive treatment","content_type":"text","pages":"27","tokens_est":92,"char_count":367,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0098","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"3. Screening for TB and ruling out TB disease before TB preventive treatment | 3.1 Screening for TB disease using signs and symptoms","content_type":"text","pages":"28","tokens_est":178,"char_count":711,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0099","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"3. Screening for TB and ruling out TB disease before TB preventive treatment | 3.1 Screening for TB disease using signs and symptoms","content_type":"text","pages":"28","tokens_est":227,"char_count":906,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0100","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"3. Screening for TB and ruling out TB disease before TB preventive treatment | 3.1 Screening for TB disease using signs and symptoms","content_type":"text","pages":"28","tokens_est":80,"char_count":319,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0101","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"3. Screening for TB and ruling out TB disease before TB preventive treatment | 3.1 Screening for TB disease using signs and symptoms","content_type":"text","pages":"28","tokens_est":201,"char_count":802,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0102","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"3. Screening for TB and ruling out TB disease before TB preventive treatment | 3.2 Screening for TB with CXR and computer aided detection (CAD) software","content_type":"text","pages":"28-29","tokens_est":156,"char_count":622,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0103","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"3. Screening for TB and ruling out TB disease before TB preventive treatment | 3.2 Screening for TB with CXR and computer aided detection (CAD) software","content_type":"text","pages":"29","tokens_est":202,"char_count":807,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0104","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"3. Screening for TB and ruling out TB disease before TB preventive treatment | 3.2 Screening for TB with CXR and computer aided detection (CAD) software","content_type":"text","pages":"29","tokens_est":179,"char_count":716,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0105","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"3. Screening for TB and ruling out TB disease before TB preventive treatment | 3.2 Screening for TB with CXR and computer aided detection (CAD) software","content_type":"text","pages":"29","tokens_est":166,"char_count":661,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0106","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"3. Screening for TB and ruling out TB disease before TB preventive treatment | 3.2 Screening for TB with CXR and computer aided detection (CAD) software","content_type":"text","pages":"29","tokens_est":200,"char_count":797,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0107","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"3. Screening for TB and ruling out TB disease before TB preventive treatment | 3.2 Screening for TB with CXR and computer aided detection (CAD) software","content_type":"text","pages":"29","tokens_est":162,"char_count":648,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0108","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"3. Screening for TB and ruling out TB disease before TB preventive treatment | 3.3 Screening for TB disease with other tests | 3.3.1 C-reactive protein","content_type":"text","pages":"30","tokens_est":220,"char_count":879,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0109","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"3. Screening for TB and ruling out TB disease before TB preventive treatment | 3.3 Screening for TB disease with other tests | 3.3.2 Molecular WHO-recommended rapid diagnostics","content_type":"text","pages":"30","tokens_est":230,"char_count":920,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0110","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"3. Screening for TB and ruling out TB disease before TB preventive treatment | 3.3 Screening for TB disease with other tests | 3.3.2 Molecular WHO-recommended rapid diagnostics","content_type":"text","pages":"30","tokens_est":54,"char_count":216,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0111","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"3. Screening for TB and ruling out TB disease before TB preventive treatment | 3.4 Screening algorithms","content_type":"text","pages":"30-31","tokens_est":197,"char_count":785,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0112","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"3. Screening for TB and ruling out TB disease before TB preventive treatment | 3.4 Screening algorithms | Box 4. The ScreenTB tool for prioritizing and planning systematic TB screening in selected risk groups","content_type":"box","pages":"31","caption":"Box 4. The ScreenTB tool for prioritizing and planning systematic TB screening in selected risk groups","tokens_est":243,"char_count":971,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0113","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"3. Screening for TB and ruling out TB disease before TB preventive treatment | 3.4 Screening algorithms | Box 4. The ScreenTB tool for prioritizing and planning systematic TB screening in selected risk groups","content_type":"box","pages":"31","caption":"Box 4. The ScreenTB tool for prioritizing and planning systematic TB screening in selected risk groups","tokens_est":137,"char_count":548,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0114","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"3. Screening for TB and ruling out TB disease before TB preventive treatment | 3.5 Considerations for ruling out TB disease","content_type":"text","pages":"31","tokens_est":47,"char_count":188,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0115","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"3. Screening for TB and ruling out TB disease before TB preventive treatment | 3.5 Considerations for ruling out TB disease","content_type":"text","pages":"31","tokens_est":120,"char_count":480,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0116","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"3. Screening for TB and ruling out TB disease before TB preventive treatment | 3.5 Considerations for ruling out TB disease","content_type":"text","pages":"31","tokens_est":152,"char_count":606,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0117","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"3. Screening for TB and ruling out TB disease before TB preventive treatment | 3.5 Considerations for ruling out TB disease","content_type":"text","pages":"31-32","tokens_est":219,"char_count":876,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0118","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"3. Screening for TB and ruling out TB disease before TB preventive treatment | 3.5 Considerations for ruling out TB disease","content_type":"text","pages":"32","tokens_est":215,"char_count":859,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0119","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"3. Screening for TB and ruling out TB disease before TB preventive treatment | 3.5 Considerations for ruling out TB disease","content_type":"text","pages":"32","tokens_est":230,"char_count":919,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0120","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"3. Screening for TB and ruling out TB disease before TB preventive treatment | 3.5 Considerations for ruling out TB disease | 3.5.1 Models of care for TB in children","content_type":"text","pages":"32","tokens_est":193,"char_count":770,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0121","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"3. Screening for TB and ruling out TB disease before TB preventive treatment | 3.5 Considerations for ruling out TB disease | 3.5.1 Models of care for TB in children","content_type":"text","pages":"32-33","tokens_est":190,"char_count":760,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0122","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"3. Screening for TB and ruling out TB disease before TB preventive treatment | 3.5 Considerations for ruling out TB disease | 3.5.1 Models of care for TB in children","content_type":"text","pages":"32-33","tokens_est":214,"char_count":854,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0123","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"4. Testing for TB infection","content_type":"text","pages":"33","tokens_est":172,"char_count":688,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0124","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"4. Testing for TB infection","content_type":"text","pages":"33","tokens_est":242,"char_count":968,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0125","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"4. Testing for TB infection | 4.1 Tests for TB infection","content_type":"text","pages":"33","tokens_est":206,"char_count":821,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0126","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"4. Testing for TB infection | 4.1 Tests for TB infection | 4.1.1 Skin tests","content_type":"text","pages":"33-34","tokens_est":237,"char_count":945,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0127","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"4. Testing for TB infection | 4.1 Tests for TB infection | 4.1.2 IGRAs","content_type":"text","pages":"34","tokens_est":234,"char_count":936,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0128","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"4. Testing for TB infection | 4.1 Tests for TB infection | 4.1.3 Selecting a test for TB infection for programme use","content_type":"text","pages":"34","tokens_est":154,"char_count":615,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0129","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"4. Testing for TB infection | 4.1 Tests for TB infection | 4.1.3 Selecting a test for TB infection for programme use | Table 2. Characteristic features of TST, TBST and IGRA","content_type":"table","pages":"34-36","caption":"Table 2. Characteristic features of TST, TBST and IGRA","tokens_est":25,"char_count":436,"has_attachment":true,"attachment_id":"Table 2.","attachment_path":"tables/WHO_TB_handbook_module1_TPT_2024/Table_2..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0130","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"4. Testing for TB infection | 4.2 Role of testing for TB infection","content_type":"text","pages":"37","tokens_est":158,"char_count":631,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0131","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"4. Testing for TB infection | 4.2 Role of testing for TB infection","content_type":"text","pages":"37","tokens_est":222,"char_count":888,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0132","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"4. Testing for TB infection | 4.2 Role of testing for TB infection","content_type":"text","pages":"37","tokens_est":67,"char_count":267,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0133","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"4. Testing for TB infection | 4.2 Role of testing for TB infection","content_type":"text","pages":"37","tokens_est":215,"char_count":859,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0134","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"4. Testing for TB infection | 4.3 Considerations for testing services for TB infection","content_type":"text","pages":"37","tokens_est":143,"char_count":572,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0135","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"4. Testing for TB infection | 4.3 Considerations for testing services for TB infection | 4.3.1 General requirements","content_type":"text","pages":"38","tokens_est":214,"char_count":854,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0136","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"4. Testing for TB infection | 4.3 Considerations for testing services for TB infection | 4.3.1 General requirements","content_type":"text","pages":"38","tokens_est":71,"char_count":284,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0137","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"4. Testing for TB infection | 4.3 Considerations for testing services for TB infection | 4.3.2 Programmatic implementation of TST and TBST","content_type":"text","pages":"38","tokens_est":219,"char_count":876,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0138","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"4. Testing for TB infection | 4.3 Considerations for testing services for TB infection | 4.3.2 Programmatic implementation of TST and TBST","content_type":"text","pages":"38","tokens_est":169,"char_count":674,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0139","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"4. Testing for TB infection | 4.3 Considerations for testing services for TB infection | 4.3.3 Programmatic implementation of IGRA","content_type":"text","pages":"38-39","tokens_est":222,"char_count":886,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0140","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"4. Testing for TB infection | 4.3 Considerations for testing services for TB infection | 4.3.3 Programmatic implementation of IGRA","content_type":"text","pages":"39","tokens_est":117,"char_count":465,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0141","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"4. Testing for TB infection | 4.3 Considerations for testing services for TB infection | 4.3.3 Programmatic implementation of IGRA | Fig. 6. Combined algorithm for screening and testing of individuals at risk before starting TB preventive treatment","content_type":"figure","pages":"39-40","caption":"Fig. 6. Combined algorithm for screening and testing of individuals at risk before starting TB preventive treatment","tokens_est":517,"char_count":2068,"has_attachment":true,"attachment_id":"Fig. 6.","attachment_path":"figures/WHO_TB_handbook_module1_TPT_2024/Fig. 6..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0142","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment","content_type":"text","pages":"43","tokens_est":234,"char_count":935,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0143","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment","content_type":"text","pages":"43","tokens_est":161,"char_count":643,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0144","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.1 Recommended TPT regimens","content_type":"text","pages":"43","tokens_est":215,"char_count":858,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0145","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.1 Recommended TPT regimens","content_type":"text","pages":"43","tokens_est":107,"char_count":428,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0146","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.1 Recommended TPT regimens","content_type":"text","pages":"43-44","tokens_est":156,"char_count":623,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0147","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.1 Recommended TPT regimens","content_type":"text","pages":"44","tokens_est":247,"char_count":986,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0148","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.1 Recommended TPT regimens","content_type":"text","pages":"44","tokens_est":73,"char_count":290,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0149","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.1 Recommended TPT regimens","content_type":"text","pages":"44","tokens_est":123,"char_count":490,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0150","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.1 Recommended TPT regimens","content_type":"text","pages":"44","tokens_est":177,"char_count":706,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0151","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.1 Recommended TPT regimens | Table 3. Key characteristics of currently recommended TPT options","content_type":"table","pages":"45-47","caption":"Table 3. Key characteristics of currently recommended TPT options","tokens_est":37,"char_count":1590,"has_attachment":true,"attachment_id":"Table 3.","attachment_path":"tables/WHO_TB_handbook_module1_TPT_2024/Table_3..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0152","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.1 Recommended TPT regimens | 5.1.1 Isoniazid monotherapy","content_type":"text","pages":"48","tokens_est":247,"char_count":988,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0153","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.1 Recommended TPT regimens | 5.1.1 Isoniazid monotherapy","content_type":"text","pages":"48","tokens_est":49,"char_count":193,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0154","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.1 Recommended TPT regimens | 5.1.1 Isoniazid monotherapy","content_type":"text","pages":"48","tokens_est":177,"char_count":707,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0155","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.1 Recommended TPT regimens | 5.1.2 Three months of weekly rifapentine plus isoniazid and one month of daily rifapentine plus isoniazid","content_type":"text","pages":"48","tokens_est":111,"char_count":442,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0156","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.1 Recommended TPT regimens | 5.1.2 Three months of weekly rifapentine plus isoniazid and one month of daily rifapentine plus isoniazid","content_type":"text","pages":"48","tokens_est":223,"char_count":892,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0157","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.1 Recommended TPT regimens | 5.1.2 Three months of weekly rifapentine plus isoniazid and one month of daily rifapentine plus isoniazid","content_type":"text","pages":"48-49","tokens_est":199,"char_count":796,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0158","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.1 Recommended TPT regimens | 5.1.2 Three months of weekly rifapentine plus isoniazid and one month of daily rifapentine plus isoniazid | Table 4.1. Drug dosage schedule for TPT regimens (6H, 9H, 4R, 3HR) according to body weight band (No. of tablets or quantity of suspension)","content_type":"table","pages":"50","caption":"Table 4.1. Drug dosage schedule for TPT regimens (6H, 9H, 4R, 3HR) according to body weight band (No. of tablets or quantity of suspension)","tokens_est":74,"char_count":1566,"has_attachment":true,"attachment_id":"Table 4.1.","attachment_path":"tables/WHO_TB_handbook_module1_TPT_2024/Table_4.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0159","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.1 Recommended TPT regimens | 5.1.2 Three months of weekly rifapentine plus isoniazid and one month of daily rifapentine plus isoniazid | Table 4.2 . Drug dosage schedule for TPT regimens (3HP, 1HP, 6Lfx) according to body weight band (No. of tablets or quantity of suspension)","content_type":"table","pages":"51","caption":"Table 4.2 . Drug dosage schedule for TPT regimens (3HP, 1HP, 6Lfx) according to body weight band (No. of tablets or quantity of suspension)","tokens_est":98,"char_count":1665,"has_attachment":true,"attachment_id":"Table 4.2","attachment_path":"tables/WHO_TB_handbook_module1_TPT_2024/Table_4.2.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0160","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.1 Recommended TPT regimens | 5.1.3 Three months of daily rifampicin plus isoniazid","content_type":"text","pages":"53","tokens_est":197,"char_count":785,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0161","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.1 Recommended TPT regimens | 5.1.3 Three months of daily rifampicin plus isoniazid","content_type":"text","pages":"53","tokens_est":147,"char_count":585,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0162","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.1 Recommended TPT regimens | 5.1.3 Three months of daily rifampicin plus isoniazid","content_type":"text","pages":"53","tokens_est":130,"char_count":518,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0163","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.1 Recommended TPT regimens | 5.1.4 Four months of daily rifampicin monotherapy","content_type":"text","pages":"53","tokens_est":227,"char_count":905,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0164","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.1 Recommended TPT regimens | 5.1.4 Four months of daily rifampicin monotherapy","content_type":"text","pages":"53","tokens_est":77,"char_count":308,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0165","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.1 Recommended TPT regimens | 5.1.5 Levofloxacin and other TPT regimens for drug-resistant TB","content_type":"text","pages":"53-54","tokens_est":178,"char_count":710,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0166","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.1 Recommended TPT regimens | 5.1.5 Levofloxacin and other TPT regimens for drug-resistant TB","content_type":"text","pages":"54","tokens_est":198,"char_count":792,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0167","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.1 Recommended TPT regimens | 5.1.5 Levofloxacin and other TPT regimens for drug-resistant TB","content_type":"text","pages":"54","tokens_est":92,"char_count":366,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0168","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.1 Recommended TPT regimens | 5.1.5 Levofloxacin and other TPT regimens for drug-resistant TB","content_type":"text","pages":"54","tokens_est":242,"char_count":968,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0169","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.1 Recommended TPT regimens | 5.1.5 Levofloxacin and other TPT regimens for drug-resistant TB","content_type":"text","pages":"54","tokens_est":69,"char_count":274,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0170","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.2 Recommended dosage of TPT medication","content_type":"text","pages":"54-55","tokens_est":228,"char_count":910,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0171","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.2 Recommended dosage of TPT medication","content_type":"text","pages":"54-55","tokens_est":183,"char_count":730,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0172","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.2 Recommended dosage of TPT medication","content_type":"text","pages":"54-55","tokens_est":81,"char_count":324,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0173","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.2 Recommended dosage of TPT medication | 5.2.1 Availability of appropriate formulations","content_type":"text","pages":"55","tokens_est":245,"char_count":980,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0174","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.2 Recommended dosage of TPT medication | 5.2.1 Availability of appropriate formulations","content_type":"text","pages":"55","tokens_est":134,"char_count":533,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0175","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.2 Recommended dosage of TPT medication | 5.2.1 Availability of appropriate formulations","content_type":"text","pages":"55-56","tokens_est":226,"char_count":901,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0176","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.2 Recommended dosage of TPT medication | 5.2.1 Availability of appropriate formulations","content_type":"text","pages":"55-56","tokens_est":244,"char_count":974,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0177","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.2 Recommended dosage of TPT medication | 5.2.1 Availability of appropriate formulations","content_type":"text","pages":"55-56","tokens_est":147,"char_count":585,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0178","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.2 Recommended dosage of TPT medication | 5.2.1 Availability of appropriate formulations","content_type":"text","pages":"56","tokens_est":181,"char_count":724,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0179","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.2 Recommended dosage of TPT medication | 5.2.2 Role of pyridoxine and its availability","content_type":"text","pages":"56","tokens_est":104,"char_count":415,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0180","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.2 Recommended dosage of TPT medication | 5.2.2 Role of pyridoxine and its availability","content_type":"text","pages":"56","tokens_est":182,"char_count":727,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0181","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.2 Recommended dosage of TPT medication | 5.2.2 Role of pyridoxine and its availability","content_type":"text","pages":"56","tokens_est":177,"char_count":708,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0182","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.2 Recommended dosage of TPT medication | 5.2.2 Role of pyridoxine and its availability","content_type":"text","pages":"56-57","tokens_est":241,"char_count":963,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0183","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.2 Recommended dosage of TPT medication | 5.2.2 Role of pyridoxine and its availability","content_type":"text","pages":"56-57","tokens_est":87,"char_count":346,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0184","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.2 Recommended dosage of TPT medication | 5.2.2 Role of pyridoxine and its availability","content_type":"text","pages":"57","tokens_est":236,"char_count":944,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0185","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.3 Provision of TPT for special populations | 5.3.1 Pregnancy and postpartum period","content_type":"text","pages":"57","tokens_est":197,"char_count":786,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0186","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.3 Provision of TPT for special populations | 5.3.1 Pregnancy and postpartum period","content_type":"text","pages":"57","tokens_est":214,"char_count":853,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0187","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.3 Provision of TPT for special populations | 5.3.1 Pregnancy and postpartum period","content_type":"text","pages":"57","tokens_est":65,"char_count":258,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0188","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.3 Provision of TPT for special populations | 5.3.1 Pregnancy and postpartum period","content_type":"text","pages":"57-58","tokens_est":193,"char_count":770,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0189","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.3 Provision of TPT for special populations | 5.3.1 Pregnancy and postpartum period","content_type":"text","pages":"58","tokens_est":209,"char_count":836,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0190","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.3 Provision of TPT for special populations | 5.3.1 Pregnancy and postpartum period","content_type":"text","pages":"58","tokens_est":130,"char_count":520,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0191","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.3 Provision of TPT for special populations | 5.3.1 Pregnancy and postpartum period","content_type":"text","pages":"58","tokens_est":104,"char_count":414,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0192","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.3 Provision of TPT for special populations | 5.3.2 Infants born to mothers with TB disease","content_type":"text","pages":"58","tokens_est":247,"char_count":985,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0193","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.3 Provision of TPT for special populations | 5.3.2 Infants born to mothers with TB disease","content_type":"text","pages":"58","tokens_est":125,"char_count":498,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0194","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.3 Provision of TPT for special populations | 5.3.3 Women taking oral or hormonal contraceptives","content_type":"text","pages":"59","tokens_est":179,"char_count":715,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0195","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.3 Provision of TPT for special populations | 5.3.4 People with hepatitis or liver disease","content_type":"text","pages":"59","tokens_est":237,"char_count":947,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0196","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.3 Provision of TPT for special populations | 5.3.5 People with renal failure","content_type":"text","pages":"59","tokens_est":74,"char_count":295,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0197","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.3 Provision of TPT for special populations | 5.3.6 People with HIV","content_type":"text","pages":"59","tokens_est":139,"char_count":556,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0198","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.3 Provision of TPT for special populations | 5.3.7 People who use drugs","content_type":"text","pages":"59-60","tokens_est":243,"char_count":971,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0199","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.3 Provision of TPT for special populations | 5.3.8 TB among older adults","content_type":"text","pages":"60","tokens_est":188,"char_count":751,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0200","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.3 Provision of TPT for special populations | 5.3.8 TB among older adults","content_type":"text","pages":"60","tokens_est":241,"char_count":963,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0201","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.4 Duration of protection","content_type":"text","pages":"60","tokens_est":236,"char_count":942,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0202","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.4 Duration of protection","content_type":"text","pages":"60-61","tokens_est":164,"char_count":653,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0203","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.4 Duration of protection","content_type":"text","pages":"61","tokens_est":220,"char_count":877,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0204","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.4 Duration of protection","content_type":"text","pages":"61","tokens_est":246,"char_count":983,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0205","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.4 Duration of protection","content_type":"text","pages":"61","tokens_est":82,"char_count":327,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0206","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.4 Duration of protection","content_type":"text","pages":"61","tokens_est":159,"char_count":636,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0207","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.5 Repeating or re-starting TPT","content_type":"text","pages":"61-62","tokens_est":246,"char_count":983,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0208","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.5 Repeating or re-starting TPT","content_type":"text","pages":"61-62","tokens_est":23,"char_count":90,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0209","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.5 Repeating or re-starting TPT","content_type":"text","pages":"62","tokens_est":223,"char_count":889,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0210","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.5 Repeating or re-starting TPT","content_type":"text","pages":"62","tokens_est":235,"char_count":938,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0211","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.5 Repeating or re-starting TPT","content_type":"text","pages":"62","tokens_est":236,"char_count":942,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0212","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.5 Repeating or re-starting TPT | 5.6.1 Isoniazid resistance after IPT","content_type":"text","pages":"62","tokens_est":130,"char_count":518,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0213","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.5 Repeating or re-starting TPT | 5.6.2 Rifamycin resistance after TPT","content_type":"text","pages":"63","tokens_est":223,"char_count":891,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0214","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.5 Repeating or re-starting TPT | 5.6.3 Resistance to levofloxacin after TPT","content_type":"text","pages":"63","tokens_est":69,"char_count":276,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0215","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.7 Introducing and scaling-up TPT","content_type":"text","pages":"63","tokens_est":125,"char_count":498,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0216","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.7 Introducing and scaling-up TPT | 5.7.1 Considerations for programmatic implementation of TPT","content_type":"text","pages":"63","tokens_est":233,"char_count":929,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0217","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.7 Introducing and scaling-up TPT | 5.7.1 Considerations for programmatic implementation of TPT","content_type":"text","pages":"63-64","tokens_est":234,"char_count":934,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0218","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.7 Introducing and scaling-up TPT | 5.7.1 Considerations for programmatic implementation of TPT","content_type":"text","pages":"64","tokens_est":237,"char_count":947,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0219","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.7 Introducing and scaling-up TPT | 5.7.1 Considerations for programmatic implementation of TPT","content_type":"text","pages":"64","tokens_est":236,"char_count":944,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0220","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.7 Introducing and scaling-up TPT | 5.7.1 Considerations for programmatic implementation of TPT","content_type":"text","pages":"64","tokens_est":68,"char_count":271,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0221","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.7 Introducing and scaling-up TPT | 5.7.1 Considerations for programmatic implementation of TPT | Box 5. Nurses play a leading role in programmatic management of TPT in Brazil","content_type":"box","pages":"64-65","caption":"Box 5. Nurses play a leading role in programmatic management of TPT in Brazil","tokens_est":220,"char_count":880,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0222","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.7 Introducing and scaling-up TPT | 5.7.1 Considerations for programmatic implementation of TPT | Box 5. Nurses play a leading role in programmatic management of TPT in Brazil","content_type":"box","pages":"64-65","caption":"Box 5. Nurses play a leading role in programmatic management of TPT in Brazil","tokens_est":104,"char_count":416,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0223","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.7 Introducing and scaling-up TPT | 5.7.1 Considerations for programmatic implementation of TPT | Box 5. Nurses play a leading role in programmatic management of TPT in Brazil","content_type":"box","pages":"65","caption":"Box 5. Nurses play a leading role in programmatic management of TPT in Brazil","tokens_est":235,"char_count":940,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0224","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.7 Introducing and scaling-up TPT | 5.7.1 Considerations for programmatic implementation of TPT | Box 6. Actions taken by high TB burden countries for recent scaling up of shorter TPT for contacts of TB patients","content_type":"box","pages":"66","caption":"Box 6. Actions taken by high TB burden countries for recent scaling up of shorter TPT for contacts of TB patients","tokens_est":210,"char_count":840,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0225","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.7 Introducing and scaling-up TPT | 5.7.1 Considerations for programmatic implementation of TPT | Box 6. Actions taken by high TB burden countries for recent scaling up of shorter TPT for contacts of TB patients","content_type":"box","pages":"66","caption":"Box 6. Actions taken by high TB burden countries for recent scaling up of shorter TPT for contacts of TB patients","tokens_est":225,"char_count":897,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0226","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.7 Introducing and scaling-up TPT | 5.7.1 Considerations for programmatic implementation of TPT | Box 6. Actions taken by high TB burden countries for recent scaling up of shorter TPT for contacts of TB patients","content_type":"box","pages":"66","caption":"Box 6. Actions taken by high TB burden countries for recent scaling up of shorter TPT for contacts of TB patients","tokens_est":241,"char_count":961,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0227","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.7 Introducing and scaling-up TPT | 5.7.1 Considerations for programmatic implementation of TPT | Box 6. Actions taken by high TB burden countries for recent scaling up of shorter TPT for contacts of TB patients","content_type":"box","pages":"66-67","caption":"Box 6. Actions taken by high TB burden countries for recent scaling up of shorter TPT for contacts of TB patients","tokens_est":222,"char_count":888,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0228","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.7 Introducing and scaling-up TPT | 5.7.1 Considerations for programmatic implementation of TPT | Box 6. Actions taken by high TB burden countries for recent scaling up of shorter TPT for contacts of TB patients","content_type":"box","pages":"67","caption":"Box 6. Actions taken by high TB burden countries for recent scaling up of shorter TPT for contacts of TB patients","tokens_est":149,"char_count":595,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0229","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.7 Introducing and scaling-up TPT | 5.7.1 Considerations for programmatic implementation of TPT | Box 6. Actions taken by high TB burden countries for recent scaling up of shorter TPT for contacts of TB patients","content_type":"box","pages":"67","caption":"Box 6. Actions taken by high TB burden countries for recent scaling up of shorter TPT for contacts of TB patients","tokens_est":218,"char_count":870,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0230","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.7 Introducing and scaling-up TPT | 5.7.1 Considerations for programmatic implementation of TPT | Box 6. Actions taken by high TB burden countries for recent scaling up of shorter TPT for contacts of TB patients","content_type":"box","pages":"67","caption":"Box 6. Actions taken by high TB burden countries for recent scaling up of shorter TPT for contacts of TB patients","tokens_est":242,"char_count":966,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0231","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.7 Introducing and scaling-up TPT | 5.7.1 Considerations for programmatic implementation of TPT | Box 6. Actions taken by high TB burden countries for recent scaling up of shorter TPT for contacts of TB patients","content_type":"box","pages":"67","caption":"Box 6. Actions taken by high TB burden countries for recent scaling up of shorter TPT for contacts of TB patients","tokens_est":245,"char_count":978,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0232","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.7 Introducing and scaling-up TPT | 5.7.1 Considerations for programmatic implementation of TPT | Box 6. Actions taken by high TB burden countries for recent scaling up of shorter TPT for contacts of TB patients","content_type":"box","pages":"67-68","caption":"Box 6. Actions taken by high TB burden countries for recent scaling up of shorter TPT for contacts of TB patients","tokens_est":237,"char_count":946,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0233","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.7 Introducing and scaling-up TPT | 5.7.1 Considerations for programmatic implementation of TPT | Box 6. Actions taken by high TB burden countries for recent scaling up of shorter TPT for contacts of TB patients","content_type":"box","pages":"68","caption":"Box 6. Actions taken by high TB burden countries for recent scaling up of shorter TPT for contacts of TB patients","tokens_est":219,"char_count":874,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0234","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.7 Introducing and scaling-up TPT | 5.7.1 Considerations for programmatic implementation of TPT | Box 6. Actions taken by high TB burden countries for recent scaling up of shorter TPT for contacts of TB patients","content_type":"box","pages":"68","caption":"Box 6. Actions taken by high TB burden countries for recent scaling up of shorter TPT for contacts of TB patients","tokens_est":107,"char_count":426,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0235","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.7 Introducing and scaling-up TPT | 5.7.2 TPT initiation and pre-TPT baseline assessment","content_type":"text","pages":"68","tokens_est":218,"char_count":870,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0236","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.7 Introducing and scaling-up TPT | 5.7.2 TPT initiation and pre-TPT baseline assessment","content_type":"text","pages":"68-69","tokens_est":213,"char_count":849,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0237","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.7 Introducing and scaling-up TPT | 5.7.2 TPT initiation and pre-TPT baseline assessment","content_type":"text","pages":"69","tokens_est":240,"char_count":958,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0238","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.7 Introducing and scaling-up TPT | 5.7.2 TPT initiation and pre-TPT baseline assessment","content_type":"text","pages":"69","tokens_est":243,"char_count":969,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0239","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.7 Introducing and scaling-up TPT | 5.7.2 TPT initiation and pre-TPT baseline assessment","content_type":"text","pages":"69","tokens_est":170,"char_count":680,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0240","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.7 Introducing and scaling-up TPT | 5.7.3 Monitoring of adherence and treatment completion","content_type":"text","pages":"69","tokens_est":101,"char_count":403,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0241","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.8 Differentiated HIV service delivery and implications for scaling up TPT","content_type":"text","pages":"70","tokens_est":178,"char_count":712,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0242","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.8 Differentiated HIV service delivery and implications for scaling up TPT","content_type":"text","pages":"70","tokens_est":105,"char_count":419,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0243","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.8 Differentiated HIV service delivery and implications for scaling up TPT","content_type":"text","pages":"70","tokens_est":172,"char_count":685,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0244","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.8 Differentiated HIV service delivery and implications for scaling up TPT | Fig. 10. Key elements of integration of TPT services into DSD models for ART","content_type":"figure","pages":"70","caption":"Fig. 10. Key elements of integration of TPT services into DSD models for ART","tokens_est":52,"char_count":205,"has_attachment":true,"attachment_id":"Fig. 10.","attachment_path":"figures/WHO_TB_handbook_module1_TPT_2024/Fig. 10..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0245","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.8 Differentiated HIV service delivery and implications for scaling up TPT","content_type":"text","pages":"70","tokens_est":216,"char_count":864,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0246","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.8 Differentiated HIV service delivery and implications for scaling up TPT","content_type":"text","pages":"70-71","tokens_est":216,"char_count":864,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0247","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"5. TB preventive treatment | 5.8 Differentiated HIV service delivery and implications for scaling up TPT","content_type":"text","pages":"71","tokens_est":59,"char_count":233,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0248","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment","content_type":"text","pages":"72","tokens_est":188,"char_count":752,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0249","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment","content_type":"text","pages":"72","tokens_est":118,"char_count":472,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0250","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment","content_type":"text","pages":"72","tokens_est":207,"char_count":825,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0251","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.1 Drug safety and adverse drug reactions","content_type":"text","pages":"72-73","tokens_est":230,"char_count":919,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0252","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.1 Drug safety and adverse drug reactions","content_type":"text","pages":"72-73","tokens_est":70,"char_count":280,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0253","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.1 Drug safety and adverse drug reactions | Table 5. Documented adverse events with drugs used for TPT","content_type":"table","pages":"73","caption":"Table 4 presents an updated dosing scheme for all recommended TPT regimens by standardized body weight-bands. In 2024, the Technical Advisory Group on dosing of TB medicines for adults and children (70) reviewed questions relating to the dosage of TPT regimens. They considered published evidence and the results of pharmacokinetics modelling and simulation in studies of 6Lfx and 3HP. (See details in Web Annex A .) Dosing of smaller children is adjusted for differences in the rate at which drugs are metabolized. For infants and young children, age cut-offs are given in the first two weight bands for 6Lfx and 3HP. It is important to note that infants in these two weight bands may be malnourished, a condition that warrants particular care to exclude TB disease before TPT is considered. A specialist should be consulted for dosing of TPT regimens for infants who weigh  3 kg.","tokens_est":237,"char_count":956,"has_attachment":true,"attachment_id":"Table 4","attachment_path":"tables/WHO_TB_handbook_module1_TPT_2024/Table_4.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0254","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.1 Drug safety and adverse drug reactions","content_type":"text","pages":"73-74","tokens_est":241,"char_count":962,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0255","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.1 Drug safety and adverse drug reactions","content_type":"text","pages":"73-74","tokens_est":164,"char_count":656,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0256","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.1 Drug safety and adverse drug reactions","content_type":"text","pages":"74","tokens_est":229,"char_count":916,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0257","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.1 Drug safety and adverse drug reactions","content_type":"text","pages":"74","tokens_est":208,"char_count":830,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0258","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.1 Drug safety and adverse drug reactions","content_type":"text","pages":"74","tokens_est":57,"char_count":228,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0259","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.1 Drug safety and adverse drug reactions | Table 6. Grade 34 adverse events and discontinuation of treatment due to adverse events in people on TPT","content_type":"table","pages":"74-77","caption":"Table 6. Grade 34 adverse events and discontinuation of treatment due to adverse events in people on TPT","tokens_est":45,"char_count":756,"has_attachment":true,"attachment_id":"Table 6.","attachment_path":"tables/WHO_TB_handbook_module1_TPT_2024/Table_6..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0260","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.1 Drug safety and adverse drug reactions | 6.1.1 Isoniazid","content_type":"text","pages":"77","tokens_est":247,"char_count":986,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0261","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.1 Drug safety and adverse drug reactions | 6.1.1 Isoniazid","content_type":"text","pages":"77","tokens_est":158,"char_count":632,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0262","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.1 Drug safety and adverse drug reactions | 6.1.2 Rifampicin","content_type":"text","pages":"77","tokens_est":146,"char_count":583,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0263","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.1 Drug safety and adverse drug reactions | 6.1.2 Rifampicin","content_type":"text","pages":"77-78","tokens_est":152,"char_count":605,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0264","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.1 Drug safety and adverse drug reactions | 6.1.3 Rifapentine","content_type":"text","pages":"78","tokens_est":216,"char_count":861,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0265","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.1 Drug safety and adverse drug reactions | 6.1.3 Rifapentine","content_type":"text","pages":"78","tokens_est":52,"char_count":207,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0266","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.1 Drug safety and adverse drug reactions | 6.1.3 Rifapentine | Box 7. Nitrosamine contamination of rifamycins","content_type":"box","pages":"78","caption":"Box 7. Nitrosamine contamination of rifamycins","tokens_est":200,"char_count":799,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0267","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.1 Drug safety and adverse drug reactions | 6.1.3 Rifapentine | Box 7. Nitrosamine contamination of rifamycins","content_type":"box","pages":"78","caption":"Box 7. Nitrosamine contamination of rifamycins","tokens_est":191,"char_count":761,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0268","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.1 Drug safety and adverse drug reactions | 6.1.3 Rifapentine | Box 7. Nitrosamine contamination of rifamycins","content_type":"box","pages":"78","caption":"Box 7. Nitrosamine contamination of rifamycins","tokens_est":88,"char_count":350,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0269","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.1 Drug safety and adverse drug reactions | 6.1.3 Rifapentine | Box 7. Nitrosamine contamination of rifamycins","content_type":"box","pages":"78","caption":"Box 7. Nitrosamine contamination of rifamycins","tokens_est":46,"char_count":183,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0270","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.1 Drug safety and adverse drug reactions | 6.1.4 Levofloxacin","content_type":"text","pages":"78-79","tokens_est":222,"char_count":887,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0271","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.1 Drug safety and adverse drug reactions | 6.1.4 Levofloxacin","content_type":"text","pages":"78-79","tokens_est":59,"char_count":235,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0272","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.1 Drug safety and adverse drug reactions | 6.1.4 Levofloxacin","content_type":"text","pages":"79","tokens_est":192,"char_count":767,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0273","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.2 Management of adverse events","content_type":"text","pages":"79","tokens_est":118,"char_count":469,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0274","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.2 Management of adverse events","content_type":"text","pages":"79","tokens_est":240,"char_count":960,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0275","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.2 Management of adverse events","content_type":"text","pages":"79-80","tokens_est":237,"char_count":945,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0276","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.2 Management of adverse events","content_type":"text","pages":"80","tokens_est":206,"char_count":822,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0277","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.2 Management of adverse events","content_type":"text","pages":"80","tokens_est":156,"char_count":623,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0278","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.2 Management of adverse events","content_type":"text","pages":"80","tokens_est":162,"char_count":645,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0279","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.2 Management of adverse events | 6.2.1 Isoniazid and rifampicin | Drug-induced hepatitis","content_type":"text","pages":"80","tokens_est":123,"char_count":490,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0280","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.2 Management of adverse events | 6.2.1 Isoniazid and rifampicin | Drug-induced hepatitis","content_type":"text","pages":"80-81","tokens_est":229,"char_count":914,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0281","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.2 Management of adverse events | 6.2.1 Isoniazid and rifampicin | Skin reactions","content_type":"text","pages":"81","tokens_est":200,"char_count":799,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0282","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.2 Management of adverse events | 6.2.1 Isoniazid and rifampicin | Skin reactions","content_type":"text","pages":"81","tokens_est":108,"char_count":430,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0283","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.2 Management of adverse events | 6.2.1 Isoniazid and rifampicin | Peripheral neuropathy","content_type":"text","pages":"81","tokens_est":119,"char_count":475,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0284","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.2 Management of adverse events | 6.2.1 Isoniazid and rifampicin | Gastrointestinal reactions","content_type":"text","pages":"81","tokens_est":223,"char_count":892,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0285","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.2 Management of adverse events | 6.2.2 Isoniazid and rifapentine","content_type":"text","pages":"81-82","tokens_est":226,"char_count":901,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0286","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.2 Management of adverse events | 6.2.2 Isoniazid and rifapentine","content_type":"text","pages":"82","tokens_est":222,"char_count":886,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0287","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.2 Management of adverse events | 6.2.2 Isoniazid and rifapentine","content_type":"text","pages":"82","tokens_est":174,"char_count":695,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0288","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.2 Management of adverse events | 6.2.2 Isoniazid and rifapentine","content_type":"text","pages":"82","tokens_est":244,"char_count":974,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0289","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.2 Management of adverse events | 6.2.2 Isoniazid and rifapentine","content_type":"text","pages":"82-83","tokens_est":81,"char_count":322,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0290","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.2 Management of adverse events | 6.2.3 Levofloxacin","content_type":"text","pages":"83","tokens_est":241,"char_count":962,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0291","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.3 Drugdrug interactions | 6.3.1 Rifamycins and ARV","content_type":"text","pages":"83","tokens_est":207,"char_count":825,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0292","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.3 Drugdrug interactions | 6.3.1 Rifamycins and ARV","content_type":"text","pages":"83-84","tokens_est":235,"char_count":940,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0293","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.3 Drugdrug interactions | 6.3.1 Rifamycins and ARV","content_type":"text","pages":"83-84","tokens_est":88,"char_count":352,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0294","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.3 Drugdrug interactions | 6.3.1 Rifamycins and ARV","content_type":"text","pages":"84","tokens_est":69,"char_count":274,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0295","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.3 Drugdrug interactions | 6.3.2 Co-administration of rifapentine and dolutegravir","content_type":"text","pages":"84","tokens_est":176,"char_count":703,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0296","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.3 Drugdrug interactions | 6.3.2 Co-administration of rifapentine and dolutegravir","content_type":"text","pages":"84","tokens_est":232,"char_count":927,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0297","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.3 Drugdrug interactions | 6.3.2 Co-administration of rifapentine and dolutegravir","content_type":"text","pages":"84","tokens_est":61,"char_count":241,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0298","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.3 Drugdrug interactions | 6.3.2 Co-administration of rifapentine and dolutegravir","content_type":"text","pages":"84","tokens_est":208,"char_count":830,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0299","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.3 Drugdrug interactions | 6.3.3 ARV options for concomitant administration with rifamycin-based TPT","content_type":"text","pages":"85","tokens_est":233,"char_count":929,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0300","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.3 Drugdrug interactions | 6.3.3 ARV options for concomitant administration with rifamycin-based TPT","content_type":"text","pages":"85","tokens_est":142,"char_count":568,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0301","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.3 Drugdrug interactions | 6.3.3 ARV options for concomitant administration with rifamycin-based TPT","content_type":"text","pages":"85","tokens_est":166,"char_count":662,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0302","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.3 Drugdrug interactions | 6.3.4 Isoniazid","content_type":"text","pages":"85","tokens_est":190,"char_count":759,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0303","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.3 Drugdrug interactions | 6.3.4 Isoniazid | Table 7. Common drugdrug interactions of isoniazid and rifamycins","content_type":"table","pages":"85-87","caption":"Table 7. Common drugdrug interactions of isoniazid and rifamycins","tokens_est":57,"char_count":365,"has_attachment":true,"attachment_id":"Table 7.","attachment_path":"tables/WHO_TB_handbook_module1_TPT_2024/Table_7..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0304","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.3 Drugdrug interactions | 6.3.5 Rifamycin-based TPT and antimalaria treatment","content_type":"text","pages":"88","tokens_est":248,"char_count":989,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0305","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.3 Drugdrug interactions | 6.3.5 Rifamycin-based TPT and antimalaria treatment","content_type":"text","pages":"88","tokens_est":179,"char_count":713,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0306","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.3 Drugdrug interactions | 6.3.5 Rifamycin-based TPT and antimalaria treatment","content_type":"text","pages":"88","tokens_est":105,"char_count":420,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0307","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"6. Safety and management of adverse drug reactions in TB preventive treatment | 6.3 Drugdrug interactions | 6.3.6 Levofloxacin","content_type":"text","pages":"88","tokens_est":178,"char_count":711,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0308","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment","content_type":"text","pages":"91","tokens_est":143,"char_count":571,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0309","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment","content_type":"text","pages":"91","tokens_est":155,"char_count":618,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0310","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.1 Monitoring TPT","content_type":"text","pages":"91","tokens_est":199,"char_count":796,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0311","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.1 Monitoring TPT","content_type":"text","pages":"91","tokens_est":147,"char_count":585,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0312","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.2 Management of missed doses","content_type":"text","pages":"92","tokens_est":151,"char_count":601,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0313","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.2 Management of missed doses | Table 8. Management of interruptions by duration for different TPT regimens","content_type":"table","pages":"92-95","caption":"Table 8. Management of interruptions by duration for different TPT regimens","tokens_est":37,"char_count":557,"has_attachment":true,"attachment_id":"Table 8.","attachment_path":"tables/WHO_TB_handbook_module1_TPT_2024/Table_8..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0314","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.3 Determining TPT completion","content_type":"text","pages":"95","tokens_est":246,"char_count":984,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0315","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.3 Determining TPT completion","content_type":"text","pages":"95","tokens_est":61,"char_count":241,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0316","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.3 Determining TPT completion | Table 9. Criteria for determining completion of different TPT regimens","content_type":"table","pages":"95-96","caption":"Table 9. Criteria for determining completion of different TPT regimens","tokens_est":68,"char_count":279,"has_attachment":true,"attachment_id":"Table 9.","attachment_path":"tables/WHO_TB_handbook_module1_TPT_2024/Table_9..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0317","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.3 Determining TPT completion","content_type":"text","pages":"96","tokens_est":200,"char_count":798,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0318","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.4 Potential barriers to adherence","content_type":"text","pages":"96","tokens_est":241,"char_count":963,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0319","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.4 Potential barriers to adherence","content_type":"text","pages":"96","tokens_est":138,"char_count":550,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0320","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.5 Strategies to improve adherence and treatment completion | 7.5.1 Supportive measures","content_type":"text","pages":"97","tokens_est":223,"char_count":890,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0321","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.5 Strategies to improve adherence and treatment completion | 7.5.1 Supportive measures","content_type":"text","pages":"97","tokens_est":208,"char_count":830,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0322","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.5 Strategies to improve adherence and treatment completion | 7.5.1 Supportive measures","content_type":"text","pages":"97","tokens_est":201,"char_count":802,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0323","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.5 Strategies to improve adherence and treatment completion | 7.5.1 Supportive measures","content_type":"text","pages":"97","tokens_est":73,"char_count":291,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0324","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.5 Strategies to improve adherence and treatment completion | 7.5.2 Providing guidance to individuals receiving TPT","content_type":"text","pages":"98","tokens_est":186,"char_count":743,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0325","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.5 Strategies to improve adherence and treatment completion | 7.5.2 Providing guidance to individuals receiving TPT","content_type":"text","pages":"98","tokens_est":235,"char_count":939,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0326","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.5 Strategies to improve adherence and treatment completion | 7.5.2 Providing guidance to individuals receiving TPT","content_type":"text","pages":"98","tokens_est":177,"char_count":708,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0327","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.5 Strategies to improve adherence and treatment completion | 7.5.2 Providing guidance to individuals receiving TPT","content_type":"text","pages":"98","tokens_est":245,"char_count":978,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0328","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.5 Strategies to improve adherence and treatment completion | 7.5.2 Providing guidance to individuals receiving TPT","content_type":"text","pages":"98-99","tokens_est":234,"char_count":934,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0329","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.5 Strategies to improve adherence and treatment completion | 7.5.2 Providing guidance to individuals receiving TPT","content_type":"text","pages":"99","tokens_est":157,"char_count":626,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0330","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.5 Strategies to improve adherence and treatment completion | 7.5.2 Providing guidance to individuals receiving TPT | Box 8. Example of an adherence plan","content_type":"box","pages":"99","caption":"Box 8. Example of an adherence plan","tokens_est":229,"char_count":916,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0331","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.5 Strategies to improve adherence and treatment completion | 7.5.2 Providing guidance to individuals receiving TPT | Box 8. Example of an adherence plan","content_type":"box","pages":"99-100","caption":"Box 8. Example of an adherence plan","tokens_est":225,"char_count":900,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0332","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.5 Strategies to improve adherence and treatment completion | 7.5.2 Providing guidance to individuals receiving TPT | Box 8. Example of an adherence plan","content_type":"box","pages":"100","caption":"Box 8. Example of an adherence plan","tokens_est":167,"char_count":666,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0333","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.5 Strategies to improve adherence and treatment completion | 7.5.3 Creating an empowering environment to improve adherence","content_type":"text","pages":"100","tokens_est":203,"char_count":809,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0334","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.5 Strategies to improve adherence and treatment completion | 7.5.3 Creating an empowering environment to improve adherence","content_type":"text","pages":"100","tokens_est":216,"char_count":863,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0335","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.5 Strategies to improve adherence and treatment completion | 7.5.3 Creating an empowering environment to improve adherence","content_type":"text","pages":"100","tokens_est":223,"char_count":892,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0336","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.5 Strategies to improve adherence and treatment completion | 7.5.3 Creating an empowering environment to improve adherence","content_type":"text","pages":"100-101","tokens_est":189,"char_count":754,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0337","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.5 Strategies to improve adherence and treatment completion | 7.5.4 Special considerations for adherence by children","content_type":"text","pages":"101","tokens_est":226,"char_count":901,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0338","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.5 Strategies to improve adherence and treatment completion | 7.5.4 Special considerations for adherence by children","content_type":"text","pages":"101","tokens_est":196,"char_count":784,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0339","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.5 Strategies to improve adherence and treatment completion | 7.5.4 Special considerations for adherence by children","content_type":"text","pages":"101","tokens_est":224,"char_count":894,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0340","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"7. Supporting people in adhering to and completing TB preventive treatment | 7.5 Strategies to improve adherence and treatment completion | 7.5.4 Special considerations for adherence by children","content_type":"text","pages":"101-102","tokens_est":243,"char_count":971,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0341","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"8. Monitoring and evaluation","content_type":"text","pages":"103","tokens_est":231,"char_count":923,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0342","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"8. Monitoring and evaluation | 8.1 The role of M&E","content_type":"text","pages":"103","tokens_est":215,"char_count":857,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0343","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"8. Monitoring and evaluation | 8.1 The role of M&E | Fig. 11. Use of health data at different levels of the health system","content_type":"figure","pages":"103","caption":"Fig. 11. Use of health data at different levels of the health system","tokens_est":20,"char_count":78,"has_attachment":true,"attachment_id":"Fig. 11.","attachment_path":"figures/WHO_TB_handbook_module1_TPT_2024/Fig. 11..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0344","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"8. Monitoring and evaluation | 8.2 Monitoring PMTPT","content_type":"text","pages":"103","tokens_est":183,"char_count":731,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0345","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"8. Monitoring and evaluation | 8.2 Monitoring PMTPT | Fig. 12. Critical numbers of people to be monitored at each step in the TPT pathway","content_type":"figure","pages":"103-104","caption":"Fig. 12. Critical numbers of people to be monitored at each step in the TPT pathway","tokens_est":122,"char_count":486,"has_attachment":true,"attachment_id":"Fig. 12.","attachment_path":"figures/WHO_TB_handbook_module1_TPT_2024/Fig. 12..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0346","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"8. Monitoring and evaluation | 8.2 Monitoring PMTPT | 8.2.1 Indicators for monitoring PMTPT","content_type":"text","pages":"104","tokens_est":146,"char_count":584,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0347","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"8. Monitoring and evaluation | 8.2 Monitoring PMTPT | 8.2.1 Indicators for monitoring PMTPT | Box 9. Calculation of the number of people eligible for TPT","content_type":"box","pages":"104","caption":"Box 9. Calculation of the number of people eligible for TPT","tokens_est":233,"char_count":931,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0348","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"8. Monitoring and evaluation | 8.2 Monitoring PMTPT | 8.2.1 Indicators for monitoring PMTPT | Box 9. Calculation of the number of people eligible for TPT","content_type":"box","pages":"104","caption":"Box 9. Calculation of the number of people eligible for TPT","tokens_est":168,"char_count":670,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0349","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"8. Monitoring and evaluation | 8.2 Monitoring PMTPT | 8.2.1 Indicators for monitoring PMTPT | Box 9. Calculation of the number of people eligible for TPT","content_type":"box","pages":"104-105","caption":"Box 9. Calculation of the number of people eligible for TPT","tokens_est":246,"char_count":984,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0350","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"8. Monitoring and evaluation | 8.2 Monitoring PMTPT | 8.2.1 Indicators for monitoring PMTPT | Box 9. Calculation of the number of people eligible for TPT","content_type":"box","pages":"105","caption":"Box 9. Calculation of the number of people eligible for TPT","tokens_est":214,"char_count":855,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0351","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"8. Monitoring and evaluation | 8.2 Monitoring PMTPT | 8.2.2 Data requirements for monitoring TPT at individual level","content_type":"text","pages":"105","tokens_est":83,"char_count":329,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0352","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"8. Monitoring and evaluation | 8.2 Monitoring PMTPT | 8.2.2 Data requirements for monitoring TPT at individual level | Box 10. Variables to be collected at individual level","content_type":"box","pages":"105","caption":"Box 10. Variables to be collected at individual level","tokens_est":227,"char_count":907,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0353","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"8. Monitoring and evaluation | 8.2 Monitoring PMTPT | 8.2.2 Data requirements for monitoring TPT at individual level | Box 10. Variables to be collected at individual level","content_type":"box","pages":"105","caption":"Box 10. Variables to be collected at individual level","tokens_est":86,"char_count":341,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0354","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"8. Monitoring and evaluation | 8.2 Monitoring PMTPT | 8.2.2 Data requirements for monitoring TPT at individual level | Table 10. Indicators for monitoring PMTPT","content_type":"table","pages":"106","caption":"Table 10 lists the minimum indicators for PMTPT that should be measured. The programme may also decide to monitor other activities, such as the coverage of testing for TB infection among people targeted for testing during investigation of eligibility for TST. Use of metrics of the timeliness of screening and implementation of TPT in household contacts of people with pulmonary TB are discussed in section 2 ( Box 1 ).","tokens_est":122,"char_count":923,"has_attachment":true,"attachment_id":"Table 10","attachment_path":"tables/WHO_TB_handbook_module1_TPT_2024/Table_10.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0355","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"8. Monitoring and evaluation | 8.2 Monitoring PMTPT | 8.2.2 Data requirements for monitoring TPT at individual level","content_type":"text","pages":"106-107","tokens_est":177,"char_count":706,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0356","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"8. Monitoring and evaluation | 8.2 Monitoring PMTPT | 8.2.2 Data requirements for monitoring TPT at individual level","content_type":"text","pages":"107","tokens_est":217,"char_count":867,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0357","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"8. Monitoring and evaluation | 8.3 Monitoring TPT completion","content_type":"text","pages":"107","tokens_est":169,"char_count":676,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0358","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"8. Monitoring and evaluation | 8.3 Monitoring TPT completion | 8.3.1 Data recording tools","content_type":"text","pages":"107","tokens_est":185,"char_count":737,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0359","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"8. Monitoring and evaluation | 8.3 Monitoring TPT completion | 8.3.1 Data recording tools","content_type":"text","pages":"107-108","tokens_est":203,"char_count":809,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0360","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"8. Monitoring and evaluation | 8.3 Monitoring TPT completion | 8.3.1 Data recording tools | Box 11. Prevent TB: a prototype mobile application to support PMTPT and screening","content_type":"box","pages":"108","caption":"Box 11. Prevent TB: a prototype mobile application to support PMTPT and screening","tokens_est":230,"char_count":919,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0361","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"8. Monitoring and evaluation | 8.3 Monitoring TPT completion | 8.3.1 Data recording tools","content_type":"text","pages":"108","tokens_est":202,"char_count":807,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0362","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"8. Monitoring and evaluation | 8.3 Monitoring TPT completion | 8.3.2 Data confidentiality","content_type":"text","pages":"108","tokens_est":220,"char_count":878,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0363","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"8. Monitoring and evaluation | 8.3 Monitoring TPT completion | 8.3.2 Data confidentiality","content_type":"text","pages":"108","tokens_est":161,"char_count":642,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0364","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"8. Monitoring and evaluation | 8.4 Supportive supervision","content_type":"text","pages":"109","tokens_est":225,"char_count":898,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0365","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"8. Monitoring and evaluation | 8.4 Supportive supervision","content_type":"text","pages":"109","tokens_est":43,"char_count":169,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0366","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"9. Ethics and TB preventive treatment","content_type":"text","pages":"109","tokens_est":199,"char_count":793,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0367","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"9. Ethics and TB preventive treatment","content_type":"text","pages":"109","tokens_est":228,"char_count":910,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0368","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"9. Ethics and TB preventive treatment","content_type":"text","pages":"109-110","tokens_est":181,"char_count":721,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0369","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"9. Ethics and TB preventive treatment","content_type":"text","pages":"110","tokens_est":200,"char_count":800,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0370","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"9. Ethics and TB preventive treatment | 9.1 Informed consent","content_type":"text","pages":"110","tokens_est":224,"char_count":895,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0371","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"9. Ethics and TB preventive treatment | 9.1 Informed consent","content_type":"text","pages":"110","tokens_est":194,"char_count":773,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0372","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"9. Ethics and TB preventive treatment | 9.2 Equity, stigmatization and human rights","content_type":"text","pages":"111","tokens_est":144,"char_count":573,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0373","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"9. Ethics and TB preventive treatment | 9.2 Equity, stigmatization and human rights","content_type":"text","pages":"111","tokens_est":136,"char_count":542,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0374","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"9. Ethics and TB preventive treatment | 9.2 Equity, stigmatization and human rights","content_type":"text","pages":"111","tokens_est":216,"char_count":862,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0375","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"9. Ethics and TB preventive treatment | 9.2 Equity, stigmatization and human rights | 9.2.1 Mandatory TB screening at borders","content_type":"text","pages":"111","tokens_est":185,"char_count":740,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0376","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"9. Ethics and TB preventive treatment | 9.2 Equity, stigmatization and human rights | 9.2.2 Screening of health-care workers","content_type":"text","pages":"111-112","tokens_est":221,"char_count":883,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0377","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"9. Ethics and TB preventive treatment | 9.2 Equity, stigmatization and human rights | 9.2.2 Screening of health-care workers","content_type":"text","pages":"111-112","tokens_est":168,"char_count":670,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module1_TPT_2024|0378","doc_id":"WHO_TB_handbook_module1_TPT_2024","section_path":"9. Ethics and TB preventive treatment | 9.2 Equity, stigmatization and human rights | 9.2.3 Community engagement","content_type":"text","pages":"112","tokens_est":121,"char_count":484,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module1_TPT_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0001","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Abbreviations and acronyms","content_type":"text","pages":"1","tokens_est":109,"char_count":434,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0002","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Definitions","content_type":"text","pages":"1","tokens_est":243,"char_count":970,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0003","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Definitions","content_type":"text","pages":"1","tokens_est":205,"char_count":818,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0004","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Definitions","content_type":"text","pages":"1","tokens_est":141,"char_count":563,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0005","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Definitions","content_type":"text","pages":"1-2","tokens_est":128,"char_count":510,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0006","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Definitions","content_type":"text","pages":"2","tokens_est":162,"char_count":646,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0007","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Definitions","content_type":"text","pages":"2","tokens_est":234,"char_count":934,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0008","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Definitions","content_type":"text","pages":"2","tokens_est":125,"char_count":497,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0009","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Definitions","content_type":"text","pages":"2","tokens_est":237,"char_count":945,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0010","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Definitions","content_type":"text","pages":"2","tokens_est":247,"char_count":988,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0011","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Definitions","content_type":"text","pages":"2-3","tokens_est":100,"char_count":398,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0012","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 1. Introduction | 1.1 Rationale for systematic screening for TB disease","content_type":"text","pages":"3","tokens_est":202,"char_count":808,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0013","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 1. Introduction | 1.1 Rationale for systematic screening for TB disease","content_type":"text","pages":"3","tokens_est":245,"char_count":977,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0014","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 1. Introduction | 1.1 Rationale for systematic screening for TB disease","content_type":"text","pages":"3","tokens_est":63,"char_count":249,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0015","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 1. Introduction | 1.1 Rationale for systematic screening for TB disease","content_type":"text","pages":"3","tokens_est":129,"char_count":516,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0016","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 1. Introduction | 1.1 Rationale for systematic screening for TB disease","content_type":"text","pages":"3","tokens_est":200,"char_count":798,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0017","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 1. Introduction | 1.1 Rationale for systematic screening for TB disease | Recommendations in the WHO consolidated guidelines on tuberculosis. Module 2: screening  systematic screening for tuberculosis disease, 2021 | Screening for TB in targeted populations","content_type":"text","pages":"3-4","tokens_est":228,"char_count":912,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0018","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 1. Introduction | 1.1 Rationale for systematic screening for TB disease | Recommendations in the WHO consolidated guidelines on tuberculosis. Module 2: screening  systematic screening for tuberculosis disease, 2021 | Screening for TB in targeted populations","content_type":"text","pages":"4","tokens_est":243,"char_count":971,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0019","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 1. Introduction | 1.1 Rationale for systematic screening for TB disease | Recommendations in the WHO consolidated guidelines on tuberculosis. Module 2: screening  systematic screening for tuberculosis disease, 2021 | Screening for TB in targeted populations","content_type":"text","pages":"4","tokens_est":61,"char_count":244,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0020","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 1. Introduction | 1.1 Rationale for systematic screening for TB disease | Recommendations in the WHO consolidated guidelines on tuberculosis. Module 2: screening  systematic screening for tuberculosis disease, 2021 | Tools for screening for TB","content_type":"text","pages":"4","tokens_est":182,"char_count":728,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0021","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 1. Introduction | 1.1 Rationale for systematic screening for TB disease | Recommendations in the WHO consolidated guidelines on tuberculosis. Module 2: screening  systematic screening for tuberculosis disease, 2021 | Tools for screening for TB","content_type":"text","pages":"4","tokens_est":214,"char_count":854,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0022","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 1. Introduction | 1.1 Rationale for systematic screening for TB disease | Recommendations in the WHO consolidated guidelines on tuberculosis. Module 2: screening  systematic screening for tuberculosis disease, 2021 | Tools for screening for TB","content_type":"text","pages":"4-5","tokens_est":229,"char_count":914,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0023","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 1. Introduction | 1.1 Rationale for systematic screening for TB disease | Recommendations in the WHO consolidated guidelines on tuberculosis. Module 2: screening  systematic screening for tuberculosis disease, 2021 | Tools for screening for TB","content_type":"text","pages":"5","tokens_est":91,"char_count":363,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0024","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 1. Introduction | 1.2 Principles of TB screening","content_type":"text","pages":"5","tokens_est":160,"char_count":640,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0025","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 1. Introduction | 1.2 Principles of TB screening","content_type":"text","pages":"5","tokens_est":189,"char_count":754,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0026","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 1. Introduction | 1.2 Principles of TB screening","content_type":"text","pages":"5","tokens_est":199,"char_count":795,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0027","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 1. Introduction | 1.2 Principles of TB screening","content_type":"text","pages":"5","tokens_est":180,"char_count":717,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0028","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 1. Introduction | 1.3 Objectives of the operational handbook","content_type":"text","pages":"5-6","tokens_est":192,"char_count":765,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0029","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 1. Introduction | 1.3 Objectives of the operational handbook","content_type":"text","pages":"6","tokens_est":231,"char_count":924,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0030","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 1. Introduction | 1.3 Objectives of the operational handbook | Fig. 1.1 The six essential steps in the cycle of designing and implementing a TB screening programme","content_type":"figure","pages":"6","caption":"Fig. 1.1 The six essential steps in the cycle of designing and implementing a TB screening programme","tokens_est":28,"char_count":110,"has_attachment":true,"attachment_id":"Fig. 1.1","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. 1.1.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0031","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 1. Introduction | 1.3 Objectives of the operational handbook","content_type":"text","pages":"6","tokens_est":206,"char_count":821,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0032","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 1. Introduction | 1.3 Objectives of the operational handbook","content_type":"text","pages":"6","tokens_est":215,"char_count":860,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0033","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 1. Introduction | 1.3 Objectives of the operational handbook","content_type":"text","pages":"6","tokens_est":215,"char_count":857,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0034","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 1. Introduction | 1.3 Objectives of the operational handbook","content_type":"text","pages":"6","tokens_est":98,"char_count":390,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0035","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 1. Introduction | 1.3 Objectives of the operational handbook","content_type":"text","pages":"6","tokens_est":71,"char_count":281,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0036","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 1. Introduction | 1.4 Target audience of the operational handbook","content_type":"text","pages":"6","tokens_est":149,"char_count":594,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0037","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.1 Introduction","content_type":"text","pages":"6","tokens_est":221,"char_count":884,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0038","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.1 Introduction | Fig. 2.1 Comparison of the provider-initiated TB screening pathway with the patient- initiated health care pathway for TB","content_type":"figure","pages":"6","caption":"Fig. 2.1 Comparison of the provider-initiated TB screening pathway with the patient- initiated health care pathway for TB","tokens_est":33,"char_count":131,"has_attachment":true,"attachment_id":"Fig. 2.1","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. 2.1.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0039","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.1 Introduction | 2.1.1 Enhancing the patient-initiated pathway to TB diagnosis","content_type":"text","pages":"6","tokens_est":219,"char_count":876,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0040","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.1 Introduction | 2.1.1 Enhancing the patient-initiated pathway to TB diagnosis","content_type":"text","pages":"6-7","tokens_est":212,"char_count":847,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0041","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.1 Introduction | 2.1.1 Enhancing the patient-initiated pathway to TB diagnosis","content_type":"text","pages":"7","tokens_est":236,"char_count":943,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0042","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.1 Introduction | 2.1.1 Enhancing the patient-initiated pathway to TB diagnosis","content_type":"text","pages":"7","tokens_est":153,"char_count":609,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0043","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.1 Introduction | 2.1.2 The provider-initiated screening pathway to TB diagnosis","content_type":"text","pages":"7","tokens_est":223,"char_count":891,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0044","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.1 Introduction | 2.1.2 The provider-initiated screening pathway to TB diagnosis","content_type":"text","pages":"7","tokens_est":197,"char_count":785,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0045","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 1. Assessing the situation","content_type":"text","pages":"7-8","tokens_est":237,"char_count":948,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0046","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 1. Assessing the situation","content_type":"text","pages":"8","tokens_est":242,"char_count":967,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0047","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 1. Assessing the situation","content_type":"text","pages":"8","tokens_est":67,"char_count":265,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0048","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 1. Assessing the situation | Table 2.1 Questions to be addressed in a situation assessment before implementing screening for TB","content_type":"table","pages":"8-11","caption":"Table 2.1 Questions to be addressed in a situation assessment before implementing screening for TB","tokens_est":35,"char_count":150,"has_attachment":true,"attachment_id":"Table 2.1","attachment_path":"tables/WHO_TB_handbook_module2_screening_2021/Table_2.1.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0049","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 1. Assessing the situation | 2.2.1 Existing screening and outreach activities","content_type":"text","pages":"11","tokens_est":164,"char_count":655,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0050","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 1. Assessing the situation | 2.2.1 Existing screening and outreach activities","content_type":"text","pages":"11","tokens_est":155,"char_count":620,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0051","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 1. Assessing the situation | 2.2.1 Existing screening and outreach activities | Table 2.2 Services, programmes and stakeholders that could collaborate in systematic screening programmes for TB","content_type":"table","pages":"11-12","caption":"Table 2.2 lists the programmes, services and stakeholders that could collaborate in screening activities.","tokens_est":39,"char_count":164,"has_attachment":true,"attachment_id":"Table 2.2","attachment_path":"tables/WHO_TB_handbook_module2_screening_2021/Table_2.2.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0052","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 1. Assessing the situation | 2.2.2 Societal context","content_type":"text","pages":"12-13","tokens_est":215,"char_count":859,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0053","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 1. Assessing the situation | 2.2.2 Societal context","content_type":"text","pages":"13","tokens_est":111,"char_count":442,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0054","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 1. Assessing the situation | 2.2.2 Societal context","content_type":"text","pages":"13","tokens_est":175,"char_count":699,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0055","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 1. Assessing the situation | 2.2.3 Epidemiology of TB","content_type":"text","pages":"13","tokens_est":248,"char_count":992,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0056","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 1. Assessing the situation | 2.2.3 Epidemiology of TB","content_type":"text","pages":"13","tokens_est":130,"char_count":518,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0057","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 1. Assessing the situation | 2.2.3 Epidemiology of TB | Box 1. WHO sources of information on collecting and interpreting data","content_type":"box","pages":"13-14","caption":"Box 1. WHO sources of information on collecting and interpreting data","tokens_est":232,"char_count":927,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0058","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 1. Assessing the situation | 2.2.4 National TB programmes and the general health-care system","content_type":"text","pages":"14","tokens_est":242,"char_count":967,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0059","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 1. Assessing the situation | 2.2.4 National TB programmes and the general health-care system","content_type":"text","pages":"14","tokens_est":151,"char_count":601,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0060","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 1. Assessing the situation | 2.2.4 National TB programmes and the general health-care system","content_type":"text","pages":"14","tokens_est":236,"char_count":943,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0061","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 1. Assessing the situation | 2.2.4 National TB programmes and the general health-care system","content_type":"text","pages":"14","tokens_est":236,"char_count":944,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0062","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 1. Assessing the situation | 2.2.5 Health-care coverage and access to health services","content_type":"text","pages":"14-15","tokens_est":154,"char_count":616,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0063","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 1. Assessing the situation | 2.2.6 Protection from stigmatization, discrimination and harm","content_type":"text","pages":"15","tokens_est":120,"char_count":478,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0064","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 1. Assessing the situation | 2.2.6 Protection from stigmatization, discrimination and harm","content_type":"text","pages":"15","tokens_est":225,"char_count":900,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0065","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 1. Assessing the situation | 2.2.6 Protection from stigmatization, discrimination and harm","content_type":"text","pages":"15","tokens_est":59,"char_count":236,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0066","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2. Setting goals and specific objectives","content_type":"text","pages":"15","tokens_est":187,"char_count":746,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0067","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2. Setting goals and specific objectives","content_type":"text","pages":"15","tokens_est":207,"char_count":825,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0068","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 3. Identifying and prioritizing risk groups","content_type":"text","pages":"15-16","tokens_est":194,"char_count":775,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0069","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 3. Identifying and prioritizing risk groups","content_type":"text","pages":"16","tokens_est":216,"char_count":863,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0070","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 3. Identifying and prioritizing risk groups","content_type":"text","pages":"16","tokens_est":54,"char_count":213,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0071","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 3. Identifying and prioritizing risk groups | Table 2.3 Additional risk groups to be considered for TB screening","content_type":"table","pages":"16","caption":"Table 2.3 Additional risk groups to be considered for TB screening","tokens_est":30,"char_count":127,"has_attachment":true,"attachment_id":"Table 2.3","attachment_path":"tables/WHO_TB_handbook_module2_screening_2021/Table_2.3.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0072","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 3. Identifying and prioritizing risk groups","content_type":"text","pages":"16","tokens_est":215,"char_count":858,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0073","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 3. Identifying and prioritizing risk groups","content_type":"text","pages":"16","tokens_est":184,"char_count":733,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0074","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 3. Identifying and prioritizing risk groups | 2.4.1 Potential benefits for the individual","content_type":"text","pages":"16","tokens_est":225,"char_count":900,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0075","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 3. Identifying and prioritizing risk groups | 2.4.2 Potential risks and harms for the individual","content_type":"text","pages":"16-17","tokens_est":198,"char_count":790,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0076","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 3. Identifying and prioritizing risk groups | 2.4.2 Potential risks and harms for the individual","content_type":"text","pages":"16-17","tokens_est":77,"char_count":307,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0077","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 3. Identifying and prioritizing risk groups | 2.4.2 Potential risks and harms for the individual","content_type":"text","pages":"17","tokens_est":198,"char_count":791,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0078","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 3. Identifying and prioritizing risk groups | 2.4.2 Potential risks and harms for the individual","content_type":"text","pages":"17","tokens_est":86,"char_count":343,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0079","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 3. Identifying and prioritizing risk groups | 2.4.3 Potential impact on prevalence and transmission","content_type":"text","pages":"17","tokens_est":191,"char_count":764,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0080","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 3. Identifying and prioritizing risk groups | 2.4.4 Potential total yield of true TB cases","content_type":"text","pages":"17","tokens_est":178,"char_count":712,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0081","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 3. Identifying and prioritizing risk groups | 2.4.4 Potential total yield of true TB cases | Fig. 2.2 Potential yield of screening as a function of the prevalence of the risk factor in the population and the relative risk of TB in the risk group (baseline incidence, 1000 cases in a population of 1 000 000)","content_type":"figure","pages":"17","caption":"Fig. 2.2 Potential yield of screening as a function of the prevalence of the risk factor in the population and the relative risk of TB in the risk group (baseline incidence, 1000 cases in a population of 1 000 000)","tokens_est":56,"char_count":224,"has_attachment":true,"attachment_id":"Fig. 2.2","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. 2.2.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0082","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 3. Identifying and prioritizing risk groups | 2.4.4 Potential total yield of true TB cases","content_type":"text","pages":"17","tokens_est":187,"char_count":747,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0083","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 3. Identifying and prioritizing risk groups | 2.4.4 Potential total yield of true TB cases","content_type":"text","pages":"17","tokens_est":245,"char_count":978,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0084","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 3. Identifying and prioritizing risk groups | 2.4.4 Potential total yield of true TB cases | Table 2.4 Number needed to screen (NNS) for TB disease in general populations and in community-based screening","content_type":"table","pages":"17","caption":"Table 2.4 Number needed to screen (NNS) for TB disease in general populations and in community-based screening","tokens_est":49,"char_count":352,"has_attachment":true,"attachment_id":"Table 2.4","attachment_path":"tables/WHO_TB_handbook_module2_screening_2021/Table_2.4.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0085","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 3. Identifying and prioritizing risk groups | 2.4.5 Number needed to screen to detect a person with TB","content_type":"text","pages":"17-18","tokens_est":184,"char_count":734,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0086","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 3. Identifying and prioritizing risk groups | 2.4.5 Number needed to screen to detect a person with TB | Fig. 2.3 The number needed to screen (NNS) in order to diagnose one person with TB in any given risk group is roughly the inverse of the prevalence of the disease in that risk group","content_type":"figure","pages":"18","caption":"Fig. 2.3 The number needed to screen (NNS) in order to diagnose one person with TB in any given risk group is roughly the inverse of the prevalence of the disease in that risk group","tokens_est":48,"char_count":191,"has_attachment":true,"attachment_id":"Fig. 2.3","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. 2.3.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0087","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 3. Identifying and prioritizing risk groups | 2.4.5 Number needed to screen to detect a person with TB","content_type":"text","pages":"18","tokens_est":207,"char_count":825,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0088","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 3. Identifying and prioritizing risk groups | 2.4.5 Number needed to screen to detect a person with TB","content_type":"text","pages":"18","tokens_est":157,"char_count":627,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0089","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 3. Identifying and prioritizing risk groups | 2.4.6 Costeffectiveness and costbenefit analyses","content_type":"text","pages":"18","tokens_est":159,"char_count":636,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0090","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 3. Identifying and prioritizing risk groups | 2.4.6 Costeffectiveness and costbenefit analyses","content_type":"text","pages":"18","tokens_est":104,"char_count":416,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0091","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.5 Choosing algorithms for screening and diagnosis","content_type":"text","pages":"18","tokens_est":86,"char_count":341,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0092","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.6 Planning, budgeting and implementing | 2.6.1 Requirements for planning, human resources, commodities and budgeting","content_type":"text","pages":"19","tokens_est":95,"char_count":379,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0093","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.6 Planning, budgeting and implementing | 2.6.1 Requirements for planning, human resources, commodities and budgeting","content_type":"text","pages":"19","tokens_est":235,"char_count":939,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0094","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.6 Planning, budgeting and implementing | 2.6.1 Requirements for planning, human resources, commodities and budgeting","content_type":"text","pages":"19","tokens_est":220,"char_count":877,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0095","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.6 Planning, budgeting and implementing | 2.6.2 Choosing a screening programme model","content_type":"text","pages":"19","tokens_est":150,"char_count":599,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0096","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.6 Planning, budgeting and implementing | 2.6.2 Choosing a screening programme model","content_type":"text","pages":"19","tokens_est":173,"char_count":690,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0097","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.6 Planning, budgeting and implementing | 2.6.2 Choosing a screening programme model | Fig. 2.4 Screening programme models","content_type":"figure","pages":"19","caption":"Fig. 2.4 Screening programme models","tokens_est":12,"char_count":45,"has_attachment":true,"attachment_id":"Fig. 2.4","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. 2.4.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0098","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.6 Planning, budgeting and implementing | 2.6.3 Ethical considerations","content_type":"text","pages":"19","tokens_est":118,"char_count":470,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0099","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.6 Planning, budgeting and implementing | 2.6.3 Ethical considerations","content_type":"text","pages":"19-20","tokens_est":233,"char_count":929,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0100","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.6 Planning, budgeting and implementing | 2.6.3 Ethical considerations","content_type":"text","pages":"19-20","tokens_est":32,"char_count":127,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0101","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.6 Planning, budgeting and implementing | 2.6.3 Ethical considerations","content_type":"text","pages":"20","tokens_est":99,"char_count":394,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0102","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.6 Planning, budgeting and implementing | 2.6.4 Involving stakeholders and partner organizations and establishing roles","content_type":"text","pages":"20","tokens_est":151,"char_count":601,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0103","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.6 Planning, budgeting and implementing | 2.6.4 Involving stakeholders and partner organizations and establishing roles","content_type":"text","pages":"20","tokens_est":138,"char_count":551,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0104","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.6 Planning, budgeting and implementing | 2.6.5 Mobilizing resources","content_type":"text","pages":"20","tokens_est":226,"char_count":901,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0105","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.6 Planning, budgeting and implementing | 2.6.6 Pilot-testing","content_type":"text","pages":"20","tokens_est":129,"char_count":514,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0106","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.7 Monitoring, evaluating and modifying the programme","content_type":"text","pages":"20-21","tokens_est":228,"char_count":910,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0107","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.7 Monitoring, evaluating and modifying the programme","content_type":"text","pages":"21","tokens_est":175,"char_count":699,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0108","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.7 Monitoring, evaluating and modifying the programme","content_type":"text","pages":"21","tokens_est":165,"char_count":659,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0109","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.7 Monitoring, evaluating and modifying the programme | 2.7.1 Developing a plan for monitoring and evaluation","content_type":"text","pages":"21","tokens_est":196,"char_count":782,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0110","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.7 Monitoring, evaluating and modifying the programme | 2.7.2 Proposed indicators","content_type":"text","pages":"21","tokens_est":87,"char_count":347,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0111","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.7 Monitoring, evaluating and modifying the programme | 2.7.2 Proposed indicators | Fig. 2.5 Data to be collected for systematic screening programmes for TB","content_type":"figure","pages":"21","caption":"Fig. 2.5 Data to be collected for systematic screening programmes for TB","tokens_est":21,"char_count":82,"has_attachment":true,"attachment_id":"Fig. 2.5","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. 2.5.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0112","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.7 Monitoring, evaluating and modifying the programme | 2.7.2 Proposed indicators","content_type":"text","pages":"21-22","tokens_est":201,"char_count":803,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0113","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.7 Monitoring, evaluating and modifying the programme | 2.7.2 Proposed indicators","content_type":"text","pages":"22","tokens_est":194,"char_count":774,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0114","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.7 Monitoring, evaluating and modifying the programme | 2.7.2 Proposed indicators","content_type":"text","pages":"22","tokens_est":90,"char_count":359,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0115","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.7 Monitoring, evaluating and modifying the programme | 2.7.2 Proposed indicators","content_type":"text","pages":"22","tokens_est":76,"char_count":303,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0116","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.7 Monitoring, evaluating and modifying the programme | 2.7.2 Proposed indicators","content_type":"text","pages":"22","tokens_est":196,"char_count":784,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0117","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.7 Monitoring, evaluating and modifying the programme | 2.7.2 Proposed indicators","content_type":"text","pages":"22","tokens_est":165,"char_count":660,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0118","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.7 Monitoring, evaluating and modifying the programme | 2.7.2 Proposed indicators","content_type":"text","pages":"22","tokens_est":234,"char_count":933,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0119","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.7 Monitoring, evaluating and modifying the programme | 2.7.3 Routines for recording and reporting","content_type":"text","pages":"22-23","tokens_est":199,"char_count":796,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0120","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.7 Monitoring, evaluating and modifying the programme | 2.7.3 Routines for recording and reporting","content_type":"text","pages":"23","tokens_est":173,"char_count":692,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0121","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.7 Monitoring, evaluating and modifying the programme | 2.7.3 Routines for recording and reporting","content_type":"text","pages":"23","tokens_est":98,"char_count":390,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0122","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.7 Monitoring, evaluating and modifying the programme | 2.7.4 Programmatic evaluations","content_type":"text","pages":"23","tokens_est":180,"char_count":717,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0123","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.7 Monitoring, evaluating and modifying the programme | 2.7.4 Programmatic evaluations","content_type":"text","pages":"23","tokens_est":129,"char_count":513,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0124","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.7 Monitoring, evaluating and modifying the programme | 2.7.5 Monitoring time trends for re-screening and re-prioritization","content_type":"text","pages":"23","tokens_est":234,"char_count":934,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0125","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 2. The six steps in the planning and implementation cycle | 2.7 Monitoring, evaluating and modifying the programme | 2.7.5 Monitoring time trends for re-screening and re-prioritization","content_type":"text","pages":"23","tokens_est":44,"char_count":175,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0126","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms","content_type":"text","pages":"23","tokens_est":53,"char_count":209,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0127","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools","content_type":"text","pages":"24","tokens_est":147,"char_count":586,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0128","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools","content_type":"text","pages":"24","tokens_est":171,"char_count":682,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0129","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools","content_type":"text","pages":"24","tokens_est":247,"char_count":988,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0130","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools","content_type":"text","pages":"24","tokens_est":47,"char_count":188,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0131","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | Table 3.1 Diagnostic accuracy of symptoms, CXR and mWRDs for screening for TB disease among HIV-negative individuals *","content_type":"table","pages":"24","caption":"Table 3.1 Diagnostic accuracy of symptoms, CXR and mWRDs for screening for TB disease among HIV-negative individuals *","tokens_est":45,"char_count":335,"has_attachment":true,"attachment_id":"Table 3.1","attachment_path":"tables/WHO_TB_handbook_module2_screening_2021/Table_3.1.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0132","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | 3.1.1 Symptom screening","content_type":"text","pages":"24-25","tokens_est":237,"char_count":948,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0133","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | 3.1.1 Symptom screening","content_type":"text","pages":"24-25","tokens_est":30,"char_count":119,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0134","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | 3.1.1 Symptom screening | Cough","content_type":"text","pages":"25","tokens_est":153,"char_count":612,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0135","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | 3.1.1 Symptom screening | Cough","content_type":"text","pages":"25","tokens_est":113,"char_count":449,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0136","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | 3.1.1 Symptom screening | Any TB symptom","content_type":"text","pages":"25","tokens_est":182,"char_count":728,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0137","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | 3.1.2 CXR screening","content_type":"text","pages":"25","tokens_est":138,"char_count":550,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0138","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | 3.1.2 CXR screening","content_type":"text","pages":"25","tokens_est":151,"char_count":604,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0139","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | 3.1.2 CXR screening","content_type":"text","pages":"25","tokens_est":152,"char_count":605,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0140","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | 3.1.2 CXR screening | Implementation considerations for CXR as a screening tool | Equipment and resources","content_type":"text","pages":"26","tokens_est":114,"char_count":455,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0141","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | 3.1.2 CXR screening | Implementation considerations for CXR as a screening tool | Digital technology","content_type":"text","pages":"26","tokens_est":212,"char_count":848,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0142","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | 3.1.2 CXR screening | Implementation considerations for CXR as a screening tool | Skilled CXR reading and interpretation and appropriate follow-up","content_type":"text","pages":"26","tokens_est":183,"char_count":732,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0143","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | 3.1.2 CXR screening | Implementation considerations for CXR as a screening tool | Access","content_type":"text","pages":"26","tokens_est":97,"char_count":388,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0144","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | 3.1.2 CXR screening | Implementation considerations for CXR as a screening tool | Safety of radiation","content_type":"text","pages":"26","tokens_est":186,"char_count":744,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0145","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | 3.1.2 CXR screening | Implementation considerations for CXR as a screening tool | Safety of radiation","content_type":"text","pages":"26-27","tokens_est":228,"char_count":912,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0146","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | 3.1.2 CXR screening | Implementation considerations for CXR as a screening tool | Safety of radiation","content_type":"text","pages":"27","tokens_est":44,"char_count":174,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0147","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | 3.1.3 CAD technologies for screening and triage","content_type":"text","pages":"27","tokens_est":131,"char_count":521,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0148","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | 3.1.3 CAD technologies for screening and triage","content_type":"text","pages":"27","tokens_est":160,"char_count":640,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0149","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | 3.1.3 CAD technologies for screening and triage","content_type":"text","pages":"27","tokens_est":192,"char_count":768,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0150","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | 3.1.3 CAD technologies for screening and triage","content_type":"text","pages":"27","tokens_est":157,"char_count":626,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0151","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | 3.1.3 CAD technologies for screening and triage","content_type":"text","pages":"27","tokens_est":193,"char_count":769,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0152","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | 3.1.3 CAD technologies for screening and triage | Considerations for implementing CAD technology for screening or triage","content_type":"text","pages":"27-28","tokens_est":198,"char_count":789,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0153","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | 3.1.3 CAD technologies for screening and triage | Considerations for implementing CAD technology for screening or triage","content_type":"text","pages":"28","tokens_est":226,"char_count":903,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0154","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | 3.1.4 Molecular WHO-recommended rapid diagnostics for screening","content_type":"text","pages":"28","tokens_est":125,"char_count":499,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0155","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | 3.1.4 Molecular WHO-recommended rapid diagnostics for screening","content_type":"text","pages":"28","tokens_est":216,"char_count":863,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0156","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | 3.1.4 Molecular WHO-recommended rapid diagnostics for screening","content_type":"text","pages":"28","tokens_est":54,"char_count":214,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0157","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | 3.1.4 Molecular WHO-recommended rapid diagnostics for screening","content_type":"text","pages":"28","tokens_est":218,"char_count":870,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0158","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | 3.1.4 Molecular WHO-recommended rapid diagnostics for screening | Considerations for using mWRDs for screening","content_type":"text","pages":"28","tokens_est":123,"char_count":491,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0159","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | 3.1.4 Molecular WHO-recommended rapid diagnostics for screening | Considerations for using mWRDs for screening","content_type":"text","pages":"28-29","tokens_est":233,"char_count":931,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0160","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | 3.1.4 Molecular WHO-recommended rapid diagnostics for screening | Considerations for using mWRDs for screening","content_type":"text","pages":"28-29","tokens_est":53,"char_count":211,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0161","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.1 Screening tools | 3.1.5 Tests of TB infection","content_type":"text","pages":"29","tokens_est":90,"char_count":357,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0162","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.2 Algorithms for screening | 3.2.1 Basic features of TB screening and diagnostic algorithms","content_type":"text","pages":"29","tokens_est":169,"char_count":676,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0163","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.2 Algorithms for screening | 3.2.1 Basic features of TB screening and diagnostic algorithms","content_type":"text","pages":"29","tokens_est":126,"char_count":504,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0164","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.2 Algorithms for screening | 3.2.1 Basic features of TB screening and diagnostic algorithms","content_type":"text","pages":"29","tokens_est":192,"char_count":766,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0165","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.2 Algorithms for screening | 3.2.1 Basic features of TB screening and diagnostic algorithms","content_type":"text","pages":"29","tokens_est":78,"char_count":312,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0166","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.2 Algorithms for screening | 3.2.1 Basic features of TB screening and diagnostic algorithms","content_type":"text","pages":"29","tokens_est":224,"char_count":895,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0167","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.2 Algorithms for screening | 3.2.1 Basic features of TB screening and diagnostic algorithms","content_type":"text","pages":"29-30","tokens_est":202,"char_count":805,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0168","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.2 Algorithms for screening | 3.2.1 Basic features of TB screening and diagnostic algorithms","content_type":"text","pages":"29-30","tokens_est":160,"char_count":638,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0169","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.2 Algorithms for screening | 3.2.2 Screening and diagnostic algorithm options","content_type":"text","pages":"30","tokens_est":115,"char_count":457,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0170","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.2 Algorithms for screening | 3.2.2 Screening and diagnostic algorithm options","content_type":"text","pages":"30","tokens_est":151,"char_count":601,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0171","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.2 Algorithms for screening | 3.2.2 Screening and diagnostic algorithm options","content_type":"text","pages":"30","tokens_est":166,"char_count":663,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0172","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.2 Algorithms for screening | 3.2.2 Screening and diagnostic algorithm options","content_type":"text","pages":"30","tokens_est":248,"char_count":992,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0173","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.2 Algorithms for screening | 3.2.2 Screening and diagnostic algorithm options","content_type":"text","pages":"30-31","tokens_est":225,"char_count":900,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0174","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.2 Algorithms for screening | 3.2.2 Screening and diagnostic algorithm options","content_type":"text","pages":"31","tokens_est":130,"char_count":519,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0175","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.2 Algorithms for screening | 3.2.3. Choosing an algorithm for a screening programme","content_type":"text","pages":"31","tokens_est":123,"char_count":490,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0176","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.2 Algorithms for screening | 3.2.3. Choosing an algorithm for a screening programme","content_type":"text","pages":"31","tokens_est":198,"char_count":792,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0177","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.2 Algorithms for screening | 3.2.3. Choosing an algorithm for a screening programme","content_type":"text","pages":"31","tokens_est":135,"char_count":539,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0178","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.2 Algorithms for screening | 3.2.3. Choosing an algorithm for a screening programme","content_type":"text","pages":"31","tokens_est":236,"char_count":943,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0179","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.2 Algorithms for screening | 3.2.3. Choosing an algorithm for a screening programme","content_type":"text","pages":"31-32","tokens_est":65,"char_count":258,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0180","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.2 Algorithms for screening | 3.2.3. Choosing an algorithm for a screening programme","content_type":"text","pages":"32","tokens_est":226,"char_count":904,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0181","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.2 Algorithms for screening | 3.2.3. Choosing an algorithm for a screening programme","content_type":"text","pages":"32","tokens_est":125,"char_count":500,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0182","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.2 Algorithms for screening | 3.2.3. Choosing an algorithm for a screening programme","content_type":"text","pages":"32","tokens_est":250,"char_count":999,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0183","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.2 Algorithms for screening | 3.2.3. Choosing an algorithm for a screening programme","content_type":"text","pages":"32","tokens_est":37,"char_count":146,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0184","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.2 Algorithms for screening | 3.2.3. Choosing an algorithm for a screening programme | Considerations for algorithms for risk groups","content_type":"text","pages":"32","tokens_est":109,"char_count":435,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0185","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.2 Algorithms for screening | 3.2.3. Choosing an algorithm for a screening programme | Considerations for algorithms for risk groups | Contacts","content_type":"text","pages":"32","tokens_est":237,"char_count":946,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0186","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.2 Algorithms for screening | 3.2.3. Choosing an algorithm for a screening programme | Considerations for algorithms for risk groups | Miners","content_type":"text","pages":"32","tokens_est":107,"char_count":428,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0187","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.2 Algorithms for screening | 3.2.3. Choosing an algorithm for a screening programme | Considerations for algorithms for risk groups | Prisoners","content_type":"text","pages":"32-33","tokens_est":108,"char_count":429,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0188","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.2 Algorithms for screening | 3.2.3. Choosing an algorithm for a screening programme | Considerations for algorithms for risk groups | People with clinical risk factors","content_type":"text","pages":"33","tokens_est":111,"char_count":442,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0189","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.2 Algorithms for screening | 3.2.3. Choosing an algorithm for a screening programme | Considerations for algorithms for risk groups | General population and communities with structural risk factors","content_type":"text","pages":"33","tokens_est":196,"char_count":783,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0190","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 3. Screening tools and algorithms | 3.3. ScreenTB tool","content_type":"text","pages":"33","tokens_est":208,"char_count":830,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0191","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 4. Implementation of CAD technologies in a new setting | 4.1 Considerations in selecting and using CAD for screening in TB programmes","content_type":"text","pages":"33-34","tokens_est":221,"char_count":883,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0192","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 4. Implementation of CAD technologies in a new setting | 4.1 Considerations in selecting and using CAD for screening in TB programmes","content_type":"text","pages":"34","tokens_est":221,"char_count":881,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0193","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 4. Implementation of CAD technologies in a new setting | 4.1 Considerations in selecting and using CAD for screening in TB programmes","content_type":"text","pages":"34","tokens_est":132,"char_count":528,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0194","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 4. Implementation of CAD technologies in a new setting | 4.1 Considerations in selecting and using CAD for screening in TB programmes","content_type":"text","pages":"34","tokens_est":175,"char_count":698,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0195","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 4. Implementation of CAD technologies in a new setting | 4.1 Considerations in selecting and using CAD for screening in TB programmes","content_type":"text","pages":"34","tokens_est":179,"char_count":716,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0196","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 4. Implementation of CAD technologies in a new setting | 4.1 Considerations in selecting and using CAD for screening in TB programmes","content_type":"text","pages":"34","tokens_est":149,"char_count":594,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0197","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 4. Implementation of CAD technologies in a new setting | 4.1 Considerations in selecting and using CAD for screening in TB programmes | Fig. 4.1 Sensitivity vs specificity over the CAD threshold spectrum","content_type":"figure","pages":"34","caption":"Fig. 4.1 Sensitivity vs specificity over the CAD threshold spectrum","tokens_est":20,"char_count":77,"has_attachment":true,"attachment_id":"Fig. 4.1","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. 4.1.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0198","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 4. Implementation of CAD technologies in a new setting | 4.1 Considerations in selecting and using CAD for screening in TB programmes","content_type":"text","pages":"34-35","tokens_est":184,"char_count":734,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0199","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 4. Implementation of CAD technologies in a new setting | 4.1 Considerations in selecting and using CAD for screening in TB programmes","content_type":"text","pages":"35","tokens_est":157,"char_count":628,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0200","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 4. Implementation of CAD technologies in a new setting | 4.2 Toolkit for CAD calibration to enable implementation","content_type":"text","pages":"35","tokens_est":226,"char_count":904,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0201","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 4. Implementation of CAD technologies in a new setting | 4.2 Toolkit for CAD calibration to enable implementation","content_type":"text","pages":"35","tokens_est":165,"char_count":659,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0202","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 4. Implementation of CAD technologies in a new setting | 4.2 Toolkit for CAD calibration to enable implementation","content_type":"text","pages":"35","tokens_est":164,"char_count":653,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0203","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 4. Implementation of CAD technologies in a new setting | 4.3 Online tool for calibration of CAD in a new setting","content_type":"text","pages":"35-36","tokens_est":248,"char_count":992,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0204","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 4. Implementation of CAD technologies in a new setting | 4.3 Online tool for calibration of CAD in a new setting","content_type":"text","pages":"35-36","tokens_est":100,"char_count":398,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0205","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV","content_type":"text","pages":"36","tokens_est":57,"char_count":225,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0206","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.1 Introduction","content_type":"text","pages":"36","tokens_est":166,"char_count":661,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0207","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.1 Introduction","content_type":"text","pages":"36","tokens_est":219,"char_count":874,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0208","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.1 Introduction","content_type":"text","pages":"36","tokens_est":201,"char_count":801,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0209","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.1 Introduction","content_type":"text","pages":"36-37","tokens_est":235,"char_count":937,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0210","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.1 Introduction","content_type":"text","pages":"37","tokens_est":147,"char_count":585,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0211","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.2 Screening tools | 5.2.1 WHO-recommended four-symptom screen","content_type":"text","pages":"37","tokens_est":181,"char_count":724,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0212","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.2 Screening tools | 5.2.1 WHO-recommended four-symptom screen | Table 5.1 Diagnostic accuracy of W4SS in different subpopulations of adults and adolescents with HIV","content_type":"table","pages":"37","caption":"Table 5.1 shows the accuracy of W4SS in different sub-populations of adults and adolescents living with HIV. The latest evidence review for the 2021 guidelines showed that W4SS has relatively high sensitivity in adults and adolescents living with HIV, 83%, but low specificity, 38%. The sensitivity of W4SS among outpatients on ART is relatively low, 53%, indicating that W4SS alone would not be sufficient to detect TB among people in regular ART care. W4SS also has low sensitivity in pregnant women living with HIV. It is relatively sensitive in outpatients not on ART (84%), indicating that W4SS is useful in finding people with TB among people who are starting HIV care, but the lack of specificity has implications for resources and rational use of diagnostic testing.","tokens_est":208,"char_count":941,"has_attachment":true,"attachment_id":"Table 5.1","attachment_path":"tables/WHO_TB_handbook_module2_screening_2021/Table_5.1.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0213","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.2 Screening tools | 5.2.1 WHO-recommended four-symptom screen","content_type":"text","pages":"37-38","tokens_est":100,"char_count":398,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0214","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.2 Screening tools | 5.2.1 WHO-recommended four-symptom screen","content_type":"text","pages":"38","tokens_est":180,"char_count":718,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0215","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.2 Screening tools | 5.2.2 C-reactive protein (CRP)","content_type":"text","pages":"38","tokens_est":209,"char_count":834,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0216","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.2 Screening tools | 5.2.2 C-reactive protein (CRP)","content_type":"text","pages":"38","tokens_est":243,"char_count":971,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0217","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.2 Screening tools | 5.2.2 C-reactive protein (CRP)","content_type":"text","pages":"38","tokens_est":26,"char_count":104,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0218","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.2 Screening tools | 5.2.2 C-reactive protein (CRP)","content_type":"text","pages":"38","tokens_est":164,"char_count":655,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0219","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.2 Screening tools | 5.2.2 C-reactive protein (CRP) | Table 5.2 Accuracy of CRP with cut-off values of > 5 mg/L and > 10 mg/L compared with a culture reference standard","content_type":"table","pages":"38-39","caption":"Table 5.2 Accuracy of CRP with cut-off values of > 5 mg/L and > 10 mg/L compared with a culture reference standard","tokens_est":70,"char_count":387,"has_attachment":true,"attachment_id":"Table 5.2","attachment_path":"tables/WHO_TB_handbook_module2_screening_2021/Table_5.2.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0220","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.2 Screening tools | 1. Chest X- ray","content_type":"text","pages":"39","tokens_est":206,"char_count":821,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0221","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.2 Screening tools | 1. Chest X- ray | Table 5.3 Diagnostic accuracy of W4SS combined with CXR (any abnormality) in different subpopulations of people living with HIV as compared with a culture reference standard, with a positive or abnormal result on either or both screens","content_type":"table","pages":"39","caption":"Table 5.3 shows the diagnostic accuracy of CXR combined with W4SS in different sub-populations of people living with HIV. A combined screening strategy of W4SS and CXR offers a significant improvement in sensitivity, particularly for screening outpatients enrolled in ART care, over W4SS alone, although with lower specificity (W4SS: sensitivity 53%, specificity 70%). However, in some subgroups like inpatients and people with advanced HIV disease the specificity is very low.","tokens_est":134,"char_count":644,"has_attachment":true,"attachment_id":"Table 5.3","attachment_path":"tables/WHO_TB_handbook_module2_screening_2021/Table_5.3.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0222","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.2 Screening tools | 2. WHO-recommended rapid molecular diagnostic tests","content_type":"text","pages":"39-40","tokens_est":213,"char_count":851,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0223","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.2 Screening tools | 2. WHO-recommended rapid molecular diagnostic tests | Table 5.4 Diagnostic accuracy of mWRD for screening for TB in different subpopulations of people living with HIV as compared with a culture reference standard","content_type":"table","pages":"40","caption":"Table 5.4 shows the accuracy of mWRD screening in different sub-populations of adults and adolescents living with HIV. The overall sensitivity of mWRD in all people living with HIV is estimated to be 69% and the specificity 98%, while W4SS followed by a mWRD is estimated to have a sensitivity of 62% and a specificity of 99% (see Web Annex B of the guidelines). The accuracy of mWRD in most sub- populations is not significantly different from that of W4SS followed by mWRD.","tokens_est":133,"char_count":642,"has_attachment":true,"attachment_id":"Table 5.4","attachment_path":"tables/WHO_TB_handbook_module2_screening_2021/Table_5.4.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0224","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.3 Considerations for use of all screening tools","content_type":"text","pages":"40","tokens_est":206,"char_count":821,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0225","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.3 Considerations for use of all screening tools","content_type":"text","pages":"40","tokens_est":247,"char_count":987,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0226","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.3 Considerations for use of all screening tools","content_type":"text","pages":"40-41","tokens_est":99,"char_count":396,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0227","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.3 Considerations for use of all screening tools | Implementation considerations for CXR | Interpretation of CXR images for people living with HIV","content_type":"text","pages":"41","tokens_est":85,"char_count":340,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0228","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.3 Considerations for use of all screening tools | Implementation considerations for CXR | Periodicity of CXR screening","content_type":"text","pages":"41","tokens_est":156,"char_count":621,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0229","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.3 Considerations for use of all screening tools | Implementation considerations for CXR | Service delivery","content_type":"text","pages":"41","tokens_est":135,"char_count":540,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0230","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.3 Considerations for use of all screening tools | Implementation considerations for CRP | Choice of cut-off value","content_type":"text","pages":"41","tokens_est":123,"char_count":492,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0231","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.3 Considerations for use of all screening tools | Implementation considerations for CRP | Requirements and service delivery","content_type":"text","pages":"41","tokens_est":208,"char_count":829,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0232","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.3 Considerations for use of all screening tools | Implementation considerations for CRP | Requirements and service delivery","content_type":"text","pages":"41-42","tokens_est":202,"char_count":808,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0233","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.3 Considerations for use of all screening tools | Implementation considerations for mWRD | Resource requirements","content_type":"text","pages":"42","tokens_est":76,"char_count":303,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0234","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.3 Considerations for use of all screening tools | Implementation considerations for mWRD | Service delivery","content_type":"text","pages":"42","tokens_est":204,"char_count":814,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0235","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.4 Algorithms for screening","content_type":"text","pages":"42","tokens_est":105,"char_count":417,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0236","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.4 Algorithms for screening","content_type":"text","pages":"42","tokens_est":183,"char_count":731,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0237","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.4 Algorithms for screening","content_type":"text","pages":"42","tokens_est":164,"char_count":656,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0238","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 5. Screening for tuberculosis disease among adults and adolescents living with HIV | 5.4 Algorithms for screening | Algorithm options","content_type":"text","pages":"42","tokens_est":207,"char_count":828,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0239","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 6. Screening for tuberculosis disease in children","content_type":"text","pages":"42","tokens_est":35,"char_count":140,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0240","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 6. Screening for tuberculosis disease in children | 6.1 Introduction","content_type":"text","pages":"42","tokens_est":215,"char_count":859,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0241","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 6. Screening for tuberculosis disease in children | 6.1 Introduction","content_type":"text","pages":"42","tokens_est":155,"char_count":620,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0242","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 6. Screening for tuberculosis disease in children | 6.1 Introduction","content_type":"text","pages":"42","tokens_est":168,"char_count":671,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0243","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 6. Screening for tuberculosis disease in children | 6.2 Screening child contacts of patients with TB","content_type":"text","pages":"42-43","tokens_est":241,"char_count":962,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0244","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 6. Screening for tuberculosis disease in children | 6.2 Screening child contacts of patients with TB","content_type":"text","pages":"43","tokens_est":69,"char_count":274,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0245","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 6. Screening for tuberculosis disease in children | 6.2 Screening child contacts of patients with TB | 6.2.1 Symptom screening","content_type":"text","pages":"43","tokens_est":229,"char_count":916,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0246","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 6. Screening for tuberculosis disease in children | 6.2 Screening child contacts of patients with TB | 6.2.1 Symptom screening","content_type":"text","pages":"43","tokens_est":231,"char_count":923,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0247","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 6. Screening for tuberculosis disease in children | 6.2 Screening child contacts of patients with TB | 6.2.1 Symptom screening","content_type":"text","pages":"43","tokens_est":49,"char_count":193,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0248","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 6. Screening for tuberculosis disease in children | 6.2 Screening child contacts of patients with TB | 6.2.2 CXR","content_type":"text","pages":"43","tokens_est":105,"char_count":417,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0249","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 6. Screening for tuberculosis disease in children | 6.2 Screening child contacts of patients with TB | 6.2.2 CXR","content_type":"text","pages":"43","tokens_est":234,"char_count":936,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0250","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 6. Screening for tuberculosis disease in children | 6.2 Screening child contacts of patients with TB | 6.2.2 CXR","content_type":"text","pages":"43","tokens_est":109,"char_count":435,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0251","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 6. Screening for tuberculosis disease in children | 6.2 Screening child contacts of patients with TB | 6.2.2 CXR","content_type":"text","pages":"43-44","tokens_est":233,"char_count":931,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0252","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 6. Screening for tuberculosis disease in children | 6.2 Screening child contacts of patients with TB | 6.2.3 WHO-recommended rapid molecular diagnostic tests","content_type":"text","pages":"44","tokens_est":36,"char_count":144,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0253","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 6. Screening for tuberculosis disease in children | 6.2 Screening child contacts of patients with TB | 6.2.4 Tests of TB infection","content_type":"text","pages":"44","tokens_est":121,"char_count":482,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0254","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 6. Screening for tuberculosis disease in children | 6.2 Screening child contacts of patients with TB | 6.2.5 Considerations for implementation","content_type":"text","pages":"44","tokens_est":188,"char_count":750,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0255","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 6. Screening for tuberculosis disease in children | 6.2 Screening child contacts of patients with TB | 6.2.5 Considerations for implementation","content_type":"text","pages":"44","tokens_est":157,"char_count":625,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0256","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 6. Screening for tuberculosis disease in children | 6.2 Screening child contacts of patients with TB | 6.2.5 Considerations for implementation","content_type":"text","pages":"44","tokens_est":148,"char_count":592,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0257","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 6. Screening for tuberculosis disease in children | 6.2 Screening child contacts of patients with TB | 6.2.5 Considerations for implementation","content_type":"text","pages":"44","tokens_est":168,"char_count":671,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0258","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 6. Screening for tuberculosis disease in children | 6.3 Screening children living with HIV","content_type":"text","pages":"44-45","tokens_est":124,"char_count":495,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0259","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 6. Screening for tuberculosis disease in children | 6.3 Screening children living with HIV | 6.3.1 Screening for symptoms and contact","content_type":"text","pages":"45","tokens_est":241,"char_count":961,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0260","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 6. Screening for tuberculosis disease in children | 6.3 Screening children living with HIV | 6.3.2 Other screening tests","content_type":"text","pages":"45","tokens_est":62,"char_count":246,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0261","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 6. Screening for tuberculosis disease in children | 6.3 Screening children living with HIV | 6.3.3 Considerations for implementation","content_type":"text","pages":"45","tokens_est":222,"char_count":885,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0262","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 6. Screening for tuberculosis disease in children | 6.3 Screening children living with HIV | 6.3.3 Considerations for implementation","content_type":"text","pages":"45","tokens_est":59,"char_count":235,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0263","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 6. Screening for tuberculosis disease in children | 6.3 Screening children living with HIV | 6.3.3 Considerations for implementation","content_type":"text","pages":"45","tokens_est":243,"char_count":969,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0264","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 6. Screening for tuberculosis disease in children | 6.4 Algorithms for screening","content_type":"text","pages":"45","tokens_est":22,"char_count":87,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0265","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 6. Screening for tuberculosis disease in children | 6.4 Algorithms for screening | Children 0 to < 15 years with a close contact with TB","content_type":"text","pages":"45-46","tokens_est":105,"char_count":419,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0266","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Chapter 6. Screening for tuberculosis disease in children | 6.4 Algorithms for screening | Children 0 to < 10 years living with HIV","content_type":"text","pages":"46","tokens_est":22,"char_count":86,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0267","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 1 Screening algorithms for the general population and high-risk groups (not including people living with HIV) | Fig. A.1.1  Screening with cough","content_type":"figure","pages":"46","caption":"Fig. A.1.1  Screening with cough","tokens_est":9,"char_count":33,"has_attachment":true,"attachment_id":"Fig. A.1.1","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. A.1.1.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0268","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 1 Screening algorithms for the general population and high-risk groups (not including people living with HIV) | Fig. A.1.2  Parallel screening with cough and CXR","content_type":"figure","pages":"46","caption":"Fig. A.1.2  Parallel screening with cough and CXR","tokens_est":13,"char_count":50,"has_attachment":true,"attachment_id":"Fig. A.1.2","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. A.1.2.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0269","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 1 Screening algorithms for the general population and high-risk groups (not including people living with HIV) | Fig. A.1.3  Sequential positive serial screening with cough and CXR","content_type":"figure","pages":"47","caption":"Fig. A.1.3  Sequential positive serial screening with cough and CXR","tokens_est":17,"char_count":68,"has_attachment":true,"attachment_id":"Fig. A.1.3","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. A.1.3.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0270","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 1 Screening algorithms for the general population and high-risk groups (not including people living with HIV) | Fig. A.1.4  Sequential negative serial screening with cough and CXR","content_type":"figure","pages":"48","caption":"Fig. A.1.4  Sequential negative serial screening with cough and CXR","tokens_est":17,"char_count":68,"has_attachment":true,"attachment_id":"Fig. A.1.4","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. A.1.4.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0271","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 1 Screening algorithms for the general population and high-risk groups (not including people living with HIV) | Fig. A.1.5  Screening with any TB symptom","content_type":"figure","pages":"49","caption":"Fig. A.1.5  Screening with any TB symptom","tokens_est":11,"char_count":42,"has_attachment":true,"attachment_id":"Fig. A.1.5","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. A.1.5.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0272","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 1 Screening algorithms for the general population and high-risk groups (not including people living with HIV) | Fig. A.1.6  Parallel screening with any TB symptom and CXR","content_type":"figure","pages":"50","caption":"Fig. A.1.6  Parallel screening with any TB symptom and CXR","tokens_est":15,"char_count":59,"has_attachment":true,"attachment_id":"Fig. A.1.6","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. A.1.6.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0273","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 1 Screening algorithms for the general population and high-risk groups (not including people living with HIV) | Fig. A.1.7  Sequential positive serial screening with any TB symptom and CXR","content_type":"figure","pages":"51","caption":"Fig. A.1.7  Sequential positive serial screening with any TB symptom and CXR","tokens_est":20,"char_count":77,"has_attachment":true,"attachment_id":"Fig. A.1.7","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. A.1.7.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0274","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 1 Screening algorithms for the general population and high-risk groups (not including people living with HIV) | Fig. A.1.8  Sequential negative serial screening with any TB symptom and CXR","content_type":"figure","pages":"52","caption":"Fig. A.1.8  Sequential negative serial screening with any TB symptom and CXR","tokens_est":20,"char_count":77,"has_attachment":true,"attachment_id":"Fig. A.1.8","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. A.1.8.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0275","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 1 Screening algorithms for the general population and high-risk groups (not including people living with HIV) | Fig. A.1.9  Screening with CXR","content_type":"figure","pages":"53","caption":"Fig. A.1.9  Screening with CXR","tokens_est":8,"char_count":31,"has_attachment":true,"attachment_id":"Fig. A.1.9","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. A.1.9.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0276","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 1 Screening algorithms for the general population and high-risk groups (not including people living with HIV) | Fig. A.1.10  Screening with mWRD","content_type":"figure","pages":"54","caption":"Fig. A.1.10  Screening with mWRD","tokens_est":9,"char_count":33,"has_attachment":true,"attachment_id":"Fig. A.1.10","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. A.1.10.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0277","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 2 Comparative performance of algorithms for the general population and high-risk groups (not including people living with HIV)","content_type":"text","pages":"55-56","tokens_est":211,"char_count":843,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0278","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 2 Comparative performance of algorithms for the general population and high-risk groups (not including people living with HIV)","content_type":"text","pages":"56","tokens_est":70,"char_count":278,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0279","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 2 Comparative performance of algorithms for the general population and high-risk groups (not including people living with HIV) | Table A.2.1 100 000 people screened with 0.5% TB prevalence (with 500 prevalent TB cases)","content_type":"table","pages":"56","caption":"Table A.2.1 100 000 people screened with 0.5% TB prevalence (with 500 prevalent TB cases)","tokens_est":44,"char_count":173,"has_attachment":true,"attachment_id":"Table A.2.1","attachment_path":"tables/WHO_TB_handbook_module2_screening_2021/Table_A.2.1.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0280","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 2 Comparative performance of algorithms for the general population and high-risk groups (not including people living with HIV) | Table A.2.2 100 000 people screened with 1% TB prevalence (with 1000 prevalent TB cases)","content_type":"table","pages":"56-57","caption":"Table A.2.2 100 000 people screened with 1% TB prevalence (with 1000 prevalent TB cases)","tokens_est":43,"char_count":172,"has_attachment":true,"attachment_id":"Table A.2.2","attachment_path":"tables/WHO_TB_handbook_module2_screening_2021/Table_A.2.2.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0281","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 2 Comparative performance of algorithms for the general population and high-risk groups (not including people living with HIV) | Table A.2.3 100 000 people screened with 2% TB prevalence (with 2000 prevalent TB cases)","content_type":"table","pages":"57","caption":"Table A.2.3 100 000 people screened with 2% TB prevalence (with 2000 prevalent TB cases)","tokens_est":43,"char_count":172,"has_attachment":true,"attachment_id":"Table A.2.3","attachment_path":"tables/WHO_TB_handbook_module2_screening_2021/Table_A.2.3.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0282","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 2 Comparative performance of algorithms for the general population and high-risk groups (not including people living with HIV)","content_type":"text","pages":"57","tokens_est":79,"char_count":316,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0283","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 3 Screening algorithms for adults and adolescents living with HIV","content_type":"text","pages":"57","tokens_est":38,"char_count":150,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0284","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 3 Screening algorithms for adults and adolescents living with HIV | Fig. A.3.1  W4SS single screening algorithm","content_type":"figure","pages":"57-58","caption":"Fig. A.3.1  W4SS single screening algorithm","tokens_est":11,"char_count":44,"has_attachment":true,"attachment_id":"Fig. A.3.1","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. A.3.1.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0285","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 3 Screening algorithms for adults and adolescents living with HIV | Fig. A.3.2  CRP single screening algorithm","content_type":"figure","pages":"58","caption":"Fig. A.3.2  CRP single screening algorithm","tokens_est":11,"char_count":43,"has_attachment":true,"attachment_id":"Fig. A.3.2","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. A.3.2.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0286","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 3 Screening algorithms for adults and adolescents living with HIV | Fig. A.3.3  CXR single screening algorithm","content_type":"figure","pages":"59","caption":"Fig. A.3.3  CXR single screening algorithm","tokens_est":11,"char_count":43,"has_attachment":true,"attachment_id":"Fig. A.3.3","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. A.3.3.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0287","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 3 Screening algorithms for adults and adolescents living with HIV | Fig. A.3.4  Parallel screening algorithm with W4SS and CRP","content_type":"figure","pages":"60","caption":"Fig. A.3.4  Parallel screening algorithm with W4SS and CRP","tokens_est":15,"char_count":59,"has_attachment":true,"attachment_id":"Fig. A.3.4","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. A.3.4.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0288","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 3 Screening algorithms for adults and adolescents living with HIV | Fig. A.3.5  Sequential positive screening algorithm with W4SS and CRP","content_type":"figure","pages":"61","caption":"Fig. A.3.5  Sequential positive screening algorithm with W4SS and CRP","tokens_est":18,"char_count":70,"has_attachment":true,"attachment_id":"Fig. A.3.5","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. A.3.5.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0289","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 3 Screening algorithms for adults and adolescents living with HIV | Fig. A.3.6  Sequential negative screening algorithm with W4SS and CRP","content_type":"figure","pages":"62","caption":"Fig. A.3.6  Sequential negative screening algorithm with W4SS and CRP","tokens_est":18,"char_count":70,"has_attachment":true,"attachment_id":"Fig. A.3.6","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. A.3.6.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0290","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 3 Screening algorithms for adults and adolescents living with HIV | Fig. A.3.7  Parallel screening algorithm with W4SS and CXR","content_type":"figure","pages":"63","caption":"Fig. A.3.7  Parallel screening algorithm with W4SS and CXR","tokens_est":15,"char_count":59,"has_attachment":true,"attachment_id":"Fig. A.3.7","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. A.3.7.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0291","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 3 Screening algorithms for adults and adolescents living with HIV | Fig. A.3.8  Sequential positive screening algorithm with W4SS and CXR","content_type":"figure","pages":"64","caption":"Fig. A.3.8  Sequential positive screening algorithm with W4SS and CXR","tokens_est":18,"char_count":70,"has_attachment":true,"attachment_id":"Fig. A.3.8","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. A.3.8.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0292","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 3 Screening algorithms for adults and adolescents living with HIV | Fig. A.3.9  Sequential negative screening algorithm with W4SS and CXR","content_type":"figure","pages":"65","caption":"Fig. A.3.9  Sequential negative screening algorithm with W4SS and CXR","tokens_est":18,"char_count":70,"has_attachment":true,"attachment_id":"Fig. A.3.9","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. A.3.9.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0293","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 3 Screening algorithms for adults and adolescents living with HIV | Fig. A.3.10  mWRD single screening algorithm for medical inpatients in settings with TB prevalence > 10%","content_type":"figure","pages":"66","caption":"Fig. A.3.10  mWRD single screening algorithm for medical inpatients in settings with TB prevalence > 10%","tokens_est":27,"char_count":105,"has_attachment":true,"attachment_id":"Fig. A.3.10","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. A.3.10.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0294","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 3 Screening algorithms for adults and adolescents living with HIV | Fig. A.3.11  mWRD single screening algorithm for people living with HIV","content_type":"figure","pages":"66","caption":"Fig. A.3.11  mWRD single screening algorithm for people living with HIV","tokens_est":18,"char_count":72,"has_attachment":true,"attachment_id":"Fig. A.3.11","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. A.3.11.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0295","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 4 Comparative performance of algorithms for adults and adolescents living with HIV","content_type":"text","pages":"67","tokens_est":160,"char_count":638,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0296","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 4 Comparative performance of algorithms for adults and adolescents living with HIV | Table A.4.1 Screening 1000 outpatients living with HIV not enrolled on antiretroviral treatment (ART) with a TB prevalence of 5%","content_type":"table","pages":"67-68","caption":"Table A.4.1 Screening 1000 outpatients living with HIV not enrolled on antiretroviral treatment (ART) with a TB prevalence of 5%","tokens_est":53,"char_count":212,"has_attachment":true,"attachment_id":"Table A.4.1","attachment_path":"tables/WHO_TB_handbook_module2_screening_2021/Table_A.4.1.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0297","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 4 Comparative performance of algorithms for adults and adolescents living with HIV | Table A.4.2 Screening 1000 outpatients living with HIV on antiretroviral treatment (ART) with a TB prevalence of 1%","content_type":"table","pages":"68","caption":"Table A.4.2 Screening 1000 outpatients living with HIV on antiretroviral treatment (ART) with a TB prevalence of 1%","tokens_est":48,"char_count":191,"has_attachment":true,"attachment_id":"Table A.4.2","attachment_path":"tables/WHO_TB_handbook_module2_screening_2021/Table_A.4.2.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0298","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 4 Comparative performance of algorithms for adults and adolescents living with HIV | Table A.4.3 Screening 1000 inpatients living with HIV with a TB prevalence of 10%","content_type":"table","pages":"68","caption":"Table A.4.3 Screening 1000 inpatients living with HIV with a TB prevalence of 10%","tokens_est":43,"char_count":171,"has_attachment":true,"attachment_id":"Table A.4.3","attachment_path":"tables/WHO_TB_handbook_module2_screening_2021/Table_A.4.3.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0299","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 5 Screening algorithms for children","content_type":"text","pages":"68","tokens_est":50,"char_count":198,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0300","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 5 Screening algorithms for children | Fig. A.5.1  Screening with symptoms","content_type":"figure","pages":"68","caption":"Fig. A.5.1  Screening with symptoms","tokens_est":9,"char_count":36,"has_attachment":true,"attachment_id":"Fig. A.5.1","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. A.5.1.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0301","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 5 Screening algorithms for children | Fig A.5.2  Screening with CXR","content_type":"figure","pages":"69","caption":"Fig A.5.2  Screening with CXR","tokens_est":8,"char_count":30,"has_attachment":true,"attachment_id":"Fig A.5.2","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig A.5.2.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0302","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 5 Screening algorithms for children | Fig. A.5.3  Parallel screening with symptoms and CXR","content_type":"figure","pages":"70","caption":"Fig. A.5.3  Parallel screening with symptoms and CXR","tokens_est":14,"char_count":53,"has_attachment":true,"attachment_id":"Fig. A.5.3","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. A.5.3.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0303","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 5 Screening algorithms for children | Fig. A.5.4  Sequential positive serial screening with symptoms and CXR","content_type":"figure","pages":"71","caption":"Fig. A.5.4  Sequential positive serial screening with symptoms and CXR","tokens_est":18,"char_count":71,"has_attachment":true,"attachment_id":"Fig. A.5.4","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. A.5.4.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0304","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 5 Screening algorithms for children | Fig. A.5.5  Sequential negative serial screening with symptoms and CXR","content_type":"figure","pages":"72","caption":"Fig. A.5.5  Sequential negative serial screening with symptoms and CXR","tokens_est":18,"char_count":71,"has_attachment":true,"attachment_id":"Fig. A.5.5","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. A.5.5.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module2_screening_2021|0305","doc_id":"WHO_TB_handbook_module2_screening_2021","section_path":"Annex 5 Screening algorithms for children | Fig. A.5.6  Screening with symptoms (for children living with HIV < 10 years)","content_type":"figure","pages":"73","caption":"Fig. A.5.6  Screening with symptoms (for children living with HIV < 10 years)","tokens_est":20,"char_count":78,"has_attachment":true,"attachment_id":"Fig. A.5.6","attachment_path":"figures/WHO_TB_handbook_module2_screening_2021/Fig. A.5.6.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module2_screening_2021_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0001","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Acknowledgements","content_type":"text","pages":"4","tokens_est":201,"char_count":803,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0002","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Acknowledgements","content_type":"text","pages":"4","tokens_est":125,"char_count":497,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0003","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Acknowledgements","content_type":"text","pages":"4","tokens_est":251,"char_count":1002,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0004","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Acknowledgements","content_type":"text","pages":"4","tokens_est":202,"char_count":807,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0005","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Acknowledgements","content_type":"text","pages":"4","tokens_est":17,"char_count":66,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0006","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Abbreviations and acronyms","content_type":"text","pages":"5","tokens_est":225,"char_count":899,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0007","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Abbreviations and acronyms","content_type":"text","pages":"5-6","tokens_est":229,"char_count":916,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0008","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Abbreviations and acronyms","content_type":"text","pages":"6","tokens_est":225,"char_count":897,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0009","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Abbreviations and acronyms","content_type":"text","pages":"6-7","tokens_est":225,"char_count":898,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0010","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Abbreviations and acronyms","content_type":"text","pages":"7","tokens_est":21,"char_count":83,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0011","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.1. Background","content_type":"text","pages":"8","tokens_est":209,"char_count":833,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0012","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.1. Background","content_type":"text","pages":"8","tokens_est":146,"char_count":584,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0013","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.1. Background","content_type":"text","pages":"8","tokens_est":215,"char_count":858,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0014","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.1. Background","content_type":"text","pages":"8","tokens_est":106,"char_count":423,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0015","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.1. Background","content_type":"text","pages":"8-9","tokens_est":249,"char_count":996,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0016","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.1. Background","content_type":"text","pages":"8-9","tokens_est":76,"char_count":304,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0017","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.1. Background","content_type":"text","pages":"9","tokens_est":219,"char_count":876,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0018","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.1. Background","content_type":"text","pages":"9","tokens_est":237,"char_count":947,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0019","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.1. Background","content_type":"text","pages":"9","tokens_est":35,"char_count":139,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0020","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.2. Advances in TB diagnostic test development, assessment and WHO recommendations","content_type":"text","pages":"9","tokens_est":133,"char_count":531,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0021","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.2. Advances in TB diagnostic test development, assessment and WHO recommendations","content_type":"text","pages":"9-10","tokens_est":206,"char_count":822,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0022","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.2. Advances in TB diagnostic test development, assessment and WHO recommendations","content_type":"text","pages":"10","tokens_est":242,"char_count":965,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0023","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.2. Advances in TB diagnostic test development, assessment and WHO recommendations","content_type":"text","pages":"10","tokens_est":56,"char_count":222,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0024","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.2. Advances in TB diagnostic test development, assessment and WHO recommendations","content_type":"text","pages":"10","tokens_est":226,"char_count":903,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0025","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.2. Advances in TB diagnostic test development, assessment and WHO recommendations","content_type":"text","pages":"10","tokens_est":67,"char_count":266,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0026","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.2. Advances in TB diagnostic test development, assessment and WHO recommendations","content_type":"text","pages":"10","tokens_est":241,"char_count":961,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0027","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.2. Advances in TB diagnostic test development, assessment and WHO recommendations","content_type":"text","pages":"10","tokens_est":80,"char_count":319,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0028","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.2. Advances in TB diagnostic test development, assessment and WHO recommendations","content_type":"text","pages":"10-11","tokens_est":77,"char_count":308,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0029","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.2. Advances in TB diagnostic test development, assessment and WHO recommendations","content_type":"text","pages":"11","tokens_est":200,"char_count":799,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0030","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.2. Advances in TB diagnostic test development, assessment and WHO recommendations","content_type":"text","pages":"11","tokens_est":103,"char_count":409,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0031","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.2. Advances in TB diagnostic test development, assessment and WHO recommendations","content_type":"text","pages":"11","tokens_est":74,"char_count":293,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0032","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.2. Advances in TB diagnostic test development, assessment and WHO recommendations | Box. Consolidated list of recommendations on TB diagnostics","content_type":"box","pages":"11","caption":"Box. Consolidated list of recommendations on TB diagnostics","tokens_est":244,"char_count":973,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0033","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.2. Advances in TB diagnostic test development, assessment and WHO recommendations | Box. Consolidated list of recommendations on TB diagnostics","content_type":"box","pages":"11","caption":"Box. Consolidated list of recommendations on TB diagnostics","tokens_est":201,"char_count":804,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0034","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.2. Advances in TB diagnostic test development, assessment and WHO recommendations | Box. Consolidated list of recommendations on TB diagnostics","content_type":"box","pages":"11","caption":"Box. Consolidated list of recommendations on TB diagnostics","tokens_est":242,"char_count":967,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0035","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.2. Advances in TB diagnostic test development, assessment and WHO recommendations | Box. Consolidated list of recommendations on TB diagnostics","content_type":"box","pages":"11","caption":"Box. Consolidated list of recommendations on TB diagnostics","tokens_est":243,"char_count":969,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0036","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.2. Advances in TB diagnostic test development, assessment and WHO recommendations | Box. Consolidated list of recommendations on TB diagnostics","content_type":"box","pages":"11","caption":"Box. Consolidated list of recommendations on TB diagnostics","tokens_est":243,"char_count":971,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0037","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.2. Advances in TB diagnostic test development, assessment and WHO recommendations | Box. Consolidated list of recommendations on TB diagnostics","content_type":"box","pages":"11-12","caption":"Box. Consolidated list of recommendations on TB diagnostics","tokens_est":214,"char_count":855,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0038","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.2. Advances in TB diagnostic test development, assessment and WHO recommendations | Box. Consolidated list of recommendations on TB diagnostics","content_type":"box","pages":"12","caption":"Box. Consolidated list of recommendations on TB diagnostics","tokens_est":217,"char_count":867,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0039","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.2. Advances in TB diagnostic test development, assessment and WHO recommendations | Box. Consolidated list of recommendations on TB diagnostics","content_type":"box","pages":"12","caption":"Box. Consolidated list of recommendations on TB diagnostics","tokens_est":229,"char_count":913,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0040","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.2. Advances in TB diagnostic test development, assessment and WHO recommendations | Box. Consolidated list of recommendations on TB diagnostics","content_type":"box","pages":"12","caption":"Box. Consolidated list of recommendations on TB diagnostics","tokens_est":145,"char_count":580,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0041","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.3. Scope of this operational handbook","content_type":"text","pages":"12-13","tokens_est":191,"char_count":762,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0042","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.3. Scope of this operational handbook","content_type":"text","pages":"13","tokens_est":229,"char_count":915,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0043","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.4. Target audience","content_type":"text","pages":"13-14","tokens_est":182,"char_count":727,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0044","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.5. New in this version: a summary of changes","content_type":"text","pages":"14","tokens_est":109,"char_count":433,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0045","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.5. New in this version: a summary of changes | Box. Summary of changes in this WHO operational handbook on tuberculosis. Module 3: diagnosis","content_type":"box","pages":"15","caption":"Box. Summary of changes in this WHO operational handbook on tuberculosis. Module 3: diagnosis","tokens_est":145,"char_count":577,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0046","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.5. New in this version: a summary of changes | Box. Summary of changes in this WHO operational handbook on tuberculosis. Module 3: diagnosis","content_type":"box","pages":"15","caption":"Box. Summary of changes in this WHO operational handbook on tuberculosis. Module 3: diagnosis","tokens_est":245,"char_count":977,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0047","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.5. New in this version: a summary of changes | Box. Summary of changes in this WHO operational handbook on tuberculosis. Module 3: diagnosis","content_type":"box","pages":"15","caption":"Box. Summary of changes in this WHO operational handbook on tuberculosis. Module 3: diagnosis","tokens_est":228,"char_count":912,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0048","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.5. New in this version: a summary of changes | Box. Summary of changes in this WHO operational handbook on tuberculosis. Module 3: diagnosis","content_type":"box","pages":"15","caption":"Box. Summary of changes in this WHO operational handbook on tuberculosis. Module 3: diagnosis","tokens_est":114,"char_count":456,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0049","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations","content_type":"text","pages":"16","tokens_est":220,"char_count":879,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0050","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations","content_type":"text","pages":"16","tokens_est":148,"char_count":591,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0051","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | Table 2.1. Classes of TB testing technologies and products included in current guidelines","content_type":"table","pages":"17","caption":"Table 2.1. Classes of TB testing technologies and products included in current guidelines","tokens_est":40,"char_count":558,"has_attachment":true,"attachment_id":"Table 2.1.","attachment_path":"tables/WHO_TB_handbook_module3_diagnosis_2025/Table_2.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0052","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations","content_type":"text","pages":"18-19","tokens_est":240,"char_count":958,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0053","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations","content_type":"text","pages":"19","tokens_est":32,"char_count":125,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0054","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations","content_type":"text","pages":"19","tokens_est":235,"char_count":938,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0055","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations","content_type":"text","pages":"19","tokens_est":55,"char_count":218,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0056","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations","content_type":"text","pages":"19","tokens_est":216,"char_count":863,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0057","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.1. Conventional tests for the diagnosis of TB","content_type":"table","pages":"21","caption":"Table 2.2. Summary of initial tests for TB diagnosis","tokens_est":77,"char_count":707,"has_attachment":true,"attachment_id":"Table 2.2.","attachment_path":"tables/WHO_TB_handbook_module3_diagnosis_2025/Table_2.2..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0058","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.1. Conventional tests for the diagnosis of TB","content_type":"text","pages":"20","tokens_est":155,"char_count":617,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0059","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.1. Conventional tests for the diagnosis of TB","content_type":"text","pages":"20","tokens_est":206,"char_count":822,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0060","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.1. Conventional tests for the diagnosis of TB","content_type":"text","pages":"20","tokens_est":161,"char_count":641,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0061","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.2. Initial tests for diagnosis of TB with drug resistance detection | 2.2.1. Low-complexity automated NAATs","content_type":"text","pages":"22","tokens_est":179,"char_count":715,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0062","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.2. Initial tests for diagnosis of TB with drug resistance detection | 2.2.1. Low-complexity automated NAATs | Table 2.3. Definition of the class of LC - aNAATs","content_type":"table","pages":"22","caption":"Table 2.3. Definition of the class of LC - aNAATs","tokens_est":26,"char_count":285,"has_attachment":true,"attachment_id":"Table 2.3.","attachment_path":"tables/WHO_TB_handbook_module3_diagnosis_2025/Table_2.3..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0063","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.2. Initial tests for diagnosis of TB with drug resistance detection | 2.2.1. Low-complexity automated NAATs","content_type":"text","pages":"22-23","tokens_est":246,"char_count":981,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0064","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.2. Initial tests for diagnosis of TB with drug resistance detection | 2.2.1. Low-complexity automated NAATs","content_type":"text","pages":"23","tokens_est":136,"char_count":544,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0065","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.2. Initial tests for diagnosis of TB with drug resistance detection | 2.2.1. Low-complexity automated NAATs","content_type":"text","pages":"23","tokens_est":133,"char_count":530,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0066","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.2. Initial tests for diagnosis of TB with drug resistance detection | 2.2.1. Low-complexity automated NAATs","content_type":"text","pages":"23","tokens_est":192,"char_count":766,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0067","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.2. Initial tests for diagnosis of TB with drug resistance detection | 2.2.1. Low-complexity automated NAATs","content_type":"text","pages":"23","tokens_est":183,"char_count":732,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0068","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.2. Initial tests for diagnosis of TB with drug resistance detection | 2.2.1. Low-complexity automated NAATs | Box 2.1. WHO recommendations on the use of LC- aNAATs (6)","content_type":"box","pages":"23","caption":"Box 2.1. WHO recommendations on the use of LC- aNAATs (6)","tokens_est":209,"char_count":834,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0069","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.2. Initial tests for diagnosis of TB with drug resistance detection | 2.2.1. Low-complexity automated NAATs | Box 2.1. WHO recommendations on the use of LC- aNAATs (6)","content_type":"box","pages":"23","caption":"Box 2.1. WHO recommendations on the use of LC- aNAATs (6)","tokens_est":161,"char_count":643,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0070","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.2. Initial tests for diagnosis of TB with drug resistance detection | 2.2.1. Low-complexity automated NAATs | Box 2.1. WHO recommendations on the use of LC- aNAATs (6)","content_type":"box","pages":"23","caption":"Box 2.1. WHO recommendations on the use of LC- aNAATs (6)","tokens_est":232,"char_count":926,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0071","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.2. Initial tests for diagnosis of TB with drug resistance detection | 2.2.1. Low-complexity automated NAATs | Box 2.1. WHO recommendations on the use of LC- aNAATs (6)","content_type":"box","pages":"23","caption":"Box 2.1. WHO recommendations on the use of LC- aNAATs (6)","tokens_est":245,"char_count":977,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0072","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.2. Initial tests for diagnosis of TB with drug resistance detection | 2.2.2. Moderate-complexity automated NAATs","content_type":"text","pages":"24","tokens_est":22,"char_count":85,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0073","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.2. Initial tests for diagnosis of TB with drug resistance detection | 2.2.2. Moderate-complexity automated NAATs | Table 2.4. Definition of the class of MC- aNAATs","content_type":"table","pages":"24","caption":"Table 2.4. Definition of the class of MC- aNAATs","tokens_est":29,"char_count":317,"has_attachment":true,"attachment_id":"Table 2.4.","attachment_path":"tables/WHO_TB_handbook_module3_diagnosis_2025/Table_2.4..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0074","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.2. Initial tests for diagnosis of TB with drug resistance detection | 2.2.2. Moderate-complexity automated NAATs","content_type":"text","pages":"24","tokens_est":219,"char_count":875,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0075","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.2. Initial tests for diagnosis of TB with drug resistance detection | 2.2.2. Moderate-complexity automated NAATs","content_type":"text","pages":"24-25","tokens_est":187,"char_count":747,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0076","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.2. Initial tests for diagnosis of TB with drug resistance detection | 2.2.2. Moderate-complexity automated NAATs | Box 2.2. WHO recommendation on MC- aNAATs (6)","content_type":"box","pages":"25","caption":"Box 2.2. WHO recommendation on MC- aNAATs (6)","tokens_est":197,"char_count":787,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0077","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.2. Initial tests for diagnosis of TB with drug resistance detection | 2.2.2. Moderate-complexity automated NAATs | Box 2.2. WHO recommendation on MC- aNAATs (6)","content_type":"box","pages":"25","caption":"Box 2.2. WHO recommendation on MC- aNAATs (6)","tokens_est":223,"char_count":892,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0078","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.2. Initial tests for diagnosis of TB with drug resistance detection | 2.2.2. Moderate-complexity automated NAATs | Fig. 2.1. Summary of testing procedures for the Bruker Hain FluoroType MTB and MTBDR","content_type":"figure","pages":"25-26","caption":"Fig. 2.1. Summary of testing procedures for the Bruker Hain FluoroType MTB and MTBDR","tokens_est":61,"char_count":241,"has_attachment":true,"attachment_id":"Fig. 2.1.","attachment_path":"figures/WHO_TB_handbook_module3_diagnosis_2025/Fig. 2.1..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0079","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.3. Initial tests for diagnosis of TB without drug resistance detection | 2.3.1. Low-complexity manual NAATs","content_type":"text","pages":"27","tokens_est":122,"char_count":486,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0080","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.3. Initial tests for diagnosis of TB without drug resistance detection | 2.3.1. Low-complexity manual NAATs","content_type":"text","pages":"27","tokens_est":246,"char_count":981,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0081","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.3. Initial tests for diagnosis of TB without drug resistance detection | 2.3.1. Low-complexity manual NAATs | Table 2.5. Definition of the class of LC- mNAATs","content_type":"table","pages":"27","caption":"Table 2.5. Definition of the class of LC- mNAATs","tokens_est":21,"char_count":239,"has_attachment":true,"attachment_id":"Table 2.5.","attachment_path":"tables/WHO_TB_handbook_module3_diagnosis_2025/Table_2.5..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0082","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.3. Initial tests for diagnosis of TB without drug resistance detection | 2.3.1. Low-complexity manual NAATs | Box 2.3. WHO recommendation on LC- mNAATs (6)","content_type":"box","pages":"27","caption":"Box 2.3. WHO recommendation on LC- mNAATs (6)","tokens_est":207,"char_count":826,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0083","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.3. Initial tests for diagnosis of TB without drug resistance detection | 2.3.1. Low-complexity manual NAATs | Box 2.3. WHO recommendation on LC- mNAATs (6)","content_type":"box","pages":"27","caption":"Box 2.3. WHO recommendation on LC- mNAATs (6)","tokens_est":153,"char_count":610,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0084","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.3. Initial tests for diagnosis of TB without drug resistance detection | 2.3.2. Urine LF- LAM","content_type":"text","pages":"27","tokens_est":231,"char_count":923,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0085","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.3. Initial tests for diagnosis of TB without drug resistance detection | 2.3.2. Urine LF- LAM","content_type":"text","pages":"27","tokens_est":34,"char_count":134,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0086","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.3. Initial tests for diagnosis of TB without drug resistance detection | 2.3.2. Urine LF- LAM","content_type":"text","pages":"27","tokens_est":62,"char_count":246,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0087","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.3. Initial tests for diagnosis of TB without drug resistance detection | 2.3.2. Urine LF- LAM | Box 2.4. WHO recommendations on concurrent use of tests in people living with HIV (5)","content_type":"box","pages":"27","caption":"Box 2.4. WHO recommendations on concurrent use of tests in people living with HIV (5)","tokens_est":230,"char_count":918,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0088","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.3. Initial tests for diagnosis of TB without drug resistance detection | 2.3.2. Urine LF- LAM | Box 2.4. WHO recommendations on concurrent use of tests in people living with HIV (5)","content_type":"box","pages":"27","caption":"Box 2.4. WHO recommendations on concurrent use of tests in people living with HIV (5)","tokens_est":213,"char_count":850,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0089","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.3. Initial tests for diagnosis of TB without drug resistance detection | 2.3.2. Urine LF- LAM | Box 2.4. WHO recommendations on concurrent use of tests in people living with HIV (5)","content_type":"box","pages":"27","caption":"Box 2.4. WHO recommendations on concurrent use of tests in people living with HIV (5)","tokens_est":229,"char_count":914,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0090","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.3. Initial tests for diagnosis of TB without drug resistance detection | 2.3.2. Urine LF- LAM | Box 2.4. WHO recommendations on concurrent use of tests in people living with HIV (5)","content_type":"box","pages":"27","caption":"Box 2.4. WHO recommendations on concurrent use of tests in people living with HIV (5)","tokens_est":49,"char_count":194,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0091","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance","content_type":"text","pages":"28","tokens_est":131,"char_count":523,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0092","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | Table 2.6. Comparison of follow-on tests for the detection of drug resistance","content_type":"table","pages":"29","caption":"Table 2.6. Comparison of follow-on tests for the detection of drug resistance","tokens_est":68,"char_count":1207,"has_attachment":true,"attachment_id":"Table 2.6.","attachment_path":"tables/WHO_TB_handbook_module3_diagnosis_2025/Table_2.6..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0093","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.1. LC- aNAATs for detection of resistance to INH and second-line anti-TB drugs","content_type":"text","pages":"30","tokens_est":246,"char_count":983,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0094","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.1. LC- aNAATs for detection of resistance to INH and second-line anti-TB drugs | Box 2.5. WHO recommendations on LC- aNAATs for detection of resistance to INH and second-line anti-TB drugs","content_type":"box","pages":"30","caption":"Box 2.5. WHO recommendations on LC- aNAATs for detection of resistance to INH and second-line anti-TB drugs","tokens_est":236,"char_count":942,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0095","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.1. LC- aNAATs for detection of resistance to INH and second-line anti-TB drugs | Box 2.5. WHO recommendations on LC- aNAATs for detection of resistance to INH and second-line anti-TB drugs","content_type":"box","pages":"30","caption":"Box 2.5. WHO recommendations on LC- aNAATs for detection of resistance to INH and second-line anti-TB drugs","tokens_est":159,"char_count":636,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0096","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.1. LC- aNAATs for detection of resistance to INH and second-line anti-TB drugs | Box 2.5. WHO recommendations on LC- aNAATs for detection of resistance to INH and second-line anti-TB drugs","content_type":"box","pages":"30-31","caption":"Box 2.5. WHO recommendations on LC- aNAATs for detection of resistance to INH and second-line anti-TB drugs","tokens_est":180,"char_count":717,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0097","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.1. LC- aNAATs for detection of resistance to INH and second-line anti-TB drugs | Box 2.5. WHO recommendations on LC- aNAATs for detection of resistance to INH and second-line anti-TB drugs","content_type":"box","pages":"31","caption":"Box 2.5. WHO recommendations on LC- aNAATs for detection of resistance to INH and second-line anti-TB drugs","tokens_est":137,"char_count":547,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0098","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.1. LC- aNAATs for detection of resistance to INH and second-line anti-TB drugs | Box 2.5. WHO recommendations on LC- aNAATs for detection of resistance to INH and second-line anti-TB drugs","content_type":"box","pages":"31","caption":"Box 2.5. WHO recommendations on LC- aNAATs for detection of resistance to INH and second-line anti-TB drugs","tokens_est":232,"char_count":926,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0099","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.1. LC- aNAATs for detection of resistance to INH and second-line anti-TB drugs | Box 2.5. WHO recommendations on LC- aNAATs for detection of resistance to INH and second-line anti-TB drugs","content_type":"box","pages":"31","caption":"Box 2.5. WHO recommendations on LC- aNAATs for detection of resistance to INH and second-line anti-TB drugs","tokens_est":65,"char_count":259,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0100","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.2. Line probe assays","content_type":"text","pages":"31","tokens_est":122,"char_count":488,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0101","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.2. Line probe assays | Table 2.7. Definition of the class criteria for LPAs","content_type":"table","pages":"32","caption":"Table 2.7. Definition of the class criteria for LPAs","tokens_est":35,"char_count":138,"has_attachment":true,"attachment_id":"Table 2.7.","attachment_path":"tables/WHO_TB_handbook_module3_diagnosis_2025/Table_2.7..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0102","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.2. Line probe assays | First-line drug LPAs","content_type":"text","pages":"32","tokens_est":60,"char_count":237,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0103","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.2. Line probe assays | First-line drug LPAs | Box 2.6. WHO recommendation on FL-LPAs (6)","content_type":"box","pages":"32","caption":"Box 2.6. WHO recommendation on FL-LPAs (6)","tokens_est":221,"char_count":881,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0104","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.2. Line probe assays | First-line drug LPAs | Box 2.6. WHO recommendation on FL-LPAs (6)","content_type":"box","pages":"32","caption":"Box 2.6. WHO recommendation on FL-LPAs (6)","tokens_est":153,"char_count":612,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0105","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.2. Line probe assays | Second-line drug LPAs","content_type":"text","pages":"33","tokens_est":38,"char_count":151,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0106","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.2. Line probe assays | Second-line drug LPAs | Box 2.7. WHO recommendations on SL-LPAs (6)","content_type":"box","pages":"33","caption":"Box 2.7. WHO recommendations on SL-LPAs (6)","tokens_est":194,"char_count":774,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0107","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.2. Line probe assays | Second-line drug LPAs | Box 2.7. WHO recommendations on SL-LPAs (6)","content_type":"box","pages":"33","caption":"Box 2.7. WHO recommendations on SL-LPAs (6)","tokens_est":229,"char_count":914,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0108","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.2. Line probe assays | Second-line drug LPAs | Box 2.7. WHO recommendations on SL-LPAs (6)","content_type":"box","pages":"33","caption":"Box 2.7. WHO recommendations on SL-LPAs (6)","tokens_est":122,"char_count":488,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0109","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.3. High-complexity reverse hybridization NAATs","content_type":"text","pages":"34","tokens_est":236,"char_count":943,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0110","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.3. High-complexity reverse hybridization NAATs","content_type":"text","pages":"34","tokens_est":30,"char_count":117,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0111","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.3. High-complexity reverse hybridization NAATs | Box 2.8. WHO recommendation on HC- rNAATs (6)","content_type":"box","pages":"34","caption":"Box 2.8. WHO recommendation on HC- rNAATs (6)","tokens_est":119,"char_count":476,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0112","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.4. Targeted NGS end-to-end solutions","content_type":"text","pages":"34","tokens_est":234,"char_count":936,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0113","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.4. Targeted NGS end-to-end solutions","content_type":"text","pages":"34","tokens_est":45,"char_count":180,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0114","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.4. Targeted NGS end-to-end solutions | Fig. 2.2. Process of testing, from sample to result report, for targeted NGS","content_type":"figure","pages":"34-35","caption":"Fig. 2.2. Process of testing, from sample to result report, for targeted NGS","tokens_est":37,"char_count":146,"has_attachment":true,"attachment_id":"Fig. 2.2.","attachment_path":"figures/WHO_TB_handbook_module3_diagnosis_2025/Fig. 2.2..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0115","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.4. Targeted NGS end-to-end solutions","content_type":"text","pages":"35","tokens_est":208,"char_count":831,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0116","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.4. Targeted NGS end-to-end solutions | Table 2.8. List of targeted NGS solutions and drugs for which WHO recommends their use","content_type":"table","pages":"35","caption":"Table 2.8. List of targeted NGS solutions and drugs for which WHO recommends their use","tokens_est":47,"char_count":464,"has_attachment":true,"attachment_id":"Table 2.8.","attachment_path":"tables/WHO_TB_handbook_module3_diagnosis_2025/Table_2.8..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0117","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.4. Targeted NGS end-to-end solutions","content_type":"text","pages":"35","tokens_est":84,"char_count":336,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0118","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.4. Targeted NGS end-to-end solutions | Box 2.9. WHO policy statement on targeted NGS solutions for detection of DR-TB, 2025","content_type":"box","pages":"35","caption":"Box 2.9. WHO policy statement on targeted NGS solutions for detection of DR-TB, 2025","tokens_est":245,"char_count":980,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0119","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.4. Targeted NGS end-to-end solutions | Box 2.9. WHO policy statement on targeted NGS solutions for detection of DR-TB, 2025","content_type":"box","pages":"35","caption":"Box 2.9. WHO policy statement on targeted NGS solutions for detection of DR-TB, 2025","tokens_est":221,"char_count":882,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0120","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.4. Targeted NGS end-to-end solutions | Box 2.9. WHO policy statement on targeted NGS solutions for detection of DR-TB, 2025","content_type":"box","pages":"35","caption":"Box 2.9. WHO policy statement on targeted NGS solutions for detection of DR-TB, 2025","tokens_est":151,"char_count":604,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0121","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.4. Targeted NGS end-to-end solutions | Box 2.9. WHO policy statement on targeted NGS solutions for detection of DR-TB, 2025","content_type":"box","pages":"35","caption":"Box 2.9. WHO policy statement on targeted NGS solutions for detection of DR-TB, 2025","tokens_est":233,"char_count":931,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0122","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.4. Targeted NGS end-to-end solutions | Box 2.9. WHO policy statement on targeted NGS solutions for detection of DR-TB, 2025","content_type":"box","pages":"35","caption":"Box 2.9. WHO policy statement on targeted NGS solutions for detection of DR-TB, 2025","tokens_est":89,"char_count":353,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0123","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.4. Targeted NGS end-to-end solutions | Implementation considerations","content_type":"text","pages":"35","tokens_est":215,"char_count":860,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0124","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.4. Targeted NGS end-to-end solutions | Implementation considerations","content_type":"text","pages":"35","tokens_est":132,"char_count":525,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0125","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.4. Targeted NGS end-to-end solutions | Implementation considerations","content_type":"text","pages":"35","tokens_est":232,"char_count":928,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0126","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.4. Targeted NGS end-to-end solutions | Implementation considerations","content_type":"text","pages":"35","tokens_est":31,"char_count":122,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0127","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.4. Targeted NGS end-to-end solutions | Implementation considerations","content_type":"text","pages":"35-36","tokens_est":184,"char_count":734,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0128","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.4. Targeted NGS end-to-end solutions | Box 2.10. WHO recommendations on targeted NGS (6)","content_type":"box","pages":"36","caption":"Box 2.10. WHO recommendations on targeted NGS (6)","tokens_est":217,"char_count":868,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0129","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.4. Targeted NGS end-to-end solutions | Box 2.10. WHO recommendations on targeted NGS (6)","content_type":"box","pages":"36","caption":"Box 2.10. WHO recommendations on targeted NGS (6)","tokens_est":182,"char_count":725,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0130","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.4. Targeted NGS end-to-end solutions | Box 2.10. WHO recommendations on targeted NGS (6)","content_type":"box","pages":"36-37","caption":"Box 2.10. WHO recommendations on targeted NGS (6)","tokens_est":230,"char_count":920,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0131","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.4. Targeted NGS end-to-end solutions | Box 2.10. WHO recommendations on targeted NGS (6)","content_type":"box","pages":"37","caption":"Box 2.10. WHO recommendations on targeted NGS (6)","tokens_est":151,"char_count":602,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0132","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.4. Targeted NGS end-to-end solutions | Box 2.10. WHO recommendations on targeted NGS (6)","content_type":"box","pages":"37","caption":"Box 2.10. WHO recommendations on targeted NGS (6)","tokens_est":124,"char_count":493,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0133","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.5. Phenotypic and genotypic drug resistance testing methods | 2.5.1. Phenotypic DST","content_type":"text","pages":"37","tokens_est":202,"char_count":807,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0134","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.5. Phenotypic and genotypic drug resistance testing methods | 2.5.1. Phenotypic DST","content_type":"text","pages":"37-38","tokens_est":236,"char_count":941,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0135","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.5. Phenotypic and genotypic drug resistance testing methods | 2.5.1. Phenotypic DST | Box 2.11. WHO policy statement on the assessment of critical concentrations for pretomanid and cycloserine , 2023","content_type":"box","pages":"38","caption":"Box 2.11. WHO policy statement on the assessment of critical concentrations for pretomanid and cycloserine , 2023","tokens_est":217,"char_count":865,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0136","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.5. Phenotypic and genotypic drug resistance testing methods | 2.5.1. Phenotypic DST | Box 2.11. WHO policy statement on the assessment of critical concentrations for pretomanid and cycloserine , 2023","content_type":"box","pages":"38","caption":"Box 2.11. WHO policy statement on the assessment of critical concentrations for pretomanid and cycloserine , 2023","tokens_est":219,"char_count":873,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0137","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.5. Phenotypic and genotypic drug resistance testing methods | 2.5.1. Phenotypic DST | Box 2.11. WHO policy statement on the assessment of critical concentrations for pretomanid and cycloserine , 2023","content_type":"box","pages":"38","caption":"Box 2.11. WHO policy statement on the assessment of critical concentrations for pretomanid and cycloserine , 2023","tokens_est":76,"char_count":304,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0138","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.5. Phenotypic and genotypic drug resistance testing methods | 2.5.1. Phenotypic DST | Implementation considerations","content_type":"text","pages":"38","tokens_est":212,"char_count":847,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0139","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.5. Phenotypic and genotypic drug resistance testing methods | 2.5.1. Phenotypic DST | Further research","content_type":"text","pages":"38","tokens_est":203,"char_count":812,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0140","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.5. Phenotypic and genotypic drug resistance testing methods | 2.5.1. Phenotypic DST | Further research","content_type":"text","pages":"38","tokens_est":131,"char_count":523,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0141","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.5. Phenotypic and genotypic drug resistance testing methods | 2.5.1. Phenotypic DST | Further research","content_type":"text","pages":"38-39","tokens_est":250,"char_count":998,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0142","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.5. Phenotypic and genotypic drug resistance testing methods | 2.5.1. Phenotypic DST | Further research","content_type":"text","pages":"39","tokens_est":141,"char_count":562,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0143","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.5. Phenotypic and genotypic drug resistance testing methods | 2.5.1. Phenotypic DST | Table 2.9. Critical concentrations for first-line medicines recommended for the treatment of drug-susceptible TB","content_type":"table","pages":"40","caption":"Table 2.9. Critical concentrations for first-line medicines recommended for the treatment of drug-susceptible TB","tokens_est":67,"char_count":1904,"has_attachment":true,"attachment_id":"Table 2.9.","attachment_path":"tables/WHO_TB_handbook_module3_diagnosis_2025/Table_2.9..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0144","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.5. Phenotypic and genotypic drug resistance testing methods | 2.5.1. Phenotypic DST | Table 2.10. Critical concentrations and clinical breakpoints for medicines recommended for the treatment of MDR/RR- TB","content_type":"table","pages":"41","caption":"Table 2.10. Critical concentrations and clinical breakpoints for medicines recommended for the treatment of MDR/RR- TB","tokens_est":71,"char_count":1500,"has_attachment":true,"attachment_id":"Table 2.10.","attachment_path":"tables/WHO_TB_handbook_module3_diagnosis_2025/Table_2.10..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0145","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.5. Phenotypic and genotypic drug resistance testing methods | 2.5.2. Whole-genome sequencing","content_type":"text","pages":"42","tokens_est":198,"char_count":791,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0146","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.5. Phenotypic and genotypic drug resistance testing methods | 2.5.2. Whole-genome sequencing","content_type":"text","pages":"42","tokens_est":207,"char_count":826,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0147","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.5. Phenotypic and genotypic drug resistance testing methods | 2.5.2. Whole-genome sequencing","content_type":"text","pages":"42","tokens_est":244,"char_count":974,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0148","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.5. Phenotypic and genotypic drug resistance testing methods | 2.5.2. Whole-genome sequencing","content_type":"text","pages":"42","tokens_est":117,"char_count":466,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0149","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.5. Phenotypic and genotypic drug resistance testing methods | 2.5.2. Whole-genome sequencing | Table 2.11. WHO-recommended-diagnostic approaches, reference methods and clinical interpretation for anti-TB medicines","content_type":"table","pages":"42-56","caption":"Table 2.11. WHO-recommended-diagnostic approaches, reference methods and clinical interpretation for anti-TB medicines","tokens_est":49,"char_count":1712,"has_attachment":true,"attachment_id":"Table 2.11.","attachment_path":"tables/WHO_TB_handbook_module3_diagnosis_2025/Table_2.11..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0150","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection","content_type":"text","pages":"57","tokens_est":235,"char_count":940,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0151","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection","content_type":"text","pages":"57","tokens_est":187,"char_count":747,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0152","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection","content_type":"text","pages":"57","tokens_est":233,"char_count":929,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0153","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | Box 2.12. WHO recommendations on tests for TB infection (6)","content_type":"box","pages":"58","caption":"Box 2.12. WHO recommendations on tests for TB infection (6)","tokens_est":162,"char_count":647,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0154","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.1. The TB infection cascade of care","content_type":"text","pages":"58","tokens_est":181,"char_count":721,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0155","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.1. The TB infection cascade of care | Fig. 2.3. Simplified four-step person- centred TB infection cascade of care","content_type":"figure","pages":"58-59","caption":"Fig. 2.3. Simplified four-step person- centred TB infection cascade of care","tokens_est":69,"char_count":274,"has_attachment":true,"attachment_id":"Fig. 2.3.","attachment_path":"figures/WHO_TB_handbook_module3_diagnosis_2025/Fig. 2.3..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0156","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.1. The TB infection cascade of care | Who should be tested for TB infection?","content_type":"text","pages":"59","tokens_est":158,"char_count":632,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0157","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.1. The TB infection cascade of care | Who should be tested for TB infection? | Box 2.13. Groups that WHO recommends should receive TPT (6)","content_type":"box","pages":"59","caption":"Box 2.13. Groups that WHO recommends should receive TPT (6)","tokens_est":193,"char_count":769,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0158","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.1. The TB infection cascade of care | Who should be tested for TB infection? | Box 2.13. Groups that WHO recommends should receive TPT (6)","content_type":"box","pages":"59","caption":"Box 2.13. Groups that WHO recommends should receive TPT (6)","tokens_est":129,"char_count":514,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0159","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.1. The TB infection cascade of care | Who should be tested for TB infection? | Household contacts of people with TB (regardless of HIV status)","content_type":"text","pages":"59","tokens_est":159,"char_count":633,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0160","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.1. The TB infection cascade of care | Who should be tested for TB infection? | Other people at risk of TB","content_type":"text","pages":"59","tokens_est":117,"char_count":466,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0161","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.2. TB infection skin test using tuberculin","content_type":"text","pages":"60","tokens_est":225,"char_count":898,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0162","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.2. TB infection skin test using tuberculin","content_type":"text","pages":"60","tokens_est":146,"char_count":583,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0163","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.3. TB infection skin tests using Mtb -specific antigens","content_type":"text","pages":"60","tokens_est":219,"char_count":873,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0164","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.3. TB infection skin tests using Mtb -specific antigens","content_type":"text","pages":"60","tokens_est":50,"char_count":198,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0165","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.3. TB infection skin tests using Mtb -specific antigens | Table 2.12. Comparison of Mtb -specific infection skin tests","content_type":"table","pages":"61","caption":"Table 2.12. Comparison of Mtb -specific infection skin tests","tokens_est":30,"char_count":267,"has_attachment":true,"attachment_id":"Table 2.12.","attachment_path":"tables/WHO_TB_handbook_module3_diagnosis_2025/Table_2.12..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0166","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.4. Interferon-gamma release assays","content_type":"text","pages":"62","tokens_est":241,"char_count":963,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0167","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.4. Interferon-gamma release assays","content_type":"text","pages":"62","tokens_est":47,"char_count":186,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0168","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.4. Interferon-gamma release assays | Box 2.14. WHO policy statement on IGRAs, 2025","content_type":"box","pages":"62","caption":"Box 2.14. WHO policy statement on IGRAs, 2025","tokens_est":237,"char_count":945,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0169","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.4. Interferon-gamma release assays | Box 2.14. WHO policy statement on IGRAs, 2025","content_type":"box","pages":"62","caption":"Box 2.14. WHO policy statement on IGRAs, 2025","tokens_est":212,"char_count":848,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0170","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.4. Interferon-gamma release assays | Box 2.14. WHO policy statement on IGRAs, 2025","content_type":"box","pages":"62","caption":"Box 2.14. WHO policy statement on IGRAs, 2025","tokens_est":190,"char_count":757,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0171","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.4. Interferon-gamma release assays | Box 2.14. WHO policy statement on IGRAs, 2025","content_type":"box","pages":"62","caption":"Box 2.14. WHO policy statement on IGRAs, 2025","tokens_est":225,"char_count":898,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0172","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.4. Interferon-gamma release assays | Box 2.14. WHO policy statement on IGRAs, 2025","content_type":"box","pages":"62","caption":"Box 2.14. WHO policy statement on IGRAs, 2025","tokens_est":135,"char_count":537,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0173","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.4. Interferon-gamma release assays | Implementation considerations","content_type":"text","pages":"62","tokens_est":181,"char_count":722,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0174","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.4. Interferon-gamma release assays | Implementation considerations","content_type":"text","pages":"62","tokens_est":231,"char_count":924,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0175","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.4. Interferon-gamma release assays | Further research","content_type":"text","pages":"62","tokens_est":224,"char_count":893,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0176","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.4. Interferon-gamma release assays | Further research","content_type":"text","pages":"62-63","tokens_est":125,"char_count":500,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0177","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.4. Interferon-gamma release assays | Further research","content_type":"text","pages":"63","tokens_est":187,"char_count":747,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0178","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.4. Interferon-gamma release assays | Further research","content_type":"text","pages":"63","tokens_est":115,"char_count":460,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0179","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.4. Interferon-gamma release assays | Table 2.13. Comparison of IGRA tests","content_type":"table","pages":"64","caption":"Table 2.13. Comparison of IGRA tests","tokens_est":40,"char_count":413,"has_attachment":true,"attachment_id":"Table 2.13.","attachment_path":"tables/WHO_TB_handbook_module3_diagnosis_2025/Table_2.13..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0180","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.7. Tests WHO recommends against using or recommends limited usage","content_type":"text","pages":"65","tokens_est":248,"char_count":990,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0181","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.7. Tests WHO recommends against using or recommends limited usage","content_type":"text","pages":"65","tokens_est":109,"char_count":436,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0182","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.7. Tests WHO recommends against using or recommends limited usage | Box 2.15. WHO recommendations on the use of the TST and IGRAs for the diagnosis of TB disease (6)","content_type":"box","pages":"65","caption":"Box 2.15. WHO recommendations on the use of the TST and IGRAs for the diagnosis of TB disease (6)","tokens_est":102,"char_count":407,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0183","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.1. Epidemiological considerations","content_type":"text","pages":"66","tokens_est":194,"char_count":775,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0184","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.2. Pretest probability and test accuracy considerations","content_type":"text","pages":"66","tokens_est":226,"char_count":904,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0185","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.2. Pretest probability and test accuracy considerations","content_type":"text","pages":"66","tokens_est":52,"char_count":208,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0186","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.2. Pretest probability and test accuracy considerations","content_type":"text","pages":"66-67","tokens_est":239,"char_count":956,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0187","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.2. Pretest probability and test accuracy considerations","content_type":"text","pages":"66-67","tokens_est":68,"char_count":269,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0188","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.2. Pretest probability and test accuracy considerations","content_type":"text","pages":"67","tokens_est":228,"char_count":911,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0189","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.2. Pretest probability and test accuracy considerations | Box 3.1. Selection of tests based on prevalence, sensitivity and specificity","content_type":"box","pages":"67","caption":"Box 3.1. Selection of tests based on prevalence, sensitivity and specificity","tokens_est":122,"char_count":485,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0190","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.2. Pretest probability and test accuracy considerations | Box 3.1. Selection of tests based on prevalence, sensitivity and specificity","content_type":"box","pages":"67","caption":"Box 3.1. Selection of tests based on prevalence, sensitivity and specificity","tokens_est":234,"char_count":933,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0191","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.2. Pretest probability and test accuracy considerations | Box 3.1. Selection of tests based on prevalence, sensitivity and specificity","content_type":"box","pages":"67","caption":"Box 3.1. Selection of tests based on prevalence, sensitivity and specificity","tokens_est":40,"char_count":158,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0192","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.2. Pretest probability and test accuracy considerations | Box 3.1. Selection of tests based on prevalence, sensitivity and specificity","content_type":"box","pages":"67","caption":"Box 3.1. Selection of tests based on prevalence, sensitivity and specificity","tokens_est":208,"char_count":829,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0193","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.2. Pretest probability and test accuracy considerations | Box 3.2. Effect of screening with CXR","content_type":"box","pages":"67","caption":"Box 3.2. Effect of screening with CXR","tokens_est":215,"char_count":858,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0194","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.2. Pretest probability and test accuracy considerations | Table 3.1. Performance of mWRDs for the detection of TB in adults with signs and symptoms being evaluated for pulmonary TB compared with a microbiological reference standard (absolute number of TP, FP, TN or FN, under a given prevalence out of 1000)","content_type":"table","pages":"68","caption":"Table 3.1 provides examples of population-level projections of the results of testing with automated NAATs (low complexity and moderate complexity) and manual NAATs (low complexity) in settings with different levels of TB prevalence, based on pooled sensitivity and specificity estimates that were extracted from the WHO consolidated guidelines on tuberculosis:","tokens_est":129,"char_count":1141,"has_attachment":true,"attachment_id":"Table 3.1","attachment_path":"tables/WHO_TB_handbook_module3_diagnosis_2025/Table_3.1.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0195","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.2. Pretest probability and test accuracy considerations | Table 3.2. Performance of molecular tests for the detection of RIF resistance in adults with signs and symptoms being evaluated for pulmonary TB a compared with a microbiological reference standard (absolute number of TP, FP, TN or FN, under a given prevalence of RIF resistance out of 1000)","content_type":"table","pages":"69","caption":"Table 3.2. Performance of molecular tests for the detection of RIF resistance in adults with signs and symptoms being evaluated for pulmonary TB a compared with a microbiological reference standard (absolute number of TP, FP, TN or FN, under a given prevalence of RIF resistance out of 1000)","tokens_est":110,"char_count":916,"has_attachment":true,"attachment_id":"Table 3.2.","attachment_path":"tables/WHO_TB_handbook_module3_diagnosis_2025/Table_3.2..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0196","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.2. Pretest probability and test accuracy considerations | Table 3.3. Performance of molecular tests for the detection of INH resistance in adults with detected pulmonary TB a compared with a microbiological reference standard (absolute number of TP, FP, TN or FN, under a given prevalence of INH resistance out of 1000)","content_type":"table","pages":"70","caption":"Table 3.3. Performance of molecular tests for the detection of INH resistance in adults with detected pulmonary TB a compared with a microbiological reference standard (absolute number of TP, FP, TN or FN, under a given prevalence of INH resistance out of 1000)","tokens_est":103,"char_count":1070,"has_attachment":true,"attachment_id":"Table 3.3.","attachment_path":"tables/WHO_TB_handbook_module3_diagnosis_2025/Table_3.3..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0197","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.2. Pretest probability and test accuracy considerations | Table 3.4. Performance of molecular tests for the detection of FQ resistance in adults with detected pulmonary TB compared with a microbiological reference standard (absolute number of TP, FP, TN or FN, under a given prevalence of FQ resistance out of 1000)","content_type":"table","pages":"71","caption":"Table 3.4. Performance of molecular tests for the detection of FQ resistance in adults with detected pulmonary TB compared with a microbiological reference standard (absolute number of TP, FP, TN or FN, under a given prevalence of FQ resistance out of 1000)","tokens_est":102,"char_count":816,"has_attachment":true,"attachment_id":"Table 3.4.","attachment_path":"tables/WHO_TB_handbook_module3_diagnosis_2025/Table_3.4..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0198","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.2. Pretest probability and test accuracy considerations | Table 3.5. Performance of molecular tests for the detection of resistance to other first-line anti-TB medicines in adults with detected pulmonary TB compared with a microbiological reference standard (absolute number of TP, FP, TN or FN, under a given prevalence of resistance out of 1000)","content_type":"table","pages":"72","caption":"Table 3.5. Performance of molecular tests for the detection of resistance to other first-line anti-TB medicines in adults with detected pulmonary TB compared with a microbiological reference standard (absolute number of TP, FP, TN or FN, under a given prevalence of resistance out of 1000)","tokens_est":126,"char_count":739,"has_attachment":true,"attachment_id":"Table 3.5.","attachment_path":"tables/WHO_TB_handbook_module3_diagnosis_2025/Table_3.5..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0199","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.2. Pretest probability and test accuracy considerations | Table 3.6. Performance of targeted NGS for the detection of resistance to anti-TB medicines used to treat MDR/RR-TB in adults with bacteriologically confirmed RIF-resistant pulmonary TB compared with a microbiological reference standard (absolute number of TP, FP, TN or FN, under a given prevalence of resistance out of 1000)","content_type":"table","pages":"73","caption":"Table 3.6. Performance of targeted NGS for the detection of resistance to anti-TB medicines used to treat MDR/RR-TB in adults with bacteriologically confirmed RIF-resistant pulmonary TB compared with a microbiological reference standard (absolute number of TP, FP, TN or FN, under a given prevalence of resistance out of 1000)","tokens_est":132,"char_count":1144,"has_attachment":true,"attachment_id":"Table 3.6.","attachment_path":"tables/WHO_TB_handbook_module3_diagnosis_2025/Table_3.6..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0200","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.3. Planning for and implementing quality-assured TB testing services","content_type":"text","pages":"74","tokens_est":194,"char_count":773,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0201","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.3. Planning for and implementing quality-assured TB testing services","content_type":"text","pages":"74","tokens_est":82,"char_count":327,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0202","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.3. Planning for and implementing quality-assured TB testing services","content_type":"text","pages":"74","tokens_est":102,"char_count":408,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0203","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.3. Planning for and implementing quality-assured TB testing services","content_type":"text","pages":"74","tokens_est":240,"char_count":960,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0204","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.3. Planning for and implementing quality-assured TB testing services","content_type":"text","pages":"74","tokens_est":60,"char_count":238,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0205","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.4. Concurrent testing to improve case detection in children and in people (of all ages) living with HIV","content_type":"text","pages":"74","tokens_est":187,"char_count":746,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0206","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.4. Concurrent testing to improve case detection in children and in people (of all ages) living with HIV","content_type":"text","pages":"74","tokens_est":99,"char_count":396,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0207","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.4. Concurrent testing to improve case detection in children and in people (of all ages) living with HIV","content_type":"text","pages":"74-75","tokens_est":245,"char_count":978,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0208","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.4. Concurrent testing to improve case detection in children and in people (of all ages) living with HIV","content_type":"text","pages":"75","tokens_est":218,"char_count":870,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0209","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.4. Concurrent testing to improve case detection in children and in people (of all ages) living with HIV","content_type":"text","pages":"75","tokens_est":125,"char_count":498,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0210","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.4. Concurrent testing to improve case detection in children and in people (of all ages) living with HIV","content_type":"text","pages":"75","tokens_est":239,"char_count":953,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0211","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.4. Concurrent testing to improve case detection in children and in people (of all ages) living with HIV","content_type":"text","pages":"75","tokens_est":91,"char_count":364,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0212","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.4. Concurrent testing to improve case detection in children and in people (of all ages) living with HIV","content_type":"text","pages":"75","tokens_est":176,"char_count":704,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0213","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.4. Concurrent testing to improve case detection in children and in people (of all ages) living with HIV","content_type":"text","pages":"75-76","tokens_est":214,"char_count":855,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0214","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.4. Concurrent testing to improve case detection in children and in people (of all ages) living with HIV","content_type":"text","pages":"76","tokens_est":175,"char_count":698,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0215","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.4. Concurrent testing to improve case detection in children and in people (of all ages) living with HIV","content_type":"text","pages":"76","tokens_est":228,"char_count":910,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0216","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.4. Concurrent testing to improve case detection in children and in people (of all ages) living with HIV","content_type":"text","pages":"76","tokens_est":223,"char_count":889,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0217","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.4. Concurrent testing to improve case detection in children and in people (of all ages) living with HIV","content_type":"text","pages":"76","tokens_est":226,"char_count":904,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0218","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.4. Concurrent testing to improve case detection in children and in people (of all ages) living with HIV","content_type":"text","pages":"76","tokens_est":111,"char_count":442,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0219","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.5. Testing for TB infection | 3.5.1. What are the advantages and disadvantages of testing for TB infection?","content_type":"text","pages":"77","tokens_est":208,"char_count":832,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0220","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.5. Testing for TB infection | 3.5.1. What are the advantages and disadvantages of testing for TB infection?","content_type":"text","pages":"77","tokens_est":151,"char_count":604,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0221","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.5. Testing for TB infection | 3.5.1. What are the advantages and disadvantages of testing for TB infection?","content_type":"text","pages":"77","tokens_est":188,"char_count":751,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0222","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.5. Testing for TB infection | 3.5.1. What are the advantages and disadvantages of testing for TB infection?","content_type":"text","pages":"77","tokens_est":172,"char_count":685,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0223","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.5. Testing for TB infection | 3.5.1. What are the advantages and disadvantages of testing for TB infection?","content_type":"text","pages":"77","tokens_est":205,"char_count":818,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0224","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.5. Testing for TB infection | 3.5.1. What are the advantages and disadvantages of testing for TB infection?","content_type":"text","pages":"77-78","tokens_est":198,"char_count":790,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0225","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.5. Testing for TB infection | 3.5.1. What are the advantages and disadvantages of testing for TB infection?","content_type":"text","pages":"78","tokens_est":136,"char_count":541,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0226","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.5. Testing for TB infection | 3.5.1. What are the advantages and disadvantages of testing for TB infection?","content_type":"text","pages":"78","tokens_est":181,"char_count":723,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0227","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.5. Testing for TB infection | 3.5.2. When is testing for TB infection not advised?","content_type":"text","pages":"78","tokens_est":37,"char_count":148,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0228","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.5. Testing for TB infection | 3.5.2. When is testing for TB infection not advised? | Prior positive TB infection tests","content_type":"text","pages":"78","tokens_est":124,"char_count":494,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0229","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.5. Testing for TB infection | 3.5.2. When is testing for TB infection not advised? | Concomitant or recent vaccines or viral illnesses","content_type":"text","pages":"78","tokens_est":138,"char_count":549,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0230","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.5. Testing for TB infection | 3.5.2. When is testing for TB infection not advised? | Concomitant or recent vaccines or viral illnesses","content_type":"text","pages":"78-79","tokens_est":162,"char_count":646,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0231","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.5. Testing for TB infection | 3.5.2. When is testing for TB infection not advised? | Clinical work-up of adults to diagnose TB disease or monitoring of the response to treatment","content_type":"text","pages":"79","tokens_est":108,"char_count":431,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0232","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.5. Testing for TB infection | 3.5.2. When is testing for TB infection not advised? | History of TST or TBST allergic reactions (but IGRAs may be used)","content_type":"text","pages":"79","tokens_est":237,"char_count":947,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0233","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.5. Testing for TB infection | 3.5.2. When is testing for TB infection not advised? | Challenges with blood collection in young children when using IGRAs (but TBST may be used)","content_type":"text","pages":"79","tokens_est":95,"char_count":380,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0234","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.6. Multidisease testing considerations","content_type":"text","pages":"79","tokens_est":215,"char_count":860,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0235","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.6. Multidisease testing considerations","content_type":"text","pages":"79","tokens_est":127,"char_count":507,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0236","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.6. Multidisease testing considerations","content_type":"text","pages":"79-80","tokens_est":214,"char_count":855,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0237","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"4. Placement of diagnostic tests in the tiered laboratory network","content_type":"text","pages":"81","tokens_est":191,"char_count":763,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0238","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"4. Placement of diagnostic tests in the tiered laboratory network","content_type":"text","pages":"81","tokens_est":119,"char_count":476,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0239","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"4. Placement of diagnostic tests in the tiered laboratory network","content_type":"text","pages":"81","tokens_est":181,"char_count":722,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0240","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"4. Placement of diagnostic tests in the tiered laboratory network | Fig. 4.1. The 12 benchmarks constituting the WHO standard are divided into four steps along the diagnostic cascade","content_type":"figure","pages":"81-82","caption":"Fig. 4.1. The 12 benchmarks constituting the WHO standard are divided into four steps along the diagnostic cascade","tokens_est":82,"char_count":326,"has_attachment":true,"attachment_id":"Fig. 4.1.","attachment_path":"figures/WHO_TB_handbook_module3_diagnosis_2025/Fig. 4.1..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0241","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"4. Placement of diagnostic tests in the tiered laboratory network | 4.1. Peripheral level","content_type":"text","pages":"82","tokens_est":186,"char_count":744,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0242","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"4. Placement of diagnostic tests in the tiered laboratory network | 4.1. Peripheral level","content_type":"text","pages":"82-83","tokens_est":128,"char_count":509,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0243","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"4. Placement of diagnostic tests in the tiered laboratory network | 4.1. Peripheral level","content_type":"text","pages":"83-84","tokens_est":236,"char_count":942,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0244","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"4. Placement of diagnostic tests in the tiered laboratory network | 4.1. Peripheral level","content_type":"text","pages":"84","tokens_est":167,"char_count":665,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0245","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"4. Placement of diagnostic tests in the tiered laboratory network | 4.1. Peripheral level","content_type":"text","pages":"84","tokens_est":122,"char_count":488,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0246","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"4. Placement of diagnostic tests in the tiered laboratory network | 4.2. Intermediate level","content_type":"text","pages":"84","tokens_est":177,"char_count":708,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0247","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"4. Placement of diagnostic tests in the tiered laboratory network | 4.2. Intermediate level","content_type":"text","pages":"84-85","tokens_est":245,"char_count":977,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0248","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"4. Placement of diagnostic tests in the tiered laboratory network | 4.3. Central level","content_type":"text","pages":"85","tokens_est":187,"char_count":745,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0249","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"4. Placement of diagnostic tests in the tiered laboratory network | 4.3. Central level","content_type":"text","pages":"85","tokens_est":90,"char_count":357,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0250","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"4. Placement of diagnostic tests in the tiered laboratory network | 4.3. Central level | Fig. 4.2. Organization of a TB diagnostic testing network","content_type":"figure","pages":"85","caption":"Fig. 4.2. Organization of a TB diagnostic testing network","tokens_est":135,"char_count":540,"has_attachment":true,"attachment_id":"Fig. 4.2.","attachment_path":"figures/WHO_TB_handbook_module3_diagnosis_2025/Fig. 4.2..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0251","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"4. Placement of diagnostic tests in the tiered laboratory network | 4.4. Structure of network and testing packages","content_type":"text","pages":"86","tokens_est":218,"char_count":869,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0252","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"4. Placement of diagnostic tests in the tiered laboratory network | 4.4. Structure of network and testing packages","content_type":"text","pages":"86","tokens_est":240,"char_count":958,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0253","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"4. Placement of diagnostic tests in the tiered laboratory network | 4.4. Structure of network and testing packages","content_type":"text","pages":"86","tokens_est":229,"char_count":913,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0254","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"4. Placement of diagnostic tests in the tiered laboratory network | 4.4. Structure of network and testing packages","content_type":"text","pages":"86-87","tokens_est":206,"char_count":823,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0255","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test","content_type":"text","pages":"88","tokens_est":182,"char_count":725,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0256","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.1. Area 1  Policies, budgeting and planning | Step 1.1  Establish a TWG with defined roles and responsibilities","content_type":"text","pages":"88","tokens_est":107,"char_count":425,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0257","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.1. Area 1  Policies, budgeting and planning | Step 1.1  Establish a TWG with defined roles and responsibilities","content_type":"text","pages":"88-89","tokens_est":231,"char_count":921,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0258","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.1. Area 1  Policies, budgeting and planning | Step 1.1  Establish a TWG with defined roles and responsibilities","content_type":"text","pages":"89","tokens_est":187,"char_count":746,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0259","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.1. Area 1  Policies, budgeting and planning | Step 1.1  Establish a TWG with defined roles and responsibilities","content_type":"text","pages":"89","tokens_est":101,"char_count":401,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0260","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.1. Area 1  Policies, budgeting and planning | Step 1.2  Review WHO policies and available technical and implementation guides","content_type":"text","pages":"89","tokens_est":152,"char_count":605,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0261","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.1. Area 1  Policies, budgeting and planning | Step 1.3  Define immediate and future purposes of the test","content_type":"text","pages":"89","tokens_est":108,"char_count":432,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0262","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.1. Area 1  Policies, budgeting and planning | Step 1.4  Update national diagnostic algorithm and guidelines","content_type":"text","pages":"90","tokens_est":224,"char_count":893,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0263","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.1. Area 1  Policies, budgeting and planning | Step 1.5  Perform a situational analysis, including biosafety","content_type":"text","pages":"90","tokens_est":190,"char_count":758,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0264","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.1. Area 1  Policies, budgeting and planning | Step 1.5  Perform a situational analysis, including biosafety","content_type":"text","pages":"90","tokens_est":81,"char_count":323,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0265","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.1. Area 1  Policies, budgeting and planning | Step 1.6  Develop a costed operational plan for phased implementation","content_type":"text","pages":"90","tokens_est":170,"char_count":680,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0266","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.1. Area 1  Policies, budgeting and planning | Step 1.6  Develop a costed operational plan for phased implementation","content_type":"text","pages":"90","tokens_est":185,"char_count":739,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0267","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.2. Area 2  Regulatory issues | Step 2.1  Complete national regulatory processes","content_type":"text","pages":"91","tokens_est":177,"char_count":705,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0268","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.2. Area 2  Regulatory issues | Step 2.1  Complete national regulatory processes","content_type":"text","pages":"91","tokens_est":120,"char_count":479,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0269","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.2. Area 2  Regulatory issues | Step 2.2  Determine importation requirements","content_type":"text","pages":"91","tokens_est":120,"char_count":477,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0270","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.2. Area 2  Regulatory issues | Step 2.3  Conduct country validation and verification studies, as required","content_type":"text","pages":"91","tokens_est":206,"char_count":821,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0271","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.2. Area 2  Regulatory issues | Step 2.3  Conduct country validation and verification studies, as required","content_type":"text","pages":"91","tokens_est":72,"char_count":286,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0272","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.2. Area 2  Regulatory issues | Step 2.3  Conduct country validation and verification studies, as required","content_type":"text","pages":"91","tokens_est":65,"char_count":259,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0273","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.2. Area 2  Regulatory issues | Step 2.3  Conduct country validation and verification studies, as required","content_type":"text","pages":"91-92","tokens_est":224,"char_count":893,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0274","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.2. Area 2  Regulatory issues | Step 2.3  Conduct country validation and verification studies, as required","content_type":"text","pages":"91-92","tokens_est":112,"char_count":446,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0275","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.2. Area 2  Regulatory issues | Step 2.3  Conduct country validation and verification studies, as required","content_type":"text","pages":"92","tokens_est":66,"char_count":261,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0276","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.3. Area 3  Equipment | Step 3.1  Select, procure, install and set up equipment","content_type":"text","pages":"92","tokens_est":238,"char_count":952,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0277","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.3. Area 3  Equipment | Step 3.1  Select, procure, install and set up equipment","content_type":"text","pages":"92-93","tokens_est":244,"char_count":973,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0278","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.3. Area 3  Equipment | Step 3.1  Select, procure, install and set up equipment","content_type":"text","pages":"93","tokens_est":128,"char_count":510,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0279","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.3. Area 3  Equipment | Step 3.2  Verify and maintain instruments","content_type":"text","pages":"93","tokens_est":204,"char_count":813,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0280","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.3. Area 3  Equipment | Step 3.2  Verify and maintain instruments","content_type":"text","pages":"93","tokens_est":144,"char_count":576,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0281","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.3. Area 3  Equipment | Step 3.2  Verify and maintain instruments","content_type":"text","pages":"93","tokens_est":150,"char_count":600,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0282","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.3. Area 3  Equipment | Step 3.3  Assess site readiness and ensure a safe and functional testing site","content_type":"text","pages":"93","tokens_est":198,"char_count":790,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0283","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.3. Area 3  Equipment | Step 3.3  Assess site readiness and ensure a safe and functional testing site","content_type":"text","pages":"93-94","tokens_est":166,"char_count":664,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0284","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.4. Area 4  Supply chain | Step 4.1  Review forecasting, ordering and distribution procedures","content_type":"text","pages":"94","tokens_est":224,"char_count":893,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0285","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.4. Area 4  Supply chain | Step 4.1  Review forecasting, ordering and distribution procedures","content_type":"text","pages":"94","tokens_est":243,"char_count":972,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0286","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.4. Area 4  Supply chain | Step 4.2  Develop procedures to monitor reagent quality and shelf life","content_type":"text","pages":"94","tokens_est":108,"char_count":432,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0287","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.4. Area 4  Supply chain | Step 4.2  Develop procedures to monitor reagent quality and shelf life","content_type":"text","pages":"94-95","tokens_est":171,"char_count":684,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0288","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.4. Area 4  Supply chain | Step 4.2  Develop procedures to monitor reagent quality and shelf life","content_type":"text","pages":"95","tokens_est":209,"char_count":834,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0289","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.5. Area 5  Procedures | Step 5.1  Develop SOPs","content_type":"text","pages":"95","tokens_est":149,"char_count":595,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0290","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.5. Area 5  Procedures | Step 5.1  Develop SOPs","content_type":"text","pages":"95","tokens_est":126,"char_count":503,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0291","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.5. Area 5  Procedures | Step 5.2  Update clinical procedures and strengthen the clinicallaboratory interface","content_type":"text","pages":"96","tokens_est":222,"char_count":885,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0292","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.5. Area 5  Procedures | Step 5.2  Update clinical procedures and strengthen the clinicallaboratory interface","content_type":"text","pages":"96","tokens_est":87,"char_count":346,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0293","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.5. Area 5  Procedures | Step 5.2  Update clinical procedures and strengthen the clinicallaboratory interface","content_type":"text","pages":"96","tokens_est":90,"char_count":360,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0294","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.6. Area 6  Digital data | Step 6.1  Develop the use of digital data and diagnostics connectivity","content_type":"text","pages":"96","tokens_est":213,"char_count":852,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0295","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.6. Area 6  Digital data | Step 6.1  Develop the use of digital data and diagnostics connectivity","content_type":"text","pages":"96","tokens_est":111,"char_count":442,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0296","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.6. Area 6  Digital data | Step 6.1  Develop the use of digital data and diagnostics connectivity","content_type":"text","pages":"96-97","tokens_est":159,"char_count":633,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0297","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.6. Area 6  Digital data | Step 6.2  Develop procedures for data backup, security and confidentiality","content_type":"text","pages":"97","tokens_est":189,"char_count":756,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0298","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.6. Area 6  Digital data | Step 6.3  Data requirements for targeted NGS","content_type":"text","pages":"97","tokens_est":103,"char_count":409,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0299","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.7. Area 7  Quality assurance, control and assessment | Step 7.1  Implement a comprehensive QA system","content_type":"text","pages":"97-98","tokens_est":204,"char_count":815,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0300","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.7. Area 7  Quality assurance, control and assessment | Step 7.2  Establish and monitor QC","content_type":"text","pages":"98","tokens_est":194,"char_count":773,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0301","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.7. Area 7  Quality assurance, control and assessment | Step 7.2  Establish and monitor QC","content_type":"text","pages":"98","tokens_est":143,"char_count":572,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0302","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.7. Area 7  Quality assurance, control and assessment | Step 7.3  Develop an EQA programme","content_type":"text","pages":"98","tokens_est":191,"char_count":762,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0303","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.7. Area 7  Quality assurance, control and assessment | Step 7.3  Develop an EQA programme","content_type":"text","pages":"98-99","tokens_est":193,"char_count":771,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0304","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.7. Area 7  Quality assurance, control and assessment | Step 7.3  Develop an EQA programme","content_type":"text","pages":"99","tokens_est":98,"char_count":389,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0305","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.7. Area 7  Quality assurance, control and assessment | Step 7.3  Develop an EQA programme","content_type":"text","pages":"99","tokens_est":162,"char_count":645,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0306","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.7. Area 7  Quality assurance, control and assessment | Step 7.3  Develop an EQA programme","content_type":"text","pages":"99","tokens_est":172,"char_count":688,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0307","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.7. Area 7  Quality assurance, control and assessment | Step 7.4  Monitor and analyse quality indicators","content_type":"text","pages":"99","tokens_est":186,"char_count":741,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0308","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.7. Area 7  Quality assurance, control and assessment | Step 7.4  Monitor and analyse quality indicators","content_type":"text","pages":"99","tokens_est":232,"char_count":925,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0309","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.7. Area 7  Quality assurance, control and assessment | Step 7.4  Monitor and analyse quality indicators","content_type":"text","pages":"99-100","tokens_est":54,"char_count":216,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0310","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.8. Area 8  Recording and reporting | Step 8.1  Review and revise request for examination and reporting forms","content_type":"text","pages":"100","tokens_est":140,"char_count":560,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0311","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.8. Area 8  Recording and reporting | Step 8.1  Review and revise request for examination and reporting forms","content_type":"text","pages":"100","tokens_est":148,"char_count":590,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0312","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.8. Area 8  Recording and reporting | Step 8.1  Review and revise request for examination and reporting forms","content_type":"text","pages":"100","tokens_est":188,"char_count":752,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0313","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.8. Area 8  Recording and reporting | Step 8.1  Review and revise request for examination and reporting forms","content_type":"text","pages":"100","tokens_est":167,"char_count":665,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0314","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.8. Area 8  Recording and reporting | Step 8.1  Review and revise request for examination and reporting forms","content_type":"text","pages":"100","tokens_est":130,"char_count":519,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0315","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.8. Area 8  Recording and reporting | Step 8.1  Review and revise request for examination and reporting forms","content_type":"text","pages":"100-101","tokens_est":143,"char_count":570,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0316","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.8. Area 8  Recording and reporting | Step 8.2  Review and revise laboratory and clinical registers","content_type":"text","pages":"101","tokens_est":157,"char_count":625,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0317","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.9. Area 9  Human resource training and competency assessment | Step 9.1  Develop terms of reference and position descriptions","content_type":"text","pages":"101","tokens_est":125,"char_count":500,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0318","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.9. Area 9  Human resource training and competency assessment | Step 9.2  Develop and implement a training curriculum and strategy","content_type":"text","pages":"101","tokens_est":247,"char_count":988,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0319","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.9. Area 9  Human resource training and competency assessment | Step 9.2  Develop and implement a training curriculum and strategy","content_type":"text","pages":"101-102","tokens_est":217,"char_count":865,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0320","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.9. Area 9  Human resource training and competency assessment | Step 9.3  Assess and document the competence of staff","content_type":"text","pages":"102","tokens_est":163,"char_count":651,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0321","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.9. Area 9  Human resource training and competency assessment | Step 9.4  Provide for post-training mentoring and support","content_type":"text","pages":"102","tokens_est":105,"char_count":418,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0322","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.10. Area 10  Monitoring and evaluation | Step 10.1  Monitor implementation of the diagnostic test","content_type":"text","pages":"102","tokens_est":172,"char_count":687,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0323","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.10. Area 10  Monitoring and evaluation | Step 10.2  Monitor and evaluate impact of the diagnostic test","content_type":"text","pages":"103","tokens_est":219,"char_count":876,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0324","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms","content_type":"text","pages":"104","tokens_est":206,"char_count":824,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0325","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms","content_type":"text","pages":"104","tokens_est":209,"char_count":836,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0326","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms","content_type":"text","pages":"104","tokens_est":241,"char_count":963,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0327","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms","content_type":"text","pages":"104-105","tokens_est":146,"char_count":583,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0328","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | TB screening strategies","content_type":"text","pages":"105","tokens_est":227,"char_count":908,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0329","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | TB screening strategies","content_type":"text","pages":"105","tokens_est":209,"char_count":836,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0330","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.1. Implementing a new diagnostic algorithm","content_type":"text","pages":"105","tokens_est":246,"char_count":982,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0331","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.1. Implementing a new diagnostic algorithm","content_type":"text","pages":"105-106","tokens_est":197,"char_count":788,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0332","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.1. Implementing a new diagnostic algorithm","content_type":"text","pages":"106","tokens_est":113,"char_count":449,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0333","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.2. The cascade of the four model algorithms","content_type":"text","pages":"106","tokens_est":170,"char_count":679,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0334","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.2. The cascade of the four model algorithms","content_type":"text","pages":"106","tokens_est":112,"char_count":447,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0335","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.2. The cascade of the four model algorithms","content_type":"text","pages":"106","tokens_est":152,"char_count":605,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0336","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.2. The cascade of the four model algorithms","content_type":"text","pages":"106","tokens_est":135,"char_count":537,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0337","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.2. The cascade of the four model algorithms | Fig. 6.1. The cascade of the four diagnostic algorithms","content_type":"figure","pages":"106-107","caption":"Fig. 6.1. The cascade of the four diagnostic algorithms","tokens_est":208,"char_count":829,"has_attachment":true,"attachment_id":"Fig. 6.1.","attachment_path":"figures/WHO_TB_handbook_module3_diagnosis_2025/Fig. 6.1..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0338","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB","content_type":"text","pages":"108","tokens_est":225,"char_count":898,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0339","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB","content_type":"text","pages":"108","tokens_est":134,"char_count":535,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0340","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB","content_type":"text","pages":"108","tokens_est":195,"char_count":777,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0341","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB","content_type":"text","pages":"108","tokens_est":74,"char_count":294,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0342","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB","content_type":"text","pages":"108","tokens_est":59,"char_count":235,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0343","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | Fig. 6.2. Algorithm 1: mWRD as the i nitial diagnostic test for T B","content_type":"figure","pages":"108-111","caption":"Fig. 6.2. Algorithm 1: mWRD as the i nitial diagnostic test for T B","tokens_est":2113,"char_count":8450,"has_attachment":true,"attachment_id":"Fig. 6.2.","attachment_path":"figures/WHO_TB_handbook_module3_diagnosis_2025/Fig. 6.2..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0344","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | General considerations","content_type":"text","pages":"112","tokens_est":207,"char_count":825,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0345","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | General considerations","content_type":"text","pages":"112","tokens_est":165,"char_count":660,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0346","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | General considerations","content_type":"text","pages":"112","tokens_est":214,"char_count":854,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0347","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | General considerations","content_type":"text","pages":"112","tokens_est":170,"char_count":677,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0348","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | General considerations","content_type":"text","pages":"112-113","tokens_est":236,"char_count":943,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0349","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | General considerations","content_type":"text","pages":"113","tokens_est":159,"char_count":634,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0350","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | General considerations","content_type":"text","pages":"113","tokens_est":172,"char_count":687,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0351","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | General considerations","content_type":"text","pages":"113","tokens_est":161,"char_count":643,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0352","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | General considerations","content_type":"text","pages":"113","tokens_est":246,"char_count":982,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0353","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | General considerations","content_type":"text","pages":"113-114","tokens_est":105,"char_count":420,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0354","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"114","tokens_est":188,"char_count":752,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0355","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"114","tokens_est":176,"char_count":702,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0356","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway | Fig 6.2.1. Pathway 1A : All tests are negative","content_type":"figure","pages":"114","caption":"Fig 6.2.1. Pathway 1A : All tests are negative","tokens_est":70,"char_count":279,"has_attachment":true,"attachment_id":"Fig 6.2.1.","attachment_path":"figures/WHO_TB_handbook_module3_diagnosis_2025/Fig 6.2.1..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0357","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"114","tokens_est":197,"char_count":788,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0358","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"114-115","tokens_est":193,"char_count":770,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0359","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway | Fig 6.2.2. Pathway 1B: MTBC detected, and RIF susceptibility confirmed","content_type":"figure","pages":"115","caption":"Fig 6.2.2. Pathway 1B: MTBC detected, and RIF susceptibility confirmed","tokens_est":109,"char_count":434,"has_attachment":true,"attachment_id":"Fig 6.2.2.","attachment_path":"figures/WHO_TB_handbook_module3_diagnosis_2025/Fig 6.2.2..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0360","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"115","tokens_est":221,"char_count":884,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0361","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"115-116","tokens_est":122,"char_count":487,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0362","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"116","tokens_est":245,"char_count":979,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0363","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"116","tokens_est":228,"char_count":912,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0364","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"116","tokens_est":178,"char_count":712,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0365","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"116","tokens_est":131,"char_count":523,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0366","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway | Fig 6.2.3. Pathway 1C: MTBC detected and RIF resistance detected","content_type":"figure","pages":"116-117","caption":"Fig 6.2.3. Pathway 1C: MTBC detected and RIF resistance detected","tokens_est":88,"char_count":352,"has_attachment":true,"attachment_id":"Fig 6.2.3.","attachment_path":"figures/WHO_TB_handbook_module3_diagnosis_2025/Fig 6.2.3..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0367","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"117-118","tokens_est":220,"char_count":878,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0368","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"118","tokens_est":222,"char_count":886,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0369","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"118","tokens_est":236,"char_count":942,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0370","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"118","tokens_est":224,"char_count":896,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0371","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"118-119","tokens_est":194,"char_count":776,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0372","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"119","tokens_est":248,"char_count":990,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0373","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"119","tokens_est":48,"char_count":192,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0374","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway | Fig 6.2.4. Pathway 1D: MTBC detected (if Ultra, not trace result) and RIF resistance unknown or indeterminate","content_type":"figure","pages":"119-120","caption":"Fig 6.2.4. Pathway 1D: MTBC detected (if Ultra, not trace result) and RIF resistance unknown or indeterminate","tokens_est":113,"char_count":451,"has_attachment":true,"attachment_id":"Fig 6.2.4.","attachment_path":"figures/WHO_TB_handbook_module3_diagnosis_2025/Fig 6.2.4..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0375","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"120-121","tokens_est":221,"char_count":884,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0376","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"120-121","tokens_est":51,"char_count":201,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0377","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"121","tokens_est":105,"char_count":420,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0378","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"121","tokens_est":192,"char_count":768,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0379","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"121","tokens_est":236,"char_count":942,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0380","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway | Fig 6.2.5. Pathway 1E: MTBC detected with trace result, RIF indeterminate","content_type":"figure","pages":"121-122","caption":"Fig 6.2.5. Pathway 1E: MTBC detected with trace result, RIF indeterminate","tokens_est":108,"char_count":429,"has_attachment":true,"attachment_id":"Fig 6.2.5.","attachment_path":"figures/WHO_TB_handbook_module3_diagnosis_2025/Fig 6.2.5..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0381","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"122-124","tokens_est":208,"char_count":829,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0382","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"124","tokens_est":223,"char_count":892,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0383","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"124","tokens_est":241,"char_count":962,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0384","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"124","tokens_est":202,"char_count":805,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0385","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"124-125","tokens_est":213,"char_count":851,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0386","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"125","tokens_est":130,"char_count":519,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0387","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway | Interpretation of discordant results","content_type":"text","pages":"125","tokens_est":194,"char_count":776,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0388","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway | Interpretation of discordant results","content_type":"text","pages":"125","tokens_est":230,"char_count":918,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0389","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway | Interpretation of discordant results","content_type":"text","pages":"125-126","tokens_est":228,"char_count":909,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0390","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway | Interpretation of discordant results","content_type":"text","pages":"126","tokens_est":211,"char_count":844,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0391","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway | Interpretation of discordant results","content_type":"text","pages":"126","tokens_est":197,"char_count":788,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0392","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway | Interpretation of discordant results","content_type":"text","pages":"126","tokens_est":223,"char_count":892,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0393","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway | Interpretation of discordant results","content_type":"text","pages":"126","tokens_est":199,"char_count":796,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0394","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway | Interpretation of discordant results","content_type":"text","pages":"126-127","tokens_est":185,"char_count":738,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0395","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway | Interpretation of discordant results","content_type":"text","pages":"127","tokens_est":224,"char_count":894,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0396","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway | Interpretation of discordant results","content_type":"text","pages":"127","tokens_est":109,"char_count":434,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0397","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway | Interpretation of discordant results","content_type":"text","pages":"127","tokens_est":238,"char_count":952,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0398","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway | Interpretation of discordant results","content_type":"text","pages":"127-128","tokens_est":241,"char_count":963,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0399","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway | Interpretation of discordant results","content_type":"text","pages":"128","tokens_est":154,"char_count":613,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0400","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB","content_type":"text","pages":"128","tokens_est":234,"char_count":935,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0401","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB","content_type":"text","pages":"128","tokens_est":135,"char_count":537,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0402","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | General considerations","content_type":"text","pages":"129","tokens_est":209,"char_count":836,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0403","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | General considerations","content_type":"text","pages":"129","tokens_est":177,"char_count":707,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0404","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | Fig. 6.3. Treatment option overview","content_type":"figure","pages":"129-130","caption":"Fig. 6.3. Treatment option overview","tokens_est":220,"char_count":878,"has_attachment":true,"attachment_id":"Fig. 6.3.","attachment_path":"figures/WHO_TB_handbook_module3_diagnosis_2025/Fig. 6.3..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0405","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB","content_type":"text","pages":"130-131","tokens_est":201,"char_count":802,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0406","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB","content_type":"text","pages":"131","tokens_est":155,"char_count":618,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0407","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB","content_type":"text","pages":"131","tokens_est":236,"char_count":942,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0408","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB","content_type":"text","pages":"131","tokens_est":179,"char_count":715,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0409","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | Fig. 6.4. Algorithm 2a: DST for MDR/RR-TB using targeted NGS","content_type":"figure","pages":"131-133","caption":"Fig. 6.4. Algorithm 2a: DST for MDR/RR-TB using targeted NGS","tokens_est":669,"char_count":2674,"has_attachment":true,"attachment_id":"Fig. 6.4.","attachment_path":"figures/WHO_TB_handbook_module3_diagnosis_2025/Fig. 6.4..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0410","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | Decision pathway for Algorithm 2a  Testing for BDQ and FQ resistance (Fig. 6.4)","content_type":"text","pages":"133","tokens_est":203,"char_count":809,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0411","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | Decision pathway for Algorithm 2a  Testing for BDQ and FQ resistance (Fig. 6.4)","content_type":"text","pages":"133","tokens_est":246,"char_count":982,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0412","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | Decision pathway for Algorithm 2a  Testing for BDQ and FQ resistance (Fig. 6.4)","content_type":"text","pages":"133-134","tokens_est":81,"char_count":321,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0413","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | Decision pathway for Algorithm 2a  Testing for BDQ and FQ resistance (Fig. 6.4)","content_type":"text","pages":"134","tokens_est":212,"char_count":846,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0414","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | Decision pathway for Algorithm 2a  Testing for BDQ and FQ resistance (Fig. 6.4)","content_type":"text","pages":"134","tokens_est":241,"char_count":964,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0415","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | Decision pathway for Algorithm 2a  Testing for BDQ and FQ resistance (Fig. 6.4)","content_type":"text","pages":"134","tokens_est":71,"char_count":282,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0416","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | Decision pathway for Algorithm 2a  Testing for BDQ and FQ resistance (Fig. 6.4)","content_type":"text","pages":"134","tokens_est":159,"char_count":635,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0417","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | Decision pathway for Algorithm 2a  Testing for BDQ and FQ resistance (Fig. 6.4)","content_type":"text","pages":"134","tokens_est":134,"char_count":536,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0418","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | Decision pathway for Algorithm 2a  Testing for BDQ and FQ resistance (Fig. 6.4)","content_type":"text","pages":"134","tokens_est":180,"char_count":720,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0419","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | Fig. 6.5. Algorithm 2b: DST for people with MDR/RR-TB (limited or no targeted NGS capacity)","content_type":"figure","pages":"134-136","caption":"Fig. 6.5. Algorithm 2b: DST for people with MDR/RR-TB (limited or no targeted NGS capacity)","tokens_est":830,"char_count":3317,"has_attachment":true,"attachment_id":"Fig. 6.5.","attachment_path":"figures/WHO_TB_handbook_module3_diagnosis_2025/Fig. 6.5..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0420","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | Decision pathway for Algorithm 2b  Testing for FQ resistance (Fig. 6.5)","content_type":"text","pages":"136","tokens_est":247,"char_count":988,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0421","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | Decision pathway for Algorithm 2b  Testing for FQ resistance (Fig. 6.5)","content_type":"text","pages":"136-137","tokens_est":232,"char_count":927,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0422","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | Decision pathway for Algorithm 2b  Testing for FQ resistance (Fig. 6.5)","content_type":"text","pages":"137","tokens_est":202,"char_count":808,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0423","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | Decision pathway for Algorithm 2b  Testing for FQ resistance (Fig. 6.5)","content_type":"text","pages":"137","tokens_est":172,"char_count":685,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0424","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | Decision pathway for Algorithm 2b  Testing for FQ resistance (Fig. 6.5)","content_type":"text","pages":"137","tokens_est":173,"char_count":691,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0425","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | Decision pathway for Algorithm 2b  Testing for FQ resistance (Fig. 6.5)","content_type":"text","pages":"137","tokens_est":237,"char_count":946,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0426","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | Decision pathway for Algorithm 2b  Testing for FQ resistance (Fig. 6.5)","content_type":"text","pages":"137-138","tokens_est":176,"char_count":701,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0427","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.5. Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs","content_type":"text","pages":"138","tokens_est":202,"char_count":806,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0428","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.5. Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs","content_type":"text","pages":"138","tokens_est":124,"char_count":494,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0429","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.5. Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs | 6.5.1. General considerations","content_type":"text","pages":"138","tokens_est":176,"char_count":703,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0430","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.5. Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs | 6.5.1. General considerations","content_type":"text","pages":"138-139","tokens_est":226,"char_count":902,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0431","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.5. Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs | 6.5.1. General considerations","content_type":"text","pages":"139","tokens_est":199,"char_count":795,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0432","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.5. Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs | 6.5.1. General considerations","content_type":"text","pages":"139","tokens_est":80,"char_count":319,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0433","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.5. Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs | 6.5.1. General considerations | Fig. 6.6. Algorithm 3: Follow-on testing for people with RIF-susceptible TB at risk of resistance to other drugs","content_type":"figure","pages":"139-141","caption":"Fig. 6.6. Algorithm 3: Follow-on testing for people with RIF-susceptible TB at risk of resistance to other drugs","tokens_est":810,"char_count":3240,"has_attachment":true,"attachment_id":"Fig. 6.6.","attachment_path":"figures/WHO_TB_handbook_module3_diagnosis_2025/Fig. 6.6..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0434","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.5. Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs | 6.5.1. General considerations | Decision pathway for Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs","content_type":"text","pages":"141","tokens_est":206,"char_count":823,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0435","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.5. Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs | 6.5.1. General considerations | Decision pathway for Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs","content_type":"text","pages":"141-142","tokens_est":220,"char_count":880,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0436","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.5. Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs | 6.5.1. General considerations | Decision pathway for Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs","content_type":"text","pages":"142","tokens_est":171,"char_count":681,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0437","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.5. Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs | 6.5.1. General considerations | Decision pathway for Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs","content_type":"text","pages":"142","tokens_est":247,"char_count":985,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0438","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.5. Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs | 6.5.1. General considerations | Decision pathway for Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs","content_type":"text","pages":"142","tokens_est":102,"char_count":407,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0439","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.5. Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs | 6.5.1. General considerations | Table 6.1. Treatment modifications and follow-on DST for Hr -TB based on results from targeted NGS","content_type":"table","pages":"142","caption":"Table 6.1. Treatment modifications and follow-on DST for Hr -TB based on results from targeted NGS","tokens_est":55,"char_count":717,"has_attachment":true,"attachment_id":"Table 6.1.","attachment_path":"tables/WHO_TB_handbook_module3_diagnosis_2025/Table_6.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0440","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.5. Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs | 6.5.1. General considerations","content_type":"text","pages":"142-143","tokens_est":208,"char_count":830,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0441","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.5. Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs | 6.5.1. General considerations","content_type":"text","pages":"143","tokens_est":201,"char_count":803,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0442","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.5. Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs | 6.5.1. General considerations","content_type":"text","pages":"143","tokens_est":234,"char_count":933,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0443","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.5. Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs | 6.5.1. General considerations","content_type":"text","pages":"143-144","tokens_est":220,"char_count":879,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0444","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.5. Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs | 6.5.1. General considerations","content_type":"text","pages":"144","tokens_est":223,"char_count":892,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0445","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.5. Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs | 6.5.1. General considerations","content_type":"text","pages":"144","tokens_est":213,"char_count":852,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0446","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.6. Discordant results | Interpretation of discordant results","content_type":"text","pages":"144","tokens_est":237,"char_count":946,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0447","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.6. Discordant results | Interpretation of discordant results","content_type":"text","pages":"144-145","tokens_est":223,"char_count":890,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0448","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.6. Discordant results | Interpretation of discordant results","content_type":"text","pages":"145","tokens_est":218,"char_count":871,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0449","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.6. Discordant results | Interpretation of discordant results","content_type":"text","pages":"145","tokens_est":192,"char_count":766,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0450","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.6. Discordant results | Interpretation of discordant results","content_type":"text","pages":"145","tokens_est":203,"char_count":812,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0451","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.6. Discordant results | Interpretation of discordant results","content_type":"text","pages":"145-146","tokens_est":245,"char_count":979,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0452","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.6. Discordant results | Interpretation of discordant results","content_type":"text","pages":"146","tokens_est":75,"char_count":298,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0453","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.7. Algorithm 4  Testing for TB infection","content_type":"text","pages":"146","tokens_est":132,"char_count":527,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0454","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.7. Algorithm 4  Testing for TB infection","content_type":"text","pages":"146","tokens_est":244,"char_count":973,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0455","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.7. Algorithm 4  Testing for TB infection","content_type":"text","pages":"146","tokens_est":121,"char_count":481,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0456","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.7. Algorithm 4  Testing for TB infection","content_type":"text","pages":"146","tokens_est":109,"char_count":436,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0457","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.7. Algorithm 4  Testing for TB infection","content_type":"text","pages":"146-147","tokens_est":207,"char_count":827,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0458","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.7. Algorithm 4  Testing for TB infection","content_type":"text","pages":"147","tokens_est":229,"char_count":915,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0459","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.7. Algorithm 4  Testing for TB infection | Fig. 6.7. Algorithm for person- centred TB infection care; integrated infection and disease assessment where testing for TB infection is available a and recommended","content_type":"figure","pages":"147-148","caption":"Fig. 6.7. Algorithm for person- centred TB infection care; integrated infection and disease assessment where testing for TB infection is available a and recommended","tokens_est":433,"char_count":1732,"has_attachment":true,"attachment_id":"Fig. 6.7.","attachment_path":"figures/WHO_TB_handbook_module3_diagnosis_2025/Fig. 6.7..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0460","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.7. Algorithm 4  Testing for TB infection","content_type":"text","pages":"148-149","tokens_est":220,"char_count":877,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0461","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.7. Algorithm 4  Testing for TB infection","content_type":"text","pages":"148-149","tokens_est":62,"char_count":245,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0462","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.8. Illustrative algorithm combinations","content_type":"text","pages":"149","tokens_est":232,"char_count":926,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0463","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.8. Illustrative algorithm combinations | Fig. 6.8. Scenario 1: High TB/HIV setting","content_type":"figure","pages":"149-150","caption":"Fig. 6.8. Scenario 1: High TB/HIV setting","tokens_est":92,"char_count":367,"has_attachment":true,"attachment_id":"Fig. 6.8.","attachment_path":"figures/WHO_TB_handbook_module3_diagnosis_2025/Fig. 6.8..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0464","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.8. Illustrative algorithm combinations | Fig. 6.9. Scenario 2: High Hr -TB setting","content_type":"figure","pages":"150-151","caption":"Fig. 6.9. Scenario 2: High Hr -TB setting","tokens_est":11,"char_count":41,"has_attachment":true,"attachment_id":"Fig. 6.9.","attachment_path":"figures/WHO_TB_handbook_module3_diagnosis_2025/Fig. 6.9..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0465","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.8. Illustrative algorithm combinations | Fig. 6.10. Scenario 3: High MDR/RR-TB setting","content_type":"figure","pages":"151-152","caption":"Fig. 6.10. Scenario 3: High MDR/RR-TB setting","tokens_est":136,"char_count":544,"has_attachment":true,"attachment_id":"Fig. 6.10.","attachment_path":"figures/WHO_TB_handbook_module3_diagnosis_2025/Fig. 6.10..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0466","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 1. Budgetary considerations for implementing a new diagnostic test","content_type":"text","pages":"160","tokens_est":203,"char_count":810,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0467","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 1. Budgetary considerations for implementing a new diagnostic test","content_type":"text","pages":"160-161","tokens_est":228,"char_count":912,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0468","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 1. Budgetary considerations for implementing a new diagnostic test","content_type":"text","pages":"161","tokens_est":241,"char_count":962,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0469","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 1. Budgetary considerations for implementing a new diagnostic test","content_type":"text","pages":"161","tokens_est":233,"char_count":932,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0470","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 1. Budgetary considerations for implementing a new diagnostic test","content_type":"text","pages":"161-162","tokens_est":144,"char_count":573,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0471","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 1. Budgetary considerations for implementing a new diagnostic test","content_type":"text","pages":"162","tokens_est":243,"char_count":970,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0472","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 1. Budgetary considerations for implementing a new diagnostic test","content_type":"text","pages":"162","tokens_est":114,"char_count":453,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0473","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 2. Drug susceptibility testing methods and critical concentrations","content_type":"text","pages":"163","tokens_est":211,"char_count":844,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0474","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 2. Drug susceptibility testing methods and critical concentrations","content_type":"text","pages":"163","tokens_est":67,"char_count":266,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0475","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 2. Drug susceptibility testing methods and critical concentrations","content_type":"text","pages":"163","tokens_est":217,"char_count":867,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0476","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 2. Drug susceptibility testing methods and critical concentrations","content_type":"text","pages":"163","tokens_est":128,"char_count":512,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0477","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 2. Drug susceptibility testing methods and critical concentrations | Table A2.1. Availability of pure powders from GDF and other manufacturers","content_type":"table","pages":"164","caption":"Table A2.1. Availability of pure powders from GDF and other manufacturers","tokens_est":51,"char_count":770,"has_attachment":true,"attachment_id":"Table A2.1.","attachment_path":"tables/WHO_TB_handbook_module3_diagnosis_2025/Table_A2.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0478","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 3. Implementation of next-generation sequencing technologies","content_type":"text","pages":"166","tokens_est":226,"char_count":903,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0479","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 3. Implementation of next-generation sequencing technologies","content_type":"text","pages":"166","tokens_est":154,"char_count":616,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0480","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 3. Implementation of next-generation sequencing technologies","content_type":"text","pages":"166","tokens_est":158,"char_count":632,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0481","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 3. Implementation of next-generation sequencing technologies","content_type":"text","pages":"166-167","tokens_est":212,"char_count":845,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0482","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 3. Implementation of next-generation sequencing technologies","content_type":"text","pages":"167","tokens_est":198,"char_count":792,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0483","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 3. Implementation of next-generation sequencing technologies","content_type":"text","pages":"167","tokens_est":220,"char_count":877,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0484","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 3. Implementation of next-generation sequencing technologies","content_type":"text","pages":"167-168","tokens_est":219,"char_count":875,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0485","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 3. Implementation of next-generation sequencing technologies","content_type":"text","pages":"168","tokens_est":135,"char_count":539,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0486","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description","content_type":"text","pages":"169","tokens_est":98,"char_count":390,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0487","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A1  Test administration | Step 1. TB Screening check","content_type":"text","pages":"169","tokens_est":187,"char_count":747,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0488","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A1  Test administration | Step 1. TB Screening check","content_type":"text","pages":"169","tokens_est":138,"char_count":552,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0489","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A1  Test administration | Step 2. Explain the administration of TST or TBST","content_type":"text","pages":"169","tokens_est":179,"char_count":713,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0490","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A1  Test administration | Step 2. Explain the administration of TST or TBST","content_type":"text","pages":"169-170","tokens_est":89,"char_count":353,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0491","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A1  Test administration | Step 3. Prepare for the administration of TST or TBST","content_type":"text","pages":"170","tokens_est":125,"char_count":500,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0492","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A1  Test administration | Step 4. Select site for injection","content_type":"text","pages":"170","tokens_est":206,"char_count":822,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0493","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A1  Test administration | Step 5. Prepare the syringe","content_type":"text","pages":"170","tokens_est":175,"char_count":697,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0494","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A1  Test administration | Step 6. Clean the injection site","content_type":"text","pages":"171","tokens_est":196,"char_count":782,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0495","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A1  Test administration | Step 7. Administer the injection","content_type":"text","pages":"171","tokens_est":124,"char_count":494,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0496","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A1  Test administration | Step 7. Administer the injection","content_type":"text","pages":"171","tokens_est":170,"char_count":678,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0497","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A1  Test administration | Step 8. After the injection","content_type":"text","pages":"171","tokens_est":108,"char_count":432,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0498","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A1  Test administration | Step 9. Take photographs (for mHealth  if applicable)","content_type":"text","pages":"172","tokens_est":94,"char_count":373,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0499","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A1  Test administration | Step 10. Provide post-TST care","content_type":"text","pages":"172","tokens_est":222,"char_count":888,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0500","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A1  Test administration | Step 10. Provide post-TST care","content_type":"text","pages":"172","tokens_est":90,"char_count":360,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0501","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A1  Test administration | Step 11. Arrange for the result to be read","content_type":"text","pages":"172","tokens_est":156,"char_count":624,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0502","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A1  Test administration | Step 12. Record the result and document details","content_type":"text","pages":"172","tokens_est":191,"char_count":761,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0503","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A2  Reading of TST or TBST result | Step 1. Seeing the patient","content_type":"text","pages":"173","tokens_est":109,"char_count":433,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0504","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A2  Reading of TST or TBST result | Step 2. Re-check symptoms","content_type":"text","pages":"173","tokens_est":201,"char_count":803,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0505","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A2  Reading of TST or TBST result | Step 3. Place and position of patient for reading","content_type":"text","pages":"173","tokens_est":71,"char_count":281,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0506","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A2  Reading of TST or TBST result | Step 4. Inspection of injection site","content_type":"text","pages":"173","tokens_est":176,"char_count":704,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0507","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A2  Reading of TST or TBST result | Step 4. Inspection of injection site","content_type":"text","pages":"173","tokens_est":140,"char_count":560,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0508","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A2  Reading of TST or TBST result | Step 5. Demarcation of induration","content_type":"text","pages":"174","tokens_est":193,"char_count":771,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0509","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A2  Reading of TST or TBST result | Step 5. Demarcation of induration","content_type":"text","pages":"174","tokens_est":101,"char_count":401,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0510","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A2  Reading of TST or TBST result | Step 6. Measurement","content_type":"text","pages":"174-175","tokens_est":220,"char_count":877,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0511","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A2  Reading of TST or TBST result | Step 7. Post-TST care","content_type":"text","pages":"175","tokens_est":158,"char_count":631,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0512","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A2  Reading of TST or TBST result | Step 8. Management of results","content_type":"text","pages":"175","tokens_est":216,"char_count":864,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0513","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A2  Reading of TST or TBST result | Step 9. Recording and registration","content_type":"text","pages":"175","tokens_est":229,"char_count":915,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0514","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A2  Reading of TST or TBST result | Step 9. Recording and registration","content_type":"text","pages":"175","tokens_est":35,"char_count":138,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0515","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A2  Reading of TST or TBST result | Step 9. Recording and registration | Global Programme on Tuberculosis & Lung Health World Health Organization","content_type":"text","pages":"177","tokens_est":37,"char_count":145,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0001","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Abbreviations and acronyms","content_type":"text","pages":"1","tokens_est":232,"char_count":925,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0002","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Abbreviations and acronyms","content_type":"text","pages":"1-2","tokens_est":220,"char_count":879,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0003","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Abbreviations and acronyms","content_type":"text","pages":"2","tokens_est":230,"char_count":920,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0004","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Abbreviations and acronyms","content_type":"text","pages":"2","tokens_est":162,"char_count":646,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0005","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Abbreviations and acronyms | TB medicines","content_type":"text","pages":"3","tokens_est":114,"char_count":455,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0006","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Definitions","content_type":"text","pages":"3","tokens_est":242,"char_count":965,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0007","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Definitions","content_type":"text","pages":"3-4","tokens_est":171,"char_count":681,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0008","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Definitions","content_type":"text","pages":"4","tokens_est":230,"char_count":917,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0009","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Definitions","content_type":"text","pages":"4","tokens_est":242,"char_count":968,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0010","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Definitions","content_type":"text","pages":"4","tokens_est":243,"char_count":970,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0011","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Definitions","content_type":"text","pages":"4-5","tokens_est":242,"char_count":965,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0012","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Definitions","content_type":"text","pages":"5","tokens_est":236,"char_count":942,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0013","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Definitions","content_type":"text","pages":"5","tokens_est":221,"char_count":881,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0014","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Executive summary","content_type":"text","pages":"6","tokens_est":172,"char_count":687,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0015","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Executive summary | Chapter 1. Drug-susceptible TB treatment","content_type":"text","pages":"6","tokens_est":135,"char_count":540,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0016","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Executive summary | Chapter 2. Drug-resistant TB treatment","content_type":"text","pages":"6","tokens_est":119,"char_count":473,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0017","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Executive summary | Chapter 3. Tuberculosis care and support","content_type":"text","pages":"6","tokens_est":98,"char_count":390,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0018","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Executive summary | Annexes","content_type":"text","pages":"6","tokens_est":109,"char_count":433,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0019","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 1. Introduction","content_type":"text","pages":"8","tokens_est":175,"char_count":697,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0020","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 1. Introduction","content_type":"text","pages":"8","tokens_est":123,"char_count":489,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0021","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 1. Introduction | WHO recommendations on DS-TB treatment | Treatment of DS-TB using the 6-month regimen","content_type":"text","pages":"8","tokens_est":216,"char_count":864,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0022","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 1. Introduction | WHO recommendations on DS-TB treatment | Treatment of DS-TB using the 6-month regimen","content_type":"text","pages":"8-9","tokens_est":85,"char_count":338,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0023","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 1. Introduction | WHO recommendations on DS-TB treatment | Treatment of DS-TB using 4-month regimens","content_type":"text","pages":"9","tokens_est":138,"char_count":550,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0024","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 1. Introduction | WHO recommendations on DS-TB treatment | DS-TB treatment and antiretroviral therapy in people living with HIV","content_type":"text","pages":"9","tokens_est":153,"char_count":609,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0025","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 1. Introduction | WHO recommendations on DS-TB treatment | The use of adjuvant steroids in the treatment of tuberculous meningitis and pericarditis","content_type":"text","pages":"9","tokens_est":119,"char_count":474,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0026","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.1 TB diagnostics and DST","content_type":"text","pages":"9-10","tokens_est":193,"char_count":772,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0027","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.1 TB diagnostics and DST","content_type":"text","pages":"9-10","tokens_est":102,"char_count":405,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0028","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.1 TB diagnostics and DST","content_type":"text","pages":"10","tokens_est":170,"char_count":680,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0029","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.1 TB diagnostics and DST","content_type":"text","pages":"10","tokens_est":237,"char_count":948,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0030","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.1 TB diagnostics and DST","content_type":"text","pages":"10","tokens_est":218,"char_count":869,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0031","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.1 TB diagnostics and DST","content_type":"text","pages":"10","tokens_est":114,"char_count":455,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0032","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.1 TB diagnostics and DST","content_type":"text","pages":"10-11","tokens_est":241,"char_count":961,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0033","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.2 Care and support during TB treatment","content_type":"text","pages":"11","tokens_est":142,"char_count":566,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0034","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.3 Options in treatment of DS-TB","content_type":"text","pages":"11","tokens_est":227,"char_count":906,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0035","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.3 Options in treatment of DS-TB","content_type":"text","pages":"11","tokens_est":80,"char_count":319,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0036","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.3 Options in treatment of DS-TB","content_type":"text","pages":"11-12","tokens_est":196,"char_count":783,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0037","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.3 Options in treatment of DS-TB","content_type":"text","pages":"12","tokens_est":230,"char_count":920,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0038","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.3 Options in treatment of DS-TB | Table 1.2.1. Guide for regimen selection for DS-TB","content_type":"table","pages":"12-13","caption":"Table 1.2.1. Guide for regimen selection for DS-TB","tokens_est":36,"char_count":392,"has_attachment":true,"attachment_id":"Table 1.2.1.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_1.2.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0039","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.3 Options in treatment of DS-TB","content_type":"text","pages":"13","tokens_est":228,"char_count":909,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0040","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.3 Options in treatment of DS-TB","content_type":"text","pages":"13","tokens_est":58,"char_count":229,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0041","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.3 Options in treatment of DS-TB | Box 2.1. Definition of non-severe pulmonary TB","content_type":"box","pages":"13","caption":"Box 2.1. Definition of non-severe pulmonary TB","tokens_est":94,"char_count":376,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0042","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.3 Options in treatment of DS-TB","content_type":"text","pages":"13","tokens_est":241,"char_count":961,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0043","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.3 Options in treatment of DS-TB","content_type":"text","pages":"13-14","tokens_est":232,"char_count":926,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0044","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.3 Options in treatment of DS-TB","content_type":"text","pages":"14","tokens_est":219,"char_count":876,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0045","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.3 Options in treatment of DS-TB | 6-month regimen","content_type":"text","pages":"14","tokens_est":70,"char_count":278,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0046","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.3 Options in treatment of DS-TB | 4-month regimens","content_type":"text","pages":"14","tokens_est":218,"char_count":871,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0047","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 3. Treatment of DS-TB using the 6-month regimen","content_type":"text","pages":"15","tokens_est":230,"char_count":919,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0048","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 3. Treatment of DS-TB using the 6-month regimen","content_type":"text","pages":"15","tokens_est":244,"char_count":973,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0049","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 3. Treatment of DS-TB using the 6-month regimen","content_type":"text","pages":"15","tokens_est":215,"char_count":859,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0050","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 3. Treatment of DS-TB using the 6-month regimen","content_type":"text","pages":"15","tokens_est":226,"char_count":902,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0051","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 3. Treatment of DS-TB using the 6-month regimen","content_type":"text","pages":"15","tokens_est":89,"char_count":356,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0052","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 3. Treatment of DS-TB using the 6-month regimen | 3.1 Eligibility","content_type":"text","pages":"15","tokens_est":234,"char_count":934,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0053","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 3. Treatment of DS-TB using the 6-month regimen | 3.2 Composition and duration of the regimen 2HRZE/4HR","content_type":"text","pages":"15","tokens_est":174,"char_count":694,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0054","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 3. Treatment of DS-TB using the 6-month regimen | 3.2 Composition and duration of the regimen 2HRZE/4HR","content_type":"text","pages":"15-16","tokens_est":229,"char_count":915,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0055","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 3. Treatment of DS-TB using the 6-month regimen | 3.2 Composition and duration of the regimen 2HRZE/4HR","content_type":"text","pages":"16","tokens_est":110,"char_count":440,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0056","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 3. Treatment of DS-TB using the 6-month regimen | 3.3 Considerations for implementation","content_type":"text","pages":"16","tokens_est":234,"char_count":936,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0057","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 3. Treatment of DS-TB using the 6-month regimen | 3.3 Considerations for implementation","content_type":"text","pages":"16","tokens_est":203,"char_count":810,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0058","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 3. Treatment of DS-TB using the 6-month regimen | 3.3 Considerations for implementation","content_type":"text","pages":"16","tokens_est":243,"char_count":970,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0059","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 3. Treatment of DS-TB using the 6-month regimen | 3.3 Considerations for implementation","content_type":"text","pages":"16-17","tokens_est":90,"char_count":358,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0060","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 3. Treatment of DS-TB using the 6-month regimen | 3.4 Subgroups","content_type":"text","pages":"17","tokens_est":64,"char_count":255,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0061","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 3. Treatment of DS-TB using the 6-month regimen | 3.4 Subgroups | 3.4.1 People living with HIV","content_type":"text","pages":"17","tokens_est":188,"char_count":752,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0062","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 3. Treatment of DS-TB using the 6-month regimen | 3.4 Subgroups | 3.4.1 People living with HIV","content_type":"text","pages":"17","tokens_est":185,"char_count":737,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0063","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 3. Treatment of DS-TB using the 6-month regimen | 3.4 Subgroups | 3.4.2 Children","content_type":"text","pages":"17","tokens_est":213,"char_count":852,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0064","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 3. Treatment of DS-TB using the 6-month regimen | 3.4 Subgroups | 3.4.2 Children","content_type":"text","pages":"17-18","tokens_est":70,"char_count":280,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0065","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 3. Treatment of DS-TB using the 6-month regimen | 3.5 Treatment monitoring","content_type":"text","pages":"18","tokens_est":240,"char_count":960,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0066","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 3. Treatment of DS-TB using the 6-month regimen | 3.5 Treatment monitoring","content_type":"text","pages":"18","tokens_est":180,"char_count":717,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0067","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen","content_type":"text","pages":"19","tokens_est":240,"char_count":959,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0068","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen","content_type":"text","pages":"19","tokens_est":247,"char_count":985,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0069","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.1 Eligibility","content_type":"text","pages":"19","tokens_est":169,"char_count":674,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0070","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.2 Composition and duration of the regimen","content_type":"text","pages":"19-20","tokens_est":204,"char_count":816,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0071","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.2 Composition and duration of the regimen","content_type":"text","pages":"20","tokens_est":182,"char_count":726,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0072","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.3 Considerations for implementation","content_type":"text","pages":"20","tokens_est":87,"char_count":345,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0073","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.3 Considerations for implementation | DST","content_type":"text","pages":"20","tokens_est":127,"char_count":506,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0074","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.3 Considerations for implementation | DST","content_type":"text","pages":"20","tokens_est":151,"char_count":603,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0075","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.3 Considerations for implementation | Treatment support","content_type":"text","pages":"20","tokens_est":114,"char_count":454,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0076","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.3 Considerations for implementation | Pill burden","content_type":"text","pages":"21","tokens_est":84,"char_count":333,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0077","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.3 Considerations for implementation | Cost of medicines","content_type":"text","pages":"21","tokens_est":140,"char_count":558,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0078","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.3 Considerations for implementation | Administration of the shorter regimen with food","content_type":"text","pages":"21","tokens_est":217,"char_count":865,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0079","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.3 Considerations for implementation | Training of health care workers","content_type":"text","pages":"21","tokens_est":79,"char_count":316,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0080","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.3 Considerations for implementation | Criteria guiding the choice of regimen","content_type":"text","pages":"21","tokens_est":65,"char_count":258,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0081","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.4 Subgroups","content_type":"text","pages":"21-22","tokens_est":125,"char_count":499,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0082","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.4 Subgroups","content_type":"text","pages":"22","tokens_est":130,"char_count":517,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0083","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.4 Subgroups | 4.4.1 Subgroups in which the shorter regimen can be used","content_type":"text","pages":"22","tokens_est":59,"char_count":234,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0084","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.4 Subgroups | 4.4.1 Subgroups in which the shorter regimen can be used | People living with HIV","content_type":"text","pages":"22","tokens_est":59,"char_count":234,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0085","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.4 Subgroups | 4.4.1 Subgroups in which the shorter regimen can be used | People with diabetes","content_type":"text","pages":"22","tokens_est":182,"char_count":726,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0086","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.4 Subgroups | 4.4.1 Subgroups in which the shorter regimen can be used | People with extensive pulmonary TB disease","content_type":"text","pages":"22","tokens_est":107,"char_count":425,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0087","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.4 Subgroups | 4.4.1 Subgroups in which the shorter regimen can be used | Children and adolescents","content_type":"text","pages":"22-23","tokens_est":140,"char_count":559,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0088","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.4 Subgroups | 4.4.2 Subgroups in which the regimen is not recommended","content_type":"text","pages":"23","tokens_est":68,"char_count":272,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0089","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.4 Subgroups | 4.4.2 Subgroups in which the regimen is not recommended | Patients weighing less than 40 kg","content_type":"text","pages":"23","tokens_est":58,"char_count":232,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0090","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.4 Subgroups | 4.4.2 Subgroups in which the regimen is not recommended | Patients with extrapulmonary TB","content_type":"text","pages":"23","tokens_est":50,"char_count":197,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0091","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.4 Subgroups | 4.4.2 Subgroups in which the regimen is not recommended | PLHIV with a CD4 count of less than 100 cells/mm 3","content_type":"text","pages":"23","tokens_est":45,"char_count":180,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0092","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.4 Subgroups | 4.4.2 Subgroups in which the regimen is not recommended | Children and adolescents aged under 12 years","content_type":"text","pages":"23","tokens_est":38,"char_count":152,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0093","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.4 Subgroups | 4.4.2 Subgroups in which the regimen is not recommended | Pregnant, breastfeeding and postpartum women","content_type":"text","pages":"23","tokens_est":43,"char_count":169,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0094","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.5 Treatment monitoring","content_type":"text","pages":"23","tokens_est":198,"char_count":789,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0095","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.5 Treatment monitoring","content_type":"text","pages":"23-24","tokens_est":169,"char_count":675,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0096","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen","content_type":"text","pages":"24","tokens_est":212,"char_count":847,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0097","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen","content_type":"text","pages":"24","tokens_est":161,"char_count":641,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0098","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen","content_type":"text","pages":"24-25","tokens_est":83,"char_count":329,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0099","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.1 Eligibility","content_type":"text","pages":"25","tokens_est":26,"char_count":102,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0100","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.1 Eligibility | Box 5.1. Eligibility criteria for the 4-month regimen m (2HRZ(E)/2HR) in children and adolescents aged between 3 months and 16 years, in various settings","content_type":"box","pages":"25","caption":"Box 5.1. Eligibility criteria for the 4-month regimen m (2HRZ(E)/2HR) in children and adolescents aged between 3 months and 16 years, in various settings","tokens_est":220,"char_count":879,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0101","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.1 Eligibility | Box 5.1. Eligibility criteria for the 4-month regimen m (2HRZ(E)/2HR) in children and adolescents aged between 3 months and 16 years, in various settings","content_type":"box","pages":"25","caption":"Box 5.1. Eligibility criteria for the 4-month regimen m (2HRZ(E)/2HR) in children and adolescents aged between 3 months and 16 years, in various settings","tokens_est":229,"char_count":915,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0102","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.1 Eligibility | Box 5.1. Eligibility criteria for the 4-month regimen m (2HRZ(E)/2HR) in children and adolescents aged between 3 months and 16 years, in various settings","content_type":"box","pages":"25-26","caption":"Box 5.1. Eligibility criteria for the 4-month regimen m (2HRZ(E)/2HR) in children and adolescents aged between 3 months and 16 years, in various settings","tokens_est":222,"char_count":888,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0103","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.1 Eligibility | Box 5.1. Eligibility criteria for the 4-month regimen m (2HRZ(E)/2HR) in children and adolescents aged between 3 months and 16 years, in various settings","content_type":"box","pages":"26","caption":"Box 5.1. Eligibility criteria for the 4-month regimen m (2HRZ(E)/2HR) in children and adolescents aged between 3 months and 16 years, in various settings","tokens_est":224,"char_count":893,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0104","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.1 Eligibility | Box 5.1. Eligibility criteria for the 4-month regimen m (2HRZ(E)/2HR) in children and adolescents aged between 3 months and 16 years, in various settings","content_type":"box","pages":"26","caption":"Box 5.1. Eligibility criteria for the 4-month regimen m (2HRZ(E)/2HR) in children and adolescents aged between 3 months and 16 years, in various settings","tokens_est":91,"char_count":364,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0105","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.2 Composition and duration of the regimen","content_type":"text","pages":"26","tokens_est":61,"char_count":241,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0106","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.2 Composition and duration of the regimen","content_type":"text","pages":"26","tokens_est":246,"char_count":983,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0107","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.2 Composition and duration of the regimen","content_type":"text","pages":"26","tokens_est":36,"char_count":142,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0108","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.2 Composition and duration of the regimen","content_type":"text","pages":"26","tokens_est":225,"char_count":897,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0109","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.2 Composition and duration of the regimen","content_type":"text","pages":"26","tokens_est":70,"char_count":279,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0110","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.3 Considerations for implementation | Assessing severity of disease","content_type":"text","pages":"27","tokens_est":217,"char_count":865,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0111","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.3 Considerations for implementation | Assessing severity of disease","content_type":"text","pages":"27","tokens_est":202,"char_count":806,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0112","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.3 Considerations for implementation | Assessing severity of disease","content_type":"text","pages":"27","tokens_est":147,"char_count":585,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0113","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.3 Considerations for implementation | Continuum between TB infection and disease","content_type":"text","pages":"27","tokens_est":122,"char_count":487,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0114","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.3 Considerations for implementation | Contact investigation","content_type":"text","pages":"27","tokens_est":59,"char_count":236,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0115","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.3 Considerations for implementation | Child-friendly formulations","content_type":"text","pages":"28","tokens_est":73,"char_count":289,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0116","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.3 Considerations for implementation | Training of health care workers","content_type":"text","pages":"28","tokens_est":158,"char_count":629,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0117","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.4 Subgroups | 5.4.1 Subgroups in which the regimen is recommended | Children with peripheral lymph node TB","content_type":"text","pages":"28","tokens_est":187,"char_count":746,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0118","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.4 Subgroups | 5.4.1 Subgroups in which the regimen is recommended | Children and adolescents living with HIV","content_type":"text","pages":"28","tokens_est":239,"char_count":955,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0119","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.4 Subgroups | 5.4.1 Subgroups in which the regimen is recommended | Children and adolescents living with HIV","content_type":"text","pages":"28","tokens_est":114,"char_count":455,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0120","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.4 Subgroups | 5.4.2 Subgroups in which the regimen is not recommended | Children with severe acute malnutrition","content_type":"text","pages":"29","tokens_est":125,"char_count":499,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0121","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.5 Treatment monitoring","content_type":"text","pages":"29","tokens_est":234,"char_count":933,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0122","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.5 Treatment monitoring","content_type":"text","pages":"29","tokens_est":242,"char_count":966,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0123","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.5 Treatment monitoring","content_type":"text","pages":"29-30","tokens_est":115,"char_count":459,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0124","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.5 Treatment monitoring","content_type":"text","pages":"30-31","tokens_est":162,"char_count":647,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0125","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 6. Treatment of DS-TB in people living with HIV","content_type":"text","pages":"32","tokens_est":180,"char_count":718,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0126","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 6. Treatment of DS-TB in people living with HIV","content_type":"text","pages":"32","tokens_est":89,"char_count":355,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0127","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 6. Treatment of DS-TB in people living with HIV | 6.1 Eligibility","content_type":"text","pages":"32","tokens_est":78,"char_count":312,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0128","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 6. Treatment of DS-TB in people living with HIV | 6.2 Composition and duration of the regimen","content_type":"text","pages":"32","tokens_est":195,"char_count":778,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0129","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 6. Treatment of DS-TB in people living with HIV | 6.2 Composition and duration of the regimen","content_type":"text","pages":"32","tokens_est":128,"char_count":511,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0130","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 6. Treatment of DS-TB in people living with HIV | 6.2 Composition and duration of the regimen","content_type":"text","pages":"32-33","tokens_est":180,"char_count":720,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0131","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 6. Treatment of DS-TB in people living with HIV | 6.3 Considerations for implementation","content_type":"text","pages":"33","tokens_est":243,"char_count":970,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0132","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 6. Treatment of DS-TB in people living with HIV | 6.4 Treatment monitoring","content_type":"text","pages":"33","tokens_est":83,"char_count":332,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0133","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 7. Treatment of extrapulmonary TB","content_type":"text","pages":"33","tokens_est":154,"char_count":615,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0134","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 7. Treatment of extrapulmonary TB","content_type":"text","pages":"33","tokens_est":146,"char_count":584,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0135","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 7. Treatment of extrapulmonary TB","content_type":"text","pages":"33","tokens_est":117,"char_count":466,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0136","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 7. Treatment of extrapulmonary TB | 7.1 Eligibility","content_type":"text","pages":"34","tokens_est":196,"char_count":781,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0137","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 7. Treatment of extrapulmonary TB | 7.2 Composition and duration of the regimen","content_type":"text","pages":"34","tokens_est":115,"char_count":460,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0138","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 7. Treatment of extrapulmonary TB | 7.2 Composition and duration of the regimen","content_type":"text","pages":"34","tokens_est":186,"char_count":741,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0139","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 7. Treatment of extrapulmonary TB | 7.2 Composition and duration of the regimen","content_type":"text","pages":"34","tokens_est":196,"char_count":782,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0140","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 7. Treatment of extrapulmonary TB | 7.2 Composition and duration of the regimen","content_type":"text","pages":"34","tokens_est":199,"char_count":794,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0141","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 7. Treatment of extrapulmonary TB | 7.2 Composition and duration of the regimen","content_type":"text","pages":"34-35","tokens_est":148,"char_count":591,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0142","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 7. Treatment of extrapulmonary TB | 7.3 Use of adjuvant steroids in the treatment of tuberculous meningitis and pericarditis","content_type":"text","pages":"35","tokens_est":191,"char_count":763,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0143","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 7. Treatment of extrapulmonary TB | 7.3 Use of adjuvant steroids in the treatment of tuberculous meningitis and pericarditis","content_type":"text","pages":"35","tokens_est":237,"char_count":946,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0144","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 7. Treatment of extrapulmonary TB | 7.3 Use of adjuvant steroids in the treatment of tuberculous meningitis and pericarditis","content_type":"text","pages":"35","tokens_est":71,"char_count":282,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0145","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 7. Treatment of extrapulmonary TB | 7.3 Use of adjuvant steroids in the treatment of tuberculous meningitis and pericarditis","content_type":"text","pages":"35","tokens_est":143,"char_count":569,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0146","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 7. Treatment of extrapulmonary TB | 7.4 Considerations for implementation","content_type":"text","pages":"35","tokens_est":155,"char_count":620,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0147","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 7. Treatment of extrapulmonary TB | 7.4 Considerations for implementation","content_type":"text","pages":"35-36","tokens_est":207,"char_count":825,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0148","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations","content_type":"text","pages":"36","tokens_est":61,"char_count":242,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0149","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.1 Diabetes","content_type":"text","pages":"36","tokens_est":99,"char_count":393,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0150","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.1 Diabetes","content_type":"text","pages":"36-37","tokens_est":230,"char_count":918,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0151","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.1 Diabetes","content_type":"text","pages":"37","tokens_est":240,"char_count":958,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0152","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.1 Diabetes","content_type":"text","pages":"37","tokens_est":122,"char_count":485,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0153","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.1 Diabetes | Implementation considerations","content_type":"text","pages":"37","tokens_est":244,"char_count":976,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0154","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.2 Pregnancy","content_type":"text","pages":"37-38","tokens_est":180,"char_count":718,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0155","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.2 Pregnancy","content_type":"text","pages":"38","tokens_est":217,"char_count":867,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0156","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.2 Pregnancy","content_type":"text","pages":"38","tokens_est":176,"char_count":701,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0157","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.2 Pregnancy","content_type":"text","pages":"38","tokens_est":190,"char_count":759,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0158","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.2 Pregnancy | Implementation considerations","content_type":"text","pages":"38","tokens_est":211,"char_count":843,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0159","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.2 Pregnancy | Implementation considerations","content_type":"text","pages":"38","tokens_est":47,"char_count":187,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0160","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.3 Older people","content_type":"text","pages":"39","tokens_est":218,"char_count":872,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0161","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.3 Older people","content_type":"text","pages":"39","tokens_est":248,"char_count":990,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0162","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.3 Older people","content_type":"text","pages":"39","tokens_est":164,"char_count":654,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0163","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.3 Older people","content_type":"text","pages":"39","tokens_est":223,"char_count":891,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0164","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.3 Older people | Implementation considerations","content_type":"text","pages":"40","tokens_est":216,"char_count":862,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0165","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.3 Older people | Implementation considerations","content_type":"text","pages":"40","tokens_est":41,"char_count":164,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0166","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.4 Chronic renal failure","content_type":"text","pages":"40","tokens_est":220,"char_count":879,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0167","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.4 Chronic renal failure","content_type":"text","pages":"40","tokens_est":165,"char_count":657,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0168","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.4 Chronic renal failure","content_type":"text","pages":"40-41","tokens_est":238,"char_count":950,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0169","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.4 Chronic renal failure | Implementation considerations","content_type":"text","pages":"41","tokens_est":132,"char_count":528,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0170","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.5 Chronic liver disease","content_type":"text","pages":"41","tokens_est":226,"char_count":904,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0171","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.5 Chronic liver disease","content_type":"text","pages":"41","tokens_est":227,"char_count":907,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0172","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.5 Chronic liver disease","content_type":"text","pages":"41-42","tokens_est":246,"char_count":982,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0173","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.5 Chronic liver disease | Table 1.8.1. ChildTurcottePugh score parameters","content_type":"table","pages":"42","caption":"Table 1.8.1. ChildTurcottePugh score parameters","tokens_est":26,"char_count":148,"has_attachment":true,"attachment_id":"Table 1.8.1.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_1.8.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0174","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.5 Chronic liver disease | Table 1.8.2. Estimated survival at 1 and 2 years based on ChildTurcottePugh","content_type":"table","pages":"42","caption":"Table 1.8.2. Estimated survival at 1 and 2 years based on ChildTurcottePugh","tokens_est":42,"char_count":175,"has_attachment":true,"attachment_id":"Table 1.8.2.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_1.8.2..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0175","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.5 Chronic liver disease","content_type":"text","pages":"42","tokens_est":215,"char_count":859,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0176","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.5 Chronic liver disease","content_type":"text","pages":"42","tokens_est":63,"char_count":250,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0177","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.5 Chronic liver disease | Implementation considerations","content_type":"text","pages":"43","tokens_est":172,"char_count":685,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0178","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response","content_type":"text","pages":"43","tokens_est":234,"char_count":936,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0179","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response","content_type":"text","pages":"43","tokens_est":171,"char_count":682,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0180","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.1 Clinical examination","content_type":"text","pages":"43-44","tokens_est":234,"char_count":936,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0181","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.1 Clinical examination","content_type":"text","pages":"43-44","tokens_est":39,"char_count":154,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0182","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.1 Clinical examination","content_type":"text","pages":"44","tokens_est":237,"char_count":946,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0183","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.2 Chest radiography","content_type":"text","pages":"44","tokens_est":148,"char_count":592,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0184","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.2 Chest radiography","content_type":"text","pages":"44","tokens_est":122,"char_count":488,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0185","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.3 Sputum smear and culture","content_type":"text","pages":"44","tokens_est":238,"char_count":951,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0186","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.3 Sputum smear and culture","content_type":"text","pages":"44-45","tokens_est":218,"char_count":872,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0187","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.3 Sputum smear and culture","content_type":"text","pages":"45","tokens_est":197,"char_count":785,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0188","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.3 Sputum smear and culture","content_type":"text","pages":"45","tokens_est":84,"char_count":336,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0189","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.3 Sputum smear and culture","content_type":"text","pages":"45","tokens_est":177,"char_count":708,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0190","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.3 Sputum smear and culture","content_type":"text","pages":"45","tokens_est":189,"char_count":756,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0191","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.3 Sputum smear and culture","content_type":"text","pages":"45","tokens_est":84,"char_count":334,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0192","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | Table 1.9.1. Summary of activities for monitoring treatment response","content_type":"table","pages":"46","caption":"Table 1.9.1. Summary of activities for monitoring treatment response","tokens_est":31,"char_count":283,"has_attachment":true,"attachment_id":"Table 1.9.1.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_1.9.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0193","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.4 Assessment of patients when treatment failure is suspected","content_type":"text","pages":"46-47","tokens_est":149,"char_count":595,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0194","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.4 Assessment of patients when treatment failure is suspected | Confirm treatment","content_type":"text","pages":"47","tokens_est":29,"char_count":116,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0195","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.4 Assessment of patients when treatment failure is suspected | Look for undetected comorbidities","content_type":"text","pages":"47","tokens_est":133,"char_count":529,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0196","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.4 Assessment of patients when treatment failure is suspected | Review the bacteriological data","content_type":"text","pages":"47","tokens_est":111,"char_count":444,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0197","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.4 Assessment of patients when treatment failure is suspected | Review the DST","content_type":"text","pages":"47","tokens_est":41,"char_count":161,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0198","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.4 Assessment of patients when treatment failure is suspected | Review CXR","content_type":"text","pages":"47","tokens_est":42,"char_count":167,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0199","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.4 Assessment of patients when treatment failure is suspected | Review treatment regimen","content_type":"text","pages":"47","tokens_est":93,"char_count":369,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0200","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.4 Assessment of patients when treatment failure is suspected | Consider malabsorption","content_type":"text","pages":"47-48","tokens_est":227,"char_count":907,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0201","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 10. Outcome definitions","content_type":"text","pages":"50","tokens_est":201,"char_count":803,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0202","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 10. Outcome definitions","content_type":"text","pages":"50","tokens_est":172,"char_count":685,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0203","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 10. Outcome definitions | 10.1 Treatment outcome definitions","content_type":"text","pages":"50","tokens_est":235,"char_count":938,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0204","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 10. Outcome definitions | 10.1 Treatment outcome definitions","content_type":"text","pages":"50-51","tokens_est":237,"char_count":948,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0205","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 10. Outcome definitions | 10.1 Treatment outcome definitions","content_type":"text","pages":"51","tokens_est":135,"char_count":537,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0206","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 10. Outcome definitions | 10.2 Considerations for implementation","content_type":"text","pages":"51","tokens_est":189,"char_count":754,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0207","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 10. Outcome definitions | Table 1.10.1. New definitions of TB treatment outcomes for both DS-TB and DR-TB","content_type":"table","pages":"51-52","caption":"Table 1.10.1. New definitions of TB treatment outcomes for both DS-TB and DR-TB","tokens_est":28,"char_count":1229,"has_attachment":true,"attachment_id":"Table 1.10.1.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_1.10.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0208","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 1. Introduction","content_type":"text","pages":"54","tokens_est":137,"char_count":545,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0209","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 1. Introduction","content_type":"text","pages":"54","tokens_est":177,"char_count":706,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0210","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 2. WHO recommendations on D R-TB treatment | Treatment of drug- resistant TB using 6-month regimens","content_type":"text","pages":"54","tokens_est":154,"char_count":615,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0211","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 2. WHO recommendations on D R-TB treatment | Treatment of drug-resistant TB using 9-month regimens","content_type":"text","pages":"54-55","tokens_est":238,"char_count":950,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0212","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 2. WHO recommendations on D R-TB treatment | Longer regimens for MDR/RR-TB","content_type":"text","pages":"55","tokens_est":234,"char_count":934,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0213","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 2. WHO recommendations on D R-TB treatment | Longer regimens for MDR/RR-TB","content_type":"text","pages":"55","tokens_est":234,"char_count":936,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0214","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 2. WHO recommendations on D R-TB treatment | Longer regimens for MDR/RR-TB","content_type":"text","pages":"55-56","tokens_est":214,"char_count":854,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0215","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 2. WHO recommendations on D R-TB treatment | Longer regimens for MDR/RR-TB","content_type":"text","pages":"56","tokens_est":244,"char_count":976,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0216","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 2. WHO recommendations on D R-TB treatment | Longer regimens for MDR/RR-TB","content_type":"text","pages":"56","tokens_est":205,"char_count":820,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0217","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 2. WHO recommendations on D R-TB treatment | Longer regimens for MDR/RR-TB","content_type":"text","pages":"56-57","tokens_est":81,"char_count":324,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0218","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 2. WHO recommendations on D R-TB treatment | Regimen for rifampicin-susceptible and isoniazid-resistant TB","content_type":"text","pages":"57","tokens_est":147,"char_count":588,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0219","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 2. WHO recommendations on D R-TB treatment | Monitoring patient response to MDR/RR-TB treatment using culture","content_type":"text","pages":"57","tokens_est":108,"char_count":431,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0220","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 2. WHO recommendations on D R-TB treatment | Start of antiretroviral therapy in patients on MDR/RR-TB regimens","content_type":"text","pages":"57","tokens_est":101,"char_count":401,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0221","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 2. WHO recommendations on D R-TB treatment | Surgery for patients on MDR/RR-TB treatment","content_type":"text","pages":"57","tokens_est":80,"char_count":320,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0222","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 2. WHO recommendations on D R-TB treatment | Hepatitis C virus (HCV) and MDR/RR-TB treatment co-administration","content_type":"text","pages":"57","tokens_est":81,"char_count":321,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0223","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.1 Access to DST","content_type":"text","pages":"60","tokens_est":228,"char_count":911,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0224","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.1 Access to DST","content_type":"text","pages":"60","tokens_est":71,"char_count":283,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0225","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.1 Access to DST","content_type":"text","pages":"60","tokens_est":242,"char_count":968,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0226","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.1 Access to DST","content_type":"text","pages":"60","tokens_est":35,"char_count":139,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0227","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.1 Access to DST","content_type":"text","pages":"60","tokens_est":120,"char_count":478,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0228","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.1 Access to DST","content_type":"text","pages":"60-61","tokens_est":212,"char_count":848,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0229","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.1 Access to DST","content_type":"text","pages":"60-61","tokens_est":86,"char_count":342,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0230","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.1 Access to DST","content_type":"text","pages":"61","tokens_est":192,"char_count":767,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0231","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.1 Access to DST","content_type":"text","pages":"61","tokens_est":98,"char_count":389,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0232","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.1 Access to DST","content_type":"text","pages":"61","tokens_est":96,"char_count":384,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0233","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.1 Access to DST","content_type":"text","pages":"61","tokens_est":230,"char_count":918,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0234","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.1 Access to DST","content_type":"text","pages":"61","tokens_est":121,"char_count":482,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0235","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.1 Access to DST","content_type":"text","pages":"61-62","tokens_est":186,"char_count":741,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0236","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.1 Access to DST","content_type":"text","pages":"61-62","tokens_est":231,"char_count":921,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0237","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.1 Access to DST","content_type":"text","pages":"62","tokens_est":188,"char_count":752,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0238","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.1 Access to DST","content_type":"text","pages":"62","tokens_est":222,"char_count":887,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0239","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.1 Access to DST","content_type":"text","pages":"62","tokens_est":74,"char_count":296,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0240","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.1 Access to DST","content_type":"text","pages":"62","tokens_est":201,"char_count":801,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0241","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.2 Safety monitoring and management and provision of patient support","content_type":"text","pages":"62-63","tokens_est":238,"char_count":950,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0242","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.2 Safety monitoring and management and provision of patient support","content_type":"text","pages":"62-63","tokens_est":120,"char_count":480,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0243","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.3 Extensive pulmonary TB disease","content_type":"text","pages":"63","tokens_est":147,"char_count":587,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0244","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.4 Regimen options in the treatment of DR-TB","content_type":"text","pages":"63","tokens_est":160,"char_count":639,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0245","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.4 Regimen options in the treatment of DR-TB","content_type":"text","pages":"63","tokens_est":218,"char_count":872,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0246","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.4 Regimen options in the treatment of DR-TB","content_type":"text","pages":"63","tokens_est":121,"char_count":484,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0247","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.4 Regimen options in the treatment of DR-TB","content_type":"text","pages":"63-64","tokens_est":248,"char_count":989,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0248","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.4 Regimen options in the treatment of DR-TB","content_type":"text","pages":"63-64","tokens_est":117,"char_count":468,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0249","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.4 Regimen options in the treatment of DR-TB","content_type":"text","pages":"64","tokens_est":233,"char_count":930,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0250","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.4 Regimen options in the treatment of DR-TB","content_type":"text","pages":"64","tokens_est":118,"char_count":472,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0251","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.4 Regimen options in the treatment of DR-TB | Table 2.3.1. Regimen options and factors to be considered for selection of treatment regimens for patients with MDR/RR-TB","content_type":"table","pages":"64-66","caption":"Table 2.3.1. Regimen options and factors to be considered for selection of treatment regimens for patients with MDR/RR-TB","tokens_est":83,"char_count":684,"has_attachment":true,"attachment_id":"Table 2.3.1.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_2.3.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0252","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.4 Regimen options in the treatment of DR-TB","content_type":"text","pages":"66-68","tokens_est":240,"char_count":959,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0253","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.4 Regimen options in the treatment of DR-TB","content_type":"text","pages":"68","tokens_est":238,"char_count":949,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0254","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.4 Regimen options in the treatment of DR-TB","content_type":"text","pages":"68","tokens_est":242,"char_count":967,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0255","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.4 Regimen options in the treatment of DR-TB","content_type":"text","pages":"68","tokens_est":27,"char_count":107,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0256","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.4 Regimen options in the treatment of DR-TB","content_type":"text","pages":"68","tokens_est":175,"char_count":697,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0257","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.4 Regimen options in the treatment of DR-TB","content_type":"text","pages":"68-69","tokens_est":246,"char_count":982,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0258","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.4 Regimen options in the treatment of DR-TB | Fig. 2.3.1. Regimen options for MDR/RR-TB treatment","content_type":"figure","pages":"69","caption":"Fig. 2.3.1. Regimen options for MDR/RR-TB treatment","tokens_est":33,"char_count":130,"has_attachment":true,"attachment_id":"Fig. 2.3.1.","attachment_path":"figures/WHO_TB_handbook_module4_treatment_2025/Fig. 2.3.1..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0259","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen","content_type":"text","pages":"69","tokens_est":178,"char_count":709,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0260","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen","content_type":"text","pages":"69","tokens_est":228,"char_count":912,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0261","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen","content_type":"text","pages":"69","tokens_est":163,"char_count":652,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0262","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen","content_type":"text","pages":"69-70","tokens_est":149,"char_count":594,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0263","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen","content_type":"text","pages":"70","tokens_est":194,"char_count":776,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0264","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen","content_type":"text","pages":"70","tokens_est":158,"char_count":632,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0265","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.1 Eligibility","content_type":"text","pages":"70","tokens_est":219,"char_count":874,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0266","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.1 Eligibility","content_type":"text","pages":"70-71","tokens_est":237,"char_count":945,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0267","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.1 Eligibility","content_type":"text","pages":"70-71","tokens_est":82,"char_count":328,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0268","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.1 Eligibility","content_type":"text","pages":"71","tokens_est":232,"char_count":926,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0269","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.1 Eligibility","content_type":"text","pages":"71","tokens_est":162,"char_count":645,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0270","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.1 Eligibility","content_type":"text","pages":"71","tokens_est":192,"char_count":766,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0271","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.1 Eligibility","content_type":"text","pages":"71","tokens_est":247,"char_count":986,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0272","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.1 Eligibility","content_type":"text","pages":"71","tokens_est":63,"char_count":252,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0273","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.2 Composition, dosing and duration of the regimen | Composition","content_type":"text","pages":"72","tokens_est":175,"char_count":699,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0274","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.2 Composition, dosing and duration of the regimen | Dosing","content_type":"text","pages":"72","tokens_est":240,"char_count":960,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0275","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.2 Composition, dosing and duration of the regimen | Dosing","content_type":"text","pages":"72","tokens_est":50,"char_count":198,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0276","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.2 Composition, dosing and duration of the regimen | Dosing | Table 2.4.1. Dosing of component drugs for adults and adolescents (aged 14 years) for BPaLM and BPaL","content_type":"table","pages":"72","caption":"Table 2.4.1. Dosing of component drugs for adults and adolescents (aged 14 years) for BPaLM and BPaL","tokens_est":31,"char_count":194,"has_attachment":true,"attachment_id":"Table 2.4.1.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_2.4.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0277","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.2 Composition, dosing and duration of the regimen | Dosing","content_type":"text","pages":"72-73","tokens_est":207,"char_count":827,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0278","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.2 Composition, dosing and duration of the regimen | Dosing","content_type":"text","pages":"73","tokens_est":68,"char_count":269,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0279","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.2 Composition, dosing and duration of the regimen | Duration","content_type":"text","pages":"73","tokens_est":248,"char_count":992,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0280","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.2 Composition, dosing and duration of the regimen | Duration","content_type":"text","pages":"73","tokens_est":248,"char_count":990,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0281","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.2 Composition, dosing and duration of the regimen | Duration","content_type":"text","pages":"73","tokens_est":146,"char_count":583,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0282","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.2 Composition, dosing and duration of the regimen | Duration","content_type":"text","pages":"73","tokens_est":62,"char_count":248,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0283","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.2 Composition, dosing and duration of the regimen | Duration | Fig. 2.4.1 Duration of treatment with BPaLM and BPaL regimen options","content_type":"figure","pages":"73","caption":"Fig. 2.4.1 Duration of treatment with BPaLM and BPaL regimen options","tokens_est":20,"char_count":78,"has_attachment":true,"attachment_id":"Fig. 2.4.1","attachment_path":"figures/WHO_TB_handbook_module4_treatment_2025/Fig. 2.4.1.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0284","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.3 Modifications of treatment | Linezolid modification","content_type":"text","pages":"74","tokens_est":96,"char_count":384,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0285","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.3 Modifications of treatment | Linezolid modification","content_type":"text","pages":"74","tokens_est":223,"char_count":892,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0286","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.3 Modifications of treatment | Linezolid modification","content_type":"text","pages":"74","tokens_est":180,"char_count":717,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0287","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.3 Modifications of treatment | Linezolid modification","content_type":"text","pages":"74","tokens_est":205,"char_count":817,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0288","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.3 Modifications of treatment | Linezolid modification","content_type":"text","pages":"74","tokens_est":233,"char_count":929,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0289","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.3 Modifications of treatment | Linezolid modification | Box 2.4.1. Examples of changes in linezolid dosing within the BPaLM / BPaL regimen","content_type":"box","pages":"75","caption":"Box 2.4.1. Examples of changes in linezolid dosing within the BPaLM / BPaL regimen","tokens_est":191,"char_count":761,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0290","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.3 Modifications of treatment | Linezolid modification | Box 2.4.1. Examples of changes in linezolid dosing within the BPaLM / BPaL regimen","content_type":"box","pages":"75","caption":"Box 2.4.1. Examples of changes in linezolid dosing within the BPaLM / BPaL regimen","tokens_est":239,"char_count":954,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0291","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.3 Modifications of treatment | Linezolid modification | Box 2.4.1. Examples of changes in linezolid dosing within the BPaLM / BPaL regimen","content_type":"box","pages":"75","caption":"Box 2.4.1. Examples of changes in linezolid dosing within the BPaLM / BPaL regimen","tokens_est":140,"char_count":559,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0292","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.3 Modifications of treatment | Linezolid modification","content_type":"text","pages":"75","tokens_est":104,"char_count":414,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0293","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.3 Modifications of treatment | Linezolid modification","content_type":"text","pages":"75","tokens_est":236,"char_count":941,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0294","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.3 Modifications of treatment | Linezolid modification","content_type":"text","pages":"75-76","tokens_est":157,"char_count":626,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0295","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.3 Modifications of treatment | Modification or discontinuation of full BPaLM / BPaL regimen","content_type":"text","pages":"76","tokens_est":165,"char_count":659,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0296","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.3 Modifications of treatment | Temporary cessation of full BPaLM / BPaL regimen","content_type":"text","pages":"76","tokens_est":199,"char_count":796,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0297","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.3 Modifications of treatment | Permanent discontinuation of BPaLM / BPaL and change to another regimen","content_type":"text","pages":"76","tokens_est":164,"char_count":654,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0298","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.3 Modifications of treatment | Permanent discontinuation of BPaLM / BPaL and change to another regimen","content_type":"text","pages":"76-77","tokens_est":237,"char_count":947,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0299","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.3 Modifications of treatment | Permanent discontinuation of BPaLM / BPaL and change to another regimen","content_type":"text","pages":"77","tokens_est":198,"char_count":789,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0300","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.3 Modifications of treatment | Permanent discontinuation of BPaLM / BPaL and change to another regimen | Table 2.4.2. Linezolid m odifications options in BPaLM / BPaL","content_type":"table","pages":"77","caption":"Table 2.4.2. Linezolid m odifications options in BPaLM / BPaL","tokens_est":24,"char_count":453,"has_attachment":true,"attachment_id":"Table 2.4.2.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_2.4.2..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0301","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.3 Modifications of treatment | Permanent discontinuation of BPaLM / BPaL and change to another regimen | Box 2.4.2. Examples of changes in the BPaLM or BPaL regimen","content_type":"box","pages":"78","caption":"Box 2.4.2. Examples of changes in the BPaLM or BPaL regimen","tokens_est":158,"char_count":629,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0302","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.3 Modifications of treatment | Permanent discontinuation of BPaLM / BPaL and change to another regimen | Box 2.4.2. Examples of changes in the BPaLM or BPaL regimen","content_type":"box","pages":"78","caption":"Box 2.4.2. Examples of changes in the BPaLM or BPaL regimen","tokens_est":158,"char_count":629,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0303","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.3 Modifications of treatment | Permanent discontinuation of BPaLM / BPaL and change to another regimen | Box 2.4.2. Examples of changes in the BPaLM or BPaL regimen","content_type":"box","pages":"78","caption":"Box 2.4.2. Examples of changes in the BPaLM or BPaL regimen","tokens_est":181,"char_count":723,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0304","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.3 Modifications of treatment | Permanent discontinuation of BPaLM / BPaL and change to another regimen | Box 2.4.2. Examples of changes in the BPaLM or BPaL regimen","content_type":"box","pages":"78","caption":"Box 2.4.2. Examples of changes in the BPaLM or BPaL regimen","tokens_est":105,"char_count":418,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0305","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.4 Key subgroups","content_type":"text","pages":"78","tokens_est":213,"char_count":852,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0306","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.4 Key subgroups | Extensive pulmonary TB","content_type":"text","pages":"78-79","tokens_est":104,"char_count":416,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0307","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.4 Key subgroups | Extrapulmonary TB","content_type":"text","pages":"79","tokens_est":195,"char_count":778,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0308","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.4 Key subgroups | People living with HIV","content_type":"text","pages":"79","tokens_est":174,"char_count":694,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0309","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.4 Key subgroups | People living with HIV","content_type":"text","pages":"79","tokens_est":231,"char_count":923,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0310","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.4 Key subgroups | People living with HIV","content_type":"text","pages":"79","tokens_est":209,"char_count":834,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0311","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.4 Key subgroups | Pregnant and breastfeeding women","content_type":"text","pages":"79-80","tokens_est":117,"char_count":466,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0312","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.4 Key subgroups | Children and adolescents","content_type":"text","pages":"80","tokens_est":226,"char_count":903,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0313","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.5 Implementation considerations | DST and resistance to the component medicines","content_type":"text","pages":"80","tokens_est":116,"char_count":464,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0314","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.5 Implementation considerations | DST and resistance to the component medicines","content_type":"text","pages":"80","tokens_est":182,"char_count":728,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0315","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.5 Implementation considerations | DST and resistance to the component medicines","content_type":"text","pages":"80","tokens_est":167,"char_count":665,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0316","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.5 Implementation considerations | DST and resistance to the component medicines","content_type":"text","pages":"80","tokens_est":122,"char_count":486,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0317","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.5 Implementation considerations | DST and resistance to the component medicines","content_type":"text","pages":"80-81","tokens_est":247,"char_count":987,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0318","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.5 Implementation considerations | DST and resistance to the component medicines","content_type":"text","pages":"81","tokens_est":227,"char_count":906,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0319","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.5 Implementation considerations | History of exposure to component drugs","content_type":"text","pages":"81","tokens_est":184,"char_count":734,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0320","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.5 Implementation considerations | History of exposure to component drugs","content_type":"text","pages":"81","tokens_est":128,"char_count":512,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0321","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.5 Implementation considerations | Drugdrug interactions","content_type":"text","pages":"81","tokens_est":124,"char_count":496,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0322","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.5 Implementation considerations | Cost and costeffectiveness analysis","content_type":"text","pages":"82","tokens_est":139,"char_count":556,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0323","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.5 Implementation considerations | Cost and costeffectiveness analysis","content_type":"text","pages":"82","tokens_est":174,"char_count":695,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0324","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.5 Implementation considerations | Treatment support","content_type":"text","pages":"82","tokens_est":191,"char_count":764,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0325","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.5 Implementation considerations | Treatment support","content_type":"text","pages":"82","tokens_est":65,"char_count":259,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0326","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen","content_type":"text","pages":"82","tokens_est":228,"char_count":909,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0327","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen","content_type":"text","pages":"82-83","tokens_est":233,"char_count":931,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0328","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen","content_type":"text","pages":"83","tokens_est":135,"char_count":540,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0329","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen","content_type":"text","pages":"83","tokens_est":147,"char_count":587,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0330","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen","content_type":"text","pages":"83","tokens_est":156,"char_count":622,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0331","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen","content_type":"text","pages":"83","tokens_est":201,"char_count":804,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0332","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen","content_type":"text","pages":"83","tokens_est":195,"char_count":780,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0333","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen","content_type":"text","pages":"83-84","tokens_est":188,"char_count":751,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0334","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen","content_type":"text","pages":"83-84","tokens_est":94,"char_count":373,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0335","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen","content_type":"text","pages":"84","tokens_est":231,"char_count":922,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0336","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.1 Eligibility","content_type":"text","pages":"84","tokens_est":240,"char_count":959,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0337","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.1 Eligibility","content_type":"text","pages":"84","tokens_est":233,"char_count":932,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0338","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.1 Eligibility","content_type":"text","pages":"84-85","tokens_est":163,"char_count":649,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0339","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen","content_type":"text","pages":"85","tokens_est":244,"char_count":974,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0340","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen","content_type":"text","pages":"85","tokens_est":192,"char_count":766,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0341","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen | Composition | BDLLfxC regimen","content_type":"text","pages":"85","tokens_est":154,"char_count":613,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0342","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen | Composition | BDLLfx regimen","content_type":"text","pages":"85-86","tokens_est":206,"char_count":821,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0343","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen | Composition | BDLC regimen","content_type":"text","pages":"86","tokens_est":228,"char_count":911,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0344","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen | Dosing","content_type":"text","pages":"86","tokens_est":60,"char_count":239,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0345","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen | Dosing | Bedaquiline","content_type":"text","pages":"86","tokens_est":237,"char_count":945,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0346","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen | Dosing | Bedaquiline","content_type":"text","pages":"86","tokens_est":108,"char_count":431,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0347","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen | Dosing | Delamanid","content_type":"text","pages":"86-87","tokens_est":172,"char_count":687,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0348","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen | Dosing | Linezolid","content_type":"text","pages":"87","tokens_est":122,"char_count":485,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0349","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen | Dosing | Levofloxacin","content_type":"text","pages":"87","tokens_est":145,"char_count":577,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0350","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen | Dosing | Clofazimine","content_type":"text","pages":"87","tokens_est":100,"char_count":398,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0351","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen | Dosing | Pregnancy and postpartum","content_type":"text","pages":"87","tokens_est":127,"char_count":506,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0352","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen | Duration","content_type":"text","pages":"89","tokens_est":40,"char_count":159,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0353","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen | Duration","content_type":"text","pages":"89","tokens_est":233,"char_count":932,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0354","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen | Duration","content_type":"text","pages":"89","tokens_est":156,"char_count":621,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0355","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen | Duration","content_type":"text","pages":"89","tokens_est":212,"char_count":847,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0356","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen | Duration","content_type":"text","pages":"89","tokens_est":68,"char_count":269,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0357","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen | Duration","content_type":"text","pages":"89","tokens_est":169,"char_count":674,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0358","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.3 Modifications of treatment | Drug toxicity","content_type":"text","pages":"89-90","tokens_est":227,"char_count":907,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0359","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.3 Modifications of treatment | Drug toxicity","content_type":"text","pages":"89-90","tokens_est":162,"char_count":648,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0360","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.3 Modifications of treatment | Drug toxicity","content_type":"text","pages":"90","tokens_est":178,"char_count":710,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0361","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.3 Modifications of treatment | Drug substitution","content_type":"text","pages":"90","tokens_est":126,"char_count":502,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0362","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.3 Modifications of treatment | Missed doses","content_type":"text","pages":"90","tokens_est":193,"char_count":771,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0363","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.3 Modifications of treatment | Discontinuation and change to another treatment regimen","content_type":"text","pages":"91","tokens_est":165,"char_count":660,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0364","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.3 Modifications of treatment | Discontinuation and change to another treatment regimen","content_type":"text","pages":"91","tokens_est":221,"char_count":882,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0365","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.4 Key subgroups | Extensive pulmonary TB and resistance to fluoroquinolones","content_type":"text","pages":"91","tokens_est":205,"char_count":820,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0366","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.4 Key subgroups | Extensive pulmonary TB and resistance to fluoroquinolones","content_type":"text","pages":"91","tokens_est":237,"char_count":947,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0367","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.4 Key subgroups | Extrapulmonary TB","content_type":"text","pages":"91-92","tokens_est":138,"char_count":550,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0368","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.4 Key subgroups | People living with HIV","content_type":"text","pages":"92","tokens_est":206,"char_count":821,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0369","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.4 Key subgroups | People living with HIV","content_type":"text","pages":"92","tokens_est":196,"char_count":784,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0370","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.4 Key subgroups | Pregnant and breastfeeding women","content_type":"text","pages":"92","tokens_est":120,"char_count":478,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0371","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.4 Key subgroups | Pregnant and breastfeeding women","content_type":"text","pages":"92","tokens_est":241,"char_count":964,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0372","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.4 Key subgroups | Pregnant and breastfeeding women","content_type":"text","pages":"92-93","tokens_est":194,"char_count":774,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0373","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.4 Key subgroups | Children and adolescents","content_type":"text","pages":"93","tokens_est":98,"char_count":391,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0374","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.4 Key subgroups | Children and adolescents","content_type":"text","pages":"93","tokens_est":225,"char_count":897,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0375","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.4 Key subgroups | Children and adolescents","content_type":"text","pages":"93","tokens_est":141,"char_count":561,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0376","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.4 Key subgroups | Children and adolescents","content_type":"text","pages":"93","tokens_est":170,"char_count":678,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0377","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.4 Key subgroups | Children and adolescents","content_type":"text","pages":"93","tokens_est":91,"char_count":364,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0378","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.4 Key subgroups | Children and adolescents","content_type":"text","pages":"93-94","tokens_est":145,"char_count":577,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0379","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.4 Key subgroups | Children and adolescents","content_type":"text","pages":"94","tokens_est":211,"char_count":842,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0380","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.5 Implementation considerations | DST results","content_type":"text","pages":"94","tokens_est":218,"char_count":871,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0381","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.5 Implementation considerations | DST results","content_type":"text","pages":"94","tokens_est":163,"char_count":649,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0382","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.5 Implementation considerations | History of exposure to component drugs","content_type":"text","pages":"94","tokens_est":226,"char_count":901,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0383","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.5 Implementation considerations | Management of anaemia and myelosuppression","content_type":"text","pages":"95","tokens_est":240,"char_count":958,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0384","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.5 Implementation considerations | Management of anaemia and myelosuppression","content_type":"text","pages":"95","tokens_est":183,"char_count":730,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0385","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.5 Implementation considerations | Management of anaemia and myelosuppression","content_type":"text","pages":"95","tokens_est":245,"char_count":977,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0386","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.5 Implementation considerations | Management of anaemia and myelosuppression","content_type":"text","pages":"95","tokens_est":169,"char_count":675,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0387","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.5 Implementation considerations | Management of anaemia and myelosuppression","content_type":"text","pages":"95","tokens_est":107,"char_count":428,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0388","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.5 Implementation considerations | QT-interval prolongation","content_type":"text","pages":"95-96","tokens_est":235,"char_count":938,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0389","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.5 Implementation considerations | QT-interval prolongation","content_type":"text","pages":"95-96","tokens_est":222,"char_count":885,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0390","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.5 Implementation considerations | Treatment interruption","content_type":"text","pages":"96","tokens_est":223,"char_count":891,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0391","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.5 Implementation considerations | Care and support","content_type":"text","pages":"96","tokens_est":247,"char_count":987,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0392","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.5 Implementation considerations | Care and support","content_type":"text","pages":"96","tokens_est":43,"char_count":170,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0393","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.5 Implementation considerations | Care and support","content_type":"text","pages":"96-97","tokens_est":197,"char_count":788,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0394","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.5 Implementation considerations | Costeffectiveness analysis","content_type":"text","pages":"97","tokens_est":124,"char_count":496,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0395","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens","content_type":"text","pages":"97","tokens_est":131,"char_count":524,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0396","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | Table 2.5.1. Overview of 9-month regimens","content_type":"table","pages":"97-98","caption":"Table 2.5.1. Overview of 9-month regimens","tokens_est":37,"char_count":328,"has_attachment":true,"attachment_id":"Table 2.5.1.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_2.5.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0397","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB","content_type":"text","pages":"98","tokens_est":172,"char_count":688,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0398","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB","content_type":"text","pages":"98","tokens_est":221,"char_count":881,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0399","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB","content_type":"text","pages":"98-99","tokens_est":169,"char_count":675,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0400","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB","content_type":"text","pages":"99","tokens_est":232,"char_count":926,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0401","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB","content_type":"text","pages":"99","tokens_est":201,"char_count":801,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0402","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB","content_type":"text","pages":"99","tokens_est":187,"char_count":748,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0403","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB","content_type":"text","pages":"99","tokens_est":152,"char_count":606,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0404","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.1 Eligibility","content_type":"text","pages":"99-100","tokens_est":204,"char_count":813,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0405","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.1 Eligibility","content_type":"text","pages":"100","tokens_est":159,"char_count":633,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0406","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.1 Eligibility","content_type":"text","pages":"100","tokens_est":108,"char_count":430,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0407","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.1 Eligibility","content_type":"text","pages":"100","tokens_est":242,"char_count":965,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0408","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.1 Eligibility","content_type":"text","pages":"100","tokens_est":36,"char_count":143,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0409","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.1 Eligibility","content_type":"text","pages":"100","tokens_est":240,"char_count":960,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0410","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.2 Composition, dosing and duration of the regimen","content_type":"text","pages":"101","tokens_est":40,"char_count":159,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0411","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.2 Composition, dosing and duration of the regimen | Ethionamide variation","content_type":"text","pages":"101","tokens_est":221,"char_count":881,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0412","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.2 Composition, dosing and duration of the regimen | Ethionamide variation","content_type":"text","pages":"101","tokens_est":87,"char_count":346,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0413","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.2 Composition, dosing and duration of the regimen | Linezolid variation","content_type":"text","pages":"101","tokens_est":236,"char_count":944,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0414","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.2 Composition, dosing and duration of the regimen | Linezolid variation","content_type":"text","pages":"101","tokens_est":55,"char_count":219,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0415","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.2 Composition, dosing and duration of the regimen | Linezolid variation","content_type":"text","pages":"101","tokens_est":95,"char_count":377,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0416","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.2 Composition, dosing and duration of the regimen | Choice of fluoroquinolone","content_type":"text","pages":"102","tokens_est":193,"char_count":772,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0417","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.2 Composition, dosing and duration of the regimen | Dosing and frequency","content_type":"text","pages":"102","tokens_est":244,"char_count":975,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0418","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.2 Composition, dosing and duration of the regimen | Dosing and frequency","content_type":"text","pages":"102","tokens_est":212,"char_count":848,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0419","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.3 Modifications of treatment","content_type":"text","pages":"102","tokens_est":121,"char_count":481,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0420","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.3 Modifications of treatment","content_type":"text","pages":"102-103","tokens_est":237,"char_count":945,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0421","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.3 Modifications of treatment","content_type":"text","pages":"102-103","tokens_est":122,"char_count":487,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0422","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.3 Modifications of treatment","content_type":"text","pages":"103","tokens_est":244,"char_count":973,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0423","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.3 Modifications of treatment","content_type":"text","pages":"103","tokens_est":141,"char_count":563,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0424","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.3 Modifications of treatment","content_type":"text","pages":"103","tokens_est":248,"char_count":992,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0425","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.3 Modifications of treatment | Discontinuation and change to another treatment regimen","content_type":"text","pages":"103-104","tokens_est":156,"char_count":621,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0426","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.3 Modifications of treatment | Discontinuation and change to another treatment regimen","content_type":"text","pages":"103-104","tokens_est":208,"char_count":829,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0427","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.3 Modifications of treatment | Discontinuation and change to another treatment regimen","content_type":"text","pages":"104","tokens_est":213,"char_count":849,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0428","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | People living with HIV","content_type":"text","pages":"104","tokens_est":221,"char_count":881,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0429","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | People living with HIV","content_type":"text","pages":"104","tokens_est":140,"char_count":558,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0430","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Children","content_type":"text","pages":"104-105","tokens_est":195,"char_count":779,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0431","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Children","content_type":"text","pages":"105","tokens_est":189,"char_count":754,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0432","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Children","content_type":"text","pages":"105","tokens_est":117,"char_count":465,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0433","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Children","content_type":"text","pages":"105","tokens_est":246,"char_count":984,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0434","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Children","content_type":"text","pages":"105","tokens_est":127,"char_count":506,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0435","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Children","content_type":"text","pages":"105","tokens_est":210,"char_count":840,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0436","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Pregnant and breastfeeding women","content_type":"text","pages":"106","tokens_est":201,"char_count":802,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0437","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Pregnant and breastfeeding women","content_type":"text","pages":"106","tokens_est":182,"char_count":725,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0438","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Pregnant and breastfeeding women","content_type":"text","pages":"106","tokens_est":186,"char_count":742,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0439","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Extensive TB disease","content_type":"text","pages":"106","tokens_est":178,"char_count":711,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0440","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Older patients","content_type":"text","pages":"106-107","tokens_est":201,"char_count":804,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0441","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Extrapulmonary TB","content_type":"text","pages":"107","tokens_est":209,"char_count":833,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0442","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Extrapulmonary TB","content_type":"text","pages":"107","tokens_est":67,"char_count":268,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0443","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Extrapulmonary TB","content_type":"text","pages":"107","tokens_est":7,"char_count":28,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0444","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Patients with co-morbidities (other than HIV) | Patients with diabetes mellitus","content_type":"text","pages":"107","tokens_est":177,"char_count":707,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0445","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Patients with co-morbidities (other than HIV) | Patients with diabetes mellitus","content_type":"text","pages":"107","tokens_est":95,"char_count":380,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0446","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Patients with co-morbidities (other than HIV) | Patients with hepatic dysfunction","content_type":"text","pages":"107","tokens_est":123,"char_count":491,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0447","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Patients with co-morbidities (other than HIV) | Patients with renal failure","content_type":"text","pages":"107-108","tokens_est":138,"char_count":551,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0448","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Patients with co-morbidities (other than HIV) | Patients with anaemia","content_type":"text","pages":"108","tokens_est":226,"char_count":903,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0449","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Patients with co-morbidities (other than HIV) | Patients with anaemia","content_type":"text","pages":"108","tokens_est":245,"char_count":977,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0450","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Patients with co-morbidities (other than HIV) | Patients with anaemia","content_type":"text","pages":"108","tokens_est":222,"char_count":888,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0451","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.5 Implementation considerations | DST results","content_type":"text","pages":"108","tokens_est":93,"char_count":371,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0452","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.5 Implementation considerations | DST results","content_type":"text","pages":"108-109","tokens_est":220,"char_count":878,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0453","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.5 Implementation considerations | DST results","content_type":"text","pages":"109","tokens_est":160,"char_count":638,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0454","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.5 Implementation considerations | DST results","content_type":"text","pages":"109","tokens_est":190,"char_count":760,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0455","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.5 Implementation considerations | DST results","content_type":"text","pages":"109-110","tokens_est":216,"char_count":861,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0456","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.5 Implementation considerations | DST results","content_type":"text","pages":"109-110","tokens_est":223,"char_count":889,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0457","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.5 Implementation considerations | DST results","content_type":"text","pages":"109-110","tokens_est":133,"char_count":530,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0458","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.5 Implementation considerations | DST results","content_type":"text","pages":"110","tokens_est":201,"char_count":803,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0459","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.5 Implementation considerations | DST results","content_type":"text","pages":"110","tokens_est":166,"char_count":664,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0460","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.5 Implementation considerations | Box 2.5.1. Regimen selection at RR-TB diagnosis  no initial linezolid contraindications","content_type":"box","pages":"110","caption":"Box 2.5.1. Regimen selection at RR-TB diagnosis  no initial linezolid contraindications","tokens_est":222,"char_count":886,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0461","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.5 Implementation considerations | Box 2.5.1. Regimen selection at RR-TB diagnosis  no initial linezolid contraindications","content_type":"box","pages":"110-111","caption":"Box 2.5.1. Regimen selection at RR-TB diagnosis  no initial linezolid contraindications","tokens_est":208,"char_count":830,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0462","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.5 Implementation considerations | Box 2.5.1. Regimen selection at RR-TB diagnosis  no initial linezolid contraindications","content_type":"box","pages":"111","caption":"Box 2.5.1. Regimen selection at RR-TB diagnosis  no initial linezolid contraindications","tokens_est":82,"char_count":327,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0463","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.5 Implementation considerations | Box 2.5.2. Regimen selection at RR-TB diagnosis  linezolid contraindications","content_type":"box","pages":"111","caption":"Box 2.5.2. Regimen selection at RR-TB diagnosis  linezolid contraindications","tokens_est":86,"char_count":341,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0464","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.5 Implementation considerations | Box 2.5.2. Regimen selection at RR-TB diagnosis  linezolid contraindications","content_type":"box","pages":"111","caption":"Box 2.5.2. Regimen selection at RR-TB diagnosis  linezolid contraindications","tokens_est":221,"char_count":883,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0465","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.5 Implementation considerations | Box 2.5.2. Regimen selection at RR-TB diagnosis  linezolid contraindications","content_type":"box","pages":"111","caption":"Box 2.5.2. Regimen selection at RR-TB diagnosis  linezolid contraindications","tokens_est":176,"char_count":703,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0466","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.5 Implementation considerations | Assessment of extent and severity of TB disease","content_type":"text","pages":"111","tokens_est":89,"char_count":354,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0467","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.5 Implementation considerations | Assessment of extent and severity of TB disease","content_type":"text","pages":"111-112","tokens_est":207,"char_count":826,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0468","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.5 Implementation considerations | Assessment of extent and severity of TB disease","content_type":"text","pages":"111-112","tokens_est":96,"char_count":384,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0469","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.5 Implementation considerations | Haematological assessment","content_type":"text","pages":"112","tokens_est":235,"char_count":938,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0470","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB","content_type":"text","pages":"112","tokens_est":242,"char_count":965,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0471","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB","content_type":"text","pages":"112","tokens_est":170,"char_count":679,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0472","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB","content_type":"text","pages":"112-113","tokens_est":167,"char_count":665,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0473","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB","content_type":"text","pages":"113","tokens_est":158,"char_count":629,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0474","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB","content_type":"text","pages":"113","tokens_est":187,"char_count":745,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0475","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB","content_type":"text","pages":"113","tokens_est":240,"char_count":957,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0476","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB","content_type":"text","pages":"113","tokens_est":114,"char_count":454,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0477","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB","content_type":"text","pages":"113-114","tokens_est":163,"char_count":649,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0478","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB","content_type":"text","pages":"114","tokens_est":146,"char_count":582,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0479","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB","content_type":"text","pages":"114","tokens_est":183,"char_count":732,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0480","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB","content_type":"text","pages":"114","tokens_est":137,"char_count":545,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0481","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB","content_type":"text","pages":"114","tokens_est":51,"char_count":203,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0482","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.1 Eligibility","content_type":"text","pages":"114","tokens_est":181,"char_count":722,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0483","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.1 Eligibility","content_type":"text","pages":"114","tokens_est":154,"char_count":616,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0484","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.1 Eligibility","content_type":"text","pages":"114-115","tokens_est":169,"char_count":676,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0485","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.1 Eligibility","content_type":"text","pages":"115","tokens_est":178,"char_count":709,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0486","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.2 Composition, dosing and duration of the regimen","content_type":"text","pages":"115","tokens_est":94,"char_count":373,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0487","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.2 Composition, dosing and duration of the regimen | Table 2.5.2. The composition of the three modified 9-month regimens","content_type":"table","pages":"115","caption":"Table 2.5.2. The composition of the three modified 9-month regimens","tokens_est":40,"char_count":169,"has_attachment":true,"attachment_id":"Table 2.5.2.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_2.5.2..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0488","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.2 Composition, dosing and duration of the regimen | Dosing and frequency of component medicines","content_type":"text","pages":"115","tokens_est":166,"char_count":663,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0489","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.2 Composition, dosing and duration of the regimen | Dosing and frequency of component medicines","content_type":"text","pages":"115-116","tokens_est":146,"char_count":581,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0490","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.2 Composition, dosing and duration of the regimen | Dosing and frequency of component medicines","content_type":"text","pages":"116","tokens_est":218,"char_count":871,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0491","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.2 Composition, dosing and duration of the regimen | Duration","content_type":"text","pages":"116","tokens_est":119,"char_count":473,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0492","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.2 Composition, dosing and duration of the regimen | Duration","content_type":"text","pages":"116","tokens_est":139,"char_count":555,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0493","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.2 Composition, dosing and duration of the regimen | Treatment discontinuation","content_type":"text","pages":"116","tokens_est":248,"char_count":990,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0494","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.2 Composition, dosing and duration of the regimen | Treatment discontinuation","content_type":"text","pages":"116","tokens_est":75,"char_count":298,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0495","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.3 Key subgroups","content_type":"text","pages":"116-117","tokens_est":103,"char_count":410,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0496","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.3 Key subgroups | Children","content_type":"text","pages":"117","tokens_est":196,"char_count":783,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0497","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.3 Key subgroups | Children","content_type":"text","pages":"117","tokens_est":179,"char_count":713,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0498","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.3 Key subgroups | Pregnancy","content_type":"text","pages":"117","tokens_est":174,"char_count":695,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0499","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.3 Key subgroups | Breastfeeding women","content_type":"text","pages":"117","tokens_est":216,"char_count":863,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0500","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.3 Key subgroups | People living with HIV","content_type":"text","pages":"118","tokens_est":163,"char_count":651,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0501","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.3 Key subgroups | Pulmonary TB","content_type":"text","pages":"118","tokens_est":185,"char_count":739,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0502","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.3 Key subgroups | Extrapulmonary TB","content_type":"text","pages":"118","tokens_est":93,"char_count":372,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0503","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.3 Key subgroups | Patients with comorbidities other than HIV | Patients with diabetes mellitus","content_type":"text","pages":"118","tokens_est":146,"char_count":581,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0504","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.3 Key subgroups | Patients with comorbidities other than HIV | Patients with hepatic dysfunction","content_type":"text","pages":"118-119","tokens_est":168,"char_count":672,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0505","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.3 Key subgroups | Patients with comorbidities other than HIV | Patients with chronic renal insufficiency","content_type":"text","pages":"119","tokens_est":137,"char_count":548,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0506","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.3 Key subgroups | Patients with comorbidities other than HIV | Patients with anaemia","content_type":"text","pages":"119","tokens_est":129,"char_count":513,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0507","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.3 Key subgroups | Patients with comorbidities other than HIV | Patients with anaemia","content_type":"text","pages":"119","tokens_est":220,"char_count":880,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0508","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.3 Key subgroups | Patients with comorbidities other than HIV | Patients with anaemia","content_type":"text","pages":"119","tokens_est":106,"char_count":422,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0509","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.4 Implementation considerations | DST considerations","content_type":"text","pages":"119","tokens_est":157,"char_count":628,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0510","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.4 Implementation considerations | Extent of the disease","content_type":"text","pages":"119","tokens_est":28,"char_count":112,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0511","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.4 Implementation considerations | Drug-drug interactions (DDIs)","content_type":"text","pages":"120","tokens_est":106,"char_count":424,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0512","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.4 Implementation considerations | Role of pyrazinamide in the modified 9-month regimen","content_type":"text","pages":"120","tokens_est":63,"char_count":252,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0513","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.4 Implementation considerations | Role of pyrazinamide in the modified 9-month regimen | Performance based on pyrazinamide sensitivity and resistance","content_type":"text","pages":"120","tokens_est":157,"char_count":627,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0514","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.4 Implementation considerations | Role of pyrazinamide in the modified 9-month regimen | Hepatotoxicity and discontinuation of pyrazinamide","content_type":"text","pages":"120","tokens_est":198,"char_count":789,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0515","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.4 Implementation considerations | Role of pyrazinamide in the modified 9-month regimen | Hepatotoxicity and discontinuation of pyrazinamide","content_type":"text","pages":"120","tokens_est":74,"char_count":296,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0516","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.4 Implementation considerations | Role of pyrazinamide in the modified 9-month regimen | Hepatotoxicity and discontinuation of pyrazinamide","content_type":"text","pages":"120","tokens_est":158,"char_count":631,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0517","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.4 Implementation considerations | Role of pyrazinamide in the modified 9-month regimen | SoC for pyrazinamide management in the modified 9-month regimens","content_type":"text","pages":"120-121","tokens_est":164,"char_count":654,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0518","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.4 Implementation considerations | Role of pyrazinamide in the modified 9-month regimen | SoC for pyrazinamide management in the modified 9-month regimens","content_type":"text","pages":"121","tokens_est":191,"char_count":761,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0519","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.4 Implementation considerations | Role of pyrazinamide in the modified 9-month regimen | SoC for pyrazinamide management in the modified 9-month regimens","content_type":"text","pages":"121","tokens_est":107,"char_count":426,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0520","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.4 Implementation considerations | Role of pyrazinamide in the modified 9-month regimen | SoC for pyrazinamide management in the modified 9-month regimens","content_type":"text","pages":"121","tokens_est":240,"char_count":957,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0521","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.4 Implementation considerations | Cost of the modified 9-month regimen","content_type":"text","pages":"121","tokens_est":181,"char_count":722,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0522","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.4 Implementation considerations | Table 2.5.3. Prices and pill burden of the modified 9-month regimens","content_type":"table","pages":"121","caption":"Table 2.5.3. Prices and pill burden of the modified 9-month regimens","tokens_est":40,"char_count":308,"has_attachment":true,"attachment_id":"Table 2.5.3.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_2.5.3..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0523","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.4 Implementation considerations | Care and support","content_type":"text","pages":"122","tokens_est":246,"char_count":983,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0524","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.4 Implementation considerations | Care and support","content_type":"text","pages":"122","tokens_est":187,"char_count":745,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0525","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.4 Implementation considerations | Care and support","content_type":"text","pages":"122","tokens_est":235,"char_count":939,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0526","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens","content_type":"text","pages":"122-123","tokens_est":203,"char_count":809,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0527","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens","content_type":"text","pages":"123","tokens_est":150,"char_count":600,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0528","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens","content_type":"text","pages":"123","tokens_est":153,"char_count":612,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0529","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens","content_type":"text","pages":"123","tokens_est":173,"char_count":692,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0530","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.1 Eligibility","content_type":"text","pages":"123","tokens_est":190,"char_count":758,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0531","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.1 Eligibility","content_type":"text","pages":"123","tokens_est":236,"char_count":942,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0532","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.1 Eligibility","content_type":"text","pages":"123-124","tokens_est":214,"char_count":853,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0533","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.1 Eligibility","content_type":"text","pages":"124","tokens_est":167,"char_count":666,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0534","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens","content_type":"text","pages":"124","tokens_est":241,"char_count":961,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0535","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens","content_type":"text","pages":"124-125","tokens_est":238,"char_count":952,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0536","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens","content_type":"text","pages":"125","tokens_est":216,"char_count":861,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0537","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens","content_type":"text","pages":"125","tokens_est":194,"char_count":773,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0538","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens","content_type":"text","pages":"125","tokens_est":141,"char_count":562,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0539","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.1 Choice of components for the longer MDR-TB regimens","content_type":"text","pages":"125","tokens_est":35,"char_count":139,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0540","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.1 Choice of components for the longer MDR-TB regimens","content_type":"text","pages":"125-126","tokens_est":244,"char_count":973,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0541","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.1 Choice of components for the longer MDR-TB regimens","content_type":"text","pages":"126","tokens_est":186,"char_count":741,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0542","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.1 Choice of components for the longer MDR-TB regimens","content_type":"text","pages":"126","tokens_est":199,"char_count":793,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0543","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.1 Choice of components for the longer MDR-TB regimens","content_type":"text","pages":"126","tokens_est":181,"char_count":723,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0544","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.1 Choice of components for the longer MDR-TB regimens","content_type":"text","pages":"126","tokens_est":214,"char_count":856,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0545","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens","content_type":"text","pages":"126-127","tokens_est":240,"char_count":959,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0546","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens","content_type":"text","pages":"127","tokens_est":214,"char_count":856,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0547","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens","content_type":"text","pages":"127","tokens_est":123,"char_count":491,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0548","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Table 2.6.1. Grouping of medicines recommended for use in longer MDR-TB regimens [a]","content_type":"table","pages":"127","caption":"Table 2.6.1. Grouping of medicines recommended for use in longer MDR-TB regimens [a]","tokens_est":35,"char_count":4893,"has_attachment":true,"attachment_id":"Table 2.6.1.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_2.6.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0549","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group A","content_type":"text","pages":"127-128","tokens_est":114,"char_count":453,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0550","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group A | Levofloxacin and moxifloxacin","content_type":"text","pages":"128","tokens_est":142,"char_count":568,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0551","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group A | Levofloxacin and moxifloxacin","content_type":"text","pages":"128","tokens_est":230,"char_count":917,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0552","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group A | Levofloxacin and moxifloxacin","content_type":"text","pages":"128","tokens_est":100,"char_count":397,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0553","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group A | Bedaquiline","content_type":"text","pages":"128","tokens_est":107,"char_count":428,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0554","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group A | Bedaquiline","content_type":"text","pages":"128","tokens_est":180,"char_count":720,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0555","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group A | Bedaquiline","content_type":"text","pages":"128-129","tokens_est":248,"char_count":992,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0556","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group A | Linezolid","content_type":"text","pages":"129","tokens_est":63,"char_count":252,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0557","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group A | Linezolid","content_type":"text","pages":"129","tokens_est":231,"char_count":923,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0558","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group A | Linezolid","content_type":"text","pages":"129","tokens_est":138,"char_count":551,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0559","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group A | Linezolid","content_type":"text","pages":"129","tokens_est":131,"char_count":524,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0560","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group B","content_type":"text","pages":"129","tokens_est":87,"char_count":345,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0561","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group B | Clofazimine","content_type":"text","pages":"129-130","tokens_est":152,"char_count":606,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0562","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group B | Clofazimine","content_type":"text","pages":"130","tokens_est":226,"char_count":902,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0563","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group B | Cycloserine","content_type":"text","pages":"130","tokens_est":245,"char_count":978,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0564","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group B | Cycloserine","content_type":"text","pages":"130","tokens_est":130,"char_count":520,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0565","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group C","content_type":"text","pages":"130","tokens_est":128,"char_count":510,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0566","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group C | Ethambutol","content_type":"text","pages":"130-131","tokens_est":128,"char_count":509,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0567","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group C | Delamanid","content_type":"text","pages":"131","tokens_est":203,"char_count":810,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0568","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group C | Delamanid","content_type":"text","pages":"131","tokens_est":234,"char_count":936,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0569","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group C | Pyrazinamide","content_type":"text","pages":"131","tokens_est":203,"char_count":810,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0570","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group C | Imipenem cilastatin and meropenem","content_type":"text","pages":"131-132","tokens_est":226,"char_count":903,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0571","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group C | Imipenem cilastatin and meropenem","content_type":"text","pages":"131-132","tokens_est":44,"char_count":176,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0572","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group C | Amikacin and streptomycin","content_type":"text","pages":"132","tokens_est":212,"char_count":848,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0573","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group C | Ethionamide and prothionamide","content_type":"text","pages":"132","tokens_est":198,"char_count":792,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0574","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group C | P- aminosalicylic acid","content_type":"text","pages":"132","tokens_est":148,"char_count":590,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0575","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Other medicines","content_type":"text","pages":"132","tokens_est":36,"char_count":144,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0576","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Other medicines | High-dose isoniazid","content_type":"text","pages":"132-133","tokens_est":203,"char_count":809,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0577","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Other medicines | High-dose isoniazid","content_type":"text","pages":"133","tokens_est":245,"char_count":980,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0578","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Other medicines | High-dose isoniazid","content_type":"text","pages":"133","tokens_est":129,"char_count":514,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0579","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.3 Duration of the regimen","content_type":"text","pages":"133","tokens_est":191,"char_count":764,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0580","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.3 Duration of the regimen","content_type":"text","pages":"133","tokens_est":227,"char_count":906,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0581","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.3 Duration of the regimen","content_type":"text","pages":"133-134","tokens_est":191,"char_count":762,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0582","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.3 Key subgroups | 6.3.1 People living with HIV","content_type":"text","pages":"134","tokens_est":71,"char_count":284,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0583","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.3 Key subgroups | 6.3.2 Children","content_type":"text","pages":"134","tokens_est":235,"char_count":939,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0584","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.3 Key subgroups | 6.3.3 Pregnant and breastfeeding women","content_type":"text","pages":"134","tokens_est":202,"char_count":808,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0585","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.3 Key subgroups | 6.3.3 Pregnant and breastfeeding women","content_type":"text","pages":"134","tokens_est":238,"char_count":950,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0586","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.3 Key subgroups | 6.3.3 Pregnant and breastfeeding women","content_type":"text","pages":"134","tokens_est":42,"char_count":165,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0587","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.3 Key subgroups | 6.3.3 Pregnant and breastfeeding women","content_type":"text","pages":"134-135","tokens_est":150,"char_count":597,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0588","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.3 Key subgroups | 6.3.4 Patients with diabetes mellitus","content_type":"text","pages":"135","tokens_est":246,"char_count":981,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0589","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.3 Key subgroups | 6.3.5 Patients with extrapulmonary TB","content_type":"text","pages":"135","tokens_est":223,"char_count":890,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0590","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.3 Key subgroups | 6.3.5 Patients with extrapulmonary TB","content_type":"text","pages":"135","tokens_est":86,"char_count":342,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0591","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.4 Implementation considerations and treatment in special situations | 6.4.1 Extensive DR-TB disease","content_type":"text","pages":"135-136","tokens_est":243,"char_count":972,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0592","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.4 Implementation considerations and treatment in special situations | 6.4.1 Extensive DR-TB disease","content_type":"text","pages":"135-136","tokens_est":56,"char_count":222,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0593","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.4 Implementation considerations and treatment in special situations | 6.4.2 Severe extrapulmonary TB","content_type":"text","pages":"136","tokens_est":223,"char_count":892,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0594","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.4 Implementation considerations and treatment in special situations | 6.4.3 DR-TB in different patient groups | DR-TB meningitis and brain tuberculomas","content_type":"text","pages":"136","tokens_est":97,"char_count":386,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0595","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.4 Implementation considerations and treatment in special situations | 6.4.3 DR-TB in different patient groups | DR-TB meningitis and brain tuberculomas","content_type":"text","pages":"136","tokens_est":244,"char_count":974,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0596","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.4 Implementation considerations and treatment in special situations | 6.4.3 DR-TB in different patient groups | DR-TB in older patients","content_type":"text","pages":"136","tokens_est":189,"char_count":753,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0597","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.4 Implementation considerations and treatment in special situations | 6.4.3 DR-TB in different patient groups | DR-TB patients with renal failure","content_type":"text","pages":"137","tokens_est":145,"char_count":579,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0598","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.4 Implementation considerations and treatment in special situations | 6.4.3 DR-TB in different patient groups | DR-TB in patients with anaemia","content_type":"text","pages":"137","tokens_est":202,"char_count":807,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0599","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.4 Implementation considerations and treatment in special situations | 6.4.3 DR-TB in different patient groups | DR-TB in malnourished patients","content_type":"text","pages":"137","tokens_est":242,"char_count":966,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0600","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.4 Implementation considerations and treatment in special situations | 6.4.3 DR-TB in different patient groups | DR-TB in malnourished patients","content_type":"text","pages":"137","tokens_est":136,"char_count":543,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0601","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.4 Implementation considerations and treatment in special situations | 6.4.3 DR-TB in different patient groups | DR-TB in patients with hepatitis B or C","content_type":"text","pages":"137","tokens_est":68,"char_count":272,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0602","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.4 Implementation considerations and treatment in special situations | 6.4.3 DR-TB in different patient groups | DR-TB in patients with depression","content_type":"text","pages":"137-138","tokens_est":214,"char_count":855,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0603","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.4 Implementation considerations and treatment in special situations | 6.4.3 DR-TB in different patient groups | DR-TB in patients who present with alcohol or other substances abuse","content_type":"text","pages":"138","tokens_est":186,"char_count":743,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0604","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.5 Treatment monitoring","content_type":"text","pages":"138","tokens_est":233,"char_count":930,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0605","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.5 Treatment monitoring | Table 2.6.2. Summary algorithm for longer MDR-TB regimen composition in commonplace situations of resistance pattern or contraindication","content_type":"table","pages":"138-142","caption":"Table 2.6.2. Summary algorithm for longer MDR-TB regimen composition in commonplace situations of resistance pattern or contraindication","tokens_est":106,"char_count":2310,"has_attachment":true,"attachment_id":"Table 2.6.2.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_2.6.2..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0606","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB","content_type":"text","pages":"144","tokens_est":242,"char_count":966,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0607","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB","content_type":"text","pages":"144","tokens_est":119,"char_count":475,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0608","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB | 7.1 Eligibility","content_type":"text","pages":"144","tokens_est":233,"char_count":931,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0609","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB | 7.1 Eligibility","content_type":"text","pages":"144","tokens_est":152,"char_count":608,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0610","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB | 7.1 Eligibility","content_type":"text","pages":"144-145","tokens_est":131,"char_count":524,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0611","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB | 7.1 Eligibility","content_type":"text","pages":"145","tokens_est":236,"char_count":942,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0612","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB | 7.1 Eligibility","content_type":"text","pages":"145","tokens_est":57,"char_count":225,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0613","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB | 7.2 Composition and duration of the regimen","content_type":"text","pages":"145","tokens_est":212,"char_count":845,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0614","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB | 7.2 Composition and duration of the regimen","content_type":"text","pages":"145","tokens_est":189,"char_count":756,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0615","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB | 7.2 Composition and duration of the regimen","content_type":"text","pages":"145","tokens_est":222,"char_count":885,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0616","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB | 7.2 Composition and duration of the regimen | Box 2.7.1. Evaluation of a typical scenario  a delayed DST result in a patient on a first-line regimen","content_type":"box","pages":"146","caption":"Box 2.7.1. Evaluation of a typical scenario  a delayed DST result in a patient on a first-line regimen","tokens_est":186,"char_count":743,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0617","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB | 7.2 Composition and duration of the regimen | Box 2.7.1. Evaluation of a typical scenario  a delayed DST result in a patient on a first-line regimen","content_type":"box","pages":"146","caption":"Box 2.7.1. Evaluation of a typical scenario  a delayed DST result in a patient on a first-line regimen","tokens_est":200,"char_count":797,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0618","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB | 7.2 Composition and duration of the regimen","content_type":"text","pages":"146","tokens_est":81,"char_count":322,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0619","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB | 7.3 Considerations for implementation","content_type":"text","pages":"146","tokens_est":109,"char_count":436,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0620","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB | 7.3 Considerations for implementation","content_type":"text","pages":"146","tokens_est":162,"char_count":646,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0621","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB | 7.3 Considerations for implementation","content_type":"text","pages":"146-147","tokens_est":219,"char_count":876,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0622","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB | 7.3 Considerations for implementation","content_type":"text","pages":"147","tokens_est":239,"char_count":954,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0623","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB | 7.3 Considerations for implementation","content_type":"text","pages":"147","tokens_est":116,"char_count":461,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0624","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB | 7.3 Considerations for implementation","content_type":"text","pages":"147","tokens_est":107,"char_count":427,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0625","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB | 7.4 Treatment monitoring","content_type":"text","pages":"147","tokens_est":134,"char_count":535,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0626","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB | 7.4 Treatment monitoring","content_type":"text","pages":"147","tokens_est":239,"char_count":956,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0627","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB | 7.4 Treatment monitoring","content_type":"text","pages":"147","tokens_est":23,"char_count":91,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0628","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB | 7.4 Treatment monitoring","content_type":"text","pages":"147-148","tokens_est":224,"char_count":895,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0629","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB | 7.4 Treatment monitoring","content_type":"text","pages":"148","tokens_est":105,"char_count":417,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0630","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB | 7.4 Treatment monitoring","content_type":"text","pages":"148","tokens_est":246,"char_count":982,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0631","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB | 7.4 Treatment monitoring","content_type":"text","pages":"148","tokens_est":36,"char_count":141,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0632","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.1 Surgery in the treatment of MDR/XDR-TB","content_type":"text","pages":"150","tokens_est":157,"char_count":628,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0633","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.1 Surgery in the treatment of MDR/XDR-TB","content_type":"text","pages":"150","tokens_est":238,"char_count":951,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0634","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.1 Surgery in the treatment of MDR/XDR-TB","content_type":"text","pages":"150","tokens_est":221,"char_count":884,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0635","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.1 Surgery in the treatment of MDR/XDR-TB","content_type":"text","pages":"150","tokens_est":92,"char_count":366,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0636","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.1 Surgery in the treatment of MDR/XDR-TB","content_type":"text","pages":"150","tokens_est":202,"char_count":807,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0637","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.1 Surgery in the treatment of MDR/XDR-TB","content_type":"text","pages":"150-151","tokens_est":195,"char_count":780,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0638","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.1 Surgery in the treatment of MDR/XDR-TB","content_type":"text","pages":"150-151","tokens_est":73,"char_count":292,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0639","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.1 Surgery in the treatment of MDR/XDR-TB","content_type":"text","pages":"151","tokens_est":214,"char_count":853,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0640","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.2 Use of corticosteroids","content_type":"text","pages":"151","tokens_est":189,"char_count":753,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0641","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.2 Use of corticosteroids","content_type":"text","pages":"151","tokens_est":152,"char_count":608,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0642","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.2 Use of corticosteroids","content_type":"text","pages":"151","tokens_est":174,"char_count":696,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0643","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.3 Treatment of MDR/RR-TB patients with HIV","content_type":"text","pages":"152","tokens_est":134,"char_count":535,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0644","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.3 Treatment of MDR/RR-TB patients with HIV","content_type":"text","pages":"152","tokens_est":160,"char_count":640,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0645","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.3 Treatment of MDR/RR-TB patients with HIV","content_type":"text","pages":"152","tokens_est":233,"char_count":932,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0646","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.3 Treatment of MDR/RR-TB patients with HIV","content_type":"text","pages":"152","tokens_est":32,"char_count":127,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0647","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.4 Treatment of MDR/RR-TB patients coinfected with HCV","content_type":"text","pages":"152","tokens_est":175,"char_count":698,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0648","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.4 Treatment of MDR/RR-TB patients coinfected with HCV | 8.4.1 Eligibility","content_type":"text","pages":"152","tokens_est":43,"char_count":170,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0649","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.4 Treatment of MDR/RR-TB patients coinfected with HCV | 8.4.2 Implementation considerations | Co-administration of MDR-TB and HCV treatments","content_type":"text","pages":"153","tokens_est":204,"char_count":815,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0650","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.4 Treatment of MDR/RR-TB patients coinfected with HCV | 8.4.2 Implementation considerations | Co-administration of MDR-TB and HCV treatments","content_type":"text","pages":"153","tokens_est":218,"char_count":872,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0651","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.4 Treatment of MDR/RR-TB patients coinfected with HCV | 8.4.2 Implementation considerations | Co-administration of MDR-TB and HCV treatments","content_type":"text","pages":"153","tokens_est":180,"char_count":719,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0652","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.4 Treatment of MDR/RR-TB patients coinfected with HCV | 8.4.2 Implementation considerations | Co-administration of MDR-TB and HCV treatments","content_type":"text","pages":"153","tokens_est":168,"char_count":672,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0653","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.4 Treatment of MDR/RR-TB patients coinfected with HCV | 8.4.2 Implementation considerations | Access to treatment for HCV and MDR-TB","content_type":"text","pages":"153","tokens_est":96,"char_count":382,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0654","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.4 Treatment of MDR/RR-TB patients coinfected with HCV | 8.4.3 Monitoring treatment response and outcome assignment","content_type":"text","pages":"154","tokens_est":231,"char_count":921,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0655","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.4 Treatment of MDR/RR-TB patients coinfected with HCV | 8.4.3 Monitoring treatment response and outcome assignment","content_type":"text","pages":"154","tokens_est":45,"char_count":180,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0656","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.4 Treatment of MDR/RR-TB patients coinfected with HCV | 8.4.4 Monitoring safety","content_type":"text","pages":"154","tokens_est":159,"char_count":633,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0657","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.4 Treatment of MDR/RR-TB patients coinfected with HCV | 8.4.4 Monitoring safety","content_type":"text","pages":"154","tokens_est":215,"char_count":860,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0658","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.4 Treatment of MDR/RR-TB patients coinfected with HCV | 8.4.4 Monitoring safety","content_type":"text","pages":"154","tokens_est":84,"char_count":333,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0659","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.4 Treatment of MDR/RR-TB patients coinfected with HCV | 8.4.4 Monitoring safety","content_type":"text","pages":"154-155","tokens_est":218,"char_count":869,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0660","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.4 Treatment of MDR/RR-TB patients coinfected with HCV | Table 2.8.1. DDIs between MDR/RR-TB and HCV drugs","content_type":"table","pages":"155-156","caption":"Table 2.8.1. DDIs between MDR/RR-TB and HCV drugs","tokens_est":38,"char_count":637,"has_attachment":true,"attachment_id":"Table 2.8.1.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_2.8.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0661","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.4 Treatment of MDR/RR-TB patients coinfected with HCV","content_type":"text","pages":"156","tokens_est":159,"char_count":634,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0662","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.4 Treatment of MDR/RR-TB patients coinfected with HCV | Table 2.8.2. Characteristics of anti-TB drugs related to liver disease","content_type":"table","pages":"156-157","caption":"Table 2.8.2. Characteristics of anti-TB drugs related to liver disease","tokens_est":40,"char_count":159,"has_attachment":true,"attachment_id":"Table 2.8.2.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_2.8.2..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0663","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.4 Treatment of MDR/RR-TB patients coinfected with HCV","content_type":"text","pages":"157","tokens_est":143,"char_count":569,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0664","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens","content_type":"text","pages":"159","tokens_est":72,"char_count":285,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0665","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.1 Policy and operational documents","content_type":"text","pages":"159","tokens_est":198,"char_count":792,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0666","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.2 National DR-TB expert committee or technical working group","content_type":"text","pages":"159","tokens_est":154,"char_count":613,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0667","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.2 National DR-TB expert committee or technical working group","content_type":"text","pages":"159","tokens_est":122,"char_count":487,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0668","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.3 Electronic recording and reporting","content_type":"text","pages":"159-160","tokens_est":237,"char_count":948,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0669","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.3 Electronic recording and reporting","content_type":"text","pages":"159-160","tokens_est":219,"char_count":873,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0670","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.4 Estimates (epidemiological and logistics)","content_type":"text","pages":"160","tokens_est":198,"char_count":792,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0671","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.4 Estimates (epidemiological and logistics)","content_type":"text","pages":"160","tokens_est":212,"char_count":846,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0672","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.4 Estimates (epidemiological and logistics)","content_type":"text","pages":"160","tokens_est":66,"char_count":262,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0673","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.5 Management of the supply chain and storage conditions for pharmaceuticals","content_type":"text","pages":"160-161","tokens_est":238,"char_count":950,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0674","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.5 Management of the supply chain and storage conditions for pharmaceuticals","content_type":"text","pages":"160-161","tokens_est":184,"char_count":734,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0675","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.5 Management of the supply chain and storage conditions for pharmaceuticals","content_type":"text","pages":"160-161","tokens_est":177,"char_count":705,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0676","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.6 Preparation for the introduction of new treatment regimens","content_type":"text","pages":"161","tokens_est":183,"char_count":732,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0677","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.6 Preparation for the introduction of new treatment regimens","content_type":"text","pages":"161","tokens_est":234,"char_count":934,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0678","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.6 Preparation for the introduction of new treatment regimens","content_type":"text","pages":"161","tokens_est":129,"char_count":516,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0679","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.6 Preparation for the introduction of new treatment regimens","content_type":"text","pages":"161-162","tokens_est":209,"char_count":834,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0680","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.6 Preparation for the introduction of new treatment regimens | National level:","content_type":"text","pages":"162","tokens_est":236,"char_count":944,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0681","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.6 Preparation for the introduction of new treatment regimens | Health facility level in adopting areas","content_type":"text","pages":"162","tokens_est":231,"char_count":922,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0682","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.6 Preparation for the introduction of new treatment regimens | Table 2.9.1. List of activities and corresponding responsible organizations","content_type":"table","pages":"162-165","caption":"Table 2.9.1. List of activities and corresponding responsible organizations","tokens_est":31,"char_count":134,"has_attachment":true,"attachment_id":"Table 2.9.1.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_2.9.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0683","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.6 Preparation for the introduction of new treatment regimens | Costing","content_type":"text","pages":"165","tokens_est":209,"char_count":834,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0684","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.6 Preparation for the introduction of new treatment regimens | Costing","content_type":"text","pages":"165","tokens_est":217,"char_count":866,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0685","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.6 Preparation for the introduction of new treatment regimens | Monitoring and evaluation","content_type":"text","pages":"166","tokens_est":128,"char_count":512,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0686","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.6 Preparation for the introduction of new treatment regimens | Monitoring and evaluation","content_type":"text","pages":"166","tokens_est":229,"char_count":916,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0687","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.6 Preparation for the introduction of new treatment regimens | Monitoring and evaluation","content_type":"text","pages":"166","tokens_est":115,"char_count":458,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0688","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.7 Monitoring treatment response and safety","content_type":"text","pages":"166","tokens_est":107,"char_count":428,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0689","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.7 Monitoring treatment response and safety | 9.7.1 Monitoring the treatment response","content_type":"text","pages":"166","tokens_est":194,"char_count":775,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0690","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.7 Monitoring treatment response and safety | 9.7.1 Monitoring the treatment response","content_type":"text","pages":"166-167","tokens_est":137,"char_count":545,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0691","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.7 Monitoring treatment response and safety | 9.7.1 Monitoring the treatment response","content_type":"text","pages":"167","tokens_est":248,"char_count":989,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0692","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.7 Monitoring treatment response and safety | 9.7.1 Monitoring the treatment response","content_type":"text","pages":"167","tokens_est":58,"char_count":232,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0693","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.7 Monitoring treatment response and safety | 9.7.1 Monitoring the treatment response | Treatment monitoring for special populations","content_type":"text","pages":"167","tokens_est":227,"char_count":907,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0694","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.7 Monitoring treatment response and safety | 9.7.1 Monitoring the treatment response | Treatment monitoring for special populations","content_type":"text","pages":"167","tokens_est":227,"char_count":906,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0695","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.7 Monitoring treatment response and safety | 9.7.1 Monitoring the treatment response | Treatment monitoring for special populations","content_type":"text","pages":"167","tokens_est":58,"char_count":230,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0696","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.7 Monitoring treatment response and safety | 9.7.2 Monitoring safety","content_type":"text","pages":"168","tokens_est":66,"char_count":263,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0697","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.7 Monitoring treatment response and safety | 9.7.2 Monitoring safety","content_type":"text","pages":"168","tokens_est":242,"char_count":968,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0698","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.7 Monitoring treatment response and safety | 9.7.2 Monitoring safety","content_type":"text","pages":"168","tokens_est":96,"char_count":383,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0699","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.7 Monitoring treatment response and safety | Table 2.9.2. Recommended schedule of baseline, routine and post-treatment monitoring examinations for patients on DR-TB treatment [ a ]","content_type":"table","pages":"168-175","caption":"Table 2.9.2. Recommended schedule of baseline, routine and post-treatment monitoring examinations for patients on DR-TB treatment [ a ]","tokens_est":74,"char_count":1181,"has_attachment":true,"attachment_id":"Table 2.9.2.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_2.9.2..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0700","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.8 Treatment outcome definitions","content_type":"text","pages":"175","tokens_est":206,"char_count":824,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0701","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.9 Post-treatment follow-up","content_type":"text","pages":"175","tokens_est":103,"char_count":409,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0702","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.9 Post-treatment follow-up","content_type":"text","pages":"175-176","tokens_est":237,"char_count":948,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0703","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.9 Post-treatment follow-up","content_type":"text","pages":"176","tokens_est":178,"char_count":712,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0704","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | Table 2.9.3. Post-end-of treatment schedule","content_type":"table","pages":"176","caption":"Table 2.9.3. Post-end-of treatment schedule","tokens_est":51,"char_count":211,"has_attachment":true,"attachment_id":"Table 2.9.3.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_2.9.3..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0705","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 1. Introduction","content_type":"text","pages":"194","tokens_est":184,"char_count":735,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0706","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 1. Introduction","content_type":"text","pages":"194","tokens_est":136,"char_count":543,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0707","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 1. Introduction","content_type":"text","pages":"194","tokens_est":157,"char_count":625,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0708","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 1. Introduction | Key WHO recommendations on TB care and support | 1. Care and support interventions for all people with TB","content_type":"text","pages":"194","tokens_est":60,"char_count":238,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0709","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 1. Introduction | Key WHO recommendations on TB care and support | 1. Care and support interventions for all people with TB","content_type":"text","pages":"194","tokens_est":240,"char_count":959,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0710","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 1. Introduction | Key WHO recommendations on TB care and support | 1. Care and support interventions for all people with TB","content_type":"text","pages":"194","tokens_est":180,"char_count":717,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0711","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 1. Introduction | Key WHO recommendations on TB care and support | 1. Care and support interventions for all people with TB","content_type":"text","pages":"194","tokens_est":235,"char_count":939,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0712","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 1. Introduction | Key WHO recommendations on TB care and support | 1. Care and support interventions for all people with TB","content_type":"text","pages":"194","tokens_est":219,"char_count":873,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0713","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 1. Introduction | Key WHO recommendations on TB care and support | 2. Models of care for people with drug-resistant TB","content_type":"text","pages":"194-195","tokens_est":112,"char_count":447,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0714","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 1. Introduction | Key WHO recommendations on TB care and support | 3. Models of care for children and adolescents exposed to TB or with TB disease","content_type":"text","pages":"195","tokens_est":149,"char_count":596,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0715","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 2. People- centred approach","content_type":"text","pages":"195","tokens_est":224,"char_count":893,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0716","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 2. People- centred approach","content_type":"text","pages":"195","tokens_est":219,"char_count":873,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0717","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 2. People- centred approach","content_type":"text","pages":"195-196","tokens_est":211,"char_count":844,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0718","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 2. People- centred approach","content_type":"text","pages":"196","tokens_est":98,"char_count":390,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0719","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 2. People- centred approach","content_type":"text","pages":"196","tokens_est":212,"char_count":848,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0720","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 2. People- centred approach","content_type":"text","pages":"196","tokens_est":107,"char_count":427,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0721","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 2. People- centred approach","content_type":"text","pages":"196","tokens_est":113,"char_count":452,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0722","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 2. People- centred approach","content_type":"text","pages":"196","tokens_est":155,"char_count":619,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0723","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 2. People- centred approach","content_type":"text","pages":"196","tokens_est":202,"char_count":808,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0724","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 2. People- centred approach","content_type":"text","pages":"196","tokens_est":60,"char_count":239,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0725","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 2. People- centred approach","content_type":"text","pages":"196-197","tokens_est":181,"char_count":722,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0726","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 2. People- centred approach","content_type":"text","pages":"197","tokens_est":222,"char_count":887,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0727","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 2. People- centred approach","content_type":"text","pages":"197","tokens_est":216,"char_count":863,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0728","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence","content_type":"text","pages":"202","tokens_est":185,"char_count":740,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0729","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence","content_type":"text","pages":"202","tokens_est":193,"char_count":769,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0730","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence","content_type":"text","pages":"202","tokens_est":195,"char_count":779,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0731","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence","content_type":"text","pages":"202","tokens_est":218,"char_count":869,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0732","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence","content_type":"text","pages":"202-203","tokens_est":235,"char_count":939,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0733","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence","content_type":"text","pages":"202-203","tokens_est":146,"char_count":583,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0734","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence","content_type":"text","pages":"203","tokens_est":191,"char_count":762,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0735","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence","content_type":"text","pages":"203","tokens_est":235,"char_count":939,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0736","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence","content_type":"text","pages":"203","tokens_est":218,"char_count":871,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0737","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management","content_type":"text","pages":"203-204","tokens_est":235,"char_count":939,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0738","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management","content_type":"text","pages":"204","tokens_est":183,"char_count":731,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0739","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management","content_type":"text","pages":"204","tokens_est":224,"char_count":894,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0740","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management","content_type":"text","pages":"204","tokens_est":193,"char_count":771,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0741","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management","content_type":"text","pages":"204-205","tokens_est":203,"char_count":812,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0742","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management","content_type":"text","pages":"205","tokens_est":160,"char_count":638,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0743","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management","content_type":"text","pages":"205","tokens_est":247,"char_count":987,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0744","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management","content_type":"text","pages":"205","tokens_est":133,"char_count":530,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0745","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management | 3.1.1 Informational and educational support","content_type":"text","pages":"205","tokens_est":210,"char_count":839,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0746","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management | 3.1.1 Informational and educational support","content_type":"text","pages":"205","tokens_est":109,"char_count":433,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0747","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management | 3.1.1 Informational and educational support","content_type":"text","pages":"205-206","tokens_est":195,"char_count":778,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0748","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management | 3.1.1 Informational and educational support","content_type":"text","pages":"206","tokens_est":103,"char_count":409,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0749","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management | 3.1.1 Informational and educational support","content_type":"text","pages":"206","tokens_est":211,"char_count":841,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0750","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management | 3.1.1 Informational and educational support","content_type":"text","pages":"206","tokens_est":150,"char_count":599,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0751","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management | 3.1.2 Psychological and emotional support","content_type":"text","pages":"206","tokens_est":74,"char_count":294,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0752","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management | 3.1.2 Psychological and emotional support","content_type":"text","pages":"206","tokens_est":243,"char_count":972,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0753","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management | 3.1.2 Psychological and emotional support","content_type":"text","pages":"206","tokens_est":36,"char_count":143,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0754","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management | 3.1.2 Psychological and emotional support","content_type":"text","pages":"206-207","tokens_est":167,"char_count":668,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0755","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management | 3.1.2 Psychological and emotional support","content_type":"text","pages":"207","tokens_est":112,"char_count":447,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0756","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management | 3.1.2 Psychological and emotional support | Box: Support group","content_type":"box","pages":"207","caption":"Box: Support group","tokens_est":221,"char_count":883,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0757","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management | 3.1.2 Psychological and emotional support | Box: Support group","content_type":"box","pages":"207","caption":"Box: Support group","tokens_est":90,"char_count":360,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0758","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management | 3.1.3 Material support","content_type":"text","pages":"207","tokens_est":210,"char_count":839,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0759","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management | 3.1.3 Material support","content_type":"text","pages":"207-208","tokens_est":228,"char_count":909,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0760","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management | 3.1.3 Material support","content_type":"text","pages":"207-208","tokens_est":57,"char_count":228,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0761","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management | 3.1.3 Material support","content_type":"text","pages":"208","tokens_est":197,"char_count":786,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0762","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management | 3.1.3 Material support","content_type":"text","pages":"208","tokens_est":65,"char_count":258,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0763","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management | 3.1.3 Material support","content_type":"text","pages":"208","tokens_est":121,"char_count":484,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0764","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management | 3.1.4 Companionship support","content_type":"text","pages":"208","tokens_est":202,"char_count":807,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0765","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management | 3.1.4 Companionship support","content_type":"text","pages":"208","tokens_est":197,"char_count":786,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0766","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.2 Treatment administration and digital adherence technologies | 3.2.1 Treatment support","content_type":"text","pages":"209","tokens_est":227,"char_count":906,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0767","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.2 Treatment administration and digital adherence technologies | 3.2.1 Treatment support","content_type":"text","pages":"209","tokens_est":158,"char_count":631,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0768","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.2 Treatment administration and digital adherence technologies | 3.2.1 Treatment support","content_type":"text","pages":"209","tokens_est":195,"char_count":778,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0769","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.2 Treatment administration and digital adherence technologies | 3.2.1 Treatment support","content_type":"text","pages":"209","tokens_est":236,"char_count":942,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0770","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.2 Treatment administration and digital adherence technologies | 3.2.1 Treatment support","content_type":"text","pages":"209","tokens_est":93,"char_count":372,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0771","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.2 Treatment administration and digital adherence technologies | 3.2.2 Digital adherence technologies","content_type":"text","pages":"209-210","tokens_est":166,"char_count":662,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0772","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.2 Treatment administration and digital adherence technologies | 3.2.2 Digital adherence technologies","content_type":"text","pages":"210","tokens_est":242,"char_count":968,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0773","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.2 Treatment administration and digital adherence technologies | 3.2.2 Digital adherence technologies","content_type":"text","pages":"210","tokens_est":225,"char_count":898,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0774","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.2 Treatment administration and digital adherence technologies | 3.2.2 Digital adherence technologies","content_type":"text","pages":"210","tokens_est":211,"char_count":844,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0775","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.2 Treatment administration and digital adherence technologies | 3.2.2 Digital adherence technologies","content_type":"text","pages":"210","tokens_est":166,"char_count":662,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0776","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.2 Treatment administration and digital adherence technologies | 3.2.2 Digital adherence technologies","content_type":"text","pages":"210-211","tokens_est":218,"char_count":869,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0777","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.2 Treatment administration and digital adherence technologies | 3.2.2 Digital adherence technologies","content_type":"text","pages":"211","tokens_est":245,"char_count":977,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0778","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.2 Treatment administration and digital adherence technologies | 3.2.2 Digital adherence technologies","content_type":"text","pages":"211","tokens_est":221,"char_count":882,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0779","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.2 Treatment administration and digital adherence technologies | 3.2.2 Digital adherence technologies","content_type":"text","pages":"211","tokens_est":147,"char_count":588,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0780","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.2 Treatment administration and digital adherence technologies | 3.2.2 Digital adherence technologies","content_type":"text","pages":"211","tokens_est":219,"char_count":873,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0781","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.2 Treatment administration and digital adherence technologies | 3.2.2 Digital adherence technologies","content_type":"text","pages":"211","tokens_est":98,"char_count":391,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0782","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.2 Treatment administration and digital adherence technologies | 3.2.2 Digital adherence technologies","content_type":"text","pages":"211-212","tokens_est":188,"char_count":750,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0783","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.2 Treatment administration and digital adherence technologies | 3.2.2 Digital adherence technologies","content_type":"text","pages":"211-212","tokens_est":251,"char_count":1002,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0784","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.3 Selecting a suitable package of care and support for a patient","content_type":"text","pages":"212","tokens_est":108,"char_count":430,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0785","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.3 Selecting a suitable package of care and support for a patient","content_type":"text","pages":"212","tokens_est":243,"char_count":971,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0786","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.3 Selecting a suitable package of care and support for a patient","content_type":"text","pages":"212-213","tokens_est":228,"char_count":910,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0787","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.3 Selecting a suitable package of care and support for a patient","content_type":"text","pages":"213","tokens_est":175,"char_count":699,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0788","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.3 Selecting a suitable package of care and support for a patient","content_type":"text","pages":"213","tokens_est":230,"char_count":920,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0789","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.3 Selecting a suitable package of care and support for a patient","content_type":"text","pages":"213-214","tokens_est":191,"char_count":763,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0790","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.3 Selecting a suitable package of care and support for a patient","content_type":"text","pages":"214","tokens_est":224,"char_count":893,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0791","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB","content_type":"text","pages":"216","tokens_est":205,"char_count":818,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0792","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB","content_type":"text","pages":"216","tokens_est":241,"char_count":964,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0793","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB","content_type":"text","pages":"216","tokens_est":50,"char_count":197,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0794","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB","content_type":"text","pages":"216","tokens_est":224,"char_count":894,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0795","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB","content_type":"text","pages":"216","tokens_est":47,"char_count":185,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0796","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.1 Guiding principles for health education and counselling","content_type":"text","pages":"216-217","tokens_est":215,"char_count":860,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0797","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.1 Guiding principles for health education and counselling","content_type":"text","pages":"217","tokens_est":195,"char_count":777,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0798","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.1 Guiding principles for health education and counselling","content_type":"text","pages":"217","tokens_est":179,"char_count":715,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0799","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.1 Guiding principles for health education and counselling","content_type":"text","pages":"217","tokens_est":123,"char_count":490,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0800","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.2 Effective communication skills to provide health education and counselling","content_type":"text","pages":"217","tokens_est":162,"char_count":648,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0801","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.2 Effective communication skills to provide health education and counselling | 4.2.1 Forming a therapeutic alliance","content_type":"text","pages":"217-218","tokens_est":179,"char_count":715,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0802","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.2 Effective communication skills to provide health education and counselling | 4.2.1 Forming a therapeutic alliance","content_type":"text","pages":"218","tokens_est":245,"char_count":977,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0803","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.2 Effective communication skills to provide health education and counselling | 4.2.1 Forming a therapeutic alliance","content_type":"text","pages":"218","tokens_est":238,"char_count":949,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0804","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.2 Effective communication skills to provide health education and counselling | 4.2.2 Active listening","content_type":"text","pages":"218","tokens_est":212,"char_count":846,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0805","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.2 Effective communication skills to provide health education and counselling | 4.2.2 Active listening","content_type":"text","pages":"218","tokens_est":175,"char_count":698,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0806","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.2 Effective communication skills to provide health education and counselling | 4.2.2 Active listening","content_type":"text","pages":"218-219","tokens_est":121,"char_count":484,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0807","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.2 Effective communication skills to provide health education and counselling | 4.2.3 Using non-verbal communication","content_type":"text","pages":"219","tokens_est":206,"char_count":824,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0808","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.2 Effective communication skills to provide health education and counselling | 4.2.3 Using non-verbal communication","content_type":"text","pages":"219","tokens_est":245,"char_count":980,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0809","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.2 Effective communication skills to provide health education and counselling | 4.2.4 Asking questions","content_type":"text","pages":"219","tokens_est":226,"char_count":902,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0810","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.2 Effective communication skills to provide health education and counselling | 4.2.4 Asking questions","content_type":"text","pages":"219-222","tokens_est":179,"char_count":713,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0811","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.2 Effective communication skills to provide health education and counselling | 4.2.5 Providing information","content_type":"text","pages":"222","tokens_est":117,"char_count":467,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0812","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.2 Effective communication skills to provide health education and counselling | 4.2.5 Providing information","content_type":"text","pages":"222","tokens_est":156,"char_count":623,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0813","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.2 Effective communication skills to provide health education and counselling | 4.2.5 Providing information","content_type":"text","pages":"222","tokens_est":133,"char_count":531,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0814","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.2 Effective communication skills to provide health education and counselling | 4.2.5 Providing information | Table 1. Effective communication skills","content_type":"table","pages":"222","caption":"Table 1. Effective communication skills","tokens_est":131,"char_count":533,"has_attachment":true,"attachment_id":"Table 1.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0816","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.2 Effective communication skills to provide health education and counselling | 4.2.5 Providing information","content_type":"text","pages":"222","tokens_est":8,"char_count":31,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0817","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.3 Counselling to provide information about TB and the responsibilities of affected individuals and communities","content_type":"text","pages":"222","tokens_est":174,"char_count":693,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0818","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.3 Counselling to provide information about TB and the responsibilities of affected individuals and communities","content_type":"text","pages":"222-223","tokens_est":137,"char_count":546,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0819","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.3 Counselling to provide information about TB and the responsibilities of affected individuals and communities | 1. Factual information about TB as a disease and its treatment","content_type":"text","pages":"223","tokens_est":217,"char_count":866,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0820","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.3 Counselling to provide information about TB and the responsibilities of affected individuals and communities | 1. Factual information about TB as a disease and its treatment","content_type":"text","pages":"223","tokens_est":57,"char_count":226,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0821","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.3 Counselling to provide information about TB and the responsibilities of affected individuals and communities | 2. The rights of people affected by TB","content_type":"text","pages":"223","tokens_est":110,"char_count":437,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0822","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.3 Counselling to provide information about TB and the responsibilities of affected individuals and communities | Table 2. The rights of people affected by TB and obligations of state and nonstate actors","content_type":"table","pages":"223-224","caption":"Table 2. The rights of people affected by TB and obligations of state and nonstate actors","tokens_est":33,"char_count":131,"has_attachment":true,"attachment_id":"Table 2.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_2..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0823","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.3 Counselling to provide information about TB and the responsibilities of affected individuals and communities","content_type":"text","pages":"224-225","tokens_est":243,"char_count":970,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0824","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.3 Counselling to provide information about TB and the responsibilities of affected individuals and communities","content_type":"text","pages":"225","tokens_est":91,"char_count":364,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0825","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.3 Counselling to provide information about TB and the responsibilities of affected individuals and communities","content_type":"text","pages":"225","tokens_est":188,"char_count":751,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0826","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.3 Counselling to provide information about TB and the responsibilities of affected individuals and communities","content_type":"text","pages":"225","tokens_est":164,"char_count":654,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0827","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.3 Counselling to provide information about TB and the responsibilities of affected individuals and communities","content_type":"text","pages":"225","tokens_est":242,"char_count":968,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0828","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.3 Counselling to provide information about TB and the responsibilities of affected individuals and communities","content_type":"text","pages":"225","tokens_est":81,"char_count":323,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0829","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.3 Counselling to provide information about TB and the responsibilities of affected individuals and communities","content_type":"text","pages":"225","tokens_est":151,"char_count":601,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0830","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment","content_type":"text","pages":"225","tokens_est":59,"char_count":236,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0831","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.1 Counselling to provide information about TB treatment","content_type":"text","pages":"226","tokens_est":142,"char_count":565,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0832","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.1 Counselling to provide information about TB treatment | Table 3. Information about TB treatment","content_type":"table","pages":"226","caption":"Table 3. Information about TB treatment","tokens_est":104,"char_count":416,"has_attachment":true,"attachment_id":"Table 3.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_3..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0833","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.1 Counselling to provide information about TB treatment","content_type":"text","pages":"226","tokens_est":45,"char_count":177,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0834","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.2 Counselling to ensure adherence to treatment","content_type":"text","pages":"226","tokens_est":232,"char_count":928,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0835","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.2 Counselling to ensure adherence to treatment","content_type":"text","pages":"226","tokens_est":71,"char_count":281,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0836","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.2 Counselling to ensure adherence to treatment | 1. Home visit to engage with the patient","content_type":"text","pages":"226-227","tokens_est":144,"char_count":575,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0837","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.2 Counselling to ensure adherence to treatment | 2. Assess the reasons for discontinuing treatment","content_type":"text","pages":"227","tokens_est":145,"char_count":578,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0838","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.2 Counselling to ensure adherence to treatment | 3. Discuss the patients concerns that caused non-adherence","content_type":"text","pages":"227","tokens_est":56,"char_count":222,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0839","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.2 Counselling to ensure adherence to treatment | 3. Discuss the patients concerns that caused non-adherence | a. Manage side-effects","content_type":"text","pages":"227","tokens_est":81,"char_count":324,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0840","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.2 Counselling to ensure adherence to treatment | 3. Discuss the patients concerns that caused non-adherence | b. Explore the persons health beliefs","content_type":"text","pages":"227","tokens_est":207,"char_count":828,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0841","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.2 Counselling to ensure adherence to treatment | 3. Discuss the patients concerns that caused non-adherence | b. Explore the persons health beliefs","content_type":"text","pages":"227","tokens_est":63,"char_count":249,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0842","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.2 Counselling to ensure adherence to treatment | 3. Discuss the patients concerns that caused non-adherence | c. Address economic problems","content_type":"text","pages":"228","tokens_est":68,"char_count":272,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0843","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.2 Counselling to ensure adherence to treatment | 3. Discuss the patients concerns that caused non-adherence | d. Address substance use or other mental health conditions","content_type":"text","pages":"228","tokens_est":94,"char_count":373,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0844","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.2 Counselling to ensure adherence to treatment | 3. Discuss the patients concerns that caused non-adherence | e. Problems with the health care service","content_type":"text","pages":"228","tokens_est":93,"char_count":371,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0845","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.2 Counselling to ensure adherence to treatment | 3. Discuss the patients concerns that caused non-adherence | f. Address social problems","content_type":"text","pages":"228","tokens_est":87,"char_count":347,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0846","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.2 Counselling to ensure adherence to treatment | 4. Educate the patient about need to continue treatment","content_type":"text","pages":"228","tokens_est":107,"char_count":427,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0847","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.2 Counselling to ensure adherence to treatment | 5. Counsel and support the patient to resume treatment promptly","content_type":"text","pages":"228","tokens_est":124,"char_count":495,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0848","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.2 Counselling to ensure adherence to treatment | 6. Engage community health workers, family members and caregivers to ensure treatment adherence","content_type":"text","pages":"228-229","tokens_est":247,"char_count":987,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0849","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.5 Counselling to provide psychological support","content_type":"text","pages":"229","tokens_est":152,"char_count":608,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0850","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.5 Counselling to provide psychological support | Table 4. Symptoms of stress","content_type":"table","pages":"229","caption":"Table 4. Symptoms of stress","tokens_est":26,"char_count":113,"has_attachment":true,"attachment_id":"Table 4.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_4..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0851","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.5 Counselling to provide psychological support","content_type":"text","pages":"229","tokens_est":145,"char_count":578,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0852","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.5 Counselling to provide psychological support","content_type":"text","pages":"229-230","tokens_est":121,"char_count":482,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0853","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.5 Counselling to provide psychological support | 4.5.1 Basic psychological support","content_type":"text","pages":"230","tokens_est":231,"char_count":921,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0854","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.5 Counselling to provide psychological support | 4.5.1 Basic psychological support","content_type":"text","pages":"230","tokens_est":200,"char_count":798,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0855","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.5 Counselling to provide psychological support | 4.5.1 Basic psychological support","content_type":"text","pages":"230","tokens_est":209,"char_count":835,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0856","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.5 Counselling to provide psychological support | 4.5.2 Strengthen social support","content_type":"text","pages":"231","tokens_est":229,"char_count":915,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0857","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.5 Counselling to provide psychological support | 4.5.2 Strengthen social support","content_type":"text","pages":"231","tokens_est":148,"char_count":590,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0858","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.5 Counselling to provide psychological support | 4.5.3 Problem-solving technique","content_type":"text","pages":"231","tokens_est":230,"char_count":918,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0859","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.5 Counselling to provide psychological support | 4.5.3 Problem-solving technique","content_type":"text","pages":"231-232","tokens_est":143,"char_count":569,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0860","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.5 Counselling to provide psychological support | 4.5.4 Provide support to the caregivers","content_type":"text","pages":"232","tokens_est":229,"char_count":915,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0861","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.5 Counselling to provide psychological support | 4.5.4 Provide support to the caregivers","content_type":"text","pages":"232","tokens_est":138,"char_count":550,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0862","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.5 Counselling to provide psychological support | 4.5.5 Refer to mental health services","content_type":"text","pages":"232","tokens_est":38,"char_count":152,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0863","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.6 Counselling on nutritional care and support","content_type":"text","pages":"233","tokens_est":169,"char_count":674,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0864","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.6 Counselling on nutritional care and support | 4.6.1 Treat the underlying cause","content_type":"text","pages":"233","tokens_est":181,"char_count":724,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0865","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.6 Counselling on nutritional care and support | 4.6.2 Educate the person","content_type":"text","pages":"233-235","tokens_est":230,"char_count":917,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0866","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.6 Counselling on nutritional care and support | 4.6.4 Motivate the person","content_type":"text","pages":"235","tokens_est":178,"char_count":710,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0867","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.6 Counselling on nutritional care and support | 4.6.5 Rewarding desired behaviour (in children)","content_type":"text","pages":"235","tokens_est":68,"char_count":269,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0868","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.7 Counselling at the end of TB treatment and on palliative care | 4.7.1 Counselling at the end of TB treatment and post-TB treatment","content_type":"text","pages":"235","tokens_est":209,"char_count":836,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0869","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.7 Counselling at the end of TB treatment and on palliative care | 4.7.1 Counselling at the end of TB treatment and post-TB treatment","content_type":"text","pages":"235","tokens_est":155,"char_count":618,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0870","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.7 Counselling at the end of TB treatment and on palliative care | 4.7.2 Counselling on palliative care","content_type":"text","pages":"236","tokens_est":178,"char_count":711,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0871","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.7 Counselling at the end of TB treatment and on palliative care | 4.7.2 Counselling on palliative care","content_type":"text","pages":"236","tokens_est":211,"char_count":843,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0872","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.7 Counselling at the end of TB treatment and on palliative care | 4.7.2 Counselling on palliative care","content_type":"text","pages":"236","tokens_est":237,"char_count":945,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0873","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.7 Counselling at the end of TB treatment and on palliative care | 4.7.2 Counselling on palliative care","content_type":"text","pages":"236-237","tokens_est":213,"char_count":851,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0874","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.7 Counselling at the end of TB treatment and on palliative care | 4.7.2 Counselling on palliative care","content_type":"text","pages":"237","tokens_est":241,"char_count":961,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0875","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.7 Counselling at the end of TB treatment and on palliative care | 4.7.2 Counselling on palliative care","content_type":"text","pages":"237","tokens_est":221,"char_count":884,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0876","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.1 Models of care for all TB patients","content_type":"text","pages":"241","tokens_est":244,"char_count":973,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0877","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.1 Models of care for all TB patients","content_type":"text","pages":"241","tokens_est":175,"char_count":698,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0878","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.1 Models of care for all TB patients | 5.1.1 Outpatient model of TB treatment: decentralized care","content_type":"text","pages":"241","tokens_est":248,"char_count":990,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0879","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.1 Models of care for all TB patients | 5.1.1 Outpatient model of TB treatment: decentralized care","content_type":"text","pages":"241","tokens_est":80,"char_count":319,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0880","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.1 Models of care for all TB patients | 5.1.1 Outpatient model of TB treatment: decentralized care","content_type":"text","pages":"241-242","tokens_est":239,"char_count":953,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0881","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.1 Models of care for all TB patients | 5.1.1 Outpatient model of TB treatment: decentralized care","content_type":"text","pages":"241-242","tokens_est":75,"char_count":299,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0882","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.1 Models of care for all TB patients | 5.1.1 Outpatient model of TB treatment: decentralized care","content_type":"text","pages":"242","tokens_est":248,"char_count":990,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0883","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.1 Models of care for all TB patients | 5.1.1 Outpatient model of TB treatment: decentralized care","content_type":"text","pages":"242","tokens_est":234,"char_count":935,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0884","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.1 Models of care for all TB patients | 5.1.1 Outpatient model of TB treatment: decentralized care","content_type":"text","pages":"242","tokens_est":91,"char_count":361,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0885","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.1 Models of care for all TB patients | 5.1.1 Outpatient model of TB treatment: decentralized care","content_type":"text","pages":"242","tokens_est":233,"char_count":929,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0886","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.1 Models of care for all TB patients | 5.1.1 Outpatient model of TB treatment: decentralized care","content_type":"text","pages":"242-243","tokens_est":179,"char_count":714,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0887","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.1 Models of care for all TB patients | 5.1.1 Outpatient model of TB treatment: decentralized care","content_type":"text","pages":"243","tokens_est":127,"char_count":506,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0888","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.1 Models of care for all TB patients | 5.1.2 Inpatient model of TB treatment and care","content_type":"text","pages":"243","tokens_est":236,"char_count":941,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0889","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.1 Models of care for all TB patients | 5.1.2 Inpatient model of TB treatment and care","content_type":"text","pages":"243","tokens_est":91,"char_count":363,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0890","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.1 Models of care for all TB patients | 5.1.2 Inpatient model of TB treatment and care","content_type":"text","pages":"243","tokens_est":231,"char_count":921,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0891","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.1 Models of care for all TB patients | 5.1.2 Inpatient model of TB treatment and care","content_type":"text","pages":"243-244","tokens_est":238,"char_count":949,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0892","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.1 Models of care for all TB patients | 5.1.2 Inpatient model of TB treatment and care","content_type":"text","pages":"244","tokens_est":111,"char_count":441,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0893","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.1 Models of care for all TB patients | 5.1.3 Deciding on the best suited model for a situation","content_type":"text","pages":"244","tokens_est":169,"char_count":675,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0894","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.1 Models of care for all TB patients | 5.1.3 Deciding on the best suited model for a situation","content_type":"text","pages":"244","tokens_est":221,"char_count":883,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0895","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.1 Models of care for all TB patients | 5.1.3 Deciding on the best suited model for a situation","content_type":"text","pages":"244","tokens_est":171,"char_count":684,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0896","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.1 Models of care for all TB patients | 5.1.3 Deciding on the best suited model for a situation","content_type":"text","pages":"244-245","tokens_est":248,"char_count":991,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0897","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.1 Models of care for all TB patients | 5.1.3 Deciding on the best suited model for a situation","content_type":"text","pages":"245","tokens_est":211,"char_count":844,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0898","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.1 Models of care for all TB patients | 5.1.3 Deciding on the best suited model for a situation","content_type":"text","pages":"245","tokens_est":227,"char_count":905,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0899","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.1 Models of care for all TB patients | 5.1.3 Deciding on the best suited model for a situation","content_type":"text","pages":"245-246","tokens_est":242,"char_count":967,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0900","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.2 Decentralized and integrated family- centred models of TB care for children and adolescents","content_type":"text","pages":"246","tokens_est":212,"char_count":845,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0901","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.2 Decentralized and integrated family- centred models of TB care for children and adolescents","content_type":"text","pages":"246","tokens_est":71,"char_count":282,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0902","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.2 Decentralized and integrated family- centred models of TB care for children and adolescents","content_type":"text","pages":"246","tokens_est":179,"char_count":713,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0903","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.2 Decentralized and integrated family- centred models of TB care for children and adolescents","content_type":"text","pages":"246","tokens_est":246,"char_count":981,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0904","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.2 Decentralized and integrated family- centred models of TB care for children and adolescents","content_type":"text","pages":"246","tokens_est":123,"char_count":492,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0905","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.2 Decentralized and integrated family- centred models of TB care for children and adolescents","content_type":"text","pages":"246-247","tokens_est":237,"char_count":945,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0906","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.2 Decentralized and integrated family- centred models of TB care for children and adolescents","content_type":"text","pages":"247","tokens_est":236,"char_count":941,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0907","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.2 Decentralized and integrated family- centred models of TB care for children and adolescents","content_type":"text","pages":"247","tokens_est":244,"char_count":976,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0908","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.2 Decentralized and integrated family- centred models of TB care for children and adolescents","content_type":"text","pages":"247","tokens_est":181,"char_count":722,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0909","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.2 Decentralized and integrated family- centred models of TB care for children and adolescents","content_type":"text","pages":"247","tokens_est":229,"char_count":913,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0910","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.2 Decentralized and integrated family- centred models of TB care for children and adolescents","content_type":"text","pages":"247-248","tokens_est":232,"char_count":927,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0911","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.2 Decentralized and integrated family- centred models of TB care for children and adolescents","content_type":"text","pages":"248","tokens_est":207,"char_count":827,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0912","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.2 Decentralized and integrated family- centred models of TB care for children and adolescents","content_type":"text","pages":"248","tokens_est":187,"char_count":748,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0913","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.2 Decentralized and integrated family- centred models of TB care for children and adolescents","content_type":"text","pages":"248","tokens_est":234,"char_count":934,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0914","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.2 Decentralized and integrated family- centred models of TB care for children and adolescents","content_type":"text","pages":"248","tokens_est":94,"char_count":375,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0915","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.2 Decentralized and integrated family- centred models of TB care for children and adolescents | Treatment support","content_type":"text","pages":"248-249","tokens_est":244,"char_count":976,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0916","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.2 Decentralized and integrated family- centred models of TB care for children and adolescents | Treatment support","content_type":"text","pages":"248-249","tokens_est":42,"char_count":166,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0917","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.2 Decentralized and integrated family- centred models of TB care for children and adolescents | Socioeconomic impact of TB on children, adolescents and families","content_type":"text","pages":"249","tokens_est":122,"char_count":487,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0918","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.2 Decentralized and integrated family- centred models of TB care for children and adolescents | Socioeconomic impact of TB on children, adolescents and families","content_type":"text","pages":"249","tokens_est":245,"char_count":980,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0919","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.3 Models of service delivery for people with TB, HIV and comorbidities","content_type":"text","pages":"249","tokens_est":212,"char_count":845,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0920","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.3 Models of service delivery for people with TB, HIV and comorbidities","content_type":"text","pages":"249","tokens_est":177,"char_count":705,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0921","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.3 Models of service delivery for people with TB, HIV and comorbidities","content_type":"text","pages":"249-250","tokens_est":181,"char_count":723,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0922","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.4 Private-sector involvement in TB care","content_type":"text","pages":"250","tokens_est":247,"char_count":987,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0923","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.4 Private-sector involvement in TB care","content_type":"text","pages":"250","tokens_est":111,"char_count":444,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0924","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.5 TB and health emergencies","content_type":"text","pages":"250","tokens_est":207,"char_count":827,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0925","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.5 TB and health emergencies","content_type":"text","pages":"250","tokens_est":85,"char_count":337,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0926","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.5 TB and health emergencies","content_type":"text","pages":"250","tokens_est":193,"char_count":772,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0927","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care","content_type":"text","pages":"254","tokens_est":202,"char_count":805,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0928","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.1 What is palliative care?","content_type":"text","pages":"254","tokens_est":166,"char_count":661,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0929","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.1 What is palliative care? | 6.1.1 Why is palliative care an essential part of comprehensive TB care?","content_type":"text","pages":"254","tokens_est":210,"char_count":839,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0930","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.1 What is palliative care? | 6.1.1 Why is palliative care an essential part of comprehensive TB care?","content_type":"text","pages":"254","tokens_est":69,"char_count":276,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0931","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.1 What is palliative care? | 6.1.2 When and where should palliative care be provided for people with TB?","content_type":"text","pages":"254-255","tokens_est":202,"char_count":806,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0932","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.1 What is palliative care? | 6.1.2 When and where should palliative care be provided for people with TB?","content_type":"text","pages":"255","tokens_est":226,"char_count":903,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0933","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.1 What is palliative care? | 6.1.2 When and where should palliative care be provided for people with TB?","content_type":"text","pages":"255","tokens_est":55,"char_count":217,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0934","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.1 What is palliative care? | 6.1.2 When and where should palliative care be provided for people with TB?","content_type":"text","pages":"255","tokens_est":134,"char_count":535,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0935","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.1 What is palliative care? | 6.1.3 Who should provide palliative care for people with TB?","content_type":"text","pages":"255","tokens_est":147,"char_count":586,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0936","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.1 What is palliative care? | 6.1.4 What is end-of-life care for people with TB?","content_type":"text","pages":"255","tokens_est":130,"char_count":518,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0937","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.2 Planning and implementing palliative care for people affected by TB | 6.2.1 Integration of palliative care into NTPs","content_type":"text","pages":"255-256","tokens_est":241,"char_count":963,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0938","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.2 Planning and implementing palliative care for people affected by TB | 6.2.1 Integration of palliative care into NTPs | Table 5. Palliative care interventions needed for people with TB","content_type":"table","pages":"256","caption":"Table 5. Palliative care interventions needed for people with TB","tokens_est":29,"char_count":125,"has_attachment":true,"attachment_id":"Table 5.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_5..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0939","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.2 Planning and implementing palliative care for people affected by TB | 6.2.2 Essential package of palliative care for people affected by TB","content_type":"text","pages":"256","tokens_est":175,"char_count":700,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0940","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.2 Planning and implementing palliative care for people affected by TB | 6.2.2 Essential package of palliative care for people affected by TB","content_type":"text","pages":"256","tokens_est":99,"char_count":395,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0941","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.2 Planning and implementing palliative care for people affected by TB | 6.2.2 Essential package of palliative care for people affected by TB | Table 6. Essential package of palliative care for people affected by TB (91, 105)","content_type":"table","pages":"257-258","caption":"Table 6. Essential package of palliative care for people affected by TB (91, 105)","tokens_est":30,"char_count":850,"has_attachment":true,"attachment_id":"Table 6.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_6..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0942","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.2 Planning and implementing palliative care for people affected by TB | 6.2.3 Oxygen for relief of mild dyspnoea","content_type":"text","pages":"258","tokens_est":70,"char_count":278,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0943","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.2 Planning and implementing palliative care for people affected by TB | 6.2.4 Morphine for safe relief of chronic or refractory dyspnoea","content_type":"text","pages":"258","tokens_est":189,"char_count":756,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0944","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.2 Planning and implementing palliative care for people affected by TB | 6.2.4 Morphine for safe relief of chronic or refractory dyspnoea","content_type":"text","pages":"258","tokens_est":96,"char_count":382,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0945","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.2 Planning and implementing palliative care for people affected by TB | 6.2.5 Palliative care teamwork","content_type":"text","pages":"258","tokens_est":128,"char_count":512,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0946","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.2 Planning and implementing palliative care for people affected by TB | 6.2.6 Management of substance use disorders and other comorbidities","content_type":"text","pages":"259","tokens_est":212,"char_count":845,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0947","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.2 Planning and implementing palliative care for people affected by TB | 6.2.6 Management of substance use disorders and other comorbidities","content_type":"text","pages":"259","tokens_est":152,"char_count":606,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0948","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.2 Planning and implementing palliative care for people affected by TB | 6.2.7 M&E of palliative care for people affected by TB","content_type":"text","pages":"259","tokens_est":212,"char_count":848,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0949","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.2 Planning and implementing palliative care for people affected by TB | 6.2.8 Cost savings from palliative care integration into TB programmes","content_type":"text","pages":"259","tokens_est":182,"char_count":725,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0950","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.3 End-of-life care for people with TB | 6.3.1 When should suspension of TB treatment be considered?","content_type":"text","pages":"259-260","tokens_est":205,"char_count":818,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0951","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.3 End-of-life care for people with TB | 6.3.2 Important considerations in suspending TB treatment","content_type":"text","pages":"260","tokens_est":98,"char_count":391,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0952","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.3 End-of-life care for people with TB | 6.3.2 Important considerations in suspending TB treatment","content_type":"text","pages":"260","tokens_est":215,"char_count":859,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0953","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.3 End-of-life care for people with TB | 6.3.3 Decision-making about suspension of TB treatment","content_type":"text","pages":"260","tokens_est":231,"char_count":924,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0954","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.3 End-of-life care for people with TB | 6.3.3 Decision-making about suspension of TB treatment","content_type":"text","pages":"260","tokens_est":216,"char_count":864,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0955","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.3 End-of-life care for people with TB | 6.3.3 Decision-making about suspension of TB treatment","content_type":"text","pages":"260-261","tokens_est":239,"char_count":954,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0956","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.3 End-of-life care for people with TB | 6.3.3 Decision-making about suspension of TB treatment","content_type":"text","pages":"261","tokens_est":154,"char_count":613,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0957","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.3 End-of-life care for people with TB | 6.3.3 Decision-making about suspension of TB treatment","content_type":"text","pages":"261","tokens_est":200,"char_count":799,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0958","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.3 End-of-life care for people with TB | 6.3.3 Decision-making about suspension of TB treatment","content_type":"text","pages":"261","tokens_est":115,"char_count":457,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0959","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.3 End-of-life care for people with TB | 6.3.4 Providing end-of-life care for people with TB","content_type":"text","pages":"261","tokens_est":228,"char_count":909,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0960","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.3 End-of-life care for people with TB | 6.3.4 Providing end-of-life care for people with TB","content_type":"text","pages":"261","tokens_est":116,"char_count":463,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0961","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Annex 4. Dosing of medicines used in TB regimens, adults and children | Table A4.1. Dosages of anti-TB medicines by weight band for treatment of DS-TB","content_type":"table","pages":"275","caption":"Table A4.1. Dosages of anti-TB medicines by weight band for treatment of DS-TB","tokens_est":57,"char_count":323,"has_attachment":true,"attachment_id":"Table A4.1.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_A4.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0962","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Annex 4. Dosing of medicines used in TB regimens, adults and children","content_type":"table","pages":"275-276","caption":"Table A4.1.1. Dosages of adult fixed-dose combinations","tokens_est":23,"char_count":189,"has_attachment":true,"attachment_id":"Table A4.1.1.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_A4.1.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0963","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Annex 4. Dosing of medicines used in TB regimens, adults and children | Table A4.2. Weight-based dosing of medicines used in multidrug-resistant TB regimens, adults and children [ a]","content_type":"table","pages":"278-310","caption":"Table A4.2. Weight-based dosing of medicines used in multidrug-resistant TB regimens, adults and children [ a]","tokens_est":83,"char_count":6648,"has_attachment":true,"attachment_id":"Table A4.2.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_A4.2..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0001","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Abbreviations","content_type":"text","pages":"1","tokens_est":221,"char_count":884,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0002","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Abbreviations","content_type":"text","pages":"1-2","tokens_est":228,"char_count":911,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0003","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Abbreviations","content_type":"text","pages":"2","tokens_est":217,"char_count":865,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0004","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Abbreviations","content_type":"text","pages":"2-3","tokens_est":72,"char_count":287,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0005","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Definitions","content_type":"text","pages":"3","tokens_est":223,"char_count":889,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0006","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Definitions","content_type":"text","pages":"3","tokens_est":153,"char_count":610,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0007","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Definitions","content_type":"text","pages":"3","tokens_est":165,"char_count":658,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0008","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Definitions","content_type":"text","pages":"3-4","tokens_est":122,"char_count":486,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0009","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Definitions","content_type":"text","pages":"4","tokens_est":190,"char_count":760,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0010","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Definitions","content_type":"text","pages":"4","tokens_est":200,"char_count":797,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0011","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Definitions","content_type":"text","pages":"4","tokens_est":202,"char_count":806,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0012","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Definitions","content_type":"text","pages":"4-5","tokens_est":239,"char_count":955,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0013","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Definitions","content_type":"text","pages":"4-5","tokens_est":69,"char_count":276,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0014","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Definitions","content_type":"text","pages":"5","tokens_est":213,"char_count":850,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0015","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Definitions","content_type":"text","pages":"5","tokens_est":227,"char_count":908,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0016","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Definitions","content_type":"text","pages":"5","tokens_est":187,"char_count":746,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0017","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Definitions","content_type":"text","pages":"5-6","tokens_est":199,"char_count":793,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0018","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Definitions","content_type":"text","pages":"6","tokens_est":190,"char_count":760,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0019","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Definitions","content_type":"text","pages":"6","tokens_est":232,"char_count":928,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0020","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Definitions","content_type":"text","pages":"6","tokens_est":146,"char_count":584,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0021","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Definitions","content_type":"text","pages":"6","tokens_est":184,"char_count":736,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0022","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Definitions","content_type":"text","pages":"6-7","tokens_est":227,"char_count":908,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0023","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Definitions","content_type":"text","pages":"7","tokens_est":207,"char_count":825,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0024","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Definitions","content_type":"text","pages":"7","tokens_est":236,"char_count":944,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0025","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Definitions","content_type":"text","pages":"7","tokens_est":104,"char_count":416,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0026","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"1. Introduction | 1.1. Background","content_type":"text","pages":"8","tokens_est":93,"char_count":371,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0027","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"1. Introduction | 1.1. Background","content_type":"text","pages":"8","tokens_est":214,"char_count":853,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0028","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"1. Introduction | 1.1. Background","content_type":"text","pages":"8","tokens_est":244,"char_count":973,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0029","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"1. Introduction | 1.2. Children and adolescents as a key vulnerable population","content_type":"text","pages":"8-9","tokens_est":183,"char_count":731,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0030","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"1. Introduction | 1.2. Children and adolescents as a key vulnerable population","content_type":"text","pages":"9","tokens_est":109,"char_count":434,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0031","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"1. Introduction | 1.3. Rationale and objectives of this operational handbook","content_type":"text","pages":"9","tokens_est":233,"char_count":930,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0032","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"1. Introduction | 1.3. Rationale and objectives of this operational handbook","content_type":"text","pages":"9","tokens_est":245,"char_count":978,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0033","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"1. Introduction | 1.3. Rationale and objectives of this operational handbook","content_type":"text","pages":"9","tokens_est":39,"char_count":155,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0034","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"1. Introduction | 1.4. Preferences of end-users regarding content and structure of this operational handbook","content_type":"text","pages":"9-10","tokens_est":237,"char_count":947,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0035","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"1. Introduction | 1.4. Preferences of end-users regarding content and structure of this operational handbook","content_type":"text","pages":"10","tokens_est":239,"char_count":956,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0036","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"1. Introduction | 1.4. Preferences of end-users regarding content and structure of this operational handbook","content_type":"text","pages":"10","tokens_est":238,"char_count":952,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0037","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"1. Introduction | 1.5. Structure of the operational handbook","content_type":"text","pages":"10","tokens_est":73,"char_count":289,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0038","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"1. Introduction | 1.5. Structure of the operational handbook | Figure 1.1. Pathway through TB exposure, infection and disease","content_type":"figure","pages":"10","caption":"Figure 1.1. Pathway through TB exposure, infection and disease","tokens_est":18,"char_count":72,"has_attachment":true,"attachment_id":"Figure 1.1.","attachment_path":"figures/WHO_TB_handbook_module5_pediatrics_2022/Figure 1.1..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0039","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"1. Introduction | 1.5. Structure of the operational handbook","content_type":"text","pages":"10","tokens_est":153,"char_count":609,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0040","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"1. Introduction | 1.5. Structure of the operational handbook","content_type":"text","pages":"10-11","tokens_est":228,"char_count":909,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0041","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"1. Introduction | 1.5. Structure of the operational handbook","content_type":"text","pages":"10-11","tokens_est":140,"char_count":558,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0042","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"1. Introduction | 1.5. Structure of the operational handbook","content_type":"text","pages":"11","tokens_est":148,"char_count":592,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0043","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"1. Introduction | 1.5. Structure of the operational handbook","content_type":"text","pages":"11","tokens_est":229,"char_count":916,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0044","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"1. Introduction | 1.6. Target audience","content_type":"text","pages":"11","tokens_est":120,"char_count":477,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0045","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.1. Introduction","content_type":"text","pages":"12","tokens_est":198,"char_count":790,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0046","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.1. Introduction","content_type":"text","pages":"12","tokens_est":164,"char_count":653,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0047","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.1. Introduction","content_type":"text","pages":"12","tokens_est":178,"char_count":711,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0048","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.1. Introduction","content_type":"text","pages":"12","tokens_est":242,"char_count":968,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0049","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.1. Introduction","content_type":"text","pages":"12-13","tokens_est":205,"char_count":817,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0050","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.1. Introduction","content_type":"text","pages":"13","tokens_est":59,"char_count":233,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0051","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.1. Prioritizing household contacts","content_type":"text","pages":"13","tokens_est":140,"char_count":557,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0052","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.1. Prioritizing household contacts","content_type":"text","pages":"13","tokens_est":205,"char_count":820,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0053","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.1. Prioritizing household contacts","content_type":"text","pages":"13","tokens_est":200,"char_count":800,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0054","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.1. Prioritizing household contacts","content_type":"text","pages":"13-14","tokens_est":199,"char_count":793,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0055","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.1. Prioritizing household contacts","content_type":"text","pages":"14","tokens_est":166,"char_count":662,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0056","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.1. Prioritizing household contacts | Box 2.1 WHO recommendations on contact investigation and HIV testing","content_type":"box","pages":"14","caption":"Box 2.1 WHO recommendations on contact investigation and HIV testing","tokens_est":235,"char_count":937,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0057","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.2. Planning and budgeting to implement or strengthen household contact investigation","content_type":"text","pages":"14","tokens_est":116,"char_count":461,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0058","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.2. Planning and budgeting to implement or strengthen household contact investigation","content_type":"text","pages":"14","tokens_est":216,"char_count":863,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0059","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.2. Planning and budgeting to implement or strengthen household contact investigation | Box 2.2 Paediatric TB Operational and Sustainability Expertise Exchange budgeting tool for household contact investigation","content_type":"box","pages":"15","caption":"Box 2.2 Paediatric TB Operational and Sustainability Expertise Exchange budgeting tool for household contact investigation","tokens_est":183,"char_count":730,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0060","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.2. Planning and budgeting to implement or strengthen household contact investigation | Box 2.2 Paediatric TB Operational and Sustainability Expertise Exchange budgeting tool for household contact investigation","content_type":"box","pages":"15","caption":"Box 2.2 Paediatric TB Operational and Sustainability Expertise Exchange budgeting tool for household contact investigation","tokens_est":181,"char_count":724,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0061","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.2. Planning and budgeting to implement or strengthen household contact investigation","content_type":"text","pages":"15","tokens_est":60,"char_count":238,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0062","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.2. Planning and budgeting to implement or strengthen household contact investigation | Figure 2.2. Costing items to strengthen contact investigation","content_type":"figure","pages":"15","caption":"Figure 2.2. Costing items to strengthen contact investigation","tokens_est":18,"char_count":71,"has_attachment":true,"attachment_id":"Figure 2.2.","attachment_path":"figures/WHO_TB_handbook_module5_pediatrics_2022/Figure 2.2..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0063","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.3. Key implementation steps in contact investigation","content_type":"text","pages":"15","tokens_est":145,"char_count":580,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0064","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.3. Key implementation steps in contact investigation","content_type":"text","pages":"15","tokens_est":231,"char_count":922,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0065","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.3. Key implementation steps in contact investigation","content_type":"text","pages":"15-16","tokens_est":234,"char_count":933,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0066","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.3. Key implementation steps in contact investigation","content_type":"text","pages":"16","tokens_est":168,"char_count":670,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0067","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.3. Key implementation steps in contact investigation","content_type":"text","pages":"16","tokens_est":98,"char_count":391,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0068","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.3. Key implementation steps in contact investigation","content_type":"text","pages":"16","tokens_est":188,"char_count":751,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0069","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.3. Key implementation steps in contact investigation","content_type":"text","pages":"16","tokens_est":217,"char_count":867,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0070","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.3. Key implementation steps in contact investigation","content_type":"text","pages":"16-17","tokens_est":191,"char_count":762,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0071","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.3. Key implementation steps in contact investigation","content_type":"text","pages":"17","tokens_est":245,"char_count":978,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0072","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.3. Key implementation steps in contact investigation","content_type":"text","pages":"17","tokens_est":242,"char_count":966,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0073","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.3. Key implementation steps in contact investigation","content_type":"text","pages":"17","tokens_est":160,"char_count":638,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0074","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.3. Key implementation steps in contact investigation | Box 2.3 Key steps in contact investigation","content_type":"box","pages":"17-18","caption":"Box 2.3 Key steps in contact investigation","tokens_est":221,"char_count":884,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0075","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.3. Key implementation steps in contact investigation | Box 2.3 Key steps in contact investigation","content_type":"box","pages":"18","caption":"Box 2.3 Key steps in contact investigation","tokens_est":69,"char_count":273,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0076","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.4. Examples of facility- and community-based approaches for TB contact investigation","content_type":"text","pages":"18","tokens_est":79,"char_count":314,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0077","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.4. Examples of facility- and community-based approaches for TB contact investigation | Box 2.4 The Catalyzing Pediatric Tuberculosis Innovation project","content_type":"box","pages":"18","caption":"Box 2.4 The Catalyzing Pediatric Tuberculosis Innovation project","tokens_est":122,"char_count":486,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0078","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.4. Examples of facility- and community-based approaches for TB contact investigation | Box 2.4 The Catalyzing Pediatric Tuberculosis Innovation project","content_type":"box","pages":"18","caption":"Box 2.4 The Catalyzing Pediatric Tuberculosis Innovation project","tokens_est":160,"char_count":637,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0079","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.4. Examples of facility- and community-based approaches for TB contact investigation | Box 2.4 The Catalyzing Pediatric Tuberculosis Innovation project","content_type":"box","pages":"18","caption":"Box 2.4 The Catalyzing Pediatric Tuberculosis Innovation project","tokens_est":111,"char_count":443,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0080","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.4. Examples of facility- and community-based approaches for TB contact investigation | Box 2.4 The Catalyzing Pediatric Tuberculosis Innovation project","content_type":"box","pages":"18-19","caption":"Box 2.4 The Catalyzing Pediatric Tuberculosis Innovation project","tokens_est":209,"char_count":834,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0081","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.4. Examples of facility- and community-based approaches for TB contact investigation | Box 2.4 The Catalyzing Pediatric Tuberculosis Innovation project","content_type":"box","pages":"18-19","caption":"Box 2.4 The Catalyzing Pediatric Tuberculosis Innovation project","tokens_est":97,"char_count":388,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0082","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.4. Examples of facility- and community-based approaches for TB contact investigation | Box 2.4 The Catalyzing Pediatric Tuberculosis Innovation project","content_type":"box","pages":"19","caption":"Box 2.4 The Catalyzing Pediatric Tuberculosis Innovation project","tokens_est":248,"char_count":992,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0083","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.4. Examples of facility- and community-based approaches for TB contact investigation | Box 2.4 The Catalyzing Pediatric Tuberculosis Innovation project","content_type":"box","pages":"19","caption":"Box 2.4 The Catalyzing Pediatric Tuberculosis Innovation project","tokens_est":230,"char_count":918,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0084","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.4. Examples of facility- and community-based approaches for TB contact investigation | Box 2.4 The Catalyzing Pediatric Tuberculosis Innovation project","content_type":"box","pages":"19","caption":"Box 2.4 The Catalyzing Pediatric Tuberculosis Innovation project","tokens_est":227,"char_count":907,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0085","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.4. Examples of facility- and community-based approaches for TB contact investigation | Box 2.4 The Catalyzing Pediatric Tuberculosis Innovation project","content_type":"box","pages":"19-20","caption":"Box 2.4 The Catalyzing Pediatric Tuberculosis Innovation project","tokens_est":235,"char_count":940,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0086","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.4. Examples of facility- and community-based approaches for TB contact investigation | Box 2.4 The Catalyzing Pediatric Tuberculosis Innovation project","content_type":"box","pages":"20","caption":"Box 2.4 The Catalyzing Pediatric Tuberculosis Innovation project","tokens_est":228,"char_count":909,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0087","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.4. Examples of facility- and community-based approaches for TB contact investigation | Box 2.4 The Catalyzing Pediatric Tuberculosis Innovation project","content_type":"box","pages":"20","caption":"Box 2.4 The Catalyzing Pediatric Tuberculosis Innovation project","tokens_est":224,"char_count":896,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0088","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.4. Examples of facility- and community-based approaches for TB contact investigation | Box 2.4 The Catalyzing Pediatric Tuberculosis Innovation project","content_type":"box","pages":"20","caption":"Box 2.4 The Catalyzing Pediatric Tuberculosis Innovation project","tokens_est":153,"char_count":609,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0089","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.4. Examples of facility- and community-based approaches for TB contact investigation | Box 2.5 Vikela Ekhaya: a novel community-based TB contact management programme in a high TB burden setting","content_type":"box","pages":"20-21","caption":"Box 2.5 Vikela Ekhaya: a novel community-based TB contact management programme in a high TB burden setting","tokens_est":174,"char_count":694,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0090","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.4. Examples of facility- and community-based approaches for TB contact investigation | Box 2.5 Vikela Ekhaya: a novel community-based TB contact management programme in a high TB burden setting","content_type":"box","pages":"21","caption":"Box 2.5 Vikela Ekhaya: a novel community-based TB contact management programme in a high TB burden setting","tokens_est":243,"char_count":972,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0091","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.4. Examples of facility- and community-based approaches for TB contact investigation","content_type":"text","pages":"21","tokens_est":23,"char_count":91,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0092","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.4. Examples of facility- and community-based approaches for TB contact investigation | Box 2.6 The Community Intervention for Tuberculosis Active Contact Tracing and Preventive Therapy study","content_type":"box","pages":"21","caption":"Box 2.6 The Community Intervention for Tuberculosis Active Contact Tracing and Preventive Therapy study","tokens_est":214,"char_count":855,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0093","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.4. Examples of facility- and community-based approaches for TB contact investigation | Box 2.6 The Community Intervention for Tuberculosis Active Contact Tracing and Preventive Therapy study","content_type":"box","pages":"21","caption":"Box 2.6 The Community Intervention for Tuberculosis Active Contact Tracing and Preventive Therapy study","tokens_est":78,"char_count":309,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0094","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.4. Examples of facility- and community-based approaches for TB contact investigation | Box 2.6 The Community Intervention for Tuberculosis Active Contact Tracing and Preventive Therapy study","content_type":"box","pages":"21","caption":"Box 2.6 The Community Intervention for Tuberculosis Active Contact Tracing and Preventive Therapy study","tokens_est":228,"char_count":909,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0095","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.4. Examples of facility- and community-based approaches for TB contact investigation | Box 2.6 The Community Intervention for Tuberculosis Active Contact Tracing and Preventive Therapy study","content_type":"box","pages":"21-22","caption":"Box 2.6 The Community Intervention for Tuberculosis Active Contact Tracing and Preventive Therapy study","tokens_est":200,"char_count":800,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0096","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.2. Contact investigation | 2.2.4. Examples of facility- and community-based approaches for TB contact investigation","content_type":"text","pages":"22","tokens_est":23,"char_count":91,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0097","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.3. TB screening approaches in children and adolescents","content_type":"text","pages":"22","tokens_est":206,"char_count":824,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0098","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.3. TB screening approaches in children and adolescents","content_type":"text","pages":"22","tokens_est":157,"char_count":628,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0099","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.3. TB screening approaches in children and adolescents","content_type":"text","pages":"22","tokens_est":246,"char_count":982,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0100","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.3. TB screening approaches in children and adolescents","content_type":"text","pages":"22","tokens_est":38,"char_count":150,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0101","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.3. TB screening approaches in children and adolescents","content_type":"text","pages":"22-23","tokens_est":156,"char_count":624,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0102","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.3. TB screening approaches in children and adolescents","content_type":"text","pages":"23","tokens_est":109,"char_count":434,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0103","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.3. TB screening approaches in children and adolescents | Box 2.7 WHO recommendations on TB screening that apply to children and adolescents","content_type":"box","pages":"23","caption":"Box 2.7 WHO recommendations on TB screening that apply to children and adolescents","tokens_est":148,"char_count":592,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0104","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.3. TB screening approaches in children and adolescents | Box 2.7 WHO recommendations on TB screening that apply to children and adolescents","content_type":"box","pages":"23","caption":"Box 2.7 WHO recommendations on TB screening that apply to children and adolescents","tokens_est":229,"char_count":913,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0105","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.3. TB screening approaches in children and adolescents | Box 2.7 WHO recommendations on TB screening that apply to children and adolescents","content_type":"box","pages":"23-24","caption":"Box 2.7 WHO recommendations on TB screening that apply to children and adolescents","tokens_est":245,"char_count":979,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0106","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.3. TB screening approaches in children and adolescents | Box 2.7 WHO recommendations on TB screening that apply to children and adolescents","content_type":"box","pages":"24","caption":"Box 2.7 WHO recommendations on TB screening that apply to children and adolescents","tokens_est":189,"char_count":754,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0107","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.3. TB screening approaches in children and adolescents | Box 2.7 WHO recommendations on TB screening that apply to children and adolescents","content_type":"box","pages":"24","caption":"Box 2.7 WHO recommendations on TB screening that apply to children and adolescents","tokens_est":231,"char_count":921,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0108","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.3. TB screening approaches in children and adolescents | 2.3.1. Screening child contacts of people with bacteriologically confirmed TB | 2.3.1.1. Symptom screening","content_type":"text","pages":"24","tokens_est":243,"char_count":970,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0109","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.3. TB screening approaches in children and adolescents | 2.3.1. Screening child contacts of people with bacteriologically confirmed TB | 2.3.1.1. Symptom screening | Figure 2.3. Algorithm for TB screening in children with symptoms","content_type":"figure","pages":"24","caption":"Figure 2.3. Algorithm for TB screening in children with symptoms","tokens_est":19,"char_count":74,"has_attachment":true,"attachment_id":"Figure 2.3.","attachment_path":"figures/WHO_TB_handbook_module5_pediatrics_2022/Figure 2.3..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0110","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.3. TB screening approaches in children and adolescents | 2.3.1. Screening child contacts of people with bacteriologically confirmed TB | 2.3.1.1. Symptom screening","content_type":"text","pages":"24","tokens_est":77,"char_count":305,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0111","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.3. TB screening approaches in children and adolescents | 2.3.1. Screening child contacts of people with bacteriologically confirmed TB | 2.3.1.1. Symptom screening","content_type":"text","pages":"24-25","tokens_est":240,"char_count":958,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0112","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.3. TB screening approaches in children and adolescents | 2.3.1. Screening child contacts of people with bacteriologically confirmed TB | 2.3.1.1. Symptom screening","content_type":"text","pages":"24-25","tokens_est":69,"char_count":273,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0113","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.3. TB screening approaches in children and adolescents | 2.3.1. Screening child contacts of people with bacteriologically confirmed TB | 2.3.1.2. Chest X-ray","content_type":"text","pages":"25","tokens_est":110,"char_count":438,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0114","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.3. TB screening approaches in children and adolescents | 2.3.1. Screening child contacts of people with bacteriologically confirmed TB | 2.3.1.2. Chest X-ray","content_type":"text","pages":"25","tokens_est":233,"char_count":931,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0115","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.3. TB screening approaches in children and adolescents | 2.3.1. Screening child contacts of people with bacteriologically confirmed TB | 2.3.1.2. Chest X-ray","content_type":"text","pages":"25","tokens_est":154,"char_count":615,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0116","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.3. TB screening approaches in children and adolescents | 2.3.1. Screening child contacts of people with bacteriologically confirmed TB | 2.3.1.2. Chest X-ray","content_type":"text","pages":"25","tokens_est":224,"char_count":896,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0117","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.3. TB screening approaches in children and adolescents | 2.3.1. Screening child contacts of people with bacteriologically confirmed TB | 2.3.1.2. Chest X-ray","content_type":"text","pages":"25-26","tokens_est":61,"char_count":242,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0118","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.3. TB screening approaches in children and adolescents | 2.3.1. Screening child contacts of people with bacteriologically confirmed TB | 2.3.1.2. Chest X-ray | Figure 2.4. Algorithm for TB screening of children with chest-X-ray","content_type":"figure","pages":"26","caption":"Figure 2.4. Algorithm for TB screening of children with chest-X-ray","tokens_est":20,"char_count":77,"has_attachment":true,"attachment_id":"Figure 2.4.","attachment_path":"figures/WHO_TB_handbook_module5_pediatrics_2022/Figure 2.4..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0119","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.3. TB screening approaches in children and adolescents | 2.3.1. Screening child contacts of people with bacteriologically confirmed TB | 2.3.1.2. Chest X-ray | Figure 2.5. Algorithm for parallel TB screening of children with symptoms and chest X-ray","content_type":"figure","pages":"26-27","caption":"Figure 2.5. Algorithm for parallel TB screening of children with symptoms and chest X-ray","tokens_est":25,"char_count":99,"has_attachment":true,"attachment_id":"Figure 2.5.","attachment_path":"figures/WHO_TB_handbook_module5_pediatrics_2022/Figure 2.5..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0120","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.3. TB screening approaches in children and adolescents | 2.3.1. Screening child contacts of people with bacteriologically confirmed TB | 2.3.1.2. Chest X-ray | Figure 2.6. Algorithm for sequential positive serial TB screening in children with symptoms and chest X-ray","content_type":"figure","pages":"27","caption":"Figure 2.6. Algorithm for sequential positive serial TB screening in children with symptoms and chest X-ray","tokens_est":30,"char_count":117,"has_attachment":true,"attachment_id":"Figure 2.6.","attachment_path":"figures/WHO_TB_handbook_module5_pediatrics_2022/Figure 2.6..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0121","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.3. TB screening approaches in children and adolescents | 2.3.1. Screening child contacts of people with bacteriologically confirmed TB | 2.3.1.2. Chest X-ray | Figure 2.7. Algorithm for sequential negative serial TB screening in children with symptoms and chest X-ray","content_type":"figure","pages":"27-28","caption":"Figure 2.7. Algorithm for sequential negative serial TB screening in children with symptoms and chest X-ray","tokens_est":30,"char_count":117,"has_attachment":true,"attachment_id":"Figure 2.7.","attachment_path":"figures/WHO_TB_handbook_module5_pediatrics_2022/Figure 2.7..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0122","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.3. TB screening approaches in children and adolescents | 2.3.1. Screening child contacts of people with bacteriologically confirmed TB | 2.3.1.3. Molecular WHO-recommended rapid diagnostic tests","content_type":"text","pages":"28","tokens_est":75,"char_count":297,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0123","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.3. TB screening approaches in children and adolescents | 2.3.1. Screening child contacts of people with bacteriologically confirmed TB | 2.3.1.4. Tests for TB infection","content_type":"text","pages":"28","tokens_est":140,"char_count":557,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0124","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.3. TB screening approaches in children and adolescents | 2.3.2. Considerations for implementation of screening of child close contacts","content_type":"text","pages":"29","tokens_est":235,"char_count":940,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0125","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.3. TB screening approaches in children and adolescents | 2.3.2. Considerations for implementation of screening of child close contacts","content_type":"text","pages":"29","tokens_est":66,"char_count":264,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0126","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.3. TB screening approaches in children and adolescents | 2.3.2. Considerations for implementation of screening of child close contacts","content_type":"text","pages":"29","tokens_est":167,"char_count":668,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0127","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.4. Screening children and adolescents living with HIV","content_type":"text","pages":"29","tokens_est":153,"char_count":610,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0128","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.4. Screening children and adolescents living with HIV | 2.4.1. Screening for symptoms and contact | Figure 2.8. Algorithm for TB screening of children living with HIV with symptoms","content_type":"figure","pages":"30","caption":"Figure 2.8. Algorithm for TB screening of children living with HIV with symptoms","tokens_est":23,"char_count":90,"has_attachment":true,"attachment_id":"Figure 2.8.","attachment_path":"figures/WHO_TB_handbook_module5_pediatrics_2022/Figure 2.8..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0129","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.4. Screening children and adolescents living with HIV | 2.4.1. Screening for symptoms and contact","content_type":"text","pages":"30","tokens_est":150,"char_count":600,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0130","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.4. Screening children and adolescents living with HIV | 2.4.1. Screening for symptoms and contact","content_type":"text","pages":"30","tokens_est":118,"char_count":470,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0131","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.4. Screening children and adolescents living with HIV | 2.4.2. Other screening tests","content_type":"text","pages":"30","tokens_est":109,"char_count":434,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0132","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.4. Screening children and adolescents living with HIV | 2.4.3. Considerations for implementation","content_type":"text","pages":"30-31","tokens_est":247,"char_count":985,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0133","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.4. Screening children and adolescents living with HIV | 2.4.3. Considerations for implementation","content_type":"text","pages":"31","tokens_est":241,"char_count":964,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0134","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.4. Screening children and adolescents living with HIV | 2.4.4. Screening of adolescents living with HIV","content_type":"text","pages":"31","tokens_est":246,"char_count":981,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0135","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.4. Screening children and adolescents living with HIV | 2.4.4. Screening of adolescents living with HIV","content_type":"text","pages":"31-32","tokens_est":230,"char_count":919,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0136","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"2. TB screening and contact investigation | 2.4. Screening children and adolescents living with HIV | 2.4.4. Screening of adolescents living with HIV","content_type":"text","pages":"32","tokens_est":222,"char_count":886,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0137","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.1. Introduction","content_type":"text","pages":"33","tokens_est":45,"char_count":178,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0138","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.2. BCG vaccination","content_type":"text","pages":"33","tokens_est":110,"char_count":437,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0139","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.2. BCG vaccination","content_type":"text","pages":"33","tokens_est":221,"char_count":882,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0140","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.2. BCG vaccination","content_type":"text","pages":"33","tokens_est":232,"char_count":928,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0141","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.2. BCG vaccination","content_type":"text","pages":"33-34","tokens_est":143,"char_count":570,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0142","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.2. BCG vaccination | 3.2.1. Recommendations from the WHO BCG position paper | 3.2.1.1. Children living with HIV and neonates | BCG in children living with HIV","content_type":"text","pages":"34","tokens_est":200,"char_count":797,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0143","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.2. BCG vaccination | 3.2.1. Recommendations from the WHO BCG position paper | 3.2.1.1. Children living with HIV and neonates | BCG in neonates","content_type":"text","pages":"34","tokens_est":184,"char_count":736,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0144","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.2. BCG vaccination | 3.2.1. Recommendations from the WHO BCG position paper | 3.2.1.1. Children living with HIV and neonates | BCG in neonates","content_type":"text","pages":"34","tokens_est":134,"char_count":535,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0145","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.2. BCG vaccination | 3.2.1. Recommendations from the WHO BCG position paper | 3.2.1.2. Administering BCG","content_type":"text","pages":"34","tokens_est":167,"char_count":667,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0146","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.2. BCG vaccination | 3.2.1. Recommendations from the WHO BCG position paper | 3.2.1.2. Administering BCG | Figure 3.2. Injection techniques","content_type":"figure","pages":"34-35","caption":"Figure 3.2. Injection techniques","tokens_est":45,"char_count":177,"has_attachment":true,"attachment_id":"Figure 3.2.","attachment_path":"figures/WHO_TB_handbook_module5_pediatrics_2022/Figure 3.2..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0147","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.2. BCG vaccination | 3.2.1. Recommendations from the WHO BCG position paper | 3.2.1.2. Administering BCG","content_type":"text","pages":"35","tokens_est":87,"char_count":347,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0148","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.2. BCG vaccination | 3.2.1. Recommendations from the WHO BCG position paper | 3.2.1.2. Administering BCG | Figure 3.3. Administering BCG injection","content_type":"figure","pages":"35","caption":"Figure 3.3. Administering BCG injection","tokens_est":28,"char_count":111,"has_attachment":true,"attachment_id":"Figure 3.3.","attachment_path":"figures/WHO_TB_handbook_module5_pediatrics_2022/Figure 3.3..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0149","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.2. BCG vaccination | 3.2.1. Recommendations from the WHO BCG position paper | 3.2.1.2. Administering BCG","content_type":"text","pages":"35-36","tokens_est":149,"char_count":594,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0150","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.2. BCG vaccination | 3.2.1. Recommendations from the WHO BCG position paper | 3.2.1.3. Contraindications for BCG","content_type":"text","pages":"36","tokens_est":90,"char_count":357,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0151","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.2. BCG vaccination | 3.2.1. Recommendations from the WHO BCG position paper | 3.2.1.4. Adverse reactions","content_type":"text","pages":"36","tokens_est":188,"char_count":751,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0152","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.2. BCG vaccination | 3.2.1. Recommendations from the WHO BCG position paper | 3.2.1.4. Adverse reactions | Mild adverse events","content_type":"text","pages":"36","tokens_est":153,"char_count":612,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0153","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.2. BCG vaccination | 3.2.1. Recommendations from the WHO BCG position paper | 3.2.1.4. Adverse reactions | Mild adverse events","content_type":"text","pages":"36","tokens_est":113,"char_count":452,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0154","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.2. BCG vaccination | 3.2.1. Recommendations from the WHO BCG position paper | 3.2.1.4. Adverse reactions | Severe adverse events","content_type":"text","pages":"36-37","tokens_est":205,"char_count":819,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0155","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.2. BCG vaccination | 3.2.1. Recommendations from the WHO BCG position paper | 3.2.1.4. Adverse reactions | Severe adverse events","content_type":"text","pages":"37","tokens_est":163,"char_count":649,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0156","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.2. BCG vaccination | 3.2.1. Recommendations from the WHO BCG position paper | 3.2.1.4. Adverse reactions | Severe adverse events","content_type":"text","pages":"37","tokens_est":169,"char_count":676,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0157","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.2. BCG vaccination | 3.2.1. Recommendations from the WHO BCG position paper | 3.2.1.4. Adverse reactions | Management of severe adverse events","content_type":"text","pages":"37","tokens_est":246,"char_count":981,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0158","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.2. BCG vaccination | 3.2.1. Recommendations from the WHO BCG position paper | 3.2.1.4. Adverse reactions | Box 3.1 COVID-19 and BCG","content_type":"box","pages":"37","caption":"Box 3.1 COVID-19 and BCG","tokens_est":138,"char_count":552,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0159","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.2. BCG vaccination | 3.2.1. Recommendations from the WHO BCG position paper | 3.2.1.4. Adverse reactions | Box 3.1 COVID-19 and BCG","content_type":"box","pages":"37-38","caption":"Box 3.1 COVID-19 and BCG","tokens_est":231,"char_count":923,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0160","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.2. BCG vaccination | 3.2.1. Recommendations from the WHO BCG position paper | 3.2.1.4. Adverse reactions | Box 3.1 COVID-19 and BCG","content_type":"box","pages":"37-38","caption":"Box 3.1 COVID-19 and BCG","tokens_est":61,"char_count":243,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0161","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.2. BCG vaccination | 3.2.1. Recommendations from the WHO BCG position paper | 3.2.1.4. Adverse reactions | Box 3.1 COVID-19 and BCG","content_type":"box","pages":"38","caption":"Box 3.1 COVID-19 and BCG","tokens_est":77,"char_count":305,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0162","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.1. Introduction","content_type":"text","pages":"38","tokens_est":179,"char_count":715,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0163","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.1. Introduction","content_type":"text","pages":"38","tokens_est":107,"char_count":428,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0164","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.1. Introduction","content_type":"text","pages":"38","tokens_est":193,"char_count":770,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0165","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.2. Target groups for TB preventive treatment","content_type":"text","pages":"38-39","tokens_est":227,"char_count":907,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0166","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.2. Target groups for TB preventive treatment | Box 3.2 WHO recommendations on target groups for TB preventive treatment","content_type":"box","pages":"39","caption":"Box 3.2 WHO recommendations on target groups for TB preventive treatment","tokens_est":236,"char_count":943,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0167","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.2. Target groups for TB preventive treatment | Box 3.2 WHO recommendations on target groups for TB preventive treatment","content_type":"box","pages":"39","caption":"Box 3.2 WHO recommendations on target groups for TB preventive treatment","tokens_est":179,"char_count":715,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0168","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.2. Target groups for TB preventive treatment | Box 3.2 WHO recommendations on target groups for TB preventive treatment","content_type":"box","pages":"39","caption":"Box 3.2 WHO recommendations on target groups for TB preventive treatment","tokens_est":190,"char_count":758,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0169","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.2. Target groups for TB preventive treatment | Box 3.2 WHO recommendations on target groups for TB preventive treatment","content_type":"box","pages":"39","caption":"Box 3.2 WHO recommendations on target groups for TB preventive treatment","tokens_est":173,"char_count":692,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0170","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.2. Target groups for TB preventive treatment | Box 3.2 WHO recommendations on target groups for TB preventive treatment","content_type":"box","pages":"39-40","caption":"Box 3.2 WHO recommendations on target groups for TB preventive treatment","tokens_est":103,"char_count":411,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0171","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.2. Target groups for TB preventive treatment | 3.3.2.1. Children and adolescents living with HIV","content_type":"text","pages":"40","tokens_est":243,"char_count":970,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0172","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.2. Target groups for TB preventive treatment | 3.3.2.1. Children and adolescents living with HIV","content_type":"text","pages":"40","tokens_est":203,"char_count":809,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0173","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.2. Target groups for TB preventive treatment | 3.3.2.1. Children and adolescents living with HIV","content_type":"text","pages":"40","tokens_est":172,"char_count":687,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0174","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.2. Target groups for TB preventive treatment | 3.3.2.1. Children and adolescents living with HIV","content_type":"text","pages":"40","tokens_est":216,"char_count":864,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0175","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.2. Target groups for TB preventive treatment | 3.3.2.1. Children and adolescents living with HIV","content_type":"text","pages":"40","tokens_est":87,"char_count":345,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0176","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.2. Target groups for TB preventive treatment | 3.3.2.2. Child and adolescent household contacts","content_type":"text","pages":"41","tokens_est":172,"char_count":685,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0177","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.2. Target groups for TB preventive treatment | 3.3.2.2. Child and adolescent household contacts","content_type":"text","pages":"41","tokens_est":176,"char_count":701,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0178","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.2. Target groups for TB preventive treatment | 3.3.2.2. Child and adolescent household contacts","content_type":"text","pages":"41","tokens_est":100,"char_count":399,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0179","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.2. Target groups for TB preventive treatment | 3.3.2.2. Child and adolescent household contacts","content_type":"text","pages":"41","tokens_est":229,"char_count":913,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0180","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.2. Target groups for TB preventive treatment | 3.3.2.2. Child and adolescent household contacts","content_type":"text","pages":"41","tokens_est":55,"char_count":217,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0181","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.2. Target groups for TB preventive treatment | 3.3.2.2. Child and adolescent household contacts","content_type":"text","pages":"41","tokens_est":37,"char_count":146,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0182","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.3. Ruling out TB disease before starting TB preventive treatment","content_type":"text","pages":"41","tokens_est":118,"char_count":472,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0183","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.3. Ruling out TB disease before starting TB preventive treatment | Box 3.3 WHO recommendations on ruling out TB disease before starting TB preventive treatment","content_type":"box","pages":"41-42","caption":"Box 3.3 WHO recommendations on ruling out TB disease before starting TB preventive treatment","tokens_est":221,"char_count":881,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0184","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.3. Ruling out TB disease before starting TB preventive treatment | Box 3.3 WHO recommendations on ruling out TB disease before starting TB preventive treatment","content_type":"box","pages":"42","caption":"Box 3.3 WHO recommendations on ruling out TB disease before starting TB preventive treatment","tokens_est":202,"char_count":808,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0185","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.3. Ruling out TB disease before starting TB preventive treatment | Box 3.3 WHO recommendations on ruling out TB disease before starting TB preventive treatment","content_type":"box","pages":"42","caption":"Box 3.3 WHO recommendations on ruling out TB disease before starting TB preventive treatment","tokens_est":152,"char_count":608,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0186","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.3. Ruling out TB disease before starting TB preventive treatment | 3.3.3.1. HIV-negative household and close contacts of a person with pulmonary TB: infants and children aged under 5 years","content_type":"text","pages":"42","tokens_est":191,"char_count":762,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0187","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.3. Ruling out TB disease before starting TB preventive treatment | 3.3.3.2. HIV-negative household and close contacts of a person with pulmonary TB: children and adolescents aged 5 years and over","content_type":"text","pages":"42","tokens_est":135,"char_count":540,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0188","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.3. Ruling out TB disease before starting TB preventive treatment | 3.3.3.3. Children and adolescents living with HIV","content_type":"text","pages":"42-43","tokens_est":169,"char_count":675,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0189","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.3. Ruling out TB disease before starting TB preventive treatment | 3.3.3.3. Children and adolescents living with HIV","content_type":"text","pages":"43","tokens_est":237,"char_count":945,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0190","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.3. Ruling out TB disease before starting TB preventive treatment | Figure 3.4. Algorithm for TB infection testing and TB preventive treatment in children and adolescents","content_type":"figure","pages":"43-45","caption":"Figure 3.4. Algorithm for TB infection testing and TB preventive treatment in children and adolescents","tokens_est":400,"char_count":1597,"has_attachment":true,"attachment_id":"Figure 3.4.","attachment_path":"figures/WHO_TB_handbook_module5_pediatrics_2022/Figure 3.4..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0191","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.4. Testing for TB infection","content_type":"text","pages":"46","tokens_est":245,"char_count":980,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0192","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.4. Testing for TB infection | 3.3.4.1. Tuberculin skin testing","content_type":"text","pages":"46","tokens_est":247,"char_count":985,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0193","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.4. Testing for TB infection | 3.3.4.1. Tuberculin skin testing","content_type":"text","pages":"46","tokens_est":69,"char_count":273,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0194","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.4. Testing for TB infection | 3.3.4.2. Interferon-gamma release assay","content_type":"text","pages":"46","tokens_est":239,"char_count":953,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0195","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.4. Testing for TB infection | 3.3.4.2. Interferon-gamma release assay","content_type":"text","pages":"46","tokens_est":41,"char_count":161,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0196","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.4. Testing for TB infection | 3.3.4.2. Interferon-gamma release assay","content_type":"text","pages":"46","tokens_est":115,"char_count":460,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0197","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.4. Testing for TB infection | 3.3.4.2. Interferon-gamma release assay","content_type":"text","pages":"46-47","tokens_est":155,"char_count":617,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0198","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.5. Options for TB preventive treatment regimens: drug susceptible TB","content_type":"text","pages":"47","tokens_est":207,"char_count":825,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0199","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.5. Options for TB preventive treatment regimens: drug susceptible TB | 3.3.5.1. Implementation considerations","content_type":"text","pages":"47","tokens_est":156,"char_count":621,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0200","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.5. Options for TB preventive treatment regimens: drug susceptible TB | 3.3.5.1. Implementation considerations | Table 3.1. TB preventive treatment options","content_type":"table","pages":"47-48","caption":"Table 3.1. TB preventive treatment options","tokens_est":30,"char_count":1031,"has_attachment":true,"attachment_id":"Table 3.1.","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_3.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0201","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.5. Options for TB preventive treatment regimens: drug susceptible TB | 3.3.5.1. Implementation considerations","content_type":"text","pages":"48","tokens_est":191,"char_count":762,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0202","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.5. Options for TB preventive treatment regimens: drug susceptible TB | 3.3.5.1. Implementation considerations","content_type":"text","pages":"48-49","tokens_est":189,"char_count":753,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0203","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.5. Options for TB preventive treatment regimens: drug susceptible TB | 3.3.5.1. Implementation considerations","content_type":"text","pages":"49","tokens_est":229,"char_count":914,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0204","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.5. Options for TB preventive treatment regimens: drug susceptible TB | 3.3.5.1. Implementation considerations","content_type":"text","pages":"49","tokens_est":186,"char_count":741,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0205","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.5. Options for TB preventive treatment regimens: drug susceptible TB | 3.3.5.2. Dosages","content_type":"text","pages":"49","tokens_est":198,"char_count":791,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0206","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.5. Options for TB preventive treatment regimens: drug susceptible TB | 3.3.5.2. Dosages","content_type":"text","pages":"49-50","tokens_est":232,"char_count":926,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0207","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.5. Options for TB preventive treatment regimens: drug susceptible TB | 3.3.5.2. Dosages","content_type":"text","pages":"50","tokens_est":177,"char_count":705,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0208","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.5. Options for TB preventive treatment regimens: drug susceptible TB | 3.3.5.2. Dosages","content_type":"text","pages":"50","tokens_est":210,"char_count":837,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0209","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.5. Options for TB preventive treatment regimens: drug susceptible TB | 3.3.5.2. Dosages","content_type":"text","pages":"50","tokens_est":103,"char_count":411,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0210","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.5. Options for TB preventive treatment regimens: drug susceptible TB | 3.3.5.2. Dosages","content_type":"text","pages":"50-51","tokens_est":192,"char_count":768,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0211","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.6. Options for TB preventive treatment regimens: drug resistant TB","content_type":"text","pages":"51","tokens_est":194,"char_count":775,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0212","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.6. Options for TB preventive treatment regimens: drug resistant TB","content_type":"text","pages":"51","tokens_est":145,"char_count":579,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0213","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.6. Options for TB preventive treatment regimens: drug resistant TB | Table 3.3. Dosing recommendations for use of levofloxacin as TB preventive treatment for drug-resistant TB","content_type":"table","pages":"51","caption":"Table 3.3. Dosing recommendations for use of levofloxacin as TB preventive treatment for drug-resistant TB","tokens_est":40,"char_count":168,"has_attachment":true,"attachment_id":"Table 3.3.","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_3.3..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0214","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.6. Options for TB preventive treatment regimens: drug resistant TB","content_type":"text","pages":"51","tokens_est":117,"char_count":468,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0215","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.7. Follow-up of children and adolescents on TB preventive treatment","content_type":"text","pages":"51-52","tokens_est":152,"char_count":607,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0216","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.7. Follow-up of children and adolescents on TB preventive treatment","content_type":"text","pages":"52","tokens_est":229,"char_count":914,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0217","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.7. Follow-up of children and adolescents on TB preventive treatment","content_type":"text","pages":"52","tokens_est":167,"char_count":665,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0218","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.7. Follow-up of children and adolescents on TB preventive treatment","content_type":"text","pages":"52","tokens_est":239,"char_count":954,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0219","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.7. Follow-up of children and adolescents on TB preventive treatment","content_type":"text","pages":"52","tokens_est":190,"char_count":757,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0220","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.8. Adherence to TB preventive treatment","content_type":"text","pages":"52-53","tokens_est":211,"char_count":844,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0221","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.8. Adherence to TB preventive treatment","content_type":"text","pages":"53","tokens_est":199,"char_count":796,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0222","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.8. Adherence to TB preventive treatment | 3.3.8.1. Special considerations for adherence in children","content_type":"text","pages":"53","tokens_est":239,"char_count":954,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0223","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.8. Adherence to TB preventive treatment | 3.3.8.1. Special considerations for adherence in children","content_type":"text","pages":"53","tokens_est":228,"char_count":910,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0224","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.8. Adherence to TB preventive treatment | 3.3.8.1. Special considerations for adherence in children","content_type":"text","pages":"53-54","tokens_est":193,"char_count":769,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0225","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.8. Adherence to TB preventive treatment | 3.3.8.1. Special considerations for adherence in children","content_type":"text","pages":"54","tokens_est":241,"char_count":964,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0226","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.8. Adherence to TB preventive treatment | 3.3.8.1. Special considerations for adherence in children","content_type":"text","pages":"54","tokens_est":101,"char_count":402,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0227","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.8. Adherence to TB preventive treatment | 3.3.8.1. Special considerations for adherence in children | Table 3.4. TB preventive treatment completion criteria","content_type":"table","pages":"54","caption":"Table 3.4 summarizes all recommended regimens and suggested criteria to assess their completion. Shorter regimens are associated with better adherence and higher treatment completion, based on 80 or 90% of recommended doses taken within 133% of planned TPT duration. Table 3.5 summarizes the suggested management of interruptions in TPT.","tokens_est":134,"char_count":831,"has_attachment":true,"attachment_id":"Table 3.4","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_3.4.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0228","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.8. Adherence to TB preventive treatment | 3.3.8.1. Special considerations for adherence in children | Table 3.5. Management of interruptions in TB preventive treatment","content_type":"table","pages":"56-58","caption":"Table 3.5. Management of interruptions in TB preventive treatment","tokens_est":39,"char_count":156,"has_attachment":true,"attachment_id":"Table 3.5.","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_3.5..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0229","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.3. TB preventive treatment | 3.3.9. Other issues related to TB preventive treatment in children and adolescents","content_type":"text","pages":"59","tokens_est":153,"char_count":609,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0230","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.4. TB infection prevention and control","content_type":"text","pages":"59","tokens_est":211,"char_count":844,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0231","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.4. TB infection prevention and control","content_type":"text","pages":"59","tokens_est":96,"char_count":382,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0232","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.4. TB infection prevention and control","content_type":"text","pages":"59","tokens_est":85,"char_count":339,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0233","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.4. TB infection prevention and control | Box 3.4 WHO recommendations on TB infection prevention and control","content_type":"box","pages":"59-60","caption":"Box 3.4 WHO recommendations on TB infection prevention and control","tokens_est":241,"char_count":961,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0234","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.4. TB infection prevention and control | Box 3.4 WHO recommendations on TB infection prevention and control","content_type":"box","pages":"60","caption":"Box 3.4 WHO recommendations on TB infection prevention and control","tokens_est":71,"char_count":281,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0235","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.4. TB infection prevention and control","content_type":"text","pages":"60","tokens_est":222,"char_count":887,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0236","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.4. TB infection prevention and control","content_type":"text","pages":"60","tokens_est":221,"char_count":882,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0237","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.4. TB infection prevention and control","content_type":"text","pages":"60","tokens_est":138,"char_count":549,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0238","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.4. TB infection prevention and control","content_type":"text","pages":"60-61","tokens_est":246,"char_count":984,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0239","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.4. TB infection prevention and control","content_type":"text","pages":"61","tokens_est":232,"char_count":925,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0240","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"3. Prevention of TB in children and adolescents | 3.4. TB infection prevention and control","content_type":"text","pages":"61","tokens_est":60,"char_count":239,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0241","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.1. Introduction","content_type":"text","pages":"61-62","tokens_est":235,"char_count":938,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0242","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.1. Introduction","content_type":"text","pages":"62","tokens_est":100,"char_count":399,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0243","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.2. Diagnosing TB in children and adolescents","content_type":"text","pages":"62","tokens_est":237,"char_count":947,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0244","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.2. Diagnosing TB in children and adolescents","content_type":"text","pages":"62","tokens_est":182,"char_count":727,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0245","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB","content_type":"text","pages":"62","tokens_est":177,"char_count":705,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0246","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.1. Typical symptoms of pulmonary TB","content_type":"text","pages":"63","tokens_est":234,"char_count":935,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0247","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.1. Typical symptoms of pulmonary TB | Figure 4.2. Differentiated cough patterns","content_type":"figure","pages":"63","caption":"Figure 4.2. Differentiated cough patterns","tokens_est":124,"char_count":495,"has_attachment":true,"attachment_id":"Figure 4.2.","attachment_path":"figures/WHO_TB_handbook_module5_pediatrics_2022/Figure 4.2..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0248","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.1. Typical symptoms of pulmonary TB | Box 4.1 Symptoms of TB in children","content_type":"box","pages":"63","caption":"Box 4.1 Symptoms of TB in children","tokens_est":101,"char_count":401,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0249","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.2. History of TB contact","content_type":"text","pages":"63-64","tokens_est":82,"char_count":326,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0250","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.2. History of TB contact","content_type":"text","pages":"64","tokens_est":239,"char_count":953,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0251","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.2. History of TB contact","content_type":"text","pages":"64","tokens_est":218,"char_count":869,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0252","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.3. Clinical examination","content_type":"text","pages":"64","tokens_est":192,"char_count":768,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0253","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.3. Clinical examination","content_type":"text","pages":"64","tokens_est":223,"char_count":892,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0254","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.3. Clinical examination","content_type":"text","pages":"64-65","tokens_est":209,"char_count":834,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0255","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.3. Clinical examination | Weight loss or failure to thrive","content_type":"text","pages":"65","tokens_est":103,"char_count":409,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0256","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.3. Clinical examination | Other causes of chronic lung disease","content_type":"text","pages":"65","tokens_est":86,"char_count":342,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0257","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.3. Clinical examination | Figure 4.3. Examples of abnormal growth curves","content_type":"figure","pages":"65-67","caption":"Figure 4.3. Examples of abnormal growth curves","tokens_est":120,"char_count":477,"has_attachment":true,"attachment_id":"Figure 4.3.","attachment_path":"figures/WHO_TB_handbook_module5_pediatrics_2022/Figure 4.3..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0258","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.4. Atypical clinical presentations of children with pulmonary TB","content_type":"text","pages":"67","tokens_est":204,"char_count":816,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0259","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.4. Atypical clinical presentations of children with pulmonary TB","content_type":"text","pages":"67","tokens_est":225,"char_count":897,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0260","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation","content_type":"text","pages":"67","tokens_est":146,"char_count":584,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0261","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.1. Sample types","content_type":"text","pages":"67-68","tokens_est":230,"char_count":918,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0262","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.1. Sample types","content_type":"text","pages":"68","tokens_est":50,"char_count":200,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0263","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.1. Sample types | Table 4.1. WHO-approved respiratory samples for diagnosis of pulmonary TB","content_type":"table","pages":"68-69","caption":"Table 4.1. WHO-approved respiratory samples for diagnosis of pulmonary TB","tokens_est":38,"char_count":160,"has_attachment":true,"attachment_id":"Table 4.1.","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_4.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0264","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.1. Sample types | Stool","content_type":"text","pages":"69","tokens_est":176,"char_count":704,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0265","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.1. Sample types | Stool","content_type":"text","pages":"69","tokens_est":218,"char_count":871,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0266","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.1. Sample types | Table 4.2. Diagnostic accuracy of Xpert MTB/RIF and Ultra in paediatric specimen types against a microbiological reference standar d [a]","content_type":"table","pages":"69-70","caption":"Table 4.2. Diagnostic accuracy of Xpert MTB/RIF and Ultra in paediatric specimen types against a microbiological reference standar d [a]","tokens_est":57,"char_count":345,"has_attachment":true,"attachment_id":"Table 4.2.","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_4.2..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0267","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.1. Sample types | Table 4.3. Commonly used stool processing methods to detect TB using a molecular WHO rapid diagnostic test (see web Annex 4 )","content_type":"table","pages":"70","caption":"Table 4.3. Commonly used stool processing methods to detect TB using a molecular WHO rapid diagnostic test (see web Annex 4 )","tokens_est":49,"char_count":204,"has_attachment":true,"attachment_id":"Table 4.3.","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_4.3..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0268","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.1. Sample types","content_type":"text","pages":"70","tokens_est":155,"char_count":620,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0269","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.1. Sample types | Nasopharyngeal aspirate","content_type":"text","pages":"70","tokens_est":165,"char_count":658,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0270","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.1. Sample types | Box 4.2 Experiences from the TB-Speed Decentralization and Pneumonia studies","content_type":"box","pages":"71","caption":"Box 4.2 Experiences from the TB-Speed Decentralization and Pneumonia studies","tokens_est":207,"char_count":828,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0271","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.1. Sample types | Box 4.2 Experiences from the TB-Speed Decentralization and Pneumonia studies","content_type":"box","pages":"71","caption":"Box 4.2 Experiences from the TB-Speed Decentralization and Pneumonia studies","tokens_est":123,"char_count":489,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0272","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.1. Sample types | Box 4.2 Experiences from the TB-Speed Decentralization and Pneumonia studies","content_type":"box","pages":"71","caption":"Box 4.2 Experiences from the TB-Speed Decentralization and Pneumonia studies","tokens_est":239,"char_count":954,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0273","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.1. Sample types | Box 4.2 Experiences from the TB-Speed Decentralization and Pneumonia studies","content_type":"box","pages":"71","caption":"Box 4.2 Experiences from the TB-Speed Decentralization and Pneumonia studies","tokens_est":211,"char_count":843,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0274","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.1. Sample types | Box 4.2 Experiences from the TB-Speed Decentralization and Pneumonia studies","content_type":"box","pages":"71","caption":"Box 4.2 Experiences from the TB-Speed Decentralization and Pneumonia studies","tokens_est":199,"char_count":796,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0275","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.1. Sample types | Box 4.2 Experiences from the TB-Speed Decentralization and Pneumonia studies","content_type":"box","pages":"71-72","caption":"Box 4.2 Experiences from the TB-Speed Decentralization and Pneumonia studies","tokens_est":169,"char_count":673,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0276","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.1. Sample types | Box 4.2 Experiences from the TB-Speed Decentralization and Pneumonia studies","content_type":"box","pages":"72","caption":"Box 4.2 Experiences from the TB-Speed Decentralization and Pneumonia studies","tokens_est":232,"char_count":925,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0277","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.1. Sample types | Box 4.2 Experiences from the TB-Speed Decentralization and Pneumonia studies","content_type":"box","pages":"72","caption":"Box 4.2 Experiences from the TB-Speed Decentralization and Pneumonia studies","tokens_est":99,"char_count":396,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0278","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.2. WHO-recommended rapid diagnostic tests","content_type":"text","pages":"72","tokens_est":149,"char_count":594,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0279","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.2. WHO-recommended rapid diagnostic tests | Table 4.4. Summary of WHO-recommended rapid diagnostic tests and specimen types that can be used with them for diagnosis of TB in children and adolescents","content_type":"table","pages":"72-73","caption":"Table 4.4. Summary of WHO-recommended rapid diagnostic tests and specimen types that can be used with them for diagnosis of TB in children and adolescents","tokens_est":58,"char_count":477,"has_attachment":true,"attachment_id":"Table 4.4.","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_4.4..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0280","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.2. WHO-recommended rapid diagnostic tests | Box 4.3 WHO recommendations on use of rapid diagnostic tests in adults a nd children with signs and symptoms of pulmonary TB","content_type":"box","pages":"73","caption":"Box 4.3 WHO recommendations on use of rapid diagnostic tests in adults a nd children with signs and symptoms of pulmonary TB","tokens_est":202,"char_count":807,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0281","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.2. WHO-recommended rapid diagnostic tests | Box 4.3 WHO recommendations on use of rapid diagnostic tests in adults a nd children with signs and symptoms of pulmonary TB","content_type":"box","pages":"73","caption":"Box 4.3 WHO recommendations on use of rapid diagnostic tests in adults a nd children with signs and symptoms of pulmonary TB","tokens_est":234,"char_count":933,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0282","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.2. WHO-recommended rapid diagnostic tests | Box 4.3 WHO recommendations on use of rapid diagnostic tests in adults a nd children with signs and symptoms of pulmonary TB","content_type":"box","pages":"73-74","caption":"Box 4.3 WHO recommendations on use of rapid diagnostic tests in adults a nd children with signs and symptoms of pulmonary TB","tokens_est":232,"char_count":925,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0283","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.2. WHO-recommended rapid diagnostic tests | Box 4.3 WHO recommendations on use of rapid diagnostic tests in adults a nd children with signs and symptoms of pulmonary TB","content_type":"box","pages":"74","caption":"Box 4.3 WHO recommendations on use of rapid diagnostic tests in adults a nd children with signs and symptoms of pulmonary TB","tokens_est":243,"char_count":970,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0284","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.2. WHO-recommended rapid diagnostic tests | Box 4.3 WHO recommendations on use of rapid diagnostic tests in adults a nd children with signs and symptoms of pulmonary TB","content_type":"box","pages":"74","caption":"Box 4.3 WHO recommendations on use of rapid diagnostic tests in adults a nd children with signs and symptoms of pulmonary TB","tokens_est":181,"char_count":723,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0285","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.2. WHO-recommended rapid diagnostic tests | Box 4.3 WHO recommendations on use of rapid diagnostic tests in adults a nd children with signs and symptoms of pulmonary TB","content_type":"box","pages":"74","caption":"Box 4.3 WHO recommendations on use of rapid diagnostic tests in adults a nd children with signs and symptoms of pulmonary TB","tokens_est":216,"char_count":862,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0286","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.3. Molecular WHO-recommended rapid diagnostic tests for TB","content_type":"text","pages":"74","tokens_est":143,"char_count":571,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0287","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.3. Molecular WHO-recommended rapid diagnostic tests for TB","content_type":"text","pages":"74-75","tokens_est":192,"char_count":766,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0288","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.3. Molecular WHO-recommended rapid diagnostic tests for TB","content_type":"text","pages":"75","tokens_est":169,"char_count":676,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0289","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.4. Antigen detection in a lateral flow format (biomarker-based detection)","content_type":"text","pages":"75","tokens_est":190,"char_count":760,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0290","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.4. Antigen detection in a lateral flow format (biomarker-based detection)","content_type":"text","pages":"75","tokens_est":156,"char_count":622,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0291","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.4. Antigen detection in a lateral flow format (biomarker-based detection) | Box 4.4 WHO recommendations on use of lateral flow lipoarabinomannan assays","content_type":"box","pages":"75","caption":"Box 4.4 WHO recommendations on use of lateral flow lipoarabinomannan assays","tokens_est":226,"char_count":901,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0292","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.4. Antigen detection in a lateral flow format (biomarker-based detection) | Box 4.4 WHO recommendations on use of lateral flow lipoarabinomannan assays","content_type":"box","pages":"75-76","caption":"Box 4.4 WHO recommendations on use of lateral flow lipoarabinomannan assays","tokens_est":235,"char_count":938,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0293","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.4. Antigen detection in a lateral flow format (biomarker-based detection) | Box 4.4 WHO recommendations on use of lateral flow lipoarabinomannan assays","content_type":"box","pages":"76","caption":"Box 4.4 WHO recommendations on use of lateral flow lipoarabinomannan assays","tokens_est":132,"char_count":526,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0294","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.4. Antigen detection in a lateral flow format (biomarker-based detection) | Box 4.4 WHO recommendations on use of lateral flow lipoarabinomannan assays","content_type":"box","pages":"76","caption":"Box 4.4 WHO recommendations on use of lateral flow lipoarabinomannan assays","tokens_est":200,"char_count":797,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0295","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.5. Repeat testing with molecular WHO-recommended rapid diagnostic tests","content_type":"text","pages":"76","tokens_est":120,"char_count":480,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0296","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.5. Repeat testing with molecular WHO-recommended rapid diagnostic tests | Box 4.5 WHO recommendations on repeat testing with Xpert MTB/RIF and Ultra","content_type":"box","pages":"76","caption":"Box 4.5 WHO recommendations on repeat testing with Xpert MTB/RIF and Ultra","tokens_est":226,"char_count":903,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0297","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.5. Repeat testing with molecular WHO-recommended rapid diagnostic tests | Box 4.5 WHO recommendations on repeat testing with Xpert MTB/RIF and Ultra","content_type":"box","pages":"76-77","caption":"Box 4.5 WHO recommendations on repeat testing with Xpert MTB/RIF and Ultra","tokens_est":194,"char_count":774,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0298","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.5. Repeat testing with molecular WHO-recommended rapid diagnostic tests | Box 4.5 WHO recommendations on repeat testing with Xpert MTB/RIF and Ultra","content_type":"box","pages":"77","caption":"Box 4.5 WHO recommendations on repeat testing with Xpert MTB/RIF and Ultra","tokens_est":234,"char_count":934,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0299","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.5. Bacteriological confirmation | 4.3.5.5. Repeat testing with molecular WHO-recommended rapid diagnostic tests | Box 4.5 WHO recommendations on repeat testing with Xpert MTB/RIF and Ultra","content_type":"box","pages":"77","caption":"Box 4.5 WHO recommendations on repeat testing with Xpert MTB/RIF and Ultra","tokens_est":66,"char_count":263,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0300","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.6. Testing for TB infection","content_type":"text","pages":"77","tokens_est":205,"char_count":820,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0301","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.6. Testing for TB infection","content_type":"text","pages":"77","tokens_est":86,"char_count":343,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0302","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.7. Role of chest X-ray","content_type":"text","pages":"77-78","tokens_est":194,"char_count":773,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0303","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.7. Role of chest X-ray","content_type":"text","pages":"78","tokens_est":239,"char_count":954,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0304","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.7. Role of chest X-ray","content_type":"text","pages":"78","tokens_est":198,"char_count":791,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0305","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.8. HIV testing","content_type":"text","pages":"78","tokens_est":178,"char_count":711,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0306","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.9. Integrated treatment decision algorithms for pulmonary TB in children","content_type":"text","pages":"78-79","tokens_est":237,"char_count":948,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0307","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.9. Integrated treatment decision algorithms for pulmonary TB in children","content_type":"text","pages":"79","tokens_est":214,"char_count":856,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0308","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.9. Integrated treatment decision algorithms for pulmonary TB in children | Box 4.6 WHO interim recommendation on use of integrated treatment decision algorithms","content_type":"box","pages":"79","caption":"Box 4.6 WHO interim recommendation on use of integrated treatment decision algorithms","tokens_est":217,"char_count":867,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0309","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.9. Integrated treatment decision algorithms for pulmonary TB in children | 4.3.9.1. Algorithm A (for settings with chest X-ray) and Algorithm B (for settings without chest X-ray) | Figure 4.4. Algorithm A","content_type":"figure","pages":"79","caption":"Figure 4.4. Algorithm A","tokens_est":9,"char_count":33,"has_attachment":true,"attachment_id":"Figure 4.4.","attachment_path":"figures/WHO_TB_handbook_module5_pediatrics_2022/Figure 4.4..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0310","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.9. Integrated treatment decision algorithms for pulmonary TB in children | 4.3.9.1. Algorithm A (for settings with chest X-ray) and Algorithm B (for settings without chest X-ray) | Figure 4.5. Algorithm B","content_type":"figure","pages":"79","caption":"Figure 4.5. Algorithm B","tokens_est":9,"char_count":33,"has_attachment":true,"attachment_id":"Figure 4.5.","attachment_path":"figures/WHO_TB_handbook_module5_pediatrics_2022/Figure 4.5..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0311","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.9. Integrated treatment decision algorithms for pulmonary TB in children | 4.3.9.2. Using the integrated treatment decision algorithms","content_type":"text","pages":"79-80","tokens_est":170,"char_count":677,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0312","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.9. Integrated treatment decision algorithms for pulmonary TB in children | 4.3.9.2. Using the integrated treatment decision algorithms","content_type":"text","pages":"80","tokens_est":226,"char_count":904,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0313","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.9. Integrated treatment decision algorithms for pulmonary TB in children | 4.3.9.2. Using the integrated treatment decision algorithms | Danger signs for Age <5 years (IMCI)","content_type":"text","pages":"80","tokens_est":94,"char_count":374,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0314","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.9. Integrated treatment decision algorithms for pulmonary TB in children | 4.3.9.2. Using the integrated treatment decision algorithms | Danger signs for Age 5 -9 years ( ETAT )","content_type":"text","pages":"80","tokens_est":122,"char_count":485,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0315","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.9. Integrated treatment decision algorithms for pulmonary TB in children | 4.3.9.2. Using the integrated treatment decision algorithms | Priority signs for age <10 years","content_type":"text","pages":"80","tokens_est":128,"char_count":509,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0316","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.9. Integrated treatment decision algorithms for pulmonary TB in children | 4.3.9.2. Using the integrated treatment decision algorithms | Priority signs for age <10 years","content_type":"text","pages":"80","tokens_est":210,"char_count":839,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0317","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.9. Integrated treatment decision algorithms for pulmonary TB in children | 4.3.9.2. Using the integrated treatment decision algorithms | Priority signs for age <10 years","content_type":"text","pages":"80","tokens_est":212,"char_count":845,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0318","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.9. Integrated treatment decision algorithms for pulmonary TB in children | 4.3.9.2. Using the integrated treatment decision algorithms | Priority signs for age <10 years","content_type":"text","pages":"80","tokens_est":217,"char_count":866,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0319","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.9. Integrated treatment decision algorithms for pulmonary TB in children | 4.3.9.2. Using the integrated treatment decision algorithms | Priority signs for age <10 years","content_type":"text","pages":"80","tokens_est":91,"char_count":363,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0320","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.9. Integrated treatment decision algorithms for pulmonary TB in children | 4.3.9.2. Using the integrated treatment decision algorithms | Priority signs for age <10 years","content_type":"text","pages":"80","tokens_est":215,"char_count":860,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0321","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.9. Integrated treatment decision algorithms for pulmonary TB in children | 4.3.9.2. Using the integrated treatment decision algorithms | Priority signs for age <10 years","content_type":"text","pages":"80-81","tokens_est":160,"char_count":638,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0322","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.9. Integrated treatment decision algorithms for pulmonary TB in children | 4.3.9.2. Using the integrated treatment decision algorithms | Box 4.7 Example of scoring via Algorithm A","content_type":"box","pages":"81","caption":"Box 4.7 Example of scoring via Algorithm A","tokens_est":154,"char_count":613,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0323","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.9. Integrated treatment decision algorithms for pulmonary TB in children | 4.3.9.2. Using the integrated treatment decision algorithms | Box 4.8 Example of scoring via Algorithm B","content_type":"box","pages":"81","caption":"Box 4.8 Example of scoring via Algorithm B","tokens_est":134,"char_count":536,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0324","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.9. Integrated treatment decision algorithms for pulmonary TB in children | 4.3.9.2. Using the integrated treatment decision algorithms","content_type":"text","pages":"81","tokens_est":148,"char_count":590,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0325","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.9. Integrated treatment decision algorithms for pulmonary TB in children | 4.3.9.2. Using the integrated treatment decision algorithms","content_type":"text","pages":"81-82","tokens_est":211,"char_count":843,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0326","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.9. Integrated treatment decision algorithms for pulmonary TB in children | 4.3.9.2. Using the integrated treatment decision algorithms | Box 4.9 Definitions of symptoms suggestive of pulmonary TB included in treatment decision algorithms","content_type":"box","pages":"82","caption":"Box 4.9 Definitions of symptoms suggestive of pulmonary TB included in treatment decision algorithms","tokens_est":216,"char_count":861,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0327","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.9. Integrated treatment decision algorithms for pulmonary TB in children | 4.3.9.2. Using the integrated treatment decision algorithms | Box 4.9 Definitions of symptoms suggestive of pulmonary TB included in treatment decision algorithms","content_type":"box","pages":"82","caption":"Box 4.9 Definitions of symptoms suggestive of pulmonary TB included in treatment decision algorithms","tokens_est":233,"char_count":931,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0328","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.3. Diagnostic approaches: pulmonary TB | 4.3.9. Integrated treatment decision algorithms for pulmonary TB in children | 4.3.9.2. Using the integrated treatment decision algorithms | Box 4.9 Definitions of symptoms suggestive of pulmonary TB included in treatment decision algorithms","content_type":"box","pages":"82","caption":"Box 4.9 Definitions of symptoms suggestive of pulmonary TB included in treatment decision algorithms","tokens_est":61,"char_count":244,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0329","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.4. Diagnostic approaches: extrapulmonary TB","content_type":"text","pages":"82","tokens_est":244,"char_count":974,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0330","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.4. Diagnostic approaches: extrapulmonary TB","content_type":"text","pages":"82-84","tokens_est":148,"char_count":590,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0331","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.4. Diagnostic approaches: extrapulmonary TB | Box 4.10 WHO recommendations on use of Xpert MTB/RIF and Xpert Ultra as initial tests in adolescents and children with signs and symptoms of extrapulmonary TB","content_type":"box","pages":"85","caption":"Box 4.10 WHO recommendations on use of Xpert MTB/RIF and Xpert Ultra as initial tests in adolescents and children with signs and symptoms of extrapulmonary TB","tokens_est":134,"char_count":533,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0332","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.4. Diagnostic approaches: extrapulmonary TB | Box 4.10 WHO recommendations on use of Xpert MTB/RIF and Xpert Ultra as initial tests in adolescents and children with signs and symptoms of extrapulmonary TB","content_type":"box","pages":"85","caption":"Box 4.10 WHO recommendations on use of Xpert MTB/RIF and Xpert Ultra as initial tests in adolescents and children with signs and symptoms of extrapulmonary TB","tokens_est":186,"char_count":744,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0333","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.4. Diagnostic approaches: extrapulmonary TB | Box 4.10 WHO recommendations on use of Xpert MTB/RIF and Xpert Ultra as initial tests in adolescents and children with signs and symptoms of extrapulmonary TB","content_type":"box","pages":"85","caption":"Box 4.10 WHO recommendations on use of Xpert MTB/RIF and Xpert Ultra as initial tests in adolescents and children with signs and symptoms of extrapulmonary TB","tokens_est":194,"char_count":776,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0334","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.4. Diagnostic approaches: extrapulmonary TB | Box 4.10 WHO recommendations on use of Xpert MTB/RIF and Xpert Ultra as initial tests in adolescents and children with signs and symptoms of extrapulmonary TB","content_type":"box","pages":"85","caption":"Box 4.10 WHO recommendations on use of Xpert MTB/RIF and Xpert Ultra as initial tests in adolescents and children with signs and symptoms of extrapulmonary TB","tokens_est":202,"char_count":806,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0335","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.4. Diagnostic approaches: extrapulmonary TB | Box 4.10 WHO recommendations on use of Xpert MTB/RIF and Xpert Ultra as initial tests in adolescents and children with signs and symptoms of extrapulmonary TB","content_type":"box","pages":"85","caption":"Box 4.10 WHO recommendations on use of Xpert MTB/RIF and Xpert Ultra as initial tests in adolescents and children with signs and symptoms of extrapulmonary TB","tokens_est":87,"char_count":348,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0336","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.4. Diagnostic approaches: extrapulmonary TB | Table 4.6. Typical clinical features of extrapulmonary TB and suggested investigations","content_type":"table","pages":"85-87","caption":"Table 4.6. Typical clinical features of extrapulmonary TB and suggested investigations","tokens_est":39,"char_count":1272,"has_attachment":true,"attachment_id":"Table 4.6.","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_4.6..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0337","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.5. Disease severity","content_type":"text","pages":"87","tokens_est":188,"char_count":751,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0338","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.5. Disease severity","content_type":"text","pages":"87","tokens_est":154,"char_count":616,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0339","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.6. Diagnostic approaches: drug-resistant TB","content_type":"text","pages":"88","tokens_est":190,"char_count":758,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0340","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.6. Diagnostic approaches: drug-resistant TB","content_type":"text","pages":"88","tokens_est":209,"char_count":835,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0341","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.6. Diagnostic approaches: drug-resistant TB","content_type":"text","pages":"88","tokens_est":196,"char_count":783,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0342","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.6. Diagnostic approaches: drug-resistant TB","content_type":"text","pages":"88","tokens_est":147,"char_count":586,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0343","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.6. Diagnostic approaches: drug-resistant TB | Box 4.11 WHO recommendations for low-complexity NAATs for detection of resistance to isoniazid and second-line TB medicines, first- and second-line LPAs, and high-complexity reverse hybridization-based NAATs for detection of pyrazinamide resistance","content_type":"box","pages":"88-89","caption":"Box 4.11 WHO recommendations for low-complexity NAATs for detection of resistance to isoniazid and second-line TB medicines, first- and second-line LPAs, and high-complexity reverse hybridization-based NAATs for detection of pyrazinamide resistance","tokens_est":223,"char_count":892,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0344","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.6. Diagnostic approaches: drug-resistant TB | Box 4.11 WHO recommendations for low-complexity NAATs for detection of resistance to isoniazid and second-line TB medicines, first- and second-line LPAs, and high-complexity reverse hybridization-based NAATs for detection of pyrazinamide resistance","content_type":"box","pages":"89","caption":"Box 4.11 WHO recommendations for low-complexity NAATs for detection of resistance to isoniazid and second-line TB medicines, first- and second-line LPAs, and high-complexity reverse hybridization-based NAATs for detection of pyrazinamide resistance","tokens_est":229,"char_count":915,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0345","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.6. Diagnostic approaches: drug-resistant TB | Box 4.11 WHO recommendations for low-complexity NAATs for detection of resistance to isoniazid and second-line TB medicines, first- and second-line LPAs, and high-complexity reverse hybridization-based NAATs for detection of pyrazinamide resistance","content_type":"box","pages":"89","caption":"Box 4.11 WHO recommendations for low-complexity NAATs for detection of resistance to isoniazid and second-line TB medicines, first- and second-line LPAs, and high-complexity reverse hybridization-based NAATs for detection of pyrazinamide resistance","tokens_est":162,"char_count":647,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0346","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.6. Diagnostic approaches: drug-resistant TB | Box 4.11 WHO recommendations for low-complexity NAATs for detection of resistance to isoniazid and second-line TB medicines, first- and second-line LPAs, and high-complexity reverse hybridization-based NAATs for detection of pyrazinamide resistance","content_type":"box","pages":"89","caption":"Box 4.11 WHO recommendations for low-complexity NAATs for detection of resistance to isoniazid and second-line TB medicines, first- and second-line LPAs, and high-complexity reverse hybridization-based NAATs for detection of pyrazinamide resistance","tokens_est":245,"char_count":979,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0347","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.6. Diagnostic approaches: drug-resistant TB | Box 4.11 WHO recommendations for low-complexity NAATs for detection of resistance to isoniazid and second-line TB medicines, first- and second-line LPAs, and high-complexity reverse hybridization-based NAATs for detection of pyrazinamide resistance","content_type":"box","pages":"89","caption":"Box 4.11 WHO recommendations for low-complexity NAATs for detection of resistance to isoniazid and second-line TB medicines, first- and second-line LPAs, and high-complexity reverse hybridization-based NAATs for detection of pyrazinamide resistance","tokens_est":110,"char_count":438,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0348","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.6. Diagnostic approaches: drug-resistant TB","content_type":"text","pages":"89","tokens_est":243,"char_count":971,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0349","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.6. Diagnostic approaches: drug-resistant TB","content_type":"text","pages":"89-90","tokens_est":248,"char_count":989,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0350","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"4. TB diagnostic approaches for children and adolescents | 4.6. Diagnostic approaches: drug-resistant TB","content_type":"text","pages":"90","tokens_est":75,"char_count":298,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0351","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.1. Introduction","content_type":"text","pages":"91","tokens_est":238,"char_count":949,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0352","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.1. Principles of TB management","content_type":"text","pages":"91","tokens_est":200,"char_count":798,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0353","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.1. Principles of TB management","content_type":"text","pages":"91-92","tokens_est":63,"char_count":250,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0354","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.1. Principles of TB management | Box 5.1 Measures to be taken when a child or adolescent is diagnosed with any form of TB","content_type":"box","pages":"92","caption":"Box 5.1 Measures to be taken when a child or adolescent is diagnosed with any form of TB","tokens_est":211,"char_count":841,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0355","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.1. Principles of TB management | Box 5.1 Measures to be taken when a child or adolescent is diagnosed with any form of TB","content_type":"box","pages":"92","caption":"Box 5.1 Measures to be taken when a child or adolescent is diagnosed with any form of TB","tokens_est":242,"char_count":967,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0356","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.1. Principles of TB management | Box 5.1 Measures to be taken when a child or adolescent is diagnosed with any form of TB","content_type":"box","pages":"92","caption":"Box 5.1 Measures to be taken when a child or adolescent is diagnosed with any form of TB","tokens_est":237,"char_count":948,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0357","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.1. Principles of TB management | Box 5.1 Measures to be taken when a child or adolescent is diagnosed with any form of TB","content_type":"box","pages":"92-93","caption":"Box 5.1 Measures to be taken when a child or adolescent is diagnosed with any form of TB","tokens_est":90,"char_count":358,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0358","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.2. Treatment of pulmonary TB in children and adolescents","content_type":"text","pages":"93","tokens_est":229,"char_count":915,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0359","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.2. Treatment of pulmonary TB in children and adolescents","content_type":"text","pages":"93","tokens_est":42,"char_count":168,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0360","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.3. Recommended regimens for treatment of drug susceptible pulmonary TB in children","content_type":"text","pages":"93","tokens_est":170,"char_count":679,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0361","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.3. Recommended regimens for treatment of drug susceptible pulmonary TB in children","content_type":"text","pages":"93","tokens_est":206,"char_count":822,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0362","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.3. Recommended regimens for treatment of drug susceptible pulmonary TB in children","content_type":"text","pages":"93","tokens_est":154,"char_count":613,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0363","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.3. Recommended regimens for treatment of drug susceptible pulmonary TB in children | Box 5.2 Recommendations on treatment regimens for children and adolescents","content_type":"box","pages":"94","caption":"Box 5.2 Recommendations on treatment regimens for children and adolescents","tokens_est":236,"char_count":943,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0364","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.3. Recommended regimens for treatment of drug susceptible pulmonary TB in children | Box 5.2 Recommendations on treatment regimens for children and adolescents","content_type":"box","pages":"94","caption":"Box 5.2 Recommendations on treatment regimens for children and adolescents","tokens_est":194,"char_count":776,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0365","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.3. Recommended regimens for treatment of drug susceptible pulmonary TB in children | Box 5.2 Recommendations on treatment regimens for children and adolescents","content_type":"box","pages":"94","caption":"Box 5.2 Recommendations on treatment regimens for children and adolescents","tokens_est":169,"char_count":675,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0366","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.3. Recommended regimens for treatment of drug susceptible pulmonary TB in children | Table 5.1. Pulmonary TB treatment regimens by age group, disease severity and local epidemiology [a]","content_type":"table","pages":"94-95","caption":"Table 5.1. Pulmonary TB treatment regimens by age group, disease severity and local epidemiology [a]","tokens_est":42,"char_count":1808,"has_attachment":true,"attachment_id":"Table 5.1.","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_5.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0367","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.4. Implementation considerations | 5.2.4.1. Assessing eligibility for the 4-month regimen","content_type":"text","pages":"95","tokens_est":170,"char_count":678,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0368","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.4. Implementation considerations | 5.2.4.1. Assessing eligibility for the 4-month regimen","content_type":"text","pages":"95","tokens_est":212,"char_count":848,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0369","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.4. Implementation considerations | 5.2.4.1. Assessing eligibility for the 4-month regimen","content_type":"text","pages":"95","tokens_est":88,"char_count":352,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0370","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.4. Implementation considerations | 5.2.4.1. Assessing eligibility for the 4-month regimen | Box 5.3 Eligibility criteria for the 4-month regimen (2HRZ(E)/2HR) in children and adolescents aged between 3 months and 16 years, in various settings","content_type":"box","pages":"96","caption":"Box 5.3 Eligibility criteria for the 4-month regimen (2HRZ(E)/2HR) in children and adolescents aged between 3 months and 16 years, in various settings","tokens_est":220,"char_count":877,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0371","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.4. Implementation considerations | 5.2.4.1. Assessing eligibility for the 4-month regimen | Box 5.3 Eligibility criteria for the 4-month regimen (2HRZ(E)/2HR) in children and adolescents aged between 3 months and 16 years, in various settings","content_type":"box","pages":"96","caption":"Box 5.3 Eligibility criteria for the 4-month regimen (2HRZ(E)/2HR) in children and adolescents aged between 3 months and 16 years, in various settings","tokens_est":229,"char_count":913,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0372","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.4. Implementation considerations | 5.2.4.1. Assessing eligibility for the 4-month regimen | Box 5.3 Eligibility criteria for the 4-month regimen (2HRZ(E)/2HR) in children and adolescents aged between 3 months and 16 years, in various settings","content_type":"box","pages":"96","caption":"Box 5.3 Eligibility criteria for the 4-month regimen (2HRZ(E)/2HR) in children and adolescents aged between 3 months and 16 years, in various settings","tokens_est":218,"char_count":869,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0373","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.4. Implementation considerations | 5.2.4.1. Assessing eligibility for the 4-month regimen | Box 5.3 Eligibility criteria for the 4-month regimen (2HRZ(E)/2HR) in children and adolescents aged between 3 months and 16 years, in various settings","content_type":"box","pages":"96-97","caption":"Box 5.3 Eligibility criteria for the 4-month regimen (2HRZ(E)/2HR) in children and adolescents aged between 3 months and 16 years, in various settings","tokens_est":225,"char_count":898,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0374","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.4. Implementation considerations | 5.2.4.2. Inclusion of ethambutol in the intensive phase of treatment","content_type":"text","pages":"97","tokens_est":240,"char_count":959,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0375","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.4. Implementation considerations | 5.2.4.2. Inclusion of ethambutol in the intensive phase of treatment","content_type":"text","pages":"97","tokens_est":115,"char_count":459,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0376","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.4. Implementation considerations | 5.2.4.3. Implementation considerations for the isoniazid, rifapentine, moxifloxacin and pyrazinamide regimen","content_type":"text","pages":"97","tokens_est":218,"char_count":872,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0377","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.4. Implementation considerations | 5.2.4.3. Implementation considerations for the isoniazid, rifapentine, moxifloxacin and pyrazinamide regimen","content_type":"text","pages":"97","tokens_est":227,"char_count":907,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0378","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.4. Implementation considerations | 5.2.4.4. Dosing frequency","content_type":"text","pages":"97-98","tokens_est":122,"char_count":488,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0379","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.5. Subgroup considerations | 5.2.5.1. Children with peripheral lymph node TB","content_type":"text","pages":"98","tokens_est":144,"char_count":576,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0380","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.5. Subgroup considerations | 5.2.5.2. Children and adolescents living with HIV","content_type":"text","pages":"98","tokens_est":198,"char_count":791,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0381","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.5. Subgroup considerations | 5.2.5.3. Children with severe acute malnutrition","content_type":"text","pages":"98","tokens_est":119,"char_count":476,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0382","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.5. Subgroup considerations | 5.2.5.4. Children with severe acute pneumonia","content_type":"text","pages":"98","tokens_est":175,"char_count":697,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0383","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.5. Subgroup considerations | 5.2.5.5. Infants aged under 3 months or weighing less than 3 kg","content_type":"text","pages":"98-99","tokens_est":234,"char_count":935,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0384","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.5. Subgroup considerations | 5.2.5.6. Children and adolescents treated for TB in past 2 years","content_type":"text","pages":"99","tokens_est":85,"char_count":338,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0385","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.5. Subgroup considerations | 5.2.5.7. Children and young adolescents with severe pulmonary TB","content_type":"text","pages":"99","tokens_est":75,"char_count":299,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0386","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.6. Treatment of drug-susceptible extrapulmonary TB in children and adolescents","content_type":"text","pages":"99","tokens_est":177,"char_count":706,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0387","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.6. Treatment of drug-susceptible extrapulmonary TB in children and adolescents | 5.2.6.1. Treatment of TB meningitis and osteoarticular TB","content_type":"text","pages":"99","tokens_est":236,"char_count":943,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0388","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.6. Treatment of drug-susceptible extrapulmonary TB in children and adolescents | 5.2.6.1. Treatment of TB meningitis and osteoarticular TB","content_type":"text","pages":"99","tokens_est":78,"char_count":309,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0389","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.6. Treatment of drug-susceptible extrapulmonary TB in children and adolescents | 5.2.6.1. Treatment of TB meningitis and osteoarticular TB","content_type":"text","pages":"99-100","tokens_est":193,"char_count":769,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0390","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.6. Treatment of drug-susceptible extrapulmonary TB in children and adolescents | 5.2.6.1. Treatment of TB meningitis and osteoarticular TB","content_type":"text","pages":"99-100","tokens_est":138,"char_count":552,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0391","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.6. Treatment of drug-susceptible extrapulmonary TB in children and adolescents | 5.2.6.1. Treatment of TB meningitis and osteoarticular TB","content_type":"text","pages":"100","tokens_est":80,"char_count":320,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0392","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.6. Treatment of drug-susceptible extrapulmonary TB in children and adolescents | 5.2.6.1. Treatment of TB meningitis and osteoarticular TB | Box 5.5 WHO recommendations on treatment of TB meningitis and osteoarticular TB in children and adolescents","content_type":"box","pages":"100","caption":"Box 5.5 WHO recommendations on treatment of TB meningitis and osteoarticular TB in children and adolescents","tokens_est":206,"char_count":823,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0393","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.6. Treatment of drug-susceptible extrapulmonary TB in children and adolescents | 5.2.6.1. Treatment of TB meningitis and osteoarticular TB | Box 5.5 WHO recommendations on treatment of TB meningitis and osteoarticular TB in children and adolescents","content_type":"box","pages":"100","caption":"Box 5.5 WHO recommendations on treatment of TB meningitis and osteoarticular TB in children and adolescents","tokens_est":138,"char_count":552,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0394","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.6. Treatment of drug-susceptible extrapulmonary TB in children and adolescents | 5.2.6.1. Treatment of TB meningitis and osteoarticular TB | Table 5.2. Treatment regimens for extrapulmonary TB [a]","content_type":"table","pages":"100-101","caption":"Table 5.2. Treatment regimens for extrapulmonary TB [a]","tokens_est":32,"char_count":1000,"has_attachment":true,"attachment_id":"Table 5.2.","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_5.2..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0395","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.6. Treatment of drug-susceptible extrapulmonary TB in children and adolescents | 5.2.6.2. Implementation considerations: treatment of TB meningitis","content_type":"text","pages":"101","tokens_est":192,"char_count":767,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0396","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.6. Treatment of drug-susceptible extrapulmonary TB in children and adolescents | 5.2.6.2. Implementation considerations: treatment of TB meningitis","content_type":"text","pages":"101","tokens_est":167,"char_count":668,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0397","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.6. Treatment of drug-susceptible extrapulmonary TB in children and adolescents | 5.2.6.2. Implementation considerations: treatment of TB meningitis","content_type":"text","pages":"101","tokens_est":239,"char_count":953,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0398","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.6. Treatment of drug-susceptible extrapulmonary TB in children and adolescents | 5.2.6.2. Implementation considerations: treatment of TB meningitis","content_type":"text","pages":"101","tokens_est":109,"char_count":436,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0399","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.7. Recommended dosing of first-line medicines in children | 5.2.7.1. Recommended dosages for first-line TB medicines | Table 5.3. Recommended dosages of first-line TB medicines for use in children and young adolescents aged 014 years (excluding TB meningitis treated with alternative short intensive regimen)","content_type":"table","pages":"102","caption":"Table 5.3 shows the recommended dosages for first-line TB medicines for children. These dosages are applicable to all children, irrespective of the type of TB (except for TBM treated with the short intensive regimen) and HIV status. They also apply to the 12-month TBM regimen. Evidence on alternative compositions or dosages in the longer TBM regimen has not been assessed by WHO. For implications of interactions between ART and TB medicines, see Section 7.1 on TB/HIV coinfection.","tokens_est":140,"char_count":724,"has_attachment":true,"attachment_id":"Table 5.3","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_5.3.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0400","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.7. Recommended dosing of first-line medicines in children | 5.2.7.1. Recommended dosages for first-line TB medicines | Table 5.4. Recommended interim dosing for the 6-month intensive regimen (6HRZEto) to treat drug-susceptible TB meningitis in children and adolescents","content_type":"table","pages":"102","caption":"Table 5.4 shows the recommended dosages of TB medicines for children with TBM for the 6-month intensive regimen (6HRZEto). The short intensive TBM regimen uses higher doses per kilogram for isoniazid, rifampicin and pyrazinamide. Following on from the recommendation on the short intensive regimen for TBM, WHO convened an expert consultation in October 2021 to discuss how to administer the regimen, given the currently available child-friendly formulations. The experts judged that when using the available isoniazid and rifampicin (HR 50/75 mg) FDC in children, children would be exposed to a higher mg/kg dose of rifampicin (22.530 mg/kg), which was considered acceptable as part of the shorter TBM regimen. The dose of isoniazid should be maintained at 1520 g/kg to avoid overexposure and associated potential toxicity.","tokens_est":231,"char_count":1088,"has_attachment":true,"attachment_id":"Table 5.4","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_5.4.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0401","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.7. Recommended dosing of first-line medicines in children | 5.2.7.2. Dosage tables and formulations for treatment of drug-susceptible TB in children and adolescents","content_type":"text","pages":"103","tokens_est":173,"char_count":689,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0402","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.7. Recommended dosing of first-line medicines in children | 5.2.7.2. Dosage tables and formulations for treatment of drug-susceptible TB in children and adolescents","content_type":"text","pages":"103","tokens_est":130,"char_count":519,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0403","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.7. Recommended dosing of first-line medicines in children | 5.2.7.2. Dosage tables and formulations for treatment of drug-susceptible TB in children and adolescents | Box 5.7 Currently available water-dispersible formulations for treatment of drug-susceptible TB","content_type":"box","pages":"103","caption":"Box 5.7 Currently available water-dispersible formulations for treatment of drug-susceptible TB","tokens_est":117,"char_count":467,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0404","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.7. Recommended dosing of first-line medicines in children | 5.2.7.2. Dosage tables and formulations for treatment of drug-susceptible TB in children and adolescents | Table 5.5. Dosing table for first-line medicines (excluding the short intensive TBM regimen)","content_type":"table","pages":"103-104","caption":"Table 5.5 shows the recommended dosages by weight band (except for the short intensive TBM regimen). Note that dosages should be adjusted based on weight changes during TB treatment (see Section 5.2.12 ).","tokens_est":82,"char_count":1073,"has_attachment":true,"attachment_id":"Table 5.5","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_5.5.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0405","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.7. Recommended dosing of first-line medicines in children | 5.2.7.3. Dosing table for the short intensive TB meningitis regimen","content_type":"text","pages":"104","tokens_est":224,"char_count":896,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0406","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.7. Recommended dosing of first-line medicines in children | 5.2.7.3. Dosing table for the short intensive TB meningitis regimen","content_type":"text","pages":"104","tokens_est":207,"char_count":827,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0407","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.7. Recommended dosing of first-line medicines in children | 5.2.7.3. Dosing table for the short intensive TB meningitis regimen | Table 5.6. Dosing table: Short intensive TB meningitis regimen (6HRZEto)","content_type":"table","pages":"105","caption":"Table 5.6. Dosing table: Short intensive TB meningitis regimen (6HRZEto)","tokens_est":122,"char_count":1339,"has_attachment":true,"attachment_id":"Table 5.6.","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_5.6..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0408","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.7. Recommended dosing of first-line medicines in children | 5.2.7.4. Dosing of first-line medicines in older children and adolescents over 25 kg (excluding the short intensive TB meningitis regimen)","content_type":"text","pages":"107","tokens_est":191,"char_count":764,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0409","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.7. Recommended dosing of first-line medicines in children | 5.2.7.4. Dosing of first-line medicines in older children and adolescents over 25 kg (excluding the short intensive TB meningitis regimen) | Table 5.7. Recommended dosage by weight for children and adolescents weighing over 25 kg using adult fixed-dose combinations (excluding the short intensive TB meningitis regimen)","content_type":"table","pages":"107","caption":"Table 5.7 gives the recommended dosages by weight band using adult FDCs. This table applies to children and adolescents aged under 16 years and weighing 25 kg or over who are being treated with the 4-month 2HRZ(E)/2HR regimen, and to children and adolescents weighing over 25 kg who are being treated with the 6-month 2HRZE/4HR regimen. Adolescents aged 12 years and over who are treated with the 4-month HPZM regimen should receive the dosages shown in Table 5.8 (87) .","tokens_est":144,"char_count":621,"has_attachment":true,"attachment_id":"Table 5.7","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_5.7.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0410","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.7. Recommended dosing of first-line medicines in children | 5.2.7.4. Dosing of first-line medicines in older children and adolescents over 25 kg (excluding the short intensive TB meningitis regimen) | Table 5.8. Recommended dosage by weight for adolescents being treated with the 4-month HPZM regimen ( 2HPMZ/2HPM regimen)","content_type":"table","pages":"107-108","caption":"Table 5.8. Recommended dosage by weight for adolescents being treated with the 4-month HPZM regimen ( 2HPMZ/2HPM regimen)","tokens_est":87,"char_count":358,"has_attachment":true,"attachment_id":"Table 5.8.","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_5.8..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0411","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.7. Recommended dosing of first-line medicines in children | 5.2.7.5. Pyridoxine supplementation","content_type":"text","pages":"108","tokens_est":194,"char_count":775,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0412","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.8. Additional management considerations | 5.2.8.1. Indications for referral and hospitalization","content_type":"text","pages":"108","tokens_est":128,"char_count":509,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0413","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.8. Additional management considerations | 5.2.8.1. Indications for referral and hospitalization","content_type":"text","pages":"108","tokens_est":186,"char_count":744,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0414","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.8. Additional management considerations | 5.2.8.1. Indications for referral and hospitalization | Box 5.8 Indications for referral or hospitalization during TB treatment or evaluation","content_type":"box","pages":"108-109","caption":"Box 5.8 Indications for referral or hospitalization during TB treatment or evaluation","tokens_est":145,"char_count":579,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0415","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.8. Additional management considerations | 5.2.8.2. Indications for adjuvant therapy","content_type":"text","pages":"109","tokens_est":173,"char_count":690,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0416","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.8. Additional management considerations | 5.2.8.2. Indications for adjuvant therapy","content_type":"text","pages":"109","tokens_est":121,"char_count":481,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0417","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.8. Additional management considerations | 5.2.8.2. Indications for adjuvant therapy | Box 5.9 WHO recommendations on adjuvant corticosteroid therapy","content_type":"box","pages":"109","caption":"Box 5.9 WHO recommendations on adjuvant corticosteroid therapy","tokens_est":154,"char_count":614,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0418","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.9. Nutritional support","content_type":"text","pages":"109","tokens_est":162,"char_count":646,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0419","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.10. Management of adverse events from medicines used to treat drug-susceptible TB | 5.2.10.1. Hepatotoxicity","content_type":"text","pages":"109-110","tokens_est":245,"char_count":979,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0420","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.10. Management of adverse events from medicines used to treat drug-susceptible TB | 5.2.10.1. Hepatotoxicity","content_type":"text","pages":"110","tokens_est":165,"char_count":657,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0421","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.10. Management of adverse events from medicines used to treat drug-susceptible TB | 5.2.10.1. Hepatotoxicity","content_type":"text","pages":"110","tokens_est":159,"char_count":634,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0422","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.10. Management of adverse events from medicines used to treat drug-susceptible TB | 5.2.10.1. Hepatotoxicity","content_type":"text","pages":"110","tokens_est":211,"char_count":843,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0423","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.10. Management of adverse events from medicines used to treat drug-susceptible TB | 5.2.10.2. Peripheral neuropathy","content_type":"text","pages":"110","tokens_est":180,"char_count":717,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0424","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.10. Management of adverse events from medicines used to treat drug-susceptible TB | 5.2.10.3. Optic neuritis","content_type":"text","pages":"111","tokens_est":148,"char_count":589,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0425","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.10. Management of adverse events from medicines used to treat drug-susceptible TB | 5.2.10.4. Overview of common adverse events and their management | Table 5.9. Significant and common adverse events of TB medicines by system","content_type":"table","pages":"112-115","caption":"Table 5.9. Significant and common adverse events of TB medicines by system","tokens_est":41,"char_count":355,"has_attachment":true,"attachment_id":"Table 5.9.","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_5.9..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0426","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.11. Treatment adherence","content_type":"text","pages":"116","tokens_est":184,"char_count":734,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0427","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.11. Treatment adherence","content_type":"text","pages":"116","tokens_est":229,"char_count":914,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0428","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.11. Treatment adherence | Box 5.10 Important messages for treatment supporters of children and a dolescents with TB","content_type":"box","pages":"116","caption":"Box 5.10 Important messages for treatment supporters of children and a dolescents with TB","tokens_est":200,"char_count":797,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0429","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.12. Follow-up and monitoring of children and adolescents on TB treatment","content_type":"text","pages":"116-117","tokens_est":200,"char_count":798,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0430","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.12. Follow-up and monitoring of children and adolescents on TB treatment","content_type":"text","pages":"117","tokens_est":208,"char_count":829,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0431","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.12. Follow-up and monitoring of children and adolescents on TB treatment","content_type":"text","pages":"117","tokens_est":228,"char_count":911,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0432","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.12. Follow-up and monitoring of children and adolescents on TB treatment","content_type":"text","pages":"117","tokens_est":139,"char_count":556,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0433","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.12. Follow-up and monitoring of children and adolescents on TB treatment | Box 5.11 School attendance","content_type":"box","pages":"117","caption":"Box 5.11 School attendance","tokens_est":143,"char_count":572,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0434","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.12. Follow-up and monitoring of children and adolescents on TB treatment | 5.2.12.1. Follow-up after treatment completion","content_type":"text","pages":"118","tokens_est":158,"char_count":631,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0435","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.12. Follow-up and monitoring of children and adolescents on TB treatment | 5.2.12.2. Treatment interruption","content_type":"text","pages":"118","tokens_est":105,"char_count":418,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0436","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.12. Follow-up and monitoring of children and adolescents on TB treatment | 5.2.12.2. Treatment interruption | Table 5.10. Management of treatment interruption in children and adolescents on drug susceptible TB treatment","content_type":"table","pages":"118-119","caption":"Table 5.10. Management of treatment interruption in children and adolescents on drug susceptible TB treatment","tokens_est":48,"char_count":190,"has_attachment":true,"attachment_id":"Table 5.10.","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_5.10..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0437","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.12. Follow-up and monitoring of children and adolescents on TB treatment | 5.2.12.2. Treatment interruption","content_type":"text","pages":"119","tokens_est":53,"char_count":210,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0438","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.12. Follow-up and monitoring of children and adolescents on TB treatment | 5.2.12.3. Treatment failure","content_type":"text","pages":"119","tokens_est":172,"char_count":686,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0439","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.12. Follow-up and monitoring of children and adolescents on TB treatment | 5.2.12.3. Treatment failure | Box 5.12 Questions to ask in children and adolescents not responding to or deteriorating on TB treatment","content_type":"box","pages":"119","caption":"Box 5.12 Questions to ask in children and adolescents not responding to or deteriorating on TB treatment","tokens_est":190,"char_count":759,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0440","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.12. Follow-up and monitoring of children and adolescents on TB treatment | 5.2.12.3. Treatment failure","content_type":"text","pages":"119-120","tokens_est":73,"char_count":291,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0441","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.12. Follow-up and monitoring of children and adolescents on TB treatment | 5.2.12.4. Children and adolescents requiring retreatment for TB","content_type":"text","pages":"120","tokens_est":158,"char_count":630,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0442","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.12. Follow-up and monitoring of children and adolescents on TB treatment | 5.2.12.4. Children and adolescents requiring retreatment for TB","content_type":"text","pages":"120","tokens_est":231,"char_count":922,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0443","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.12. Follow-up and monitoring of children and adolescents on TB treatment | 5.2.12.4. Children and adolescents requiring retreatment for TB","content_type":"text","pages":"120","tokens_est":68,"char_count":270,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0444","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.12. Follow-up and monitoring of children and adolescents on TB treatment | 5.2.12.5. Registration of TB treatment in children and adolescents","content_type":"text","pages":"120","tokens_est":183,"char_count":731,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0445","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.12. Follow-up and monitoring of children and adolescents on TB treatment | 5.2.12.5. Registration of TB treatment in children and adolescents","content_type":"text","pages":"120","tokens_est":225,"char_count":898,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0446","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.12. Follow-up and monitoring of children and adolescents on TB treatment | 5.2.12.5. Registration of TB treatment in children and adolescents","content_type":"text","pages":"120-121","tokens_est":234,"char_count":935,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0447","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.12. Follow-up and monitoring of children and adolescents on TB treatment | 5.2.12.5. Registration of TB treatment in children and adolescents","content_type":"text","pages":"121","tokens_est":218,"char_count":869,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0448","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.2. Treatment of drug-susceptible TB in children and adolescents | 5.2.12. Follow-up and monitoring of children and adolescents on TB treatment | 5.2.12.5. Registration of TB treatment in children and adolescents","content_type":"text","pages":"121","tokens_est":60,"char_count":238,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0449","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents","content_type":"text","pages":"121","tokens_est":115,"char_count":457,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0450","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.1. Identifying children who should be treated for multidrug-resistant and rifampicin-resistant TB","content_type":"text","pages":"121-122","tokens_est":214,"char_count":854,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0451","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.1. Identifying children who should be treated for multidrug-resistant and rifampicin-resistant TB","content_type":"text","pages":"122","tokens_est":120,"char_count":480,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0452","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.1. Identifying children who should be treated for multidrug-resistant and rifampicin-resistant TB","content_type":"text","pages":"122","tokens_est":157,"char_count":628,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0453","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.1. Identifying children who should be treated for multidrug-resistant and rifampicin-resistant TB","content_type":"text","pages":"122","tokens_est":220,"char_count":879,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0454","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.1. Identifying children who should be treated for multidrug-resistant and rifampicin-resistant TB","content_type":"text","pages":"122","tokens_est":77,"char_count":305,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0455","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.1. Identifying children who should be treated for multidrug-resistant and rifampicin-resistant TB","content_type":"text","pages":"122","tokens_est":230,"char_count":917,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0456","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.1. Overview and approach to selecting a treatment regimen","content_type":"text","pages":"122-123","tokens_est":221,"char_count":884,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0457","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.1. Overview and approach to selecting a treatment regimen","content_type":"text","pages":"123","tokens_est":128,"char_count":509,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0458","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.1. Overview and approach to selecting a treatment regimen | Table 5.11. WHO drug groupings","content_type":"table","pages":"123","caption":"Table 5.11. WHO drug groupings","tokens_est":17,"char_count":651,"has_attachment":true,"attachment_id":"Table 5.11.","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_5.11..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0459","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.1. Overview and approach to selecting a treatment regimen","content_type":"text","pages":"123-124","tokens_est":203,"char_count":812,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0460","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.1. Overview and approach to selecting a treatment regimen","content_type":"text","pages":"124","tokens_est":204,"char_count":814,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0461","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.1. Overview and approach to selecting a treatment regimen","content_type":"text","pages":"124","tokens_est":237,"char_count":948,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0462","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.1. Overview and approach to selecting a treatment regimen","content_type":"text","pages":"124","tokens_est":116,"char_count":462,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0463","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.1. Overview and approach to selecting a treatment regimen","content_type":"text","pages":"124-125","tokens_est":207,"char_count":825,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0464","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.1. Overview and approach to selecting a treatment regimen","content_type":"text","pages":"125","tokens_est":235,"char_count":937,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0465","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.1. Overview and approach to selecting a treatment regimen","content_type":"text","pages":"125","tokens_est":196,"char_count":784,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0466","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.1. Overview and approach to selecting a treatment regimen","content_type":"text","pages":"125","tokens_est":178,"char_count":711,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0467","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.1. Overview and approach to selecting a treatment regimen","content_type":"text","pages":"125","tokens_est":180,"char_count":720,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0468","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.2. Shorter all-oral bedaquiline-containing regimen for multidrug-resistant and rifampicin-resistant TB in children","content_type":"text","pages":"126","tokens_est":232,"char_count":926,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0469","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.2. Shorter all-oral bedaquiline-containing regimen for multidrug-resistant and rifampicin-resistant TB in children","content_type":"text","pages":"126","tokens_est":176,"char_count":703,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0470","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.2. Shorter all-oral bedaquiline-containing regimen for multidrug-resistant and rifampicin-resistant TB in children","content_type":"text","pages":"126","tokens_est":158,"char_count":631,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0471","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.2. Shorter all-oral bedaquiline-containing regimen for multidrug-resistant and rifampicin-resistant TB in children | 1. High-dose isoniazid : Months 1-4; extend months 5 and 6 if still smear-/culture-positive after 4 months of treatment .","content_type":"text","pages":"126","tokens_est":177,"char_count":706,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0472","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.2. Shorter all-oral bedaquiline-containing regimen for multidrug-resistant and rifampicin-resistant TB in children | 1. High-dose isoniazid : Months 1-4; extend months 5 and 6 if still smear-/culture-positive after 4 months of treatment .","content_type":"text","pages":"127","tokens_est":199,"char_count":796,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0473","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.2. Shorter all-oral bedaquiline-containing regimen for multidrug-resistant and rifampicin-resistant TB in children | 1. High-dose isoniazid : Months 1-4; extend months 5 and 6 if still smear-/culture-positive after 4 months of treatment .","content_type":"text","pages":"127","tokens_est":189,"char_count":756,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0474","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.2. Shorter all-oral bedaquiline-containing regimen for multidrug-resistant and rifampicin-resistant TB in children | 1. High-dose isoniazid : Months 1-4; extend months 5 and 6 if still smear-/culture-positive after 4 months of treatment .","content_type":"text","pages":"127","tokens_est":187,"char_count":745,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0475","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.3. Longer individualized regimens for children with multidrug-resistant and rifampicin-resistant TB who are not eligible for the standardized all-oral bedaquiline-containing regimen","content_type":"text","pages":"127","tokens_est":231,"char_count":924,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0476","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.3. Longer individualized regimens for children with multidrug-resistant and rifampicin-resistant TB who are not eligible for the standardized all-oral bedaquiline-containing regimen","content_type":"text","pages":"127","tokens_est":224,"char_count":895,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0477","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.3. Longer individualized regimens for children with multidrug-resistant and rifampicin-resistant TB who are not eligible for the standardized all-oral bedaquiline-containing regimen","content_type":"text","pages":"127-128","tokens_est":111,"char_count":441,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0478","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.3. Longer individualized regimens for children with multidrug-resistant and rifampicin-resistant TB who are not eligible for the standardized all-oral bedaquiline-containing regimen","content_type":"text","pages":"128","tokens_est":217,"char_count":866,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0479","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.3. Longer individualized regimens for children with multidrug-resistant and rifampicin-resistant TB who are not eligible for the standardized all-oral bedaquiline-containing regimen","content_type":"text","pages":"128","tokens_est":129,"char_count":514,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0480","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.3. Longer individualized regimens for children with multidrug-resistant and rifampicin-resistant TB who are not eligible for the standardized all-oral bedaquiline-containing regimen","content_type":"text","pages":"128","tokens_est":194,"char_count":773,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0481","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.3. Longer individualized regimens for children with multidrug-resistant and rifampicin-resistant TB who are not eligible for the standardized all-oral bedaquiline-containing regimen","content_type":"text","pages":"128","tokens_est":130,"char_count":519,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0482","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.3. Longer individualized regimens for children with multidrug-resistant and rifampicin-resistant TB who are not eligible for the standardized all-oral bedaquiline-containing regimen","content_type":"text","pages":"128","tokens_est":246,"char_count":983,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0483","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.3. Longer individualized regimens for children with multidrug-resistant and rifampicin-resistant TB who are not eligible for the standardized all-oral bedaquiline-containing regimen","content_type":"text","pages":"128","tokens_est":202,"char_count":806,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0484","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.3. Longer individualized regimens for children with multidrug-resistant and rifampicin-resistant TB who are not eligible for the standardized all-oral bedaquiline-containing regimen","content_type":"text","pages":"128","tokens_est":209,"char_count":833,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0485","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.3. Longer individualized regimens for children with multidrug-resistant and rifampicin-resistant TB who are not eligible for the standardized all-oral bedaquiline-containing regimen","content_type":"text","pages":"128-129","tokens_est":209,"char_count":834,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0486","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.3. Longer individualized regimens for children with multidrug-resistant and rifampicin-resistant TB who are not eligible for the standardized all-oral bedaquiline-containing regimen | Box 5.15 Extent of disease","content_type":"box","pages":"129","caption":"Box 5.15 Extent of disease","tokens_est":140,"char_count":559,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0487","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.4. Practical approach to designing individualized multidrug-resistant and rifampicin-resistant TB treatment regimens | Table 5.12. Possible individualized multidrug-resistant and rifampicin-resistant TB treatment regimens for children of all ages and adolescents, by fluoroquinolone resistance and disease severity","content_type":"table","pages":"129","caption":"Table 5.12 summarizes possible individualized MDR/RR-TB treatment regimens for children of all ages and adolescents based on the above-described principles and taking into consideration fluoroquinolone and other resistance and eligibility for the shorter regimen.","tokens_est":85,"char_count":1318,"has_attachment":true,"attachment_id":"Table 5.12","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_5.12.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0488","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.4. Practical approach to designing individualized multidrug-resistant and rifampicin-resistant TB treatment regimens | The bedaquiline, pretomanid and linezolid regimen for multidrug-resistant TB with additional fluoroquinolone resistance in adolescents aged 14 years and over","content_type":"text","pages":"130","tokens_est":189,"char_count":754,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0489","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.4. Practical approach to designing individualized multidrug-resistant and rifampicin-resistant TB treatment regimens | Box 5.16 WHO recommendation on the BPaL regimen","content_type":"box","pages":"130","caption":"Box 5.16 WHO recommendation on the BPaL regimen","tokens_est":164,"char_count":653,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0490","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.4. Practical approach to designing individualized multidrug-resistant and rifampicin-resistant TB treatment regimens","content_type":"text","pages":"130","tokens_est":209,"char_count":836,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0491","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.4. Practical approach to designing individualized multidrug-resistant and rifampicin-resistant TB treatment regimens","content_type":"text","pages":"130","tokens_est":131,"char_count":521,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0492","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.5. Special considerations: TB meningitis","content_type":"text","pages":"131","tokens_est":126,"char_count":502,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0493","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.5. Special considerations: TB meningitis | Table 5.13. Cerebrospinal fluid penetration of TB medicines used for treatment of multidrug-resistant and rifampicin-resistant TB","content_type":"table","pages":"131","caption":"Table 5.13. Cerebrospinal fluid penetration of TB medicines used for treatment of multidrug-resistant and rifampicin-resistant TB","tokens_est":42,"char_count":176,"has_attachment":true,"attachment_id":"Table 5.13.","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_5.13..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0494","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.5. Special considerations: TB meningitis","content_type":"text","pages":"131","tokens_est":175,"char_count":697,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0495","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.5. Special considerations: TB meningitis","content_type":"text","pages":"131","tokens_est":178,"char_count":710,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0496","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.6. Special considerations: TB/HIV coinfection","content_type":"text","pages":"131-132","tokens_est":219,"char_count":876,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0497","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.2. Multidrug-resistant and rifampicin-resistant TB treatment regimens for children and adolescents | 5.3.2.6. Special considerations: TB/HIV coinfection","content_type":"text","pages":"132","tokens_est":170,"char_count":677,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0498","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.3. Dosing and formulations of second-line TB medicines in children and young adolescents | 5.3.3.1. Dosing","content_type":"text","pages":"132","tokens_est":190,"char_count":759,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0499","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.3. Dosing and formulations of second-line TB medicines in children and young adolescents | 5.3.3.1. Dosing","content_type":"text","pages":"132","tokens_est":109,"char_count":433,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0500","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.3. Dosing and formulations of second-line TB medicines in children and young adolescents | 5.3.3.2. Formulations","content_type":"text","pages":"132","tokens_est":240,"char_count":959,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0501","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.3. Dosing and formulations of second-line TB medicines in children and young adolescents | 5.3.3.2. Formulations","content_type":"text","pages":"132","tokens_est":66,"char_count":262,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0502","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.3. Dosing and formulations of second-line TB medicines in children and young adolescents | 5.3.3.2. Formulations","content_type":"text","pages":"132-133","tokens_est":212,"char_count":845,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0503","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.3. Dosing and formulations of second-line TB medicines in children and young adolescents | 5.3.3.2. Formulations","content_type":"text","pages":"133","tokens_est":190,"char_count":759,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0504","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.4. Monitoring of children and adolescents on multidrugresistant and rifampicin-resistant TB treatment","content_type":"text","pages":"133","tokens_est":96,"char_count":383,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0505","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.4. Monitoring of children and adolescents on multidrugresistant and rifampicin-resistant TB treatment | 5.3.4.1. Monitoring response to treatment","content_type":"text","pages":"133","tokens_est":191,"char_count":763,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0506","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.4. Monitoring of children and adolescents on multidrugresistant and rifampicin-resistant TB treatment | 5.3.4.1. Monitoring response to treatment","content_type":"text","pages":"133","tokens_est":171,"char_count":682,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0507","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.4. Monitoring of children and adolescents on multidrugresistant and rifampicin-resistant TB treatment | 5.3.4.1. Monitoring response to treatment","content_type":"text","pages":"133-134","tokens_est":106,"char_count":424,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0508","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.4. Monitoring of children and adolescents on multidrugresistant and rifampicin-resistant TB treatment | 5.3.4.2. Monitoring for adverse effects","content_type":"text","pages":"134","tokens_est":60,"char_count":237,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0509","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.4. Monitoring of children and adolescents on multidrugresistant and rifampicin-resistant TB treatment | 5.3.4.2. Monitoring for adverse effects | Table 5.14. Adverse effects of medicines used for multidrug-resistant and rifampicin resistant TB by group","content_type":"table","pages":"134-136","caption":"Table 5.14 summarizes the most common adverse effects of the medicines used for MDR/RR-TB.","tokens_est":33,"char_count":132,"has_attachment":true,"attachment_id":"Table 5.14","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_5.14.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0510","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.4. Monitoring of children and adolescents on multidrugresistant and rifampicin-resistant TB treatment | 5.3.4.2. Monitoring for adverse effects","content_type":"text","pages":"136","tokens_est":206,"char_count":822,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0511","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.4. Monitoring of children and adolescents on multidrugresistant and rifampicin-resistant TB treatment | 5.3.4.2. Monitoring for adverse effects | Electrocardiogram monitoring","content_type":"text","pages":"136-137","tokens_est":182,"char_count":726,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0512","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.4. Monitoring of children and adolescents on multidrugresistant and rifampicin-resistant TB treatment | 5.3.4.2. Monitoring for adverse effects | Electrocardiogram monitoring","content_type":"text","pages":"137","tokens_est":151,"char_count":601,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0513","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.4. Monitoring of children and adolescents on multidrugresistant and rifampicin-resistant TB treatment | 5.3.4.2. Monitoring for adverse effects | Electrocardiogram monitoring","content_type":"text","pages":"137","tokens_est":115,"char_count":459,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0514","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.4. Monitoring of children and adolescents on multidrugresistant and rifampicin-resistant TB treatment | 5.3.4.2. Monitoring for adverse effects | Electrocardiogram monitoring","content_type":"text","pages":"137","tokens_est":171,"char_count":682,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0515","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.4. Monitoring of children and adolescents on multidrugresistant and rifampicin-resistant TB treatment | 5.3.4.2. Monitoring for adverse effects | Full blood count and differential white cell count","content_type":"text","pages":"137","tokens_est":129,"char_count":516,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0516","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.4. Monitoring of children and adolescents on multidrugresistant and rifampicin-resistant TB treatment | 5.3.4.2. Monitoring for adverse effects | Full blood count and differential white cell count","content_type":"text","pages":"137","tokens_est":220,"char_count":878,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0517","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.4. Monitoring of children and adolescents on multidrugresistant and rifampicin-resistant TB treatment | 5.3.4.2. Monitoring for adverse effects | Full blood count and differential white cell count","content_type":"text","pages":"137","tokens_est":128,"char_count":511,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0518","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.4. Monitoring of children and adolescents on multidrugresistant and rifampicin-resistant TB treatment | 5.3.4.2. Monitoring for adverse effects | Neuropsychiatric side-effects","content_type":"text","pages":"137-138","tokens_est":79,"char_count":313,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0519","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.4. Monitoring of children and adolescents on multidrugresistant and rifampicin-resistant TB treatment | 5.3.4.2. Monitoring for adverse effects | Thyroid function testing","content_type":"text","pages":"138","tokens_est":170,"char_count":680,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0520","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.4. Monitoring of children and adolescents on multidrugresistant and rifampicin-resistant TB treatment | 5.3.4.2. Monitoring for adverse effects | Assessments for hepatotoxicity","content_type":"text","pages":"138","tokens_est":146,"char_count":583,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0521","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.4. Monitoring of children and adolescents on multidrugresistant and rifampicin-resistant TB treatment | 5.3.4.2. Monitoring for adverse effects | Assessments for hepatotoxicity","content_type":"text","pages":"138","tokens_est":168,"char_count":671,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0522","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.4. Monitoring of children and adolescents on multidrugresistant and rifampicin-resistant TB treatment | 5.3.4.2. Monitoring for adverse effects | Social support and adherence measures","content_type":"text","pages":"138","tokens_est":230,"char_count":919,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0523","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.4. Monitoring of children and adolescents on multidrugresistant and rifampicin-resistant TB treatment | 5.3.4.2. Monitoring for adverse effects | Social support and adherence measures","content_type":"text","pages":"138","tokens_est":212,"char_count":848,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0524","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.4. Monitoring of children and adolescents on multidrugresistant and rifampicin-resistant TB treatment | 5.3.4.2. Monitoring for adverse effects | Social support and adherence measures","content_type":"text","pages":"138","tokens_est":238,"char_count":952,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0525","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.4. Monitoring of children and adolescents on multidrugresistant and rifampicin-resistant TB treatment | 5.3.4.2. Monitoring for adverse effects | Social support and adherence measures","content_type":"text","pages":"138","tokens_est":210,"char_count":838,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0526","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.3. Treatment of multidrug-resistant and rifampicin resistant TB in children and adolescents | 5.3.4. Monitoring of children and adolescents on multidrugresistant and rifampicin-resistant TB treatment | 5.3.4.2. Monitoring for adverse effects | Social support and adherence measures","content_type":"text","pages":"138","tokens_est":53,"char_count":212,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0527","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.4. Practical guidance for assessment and management of post-TB health in children and adolescents | 5.4.1. Post-TB health","content_type":"text","pages":"138-139","tokens_est":196,"char_count":781,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0528","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.4. Practical guidance for assessment and management of post-TB health in children and adolescents | 5.4.1. Post-TB health","content_type":"text","pages":"139","tokens_est":217,"char_count":866,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0529","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.4. Practical guidance for assessment and management of post-TB health in children and adolescents | 5.4.2. Post-TB meningitis in children and adolescents","content_type":"text","pages":"139","tokens_est":206,"char_count":824,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0530","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.4. Practical guidance for assessment and management of post-TB health in children and adolescents | 5.4.2. Post-TB meningitis in children and adolescents","content_type":"text","pages":"139","tokens_est":84,"char_count":336,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0531","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.4. Practical guidance for assessment and management of post-TB health in children and adolescents | 5.4.2. Post-TB meningitis in children and adolescents","content_type":"text","pages":"139","tokens_est":197,"char_count":787,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0532","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.4. Practical guidance for assessment and management of post-TB health in children and adolescents | 5.4.2. Post-TB meningitis in children and adolescents","content_type":"text","pages":"139","tokens_est":197,"char_count":787,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0533","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.4. Practical guidance for assessment and management of post-TB health in children and adolescents | 5.4.2. Post-TB meningitis in children and adolescents","content_type":"text","pages":"139-140","tokens_est":81,"char_count":324,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0534","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.4. Practical guidance for assessment and management of post-TB health in children and adolescents | 5.4.2. Post-TB meningitis in children and adolescents | Table 5.15. End-of-treatment clinical assessment in children with TB meningitis","content_type":"table","pages":"140","caption":"Table 5.15 summarizes end-of-treatment clinical assessment in children with TBM.","tokens_est":33,"char_count":139,"has_attachment":true,"attachment_id":"Table 5.15","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_5.15.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0535","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.4. Practical guidance for assessment and management of post-TB health in children and adolescents | 5.4.3. Post-TB lung disease in children and adolescents","content_type":"text","pages":"140","tokens_est":117,"char_count":467,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0536","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.4. Practical guidance for assessment and management of post-TB health in children and adolescents | 5.4.3. Post-TB lung disease in children and adolescents","content_type":"text","pages":"140","tokens_est":165,"char_count":657,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0537","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.4. Practical guidance for assessment and management of post-TB health in children and adolescents | 5.4.3. Post-TB lung disease in children and adolescents","content_type":"text","pages":"140-141","tokens_est":249,"char_count":996,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0538","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.4. Practical guidance for assessment and management of post-TB health in children and adolescents | 5.4.3. Post-TB lung disease in children and adolescents","content_type":"text","pages":"141","tokens_est":105,"char_count":418,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0539","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.4. Practical guidance for assessment and management of post-TB health in children and adolescents | 5.4.3. Post-TB lung disease in children and adolescents | Table 5.16. End-of-treatment assessment of post-TB lung disease in children","content_type":"table","pages":"141","caption":"Table 5.16. End-of-treatment assessment of post-TB lung disease in children","tokens_est":29,"char_count":123,"has_attachment":true,"attachment_id":"Table 5.16.","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_5.16..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0540","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.4. Practical guidance for assessment and management of post-TB health in children and adolescents | 5.4.3. Post-TB lung disease in children and adolescents","content_type":"text","pages":"141","tokens_est":206,"char_count":824,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0541","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.4. Practical guidance for assessment and management of post-TB health in children and adolescents | 5.4.4. Post-TB osteoarticular disease in children and adolescents","content_type":"text","pages":"141","tokens_est":70,"char_count":280,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0542","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.4. Practical guidance for assessment and management of post-TB health in children and adolescents | 5.4.4. Post-TB osteoarticular disease in children and adolescents","content_type":"text","pages":"141-142","tokens_est":236,"char_count":941,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0543","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.4. Practical guidance for assessment and management of post-TB health in children and adolescents | 5.4.4. Post-TB osteoarticular disease in children and adolescents | Table 5.17. Practical guidance to mitigate and assess post-TB morbidity in children with osteoarticular TB","content_type":"table","pages":"142","caption":"Table 5.17. Practical guidance to mitigate and assess post-TB morbidity in children with osteoarticular TB","tokens_est":46,"char_count":192,"has_attachment":true,"attachment_id":"Table 5.17.","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_5.17..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0544","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"5. Treatment of drug-susceptible and drug-resistant pulmonary and extrapulmonary TB in children and adolescents | 5.4. Practical guidance for assessment and management of post-TB health in children and adolescents | 5.4.5. Post-TB health-related quality of life","content_type":"text","pages":"142","tokens_est":152,"char_count":607,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0545","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.1. Introduction","content_type":"text","pages":"142","tokens_est":176,"char_count":701,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0546","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.1. Introduction","content_type":"text","pages":"142-143","tokens_est":203,"char_count":811,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0547","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.1. Introduction | Box 6.1 Key action number 8 from the 2018 Roadmap towards Ending TB in Children and Adolescents (5)","content_type":"box","pages":"143","caption":"Box 6.1 Key action number 8 from the 2018 Roadmap towards Ending TB in Children and Adolescents (5)","tokens_est":231,"char_count":922,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0548","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.1. Introduction | Box 6.1 Key action number 8 from the 2018 Roadmap towards Ending TB in Children and Adolescents (5)","content_type":"box","pages":"143","caption":"Box 6.1 Key action number 8 from the 2018 Roadmap towards Ending TB in Children and Adolescents (5)","tokens_est":216,"char_count":862,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0549","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.1. Introduction | Box 6.1 Key action number 8 from the 2018 Roadmap towards Ending TB in Children and Adolescents (5)","content_type":"box","pages":"143","caption":"Box 6.1 Key action number 8 from the 2018 Roadmap towards Ending TB in Children and Adolescents (5)","tokens_est":77,"char_count":308,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0550","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.1. Introduction","content_type":"text","pages":"143-144","tokens_est":199,"char_count":793,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0551","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.1. Introduction | Box 6.2 WHO recommendations on models of TB care for children and adolescents","content_type":"box","pages":"144","caption":"Box 6.2 WHO recommendations on models of TB care for children and adolescents","tokens_est":133,"char_count":529,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0552","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.1. Introduction | Box 6.2 WHO recommendations on models of TB care for children and adolescents","content_type":"box","pages":"144","caption":"Box 6.2 WHO recommendations on models of TB care for children and adolescents","tokens_est":232,"char_count":925,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0553","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.1. Introduction | Box 6.2 WHO recommendations on models of TB care for children and adolescents","content_type":"box","pages":"144","caption":"Box 6.2 WHO recommendations on models of TB care for children and adolescents","tokens_est":248,"char_count":990,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0554","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.1. Introduction | Box 6.2 WHO recommendations on models of TB care for children and adolescents","content_type":"box","pages":"144-145","caption":"Box 6.2 WHO recommendations on models of TB care for children and adolescents","tokens_est":231,"char_count":921,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0555","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.1. Introduction | Box 6.2 WHO recommendations on models of TB care for children and adolescents","content_type":"box","pages":"145","caption":"Box 6.2 WHO recommendations on models of TB care for children and adolescents","tokens_est":239,"char_count":955,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0556","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.1. Introduction | Box 6.2 WHO recommendations on models of TB care for children and adolescents","content_type":"box","pages":"145","caption":"Box 6.2 WHO recommendations on models of TB care for children and adolescents","tokens_est":208,"char_count":829,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0557","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.1. Introduction | Box 6.2 WHO recommendations on models of TB care for children and adolescents","content_type":"box","pages":"145","caption":"Box 6.2 WHO recommendations on models of TB care for children and adolescents","tokens_est":239,"char_count":955,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0558","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.1. Introduction | Box 6.2 WHO recommendations on models of TB care for children and adolescents","content_type":"box","pages":"145","caption":"Box 6.2 WHO recommendations on models of TB care for children and adolescents","tokens_est":144,"char_count":574,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0559","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services","content_type":"text","pages":"145","tokens_est":161,"char_count":643,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0560","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services","content_type":"text","pages":"145-146","tokens_est":244,"char_count":975,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0561","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services","content_type":"text","pages":"146","tokens_est":185,"char_count":740,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0562","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations","content_type":"text","pages":"146","tokens_est":161,"char_count":642,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0563","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations","content_type":"text","pages":"146","tokens_est":106,"char_count":421,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0564","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.1. Stakeholder engagement","content_type":"text","pages":"146","tokens_est":187,"char_count":748,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0565","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.1. Stakeholder engagement","content_type":"text","pages":"146-147","tokens_est":124,"char_count":495,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0566","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.2. Regulatory framework and policy guidance","content_type":"text","pages":"147","tokens_est":140,"char_count":559,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0567","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.2. Regulatory framework and policy guidance","content_type":"text","pages":"147","tokens_est":189,"char_count":754,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0568","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.3. Health workforce","content_type":"text","pages":"147","tokens_est":139,"char_count":553,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0569","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.3. Health workforce | Table 6.1. Health care workers tasks at different levels of care","content_type":"table","pages":"147-149","caption":"Table 6.1 provides examples of the tasks related to health care providers at different levels of the health care system (6) .","tokens_est":38,"char_count":159,"has_attachment":true,"attachment_id":"Table 6.1","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_6.1.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0570","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.4. Treatment support","content_type":"text","pages":"149","tokens_est":244,"char_count":975,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0571","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.4. Treatment support","content_type":"text","pages":"149","tokens_est":44,"char_count":175,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0572","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.4. Treatment support","content_type":"text","pages":"149-150","tokens_est":77,"char_count":307,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0573","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.5. Recording and reporting","content_type":"text","pages":"150","tokens_est":96,"char_count":382,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0574","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.6. Access to diagnostic supplies and child-friendly formulations of TB medicines","content_type":"text","pages":"150","tokens_est":101,"char_count":404,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0575","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.7. Resource requirements","content_type":"text","pages":"150","tokens_est":140,"char_count":559,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0576","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.7. Resource requirements | Table 6.2. Aspects to consider when planning for the provision of decentralized, family centred , integrated TB services","content_type":"table","pages":"150-152","caption":"Table 6.2 summarizes aspects to consider when planning for the provision of decentralized, familycentred, integrated TB services. These services are in addition to (and do not replace) centralized or specialized TB services.","tokens_est":67,"char_count":275,"has_attachment":true,"attachment_id":"Table 6.2","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_6.2.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0577","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.8. Opportunities for integration of TB services into other services","content_type":"text","pages":"152","tokens_est":172,"char_count":688,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0578","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.8. Opportunities for integration of TB services into other services","content_type":"text","pages":"152","tokens_est":182,"char_count":728,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0579","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.8. Opportunities for integration of TB services into other services","content_type":"text","pages":"152","tokens_est":228,"char_count":910,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0580","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.8. Opportunities for integration of TB services into other services | Table 6.3. Opportunities for integrating TB services into other services","content_type":"table","pages":"152-154","caption":"Table 6.3. Opportunities for integrating TB services into other services","tokens_est":43,"char_count":179,"has_attachment":true,"attachment_id":"Table 6.3.","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_6.3..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0581","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.9. Socioeconomic impact of TB on children, adolescents and families","content_type":"text","pages":"154","tokens_est":203,"char_count":812,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0582","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.9. Socioeconomic impact of TB on children, adolescents and families","content_type":"text","pages":"154","tokens_est":161,"char_count":644,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0583","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.9. Socioeconomic impact of TB on children, adolescents and families","content_type":"text","pages":"154","tokens_est":208,"char_count":831,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0584","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.9. Socioeconomic impact of TB on children, adolescents and families","content_type":"text","pages":"154","tokens_est":188,"char_count":749,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0585","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.9. Socioeconomic impact of TB on children, adolescents and families","content_type":"text","pages":"154-155","tokens_est":248,"char_count":990,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0586","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.9. Socioeconomic impact of TB on children, adolescents and families","content_type":"text","pages":"155","tokens_est":211,"char_count":841,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0587","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.10. Examples of country experiences in development of family-centred, decentralized and integrated TB services for children and adolescents | Box 6.3 Finding the missing children affected by TB: preliminary data from the Catalyzing Pediatric Tuberculosis Innovation project experience in sub- Saharan African countries (unpublished data, 2021)","content_type":"box","pages":"155","caption":"Box 6.3 Finding the missing children affected by TB: preliminary data from the Catalyzing Pediatric Tuberculosis Innovation project experience in sub- Saharan African countries (unpublished data, 2021)","tokens_est":212,"char_count":846,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0588","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.10. Examples of country experiences in development of family-centred, decentralized and integrated TB services for children and adolescents | Box 6.3 Finding the missing children affected by TB: preliminary data from the Catalyzing Pediatric Tuberculosis Innovation project experience in sub- Saharan African countries (unpublished data, 2021)","content_type":"box","pages":"155","caption":"Box 6.3 Finding the missing children affected by TB: preliminary data from the Catalyzing Pediatric Tuberculosis Innovation project experience in sub- Saharan African countries (unpublished data, 2021)","tokens_est":230,"char_count":917,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0589","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.10. Examples of country experiences in development of family-centred, decentralized and integrated TB services for children and adolescents | Box 6.3 Finding the missing children affected by TB: preliminary data from the Catalyzing Pediatric Tuberculosis Innovation project experience in sub- Saharan African countries (unpublished data, 2021)","content_type":"box","pages":"155-156","caption":"Box 6.3 Finding the missing children affected by TB: preliminary data from the Catalyzing Pediatric Tuberculosis Innovation project experience in sub- Saharan African countries (unpublished data, 2021)","tokens_est":115,"char_count":460,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0590","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.10. Examples of country experiences in development of family-centred, decentralized and integrated TB services for children and adolescents | Box 6.3 Finding the missing children affected by TB: preliminary data from the Catalyzing Pediatric Tuberculosis Innovation project experience in sub- Saharan African countries (unpublished data, 2021)","content_type":"box","pages":"156","caption":"Box 6.3 Finding the missing children affected by TB: preliminary data from the Catalyzing Pediatric Tuberculosis Innovation project experience in sub- Saharan African countries (unpublished data, 2021)","tokens_est":240,"char_count":960,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0591","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.10. Examples of country experiences in development of family-centred, decentralized and integrated TB services for children and adolescents | Box 6.3 Finding the missing children affected by TB: preliminary data from the Catalyzing Pediatric Tuberculosis Innovation project experience in sub- Saharan African countries (unpublished data, 2021)","content_type":"box","pages":"156","caption":"Box 6.3 Finding the missing children affected by TB: preliminary data from the Catalyzing Pediatric Tuberculosis Innovation project experience in sub- Saharan African countries (unpublished data, 2021)","tokens_est":109,"char_count":435,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0592","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.10. Examples of country experiences in development of family-centred, decentralized and integrated TB services for children and adolescents | Box 6.3 Finding the missing children affected by TB: preliminary data from the Catalyzing Pediatric Tuberculosis Innovation project experience in sub- Saharan African countries (unpublished data, 2021)","content_type":"box","pages":"156","caption":"Box 6.3 Finding the missing children affected by TB: preliminary data from the Catalyzing Pediatric Tuberculosis Innovation project experience in sub- Saharan African countries (unpublished data, 2021)","tokens_est":192,"char_count":767,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0593","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.10. Examples of country experiences in development of family-centred, decentralized and integrated TB services for children and adolescents | Box 6.3 Finding the missing children affected by TB: preliminary data from the Catalyzing Pediatric Tuberculosis Innovation project experience in sub- Saharan African countries (unpublished data, 2021)","content_type":"box","pages":"156","caption":"Box 6.3 Finding the missing children affected by TB: preliminary data from the Catalyzing Pediatric Tuberculosis Innovation project experience in sub- Saharan African countries (unpublished data, 2021)","tokens_est":179,"char_count":714,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0594","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.10. Examples of country experiences in development of family-centred, decentralized and integrated TB services for children and adolescents | Box 6.4 TB-Speed project: strengthening paediatric TB services for enhanced early detection (unpublished data, 2021)","content_type":"box","pages":"156-157","caption":"Box 6.4 TB-Speed project: strengthening paediatric TB services for enhanced early detection (unpublished data, 2021)","tokens_est":238,"char_count":952,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0595","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.10. Examples of country experiences in development of family-centred, decentralized and integrated TB services for children and adolescents | Box 6.4 TB-Speed project: strengthening paediatric TB services for enhanced early detection (unpublished data, 2021)","content_type":"box","pages":"157","caption":"Box 6.4 TB-Speed project: strengthening paediatric TB services for enhanced early detection (unpublished data, 2021)","tokens_est":230,"char_count":917,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0596","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.10. Examples of country experiences in development of family-centred, decentralized and integrated TB services for children and adolescents | Box 6.4 TB-Speed project: strengthening paediatric TB services for enhanced early detection (unpublished data, 2021)","content_type":"box","pages":"157","caption":"Box 6.4 TB-Speed project: strengthening paediatric TB services for enhanced early detection (unpublished data, 2021)","tokens_est":225,"char_count":898,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0597","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.10. Examples of country experiences in development of family-centred, decentralized and integrated TB services for children and adolescents | Box 6.4 TB-Speed project: strengthening paediatric TB services for enhanced early detection (unpublished data, 2021)","content_type":"box","pages":"157","caption":"Box 6.4 TB-Speed project: strengthening paediatric TB services for enhanced early detection (unpublished data, 2021)","tokens_est":243,"char_count":971,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0598","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.10. Examples of country experiences in development of family-centred, decentralized and integrated TB services for children and adolescents | Box 6.4 TB-Speed project: strengthening paediatric TB services for enhanced early detection (unpublished data, 2021)","content_type":"box","pages":"157","caption":"Box 6.4 TB-Speed project: strengthening paediatric TB services for enhanced early detection (unpublished data, 2021)","tokens_est":83,"char_count":329,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0599","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.10. Examples of country experiences in development of family-centred, decentralized and integrated TB services for children and adolescents | Box 6.5 The DEcentralise TB services and Engage Communities to Transform lives of Children with TB project (158)","content_type":"box","pages":"157-158","caption":"Box 6.5 The DEcentralise TB services and Engage Communities to Transform lives of Children with TB project (158)","tokens_est":208,"char_count":830,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0600","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.10. Examples of country experiences in development of family-centred, decentralized and integrated TB services for children and adolescents | Box 6.5 The DEcentralise TB services and Engage Communities to Transform lives of Children with TB project (158)","content_type":"box","pages":"158","caption":"Box 6.5 The DEcentralise TB services and Engage Communities to Transform lives of Children with TB project (158)","tokens_est":150,"char_count":598,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0601","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.10. Examples of country experiences in development of family-centred, decentralized and integrated TB services for children and adolescents | Box 6.5 The DEcentralise TB services and Engage Communities to Transform lives of Children with TB project (158)","content_type":"box","pages":"158","caption":"Box 6.5 The DEcentralise TB services and Engage Communities to Transform lives of Children with TB project (158)","tokens_est":227,"char_count":905,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0602","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.10. Examples of country experiences in development of family-centred, decentralized and integrated TB services for children and adolescents | Box 6.5 The DEcentralise TB services and Engage Communities to Transform lives of Children with TB project (158)","content_type":"box","pages":"158","caption":"Box 6.5 The DEcentralise TB services and Engage Communities to Transform lives of Children with TB project (158)","tokens_est":242,"char_count":967,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0603","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.10. Examples of country experiences in development of family-centred, decentralized and integrated TB services for children and adolescents | Box 6.6 Childhood TB integration into integrated management of newborn and childhood illness in health facilities of Addis Ababa (173)","content_type":"box","pages":"158","caption":"Box 6.6 Childhood TB integration into integrated management of newborn and childhood illness in health facilities of Addis Ababa (173)","tokens_est":98,"char_count":392,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0604","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.10. Examples of country experiences in development of family-centred, decentralized and integrated TB services for children and adolescents | Box 6.6 Childhood TB integration into integrated management of newborn and childhood illness in health facilities of Addis Ababa (173)","content_type":"box","pages":"158-159","caption":"Box 6.6 Childhood TB integration into integrated management of newborn and childhood illness in health facilities of Addis Ababa (173)","tokens_est":231,"char_count":921,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0605","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.10. Examples of country experiences in development of family-centred, decentralized and integrated TB services for children and adolescents | Box 6.6 Childhood TB integration into integrated management of newborn and childhood illness in health facilities of Addis Ababa (173)","content_type":"box","pages":"159","caption":"Box 6.6 Childhood TB integration into integrated management of newborn and childhood illness in health facilities of Addis Ababa (173)","tokens_est":168,"char_count":671,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0606","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.2. Decentralized, family- centred , integrated TB services | 6.2.1. Implementation considerations | 6.2.1.10. Examples of country experiences in development of family-centred, decentralized and integrated TB services for children and adolescents | Box 6.6 Childhood TB integration into integrated management of newborn and childhood illness in health facilities of Addis Ababa (173)","content_type":"box","pages":"159","caption":"Box 6.6 Childhood TB integration into integrated management of newborn and childhood illness in health facilities of Addis Ababa (173)","tokens_est":151,"char_count":602,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0607","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.3. Private-sector involvement in care for children and adolescents with TB | 6.3.1. Background","content_type":"text","pages":"159","tokens_est":146,"char_count":581,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0608","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.3. Private-sector involvement in care for children and adolescents with TB | 6.3.1. Background","content_type":"text","pages":"159","tokens_est":131,"char_count":524,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0609","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.3. Private-sector involvement in care for children and adolescents with TB | 6.3.2. Rationale","content_type":"text","pages":"159-160","tokens_est":152,"char_count":608,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0610","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.3. Private-sector involvement in care for children and adolescents with TB | 6.3.2. Rationale","content_type":"text","pages":"159-160","tokens_est":187,"char_count":745,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0611","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.3. Private-sector involvement in care for children and adolescents with TB | 6.3.3. Benefits of involving the private sector in TB care","content_type":"text","pages":"160","tokens_est":68,"char_count":270,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0612","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.3. Private-sector involvement in care for children and adolescents with TB | 6.3.3. Benefits of involving the private sector in TB care","content_type":"text","pages":"160","tokens_est":246,"char_count":984,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0613","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.3. Private-sector involvement in care for children and adolescents with TB | 6.3.4. Implementation considerations","content_type":"text","pages":"160","tokens_est":243,"char_count":972,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0614","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.3. Private-sector involvement in care for children and adolescents with TB | 6.3.4. Implementation considerations | Box 6.7 Key actions applied to child and adolescent TB services from the WHO Publicprivate mix for TB prevention and care: a roadmap","content_type":"box","pages":"160-161","caption":"Box 6.7 Key actions applied to child and adolescent TB services from the WHO Publicprivate mix for TB prevention and care: a roadmap","tokens_est":242,"char_count":967,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0615","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.3. Private-sector involvement in care for children and adolescents with TB | 6.3.4. Implementation considerations | Box 6.7 Key actions applied to child and adolescent TB services from the WHO Publicprivate mix for TB prevention and care: a roadmap","content_type":"box","pages":"161","caption":"Box 6.7 Key actions applied to child and adolescent TB services from the WHO Publicprivate mix for TB prevention and care: a roadmap","tokens_est":174,"char_count":695,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0616","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.3. Private-sector involvement in care for children and adolescents with TB | 6.3.4. Implementation considerations | Box 6.7 Key actions applied to child and adolescent TB services from the WHO Publicprivate mix for TB prevention and care: a roadmap","content_type":"box","pages":"161","caption":"Box 6.7 Key actions applied to child and adolescent TB services from the WHO Publicprivate mix for TB prevention and care: a roadmap","tokens_est":230,"char_count":920,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0617","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.3. Private-sector involvement in care for children and adolescents with TB | 6.3.4. Implementation considerations | Box 6.7 Key actions applied to child and adolescent TB services from the WHO Publicprivate mix for TB prevention and care: a roadmap","content_type":"box","pages":"161","caption":"Box 6.7 Key actions applied to child and adolescent TB services from the WHO Publicprivate mix for TB prevention and care: a roadmap","tokens_est":238,"char_count":952,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0618","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.3. Private-sector involvement in care for children and adolescents with TB | 6.3.4. Implementation considerations | Box 6.7 Key actions applied to child and adolescent TB services from the WHO Publicprivate mix for TB prevention and care: a roadmap","content_type":"box","pages":"161","caption":"Box 6.7 Key actions applied to child and adolescent TB services from the WHO Publicprivate mix for TB prevention and care: a roadmap","tokens_est":226,"char_count":904,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0619","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.3. Private-sector involvement in care for children and adolescents with TB | 6.3.4. Implementation considerations | Box 6.7 Key actions applied to child and adolescent TB services from the WHO Publicprivate mix for TB prevention and care: a roadmap","content_type":"box","pages":"161-162","caption":"Box 6.7 Key actions applied to child and adolescent TB services from the WHO Publicprivate mix for TB prevention and care: a roadmap","tokens_est":127,"char_count":505,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0620","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.3. Private-sector involvement in care for children and adolescents with TB | 6.3.4. Implementation considerations","content_type":"text","pages":"162","tokens_est":118,"char_count":470,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0621","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.3. Private-sector involvement in care for children and adolescents with TB | 6.3.4. Implementation considerations | Box 6.8 The Catalyzing Pediatric Tuberculosis Innovation project: enabling access to public paediatric TB medicines for private-sector patients in India  translating policy into action","content_type":"box","pages":"162","caption":"Box 6.8 The Catalyzing Pediatric Tuberculosis Innovation project: enabling access to public paediatric TB medicines for private-sector patients in India  translating policy into action","tokens_est":244,"char_count":974,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0622","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.3. Private-sector involvement in care for children and adolescents with TB | 6.3.4. Implementation considerations | Box 6.8 The Catalyzing Pediatric Tuberculosis Innovation project: enabling access to public paediatric TB medicines for private-sector patients in India  translating policy into action","content_type":"box","pages":"162","caption":"Box 6.8 The Catalyzing Pediatric Tuberculosis Innovation project: enabling access to public paediatric TB medicines for private-sector patients in India  translating policy into action","tokens_est":202,"char_count":806,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0623","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.3. Private-sector involvement in care for children and adolescents with TB | 6.3.4. Implementation considerations | Box 6.8 The Catalyzing Pediatric Tuberculosis Innovation project: enabling access to public paediatric TB medicines for private-sector patients in India  translating policy into action","content_type":"box","pages":"162","caption":"Box 6.8 The Catalyzing Pediatric Tuberculosis Innovation project: enabling access to public paediatric TB medicines for private-sector patients in India  translating policy into action","tokens_est":245,"char_count":979,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0624","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.3. Private-sector involvement in care for children and adolescents with TB | 6.3.4. Implementation considerations | Box 6.8 The Catalyzing Pediatric Tuberculosis Innovation project: enabling access to public paediatric TB medicines for private-sector patients in India  translating policy into action","content_type":"box","pages":"162-163","caption":"Box 6.8 The Catalyzing Pediatric Tuberculosis Innovation project: enabling access to public paediatric TB medicines for private-sector patients in India  translating policy into action","tokens_est":230,"char_count":920,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0625","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.3. Private-sector involvement in care for children and adolescents with TB | 6.3.4. Implementation considerations | Box 6.8 The Catalyzing Pediatric Tuberculosis Innovation project: enabling access to public paediatric TB medicines for private-sector patients in India  translating policy into action","content_type":"box","pages":"163","caption":"Box 6.8 The Catalyzing Pediatric Tuberculosis Innovation project: enabling access to public paediatric TB medicines for private-sector patients in India  translating policy into action","tokens_est":194,"char_count":775,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0626","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.3. Private-sector involvement in care for children and adolescents with TB | 6.3.4. Implementation considerations | Box 6.8 The Catalyzing Pediatric Tuberculosis Innovation project: enabling access to public paediatric TB medicines for private-sector patients in India  translating policy into action","content_type":"box","pages":"163","caption":"Box 6.8 The Catalyzing Pediatric Tuberculosis Innovation project: enabling access to public paediatric TB medicines for private-sector patients in India  translating policy into action","tokens_est":198,"char_count":792,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0627","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.4. Differentiated TB service delivery | 6.4.1. Background","content_type":"text","pages":"163","tokens_est":173,"char_count":691,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0628","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.4. Differentiated TB service delivery | 6.4.1. Background","content_type":"text","pages":"163","tokens_est":184,"char_count":734,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0629","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.4. Differentiated TB service delivery | 6.4.2. Rationale","content_type":"text","pages":"164","tokens_est":101,"char_count":404,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0630","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.4. Differentiated TB service delivery | 6.4.3. Implementation considerations","content_type":"text","pages":"164","tokens_est":243,"char_count":970,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0631","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.4. Differentiated TB service delivery | 6.4.3. Implementation considerations","content_type":"text","pages":"164","tokens_est":153,"char_count":612,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0632","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.4. Differentiated TB service delivery | 6.4.3. Implementation considerations","content_type":"text","pages":"164","tokens_est":215,"char_count":860,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0633","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.4. Differentiated TB service delivery | 6.4.3. Implementation considerations","content_type":"text","pages":"164","tokens_est":180,"char_count":720,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0634","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.4. Differentiated TB service delivery | 6.4.3. Implementation considerations | Box 6.9 Stable 1-year-old child with an antiretroviral therapy plan consisting of clinic visits every 2 months","content_type":"box","pages":"165","caption":"Box 6.9 Stable 1-year-old child with an antiretroviral therapy plan consisting of clinic visits every 2 months","tokens_est":237,"char_count":947,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0635","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.4. Differentiated TB service delivery | 6.4.3. Implementation considerations | Box 6.9 Stable 1-year-old child with an antiretroviral therapy plan consisting of clinic visits every 2 months","content_type":"box","pages":"165","caption":"Box 6.9 Stable 1-year-old child with an antiretroviral therapy plan consisting of clinic visits every 2 months","tokens_est":148,"char_count":591,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0636","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.4. Differentiated TB service delivery | 6.4.3. Implementation considerations | Box 6.9 Stable 1-year-old child with an antiretroviral therapy plan consisting of clinic visits every 2 months","content_type":"box","pages":"165","caption":"Box 6.9 Stable 1-year-old child with an antiretroviral therapy plan consisting of clinic visits every 2 months","tokens_est":200,"char_count":800,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0637","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.4. Differentiated TB service delivery | 6.4.3. Implementation considerations | Box 6.9 Stable 1-year-old child with an antiretroviral therapy plan consisting of clinic visits every 2 months","content_type":"box","pages":"165","caption":"Box 6.9 Stable 1-year-old child with an antiretroviral therapy plan consisting of clinic visits every 2 months","tokens_est":195,"char_count":779,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0638","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.4. Differentiated TB service delivery | 6.4.3. Implementation considerations | Box 6.10 Stable 15-year-old adolescent with an antiretroviral therapy plan consisting of clinic visits every 6 months","content_type":"box","pages":"165","caption":"Box 6.10 Stable 15-year-old adolescent with an antiretroviral therapy plan consisting of clinic visits every 6 months","tokens_est":210,"char_count":840,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0639","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.4. Differentiated TB service delivery | 6.4.3. Implementation considerations | Box 6.11 HIV-negative 4-year-old child in close contact with caregiver living with HIV recently diagnosed with TB","content_type":"box","pages":"165","caption":"Box 6.11 HIV-negative 4-year-old child in close contact with caregiver living with HIV recently diagnosed with TB","tokens_est":198,"char_count":792,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0640","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.4. Differentiated TB service delivery | 6.4.3. Implementation considerations | Box 6.11 HIV-negative 4-year-old child in close contact with caregiver living with HIV recently diagnosed with TB","content_type":"box","pages":"165","caption":"Box 6.11 HIV-negative 4-year-old child in close contact with caregiver living with HIV recently diagnosed with TB","tokens_est":241,"char_count":962,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0641","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.4. Differentiated TB service delivery | 6.4.3. Implementation considerations | Box 6.11 HIV-negative 4-year-old child in close contact with caregiver living with HIV recently diagnosed with TB","content_type":"box","pages":"165","caption":"Box 6.11 HIV-negative 4-year-old child in close contact with caregiver living with HIV recently diagnosed with TB","tokens_est":79,"char_count":314,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0642","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.5. TB and health emergencies","content_type":"text","pages":"165","tokens_est":70,"char_count":279,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0643","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.5. TB and health emergencies","content_type":"text","pages":"165","tokens_est":192,"char_count":765,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0644","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.5. TB and health emergencies","content_type":"text","pages":"165-166","tokens_est":230,"char_count":920,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0645","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.5. TB and health emergencies","content_type":"text","pages":"166","tokens_est":205,"char_count":819,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0646","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.5. TB and health emergencies","content_type":"text","pages":"166","tokens_est":236,"char_count":943,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0647","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.5. TB and health emergencies","content_type":"text","pages":"166","tokens_est":227,"char_count":908,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0648","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"6. Models of TB care for children and adolescents | 6.5. TB and health emergencies","content_type":"text","pages":"166","tokens_est":120,"char_count":480,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0649","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV","content_type":"text","pages":"167","tokens_est":50,"char_count":199,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0650","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.1. Introduction","content_type":"text","pages":"167","tokens_est":228,"char_count":912,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0651","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.1. Introduction","content_type":"text","pages":"167","tokens_est":116,"char_count":463,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0652","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.2. TB screening in children and adolescents living with HIV","content_type":"text","pages":"167","tokens_est":205,"char_count":817,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0653","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.2. TB screening in children and adolescents living with HIV","content_type":"text","pages":"167","tokens_est":159,"char_count":636,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0654","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.2. TB screening in children and adolescents living with HIV","content_type":"text","pages":"167-168","tokens_est":189,"char_count":756,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0655","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.2. TB screening in children and adolescents living with HIV","content_type":"text","pages":"168","tokens_est":103,"char_count":411,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0656","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.2. TB screening in children and adolescents living with HIV","content_type":"text","pages":"168","tokens_est":243,"char_count":969,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0657","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.2. TB screening in children and adolescents living with HIV","content_type":"text","pages":"168","tokens_est":232,"char_count":925,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0658","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.3. Prevention of TB in children and adolescents living with HIV","content_type":"text","pages":"168","tokens_est":129,"char_count":514,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0659","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.3. Prevention of TB in children and adolescents living with HIV","content_type":"text","pages":"168","tokens_est":224,"char_count":895,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0660","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.3. Prevention of TB in children and adolescents living with HIV","content_type":"text","pages":"168-169","tokens_est":229,"char_count":913,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0661","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.3. Prevention of TB in children and adolescents living with HIV","content_type":"text","pages":"169","tokens_est":217,"char_count":868,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0662","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.4. Diagnosis of TB in children and adolescents living with HIV","content_type":"text","pages":"169","tokens_est":201,"char_count":802,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0663","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.4. Diagnosis of TB in children and adolescents living with HIV","content_type":"text","pages":"169","tokens_est":160,"char_count":639,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0664","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.4. Diagnosis of TB in children and adolescents living with HIV","content_type":"text","pages":"169","tokens_est":200,"char_count":798,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0665","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.4. Diagnosis of TB in children and adolescents living with HIV","content_type":"text","pages":"169-170","tokens_est":181,"char_count":722,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0666","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.4. Diagnosis of TB in children and adolescents living with HIV","content_type":"text","pages":"170","tokens_est":220,"char_count":878,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0667","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.5. Treatment of TB in children and adolescents living with HIV","content_type":"text","pages":"170","tokens_est":231,"char_count":921,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0668","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.5. Treatment of TB in children and adolescents living with HIV","content_type":"text","pages":"170","tokens_est":218,"char_count":871,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0669","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.5. Treatment of TB in children and adolescents living with HIV","content_type":"text","pages":"170","tokens_est":81,"char_count":323,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0670","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.6. Co-trimoxazole preventive therapy","content_type":"text","pages":"170-171","tokens_est":207,"char_count":826,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0671","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.6. Co-trimoxazole preventive therapy | Box 7.2 WHO recommendations on co-trimoxazole prophylaxis","content_type":"box","pages":"171","caption":"Box 7.2 WHO recommendations on co-trimoxazole prophylaxis","tokens_est":203,"char_count":810,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0672","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.6. Co-trimoxazole preventive therapy | Box 7.2 WHO recommendations on co-trimoxazole prophylaxis","content_type":"box","pages":"171","caption":"Box 7.2 WHO recommendations on co-trimoxazole prophylaxis","tokens_est":227,"char_count":906,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0673","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.6. Co-trimoxazole preventive therapy | Box 7.2 WHO recommendations on co-trimoxazole prophylaxis","content_type":"box","pages":"171","caption":"Box 7.2 WHO recommendations on co-trimoxazole prophylaxis","tokens_est":66,"char_count":262,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0674","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.7. Antiretroviral therapy","content_type":"text","pages":"171","tokens_est":246,"char_count":983,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0675","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.7. Antiretroviral therapy","content_type":"text","pages":"171-172","tokens_est":159,"char_count":636,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0676","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.7. Antiretroviral therapy | 7.1.7.1. Timing of antiretroviral therapy","content_type":"text","pages":"172","tokens_est":191,"char_count":764,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0677","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.7. Antiretroviral therapy | 7.1.7.1. Timing of antiretroviral therapy | Box 7.3 WHO recommendations on timing of antiretroviral therapy in children and adolescents with TB","content_type":"box","pages":"172","caption":"Box 7.3 WHO recommendations on timing of antiretroviral therapy in children and adolescents with TB","tokens_est":231,"char_count":924,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0678","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.7. Antiretroviral therapy | 7.1.7.2. Choice of antiretroviral therapy regimen","content_type":"text","pages":"172","tokens_est":204,"char_count":813,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0679","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.7. Antiretroviral therapy | 7.1.7.2. Choice of antiretroviral therapy regimen","content_type":"text","pages":"172-173","tokens_est":241,"char_count":963,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0680","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.7. Antiretroviral therapy | 7.1.7.2. Choice of antiretroviral therapy regimen | Table 7.1. Preferred and alternative first-line antiretroviral therapy regimens for neonates, children and adolescents on TB treatment","content_type":"table","pages":"173","caption":"Table 7.1. Preferred and alternative first-line antiretroviral therapy regimens for neonates, children and adolescents on TB treatment","tokens_est":71,"char_count":2635,"has_attachment":true,"attachment_id":"Table 7.1.","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_7.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0681","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.7. Antiretroviral therapy | 7.1.7.2. Choice of antiretroviral therapy regimen","content_type":"text","pages":"174","tokens_est":116,"char_count":462,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0682","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.7. Antiretroviral therapy | 7.1.7.3. Adjustments to antiretroviral therapy regimens with TB treatment","content_type":"text","pages":"174","tokens_est":97,"char_count":387,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0683","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.7. Antiretroviral therapy | 7.1.7.3. Adjustments to antiretroviral therapy regimens with TB treatment | Table 7.2. Changes needed to antiretroviral therapy regimens for neonates, children and adolescents on drug-susceptible TB treatment","content_type":"table","pages":"174-175","caption":"Table 7.2. Changes needed to antiretroviral therapy regimens for neonates, children and adolescents on drug-susceptible TB treatment","tokens_est":70,"char_count":593,"has_attachment":true,"attachment_id":"Table 7.2.","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_7.2..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0684","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.7. Antiretroviral therapy | 7.1.7.3. Adjustments to antiretroviral therapy regimens with TB treatment","content_type":"text","pages":"175","tokens_est":83,"char_count":331,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0685","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.7. Antiretroviral therapy | 7.1.7.4. TPT in children and adolescents living with HIV on antiretroviral therapy","content_type":"text","pages":"175-176","tokens_est":223,"char_count":890,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0686","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.7. Antiretroviral therapy | 7.1.7.4. TPT in children and adolescents living with HIV on antiretroviral therapy | Table 7.3. TB preventive treatment options for children and adolescents on antiretroviral therapy","content_type":"table","pages":"176","caption":"Table 7.3. TB preventive treatment options for children and adolescents on antiretroviral therapy","tokens_est":38,"char_count":794,"has_attachment":true,"attachment_id":"Table 7.3.","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_7.3..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0687","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.8. Immune reconstitution inflammatory syndrome","content_type":"text","pages":"176","tokens_est":231,"char_count":923,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0688","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.8. Immune reconstitution inflammatory syndrome","content_type":"text","pages":"176-177","tokens_est":169,"char_count":673,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0689","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.8. Immune reconstitution inflammatory syndrome","content_type":"text","pages":"177","tokens_est":101,"char_count":404,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0690","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.1. Management of TB in children and adolescents living with HIV | 7.1.8. Immune reconstitution inflammatory syndrome","content_type":"text","pages":"177","tokens_est":186,"char_count":744,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0691","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.2. TB in pregnancy and management of newborns of mothers with TB disease","content_type":"text","pages":"177","tokens_est":227,"char_count":907,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0692","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.2. TB in pregnancy and management of newborns of mothers with TB disease","content_type":"text","pages":"177","tokens_est":67,"char_count":267,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0693","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.2. TB in pregnancy and management of newborns of mothers with TB disease","content_type":"text","pages":"177","tokens_est":133,"char_count":530,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0694","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.2. TB in pregnancy and management of newborns of mothers with TB disease","content_type":"text","pages":"177-178","tokens_est":247,"char_count":987,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0695","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.2. TB in pregnancy and management of newborns of mothers with TB disease | 7.2.1. Screening for TB in pregnant women living with HIV","content_type":"text","pages":"178","tokens_est":91,"char_count":362,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0696","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.2. TB in pregnancy and management of newborns of mothers with TB disease | 7.2.1. Screening for TB in pregnant women living with HIV | Table 7.4. Diagnostic accuracy of WHO-recommended screening tools in pregnant women living with HIV","content_type":"table","pages":"178","caption":"Table 7.4 provides an overview of the diagnostic accuracy of different screening tools (13) .","tokens_est":48,"char_count":202,"has_attachment":true,"attachment_id":"Table 7.4","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_7.4.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0697","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.2. TB in pregnancy and management of newborns of mothers with TB disease | 7.2.2. Congenital and neonatal TB","content_type":"text","pages":"178","tokens_est":162,"char_count":645,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0698","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.2. TB in pregnancy and management of newborns of mothers with TB disease | 7.2.2. Congenital and neonatal TB","content_type":"text","pages":"178","tokens_est":211,"char_count":844,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0699","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.2. TB in pregnancy and management of newborns of mothers with TB disease | 7.2.2. Congenital and neonatal TB | 7.2.2.1. Management of congenital and neonatal TB","content_type":"text","pages":"178-179","tokens_est":236,"char_count":942,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0700","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.2. TB in pregnancy and management of newborns of mothers with TB disease | 7.2.2. Congenital and neonatal TB | 7.2.2.1. Management of congenital and neonatal TB","content_type":"text","pages":"179","tokens_est":169,"char_count":673,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0701","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.2. TB in pregnancy and management of newborns of mothers with TB disease | 7.2.2. Congenital and neonatal TB | 7.2.2.1. Management of congenital and neonatal TB","content_type":"text","pages":"179","tokens_est":206,"char_count":821,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0702","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.2. TB in pregnancy and management of newborns of mothers with TB disease | 7.2.3. Management of asymptomatic neonates of mothers with TB","content_type":"text","pages":"179","tokens_est":168,"char_count":672,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0703","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.2. TB in pregnancy and management of newborns of mothers with TB disease | 7.2.3. Management of asymptomatic neonates of mothers with TB","content_type":"text","pages":"179","tokens_est":102,"char_count":406,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0704","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.2. TB in pregnancy and management of newborns of mothers with TB disease | 7.2.3. Management of asymptomatic neonates of mothers with TB","content_type":"text","pages":"179","tokens_est":229,"char_count":915,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0705","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.2. TB in pregnancy and management of newborns of mothers with TB disease | 7.2.3. Management of asymptomatic neonates of mothers with TB","content_type":"text","pages":"179","tokens_est":100,"char_count":400,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0706","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.2. TB in pregnancy and management of newborns of mothers with TB disease | 7.2.3. Management of asymptomatic neonates of mothers with TB","content_type":"text","pages":"179-180","tokens_est":134,"char_count":534,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0707","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.2. TB in pregnancy and management of newborns of mothers with TB disease | 7.2.3. Management of asymptomatic neonates of mothers with TB | Box 7.4 Management of babies born to women with TB disease (15)","content_type":"box","pages":"180","caption":"Box 7.4 Management of babies born to women with TB disease (15)","tokens_est":223,"char_count":892,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0708","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.2. TB in pregnancy and management of newborns of mothers with TB disease | 7.2.3. Management of asymptomatic neonates of mothers with TB | Box 7.4 Management of babies born to women with TB disease (15)","content_type":"box","pages":"180","caption":"Box 7.4 Management of babies born to women with TB disease (15)","tokens_est":137,"char_count":548,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0709","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.3. Palliative care for children and adolescents with TB | 7.3.1. Introduction","content_type":"text","pages":"180","tokens_est":122,"char_count":486,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0710","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.3. Palliative care for children and adolescents with TB | 7.3.1. Introduction | Figure 7.1. Palliative care","content_type":"figure","pages":"180","caption":"Figure 7.1. Palliative care","tokens_est":44,"char_count":175,"has_attachment":true,"attachment_id":"Figure 7.1.","attachment_path":"figures/WHO_TB_handbook_module5_pediatrics_2022/Figure 7.1..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0711","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.3. Palliative care for children and adolescents with TB | 7.3.1. Introduction","content_type":"text","pages":"180","tokens_est":184,"char_count":733,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0712","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.3. Palliative care for children and adolescents with TB | 7.3.1. Introduction","content_type":"text","pages":"180-181","tokens_est":159,"char_count":634,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0713","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.3. Palliative care for children and adolescents with TB | 7.3.2. Palliative care for people with TB","content_type":"text","pages":"181","tokens_est":248,"char_count":990,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0714","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.3. Palliative care for children and adolescents with TB | 7.3.2. Palliative care for people with TB | Box 7.5 Circumstances that may require palliative care in children and adolescents with TB","content_type":"box","pages":"181","caption":"Box 7.5 Circumstances that may require palliative care in children and adolescents with TB","tokens_est":230,"char_count":917,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0715","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.3. Palliative care for children and adolescents with TB | 7.3.2. Palliative care for people with TB","content_type":"text","pages":"181","tokens_est":94,"char_count":374,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0716","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.3. Palliative care for children and adolescents with TB | 7.3.2. Palliative care for people with TB","content_type":"text","pages":"181-182","tokens_est":201,"char_count":803,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0717","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.3. Palliative care for children and adolescents with TB | 7.3.3. Palliative care for children and adolescents with TB","content_type":"text","pages":"182","tokens_est":231,"char_count":923,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0718","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.3. Palliative care for children and adolescents with TB | 7.3.3. Palliative care for children and adolescents with TB","content_type":"text","pages":"182","tokens_est":163,"char_count":651,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0719","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.3. Palliative care for children and adolescents with TB | 7.3.3. Palliative care for children and adolescents with TB","content_type":"text","pages":"182","tokens_est":160,"char_count":638,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0720","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.3. Palliative care for children and adolescents with TB | 7.3.3. Palliative care for children and adolescents with TB","content_type":"text","pages":"182","tokens_est":109,"char_count":436,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0721","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.3. Palliative care for children and adolescents with TB | 7.3.3. Palliative care for children and adolescents with TB | Table 7.5. Actions to promote accessibility and availability of palliative care for children","content_type":"table","pages":"182-183","caption":"Table 7.5. Actions to promote accessibility and availability of palliative care for children","tokens_est":32,"char_count":137,"has_attachment":true,"attachment_id":"Table 7.5.","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_7.5..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0722","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.3. Palliative care for children and adolescents with TB | 7.3.3. Palliative care for children and adolescents with TB","content_type":"text","pages":"183","tokens_est":121,"char_count":484,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0723","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.3. Palliative care for children and adolescents with TB | 7.3.3. Palliative care for children and adolescents with TB | Table 7.6. Examples of symptom management for children and adolescents with TB in need of palliative care (207, 208)","content_type":"table","pages":"183","caption":"Table 7.6. Examples of symptom management for children and adolescents with TB in need of palliative care (207, 208)","tokens_est":40,"char_count":471,"has_attachment":true,"attachment_id":"Table 7.6.","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_7.6..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0724","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.4. Care for adolescents with or at risk of TB","content_type":"text","pages":"183-184","tokens_est":155,"char_count":618,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0725","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.4. Care for adolescents with or at risk of TB","content_type":"text","pages":"184","tokens_est":224,"char_count":894,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0726","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.4. Care for adolescents with or at risk of TB | Figure 7.2. New and relapse TB case notification rates by age group for children and adolescents in 13 high TB burden countries, 2020","content_type":"figure","pages":"184","caption":"Figure 7.2. New and relapse TB case notification rates by age group for children and adolescents in 13 high TB burden countries, 2020","tokens_est":36,"char_count":143,"has_attachment":true,"attachment_id":"Figure 7.2.","attachment_path":"figures/WHO_TB_handbook_module5_pediatrics_2022/Figure 7.2..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0727","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.4. Care for adolescents with or at risk of TB","content_type":"text","pages":"184","tokens_est":159,"char_count":635,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0728","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.4. Care for adolescents with or at risk of TB | 7.4.1. Physical and mental health","content_type":"text","pages":"184","tokens_est":179,"char_count":713,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0729","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.4. Care for adolescents with or at risk of TB | 7.4.1. Physical and mental health","content_type":"text","pages":"184","tokens_est":203,"char_count":810,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0730","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.4. Care for adolescents with or at risk of TB | 7.4.1. Physical and mental health","content_type":"text","pages":"184-185","tokens_est":212,"char_count":848,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0731","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.4. Care for adolescents with or at risk of TB | 7.4.2. Connectedness and positive contribution to society","content_type":"text","pages":"185","tokens_est":116,"char_count":464,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0732","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.4. Care for adolescents with or at risk of TB | 7.4.3. Safety and a supportive environment","content_type":"text","pages":"185","tokens_est":177,"char_count":707,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0733","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.4. Care for adolescents with or at risk of TB | 7.4.4. Learning, competence, education, skills and employability","content_type":"text","pages":"185","tokens_est":134,"char_count":535,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0734","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.4. Care for adolescents with or at risk of TB | 7.4.5. Agency and resilience","content_type":"text","pages":"185","tokens_est":123,"char_count":490,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0735","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.4. Care for adolescents with or at risk of TB | 7.4.6. Substance abuse and late presentation to care","content_type":"text","pages":"185","tokens_est":196,"char_count":781,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0736","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.4. Care for adolescents with or at risk of TB | 7.4.7. Poor adherence","content_type":"text","pages":"186","tokens_est":236,"char_count":943,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0737","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.4. Care for adolescents with or at risk of TB | 7.4.8. Making TB services more adolescent-friendly","content_type":"text","pages":"186","tokens_est":123,"char_count":491,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0738","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.4. Care for adolescents with or at risk of TB | 7.4.8. Making TB services more adolescent-friendly | Box 7.6 Proposed interventions to address needs of adolescents with or at risk of TB","content_type":"box","pages":"186","caption":"Box 7.6 Proposed interventions to address needs of adolescents with or at risk of TB","tokens_est":196,"char_count":784,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0739","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.4. Care for adolescents with or at risk of TB | 7.4.8. Making TB services more adolescent-friendly | Box 7.6 Proposed interventions to address needs of adolescents with or at risk of TB","content_type":"box","pages":"186","caption":"Box 7.6 Proposed interventions to address needs of adolescents with or at risk of TB","tokens_est":221,"char_count":881,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0740","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.4. Care for adolescents with or at risk of TB | 7.4.8. Making TB services more adolescent-friendly | Box 7.6 Proposed interventions to address needs of adolescents with or at risk of TB","content_type":"box","pages":"186","caption":"Box 7.6 Proposed interventions to address needs of adolescents with or at risk of TB","tokens_est":96,"char_count":384,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0741","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.4. Care for adolescents with or at risk of TB | 7.4.8. Making TB services more adolescent-friendly | Box 7.6 Proposed interventions to address needs of adolescents with or at risk of TB","content_type":"box","pages":"186-187","caption":"Box 7.6 Proposed interventions to address needs of adolescents with or at risk of TB","tokens_est":242,"char_count":966,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0742","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.4. Care for adolescents with or at risk of TB | 7.4.8. Making TB services more adolescent-friendly | Box 7.6 Proposed interventions to address needs of adolescents with or at risk of TB","content_type":"box","pages":"187","caption":"Box 7.6 Proposed interventions to address needs of adolescents with or at risk of TB","tokens_est":196,"char_count":782,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0743","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.4. Care for adolescents with or at risk of TB | 7.4.8. Making TB services more adolescent-friendly | Box 7.6 Proposed interventions to address needs of adolescents with or at risk of TB","content_type":"box","pages":"187","caption":"Box 7.6 Proposed interventions to address needs of adolescents with or at risk of TB","tokens_est":214,"char_count":856,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0744","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.4. Care for adolescents with or at risk of TB | 7.4.8. Making TB services more adolescent-friendly | Box 7.6 Proposed interventions to address needs of adolescents with or at risk of TB","content_type":"box","pages":"187","caption":"Box 7.6 Proposed interventions to address needs of adolescents with or at risk of TB","tokens_est":205,"char_count":820,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0745","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.4. Care for adolescents with or at risk of TB | 7.4.8. Making TB services more adolescent-friendly | Box 7.6 Proposed interventions to address needs of adolescents with or at risk of TB","content_type":"box","pages":"187","caption":"Box 7.6 Proposed interventions to address needs of adolescents with or at risk of TB","tokens_est":246,"char_count":982,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0746","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.5. TB in children with severe acute pneumonia","content_type":"text","pages":"187-188","tokens_est":133,"char_count":531,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0747","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.5. TB in children with severe acute pneumonia","content_type":"text","pages":"188","tokens_est":221,"char_count":884,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0748","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.5. TB in children with severe acute pneumonia","content_type":"text","pages":"188","tokens_est":137,"char_count":548,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0749","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.5. TB in children with severe acute pneumonia | Box 7.7 Implications for implementation","content_type":"box","pages":"188","caption":"Box 7.7 Implications for implementation","tokens_est":212,"char_count":847,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0750","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.5. TB in children with severe acute pneumonia | Box 7.7 Implications for implementation","content_type":"box","pages":"188","caption":"Box 7.7 Implications for implementation","tokens_est":140,"char_count":560,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0751","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.5. TB in children with severe acute pneumonia | Box 7.8 Findings from the TB-Speed Pneumonia study","content_type":"box","pages":"188","caption":"Box 7.8 Findings from the TB-Speed Pneumonia study","tokens_est":169,"char_count":675,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0752","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.5. TB in children with severe acute pneumonia | Box 7.8 Findings from the TB-Speed Pneumonia study","content_type":"box","pages":"188-189","caption":"Box 7.8 Findings from the TB-Speed Pneumonia study","tokens_est":217,"char_count":868,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0753","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.5. TB in children with severe acute pneumonia | Box 7.8 Findings from the TB-Speed Pneumonia study","content_type":"box","pages":"189","caption":"Box 7.8 Findings from the TB-Speed Pneumonia study","tokens_est":250,"char_count":997,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0754","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.5. TB in children with severe acute pneumonia | Box 7.8 Findings from the TB-Speed Pneumonia study","content_type":"box","pages":"189","caption":"Box 7.8 Findings from the TB-Speed Pneumonia study","tokens_est":46,"char_count":182,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0755","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.5. TB in children with severe acute pneumonia | Box 7.8 Findings from the TB-Speed Pneumonia study","content_type":"box","pages":"189","caption":"Box 7.8 Findings from the TB-Speed Pneumonia study","tokens_est":234,"char_count":933,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0756","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.5. TB in children with severe acute pneumonia | Box 7.8 Findings from the TB-Speed Pneumonia study","content_type":"box","pages":"189","caption":"Box 7.8 Findings from the TB-Speed Pneumonia study","tokens_est":167,"char_count":665,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0757","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.6. Management of children with TB and malnutrition | 7.6.1. Introduction","content_type":"text","pages":"189-190","tokens_est":183,"char_count":729,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0758","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.6. Management of children with TB and malnutrition | 7.6.1. Introduction","content_type":"text","pages":"190","tokens_est":159,"char_count":636,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0759","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.6. Management of children with TB and malnutrition | 7.6.2. Diagnosis and treatment of TB in children with malnutrition","content_type":"text","pages":"190","tokens_est":151,"char_count":601,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0760","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.6. Management of children with TB and malnutrition | 7.6.2. Diagnosis and treatment of TB in children with malnutrition","content_type":"text","pages":"190","tokens_est":218,"char_count":871,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0761","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.6. Management of children with TB and malnutrition | 7.6.2. Diagnosis and treatment of TB in children with malnutrition","content_type":"text","pages":"190","tokens_est":171,"char_count":683,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0762","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.6. Management of children with TB and malnutrition | 7.6.3. Nutritional care for children and adolescents with TB","content_type":"text","pages":"190","tokens_est":84,"char_count":336,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0763","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.6. Management of children with TB and malnutrition | 7.6.3. Nutritional care for children and adolescents with TB","content_type":"text","pages":"190-191","tokens_est":230,"char_count":920,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0764","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.6. Management of children with TB and malnutrition | 7.6.3. Nutritional care for children and adolescents with TB","content_type":"text","pages":"191","tokens_est":224,"char_count":893,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0765","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.6. Management of children with TB and malnutrition | 7.6.3. Nutritional care for children and adolescents with TB","content_type":"text","pages":"191","tokens_est":83,"char_count":330,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0766","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.6. Management of children with TB and malnutrition | 7.6.3. Nutritional care for children and adolescents with TB | Nutrition assessment and counselling","content_type":"text","pages":"191","tokens_est":75,"char_count":299,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0767","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.6. Management of children with TB and malnutrition | 7.6.3. Nutritional care for children and adolescents with TB | Management of severe acute malnutrition","content_type":"text","pages":"191","tokens_est":163,"char_count":651,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0768","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.6. Management of children with TB and malnutrition | 7.6.3. Nutritional care for children and adolescents with TB | Management of moderate undernutrition","content_type":"text","pages":"191","tokens_est":248,"char_count":992,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0769","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.6. Management of children with TB and malnutrition | 7.6.3. Nutritional care for children and adolescents with TB | Management of moderate undernutrition","content_type":"text","pages":"191-192","tokens_est":159,"char_count":635,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0770","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.6. Management of children with TB and malnutrition | 7.6.3. Nutritional care for children and adolescents with TB | Contact investigation","content_type":"text","pages":"192","tokens_est":188,"char_count":752,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0771","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.6. Management of children with TB and malnutrition | 7.6.3. Nutritional care for children and adolescents with TB | Contact investigation","content_type":"text","pages":"192","tokens_est":229,"char_count":914,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0772","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.6. Management of children with TB and malnutrition | 7.6.3. Nutritional care for children and adolescents with TB | Contact investigation","content_type":"text","pages":"192","tokens_est":223,"char_count":892,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0773","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.6. Management of children with TB and malnutrition | 7.6.3. Nutritional care for children and adolescents with TB | Contact investigation","content_type":"text","pages":"192-193","tokens_est":222,"char_count":888,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0774","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.6. Management of children with TB and malnutrition | 7.6.3. Nutritional care for children and adolescents with TB | Contact investigation","content_type":"text","pages":"193","tokens_est":239,"char_count":956,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0775","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.6. Management of children with TB and malnutrition | 7.6.3. Nutritional care for children and adolescents with TB | Contact investigation","content_type":"text","pages":"193","tokens_est":229,"char_count":914,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0776","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.6. Management of children with TB and malnutrition | 7.6.3. Nutritional care for children and adolescents with TB | Contact investigation","content_type":"text","pages":"193","tokens_est":242,"char_count":967,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0777","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"7. Special situations | 7.6. Management of children with TB and malnutrition | 7.6.3. Nutritional care for children and adolescents with TB | Contact investigation","content_type":"text","pages":"193-194","tokens_est":166,"char_count":663,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0778","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 2. Tuberculin skin testing: administration, reading and interpretation","content_type":"text","pages":"208","tokens_est":214,"char_count":856,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0779","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 2. Tuberculin skin testing: administration, reading and interpretation | Administration","content_type":"text","pages":"208","tokens_est":217,"char_count":868,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0780","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 2. Tuberculin skin testing: administration, reading and interpretation | Administration","content_type":"text","pages":"208-209","tokens_est":238,"char_count":952,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0781","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 2. Tuberculin skin testing: administration, reading and interpretation | Administration","content_type":"text","pages":"209","tokens_est":63,"char_count":251,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0782","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 2. Tuberculin skin testing: administration, reading and interpretation | Reading","content_type":"text","pages":"209","tokens_est":173,"char_count":689,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0783","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 2. Tuberculin skin testing: administration, reading and interpretation | Reading","content_type":"text","pages":"209","tokens_est":129,"char_count":515,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0784","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 2. Tuberculin skin testing: administration, reading and interpretation | Reading","content_type":"text","pages":"209","tokens_est":133,"char_count":531,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0785","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 2. Tuberculin skin testing: administration, reading and interpretation | Recording","content_type":"text","pages":"209","tokens_est":90,"char_count":360,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0786","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 2. Tuberculin skin testing: administration, reading and interpretation | Interpretation","content_type":"text","pages":"209","tokens_est":204,"char_count":816,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0787","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 2. Tuberculin skin testing: administration, reading and interpretation | Interpretation","content_type":"text","pages":"209-210","tokens_est":176,"char_count":701,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0788","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 2. Tuberculin skin testing: administration, reading and interpretation | Interpretation","content_type":"text","pages":"210","tokens_est":186,"char_count":743,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0789","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 2. Tuberculin skin testing: administration, reading and interpretation | Interpretation | Table A2.1. Causes of false-negative and false-positive tuberculin skin tests","content_type":"table","pages":"210","caption":"Table A2.1. Causes of false-negative and false-positive tuberculin skin tests","tokens_est":30,"char_count":577,"has_attachment":true,"attachment_id":"Table A2.1.","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_A2.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0790","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 3. Sample collection methods","content_type":"text","pages":"211","tokens_est":82,"char_count":326,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0791","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 3. Sample collection methods | Table A3.1. Respiratory specimens","content_type":"table","pages":"211-212","caption":"Table A3.1. Respiratory specimens","tokens_est":65,"char_count":270,"has_attachment":true,"attachment_id":"Table A3.1.","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_A3.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0792","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 3. Sample collection methods | Table A3.2. Non-respiratory specimens","content_type":"table","pages":"212-213","caption":"Table A3.2. Non-respiratory specimens","tokens_est":41,"char_count":593,"has_attachment":true,"attachment_id":"Table A3.2.","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_A3.2..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0793","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 4. Standard operating procedures for sample collection methods","content_type":"text","pages":"215","tokens_est":81,"char_count":321,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0794","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 4. Standard operating procedures for sample collection methods | Biosafety and infection prevention and control practices to be followed during cough-inducing and aerosol-generating procedures","content_type":"text","pages":"215","tokens_est":198,"char_count":791,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0795","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 4. Standard operating procedures for sample collection methods | Biosafety and infection prevention and control practices to be followed during cough-inducing and aerosol-generating procedures","content_type":"text","pages":"215","tokens_est":242,"char_count":966,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0796","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 4. Standard operating procedures for sample collection methods | Biosafety and infection prevention and control practices to be followed during cough-inducing and aerosol-generating procedures","content_type":"text","pages":"215","tokens_est":117,"char_count":467,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0797","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 4. Standard operating procedures for sample collection methods | Expectoration | Background","content_type":"text","pages":"216","tokens_est":90,"char_count":359,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0798","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 4. Standard operating procedures for sample collection methods | Expectoration | Procedure","content_type":"text","pages":"216","tokens_est":191,"char_count":764,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0799","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 4. Standard operating procedures for sample collection methods | Expectoration | Procedure","content_type":"text","pages":"216","tokens_est":117,"char_count":467,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0800","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 4. Standard operating procedures for sample collection methods | Gastric aspiration | Background","content_type":"text","pages":"216","tokens_est":208,"char_count":830,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0801","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 4. Standard operating procedures for sample collection methods | Gastric aspiration | Materials needed","content_type":"text","pages":"216-217","tokens_est":97,"char_count":388,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0802","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 4. Standard operating procedures for sample collection methods | Gastric aspiration | Contraindications","content_type":"text","pages":"217","tokens_est":134,"char_count":535,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0803","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 4. Standard operating procedures for sample collection methods | Gastric aspiration | Procedure","content_type":"text","pages":"217","tokens_est":212,"char_count":847,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0804","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 4. Standard operating procedures for sample collection methods | Gastric aspiration | Procedure","content_type":"text","pages":"217","tokens_est":243,"char_count":969,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0805","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 4. Standard operating procedures for sample collection methods | Gastric aspiration | Procedure","content_type":"text","pages":"217-218","tokens_est":238,"char_count":951,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0806","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 4. Standard operating procedures for sample collection methods | Gastric aspiration | Procedure","content_type":"text","pages":"218","tokens_est":77,"char_count":306,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0807","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 4. Standard operating procedures for sample collection methods | Gastric aspiration | After the procedure","content_type":"text","pages":"218","tokens_est":136,"char_count":542,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0808","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 4. Standard operating procedures for sample collection methods | Nasopharyngeal aspiration (NPA) | Materials needed","content_type":"text","pages":"218","tokens_est":145,"char_count":577,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0809","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 4. Standard operating procedures for sample collection methods | Nasopharyngeal aspiration (NPA) | Contraindications","content_type":"text","pages":"218-219","tokens_est":36,"char_count":142,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0810","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 4. Standard operating procedures for sample collection methods | Nasopharyngeal aspiration (NPA) | Procedure","content_type":"text","pages":"219","tokens_est":232,"char_count":926,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0811","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 4. Standard operating procedures for sample collection methods | Nasopharyngeal aspiration (NPA) | Procedure","content_type":"text","pages":"219","tokens_est":223,"char_count":891,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0812","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 4. Standard operating procedures for sample collection methods | Nasopharyngeal aspiration (NPA) | Procedure","content_type":"text","pages":"219","tokens_est":219,"char_count":873,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0813","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 4. Standard operating procedures for sample collection methods | Nasopharyngeal aspiration (NPA) | After the procedure","content_type":"text","pages":"219-220","tokens_est":113,"char_count":451,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0814","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 4. Standard operating procedures for sample collection methods | Sputum induction | Background","content_type":"text","pages":"220","tokens_est":246,"char_count":984,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0815","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 4. Standard operating procedures for sample collection methods | Sputum induction | Background","content_type":"text","pages":"220","tokens_est":108,"char_count":431,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0816","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 4. Standard operating procedures for sample collection methods | Sputum induction | Materials needed","content_type":"text","pages":"220-221","tokens_est":220,"char_count":878,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0817","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 4. Standard operating procedures for sample collection methods | Sputum induction | Procedure","content_type":"text","pages":"221","tokens_est":221,"char_count":882,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0818","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 4. Standard operating procedures for sample collection methods | Sputum induction | Procedure","content_type":"text","pages":"221","tokens_est":214,"char_count":853,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0819","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 4. Standard operating procedures for sample collection methods | Sputum induction | Procedure","content_type":"text","pages":"221-222","tokens_est":205,"char_count":819,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module5_pediatrics_2022|0820","doc_id":"WHO_TB_handbook_module5_pediatrics_2022","section_path":"Annex 7. Overview of options for neurocognitive and functional testing at end of treatment for TB meningitis | Table A7.1. Options for neurocognitive and functional testing at end of treatment for TB meningitis","content_type":"table","pages":"223","caption":"Table A7.1. Options for neurocognitive and functional testing at end of treatment for TB meningitis","tokens_est":34,"char_count":1475,"has_attachment":true,"attachment_id":"Table A7.1.","attachment_path":"tables/WHO_TB_handbook_module5_pediatrics_2022/Table_A7.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module5_pediatrics_2022_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0001","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Introduction","content_type":"text","pages":"1","tokens_est":226,"char_count":904,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0002","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Introduction","content_type":"text","pages":"1","tokens_est":169,"char_count":675,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0003","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Introduction","content_type":"text","pages":"1","tokens_est":114,"char_count":454,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0004","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Introduction","content_type":"text","pages":"1","tokens_est":200,"char_count":800,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0005","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Introduction","content_type":"text","pages":"1","tokens_est":151,"char_count":601,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0006","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Introduction","content_type":"text","pages":"1-2","tokens_est":242,"char_count":965,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0007","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Introduction","content_type":"text","pages":"2","tokens_est":195,"char_count":778,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0008","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Introduction","content_type":"text","pages":"2","tokens_est":188,"char_count":752,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0009","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | Abbreviations","content_type":"text","pages":"2-3","tokens_est":145,"char_count":579,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0010","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | Definitions","content_type":"text","pages":"3","tokens_est":184,"char_count":736,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0011","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | Definitions","content_type":"text","pages":"3","tokens_est":199,"char_count":793,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0012","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | Definitions","content_type":"text","pages":"3-4","tokens_est":213,"char_count":851,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0013","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | Definitions","content_type":"text","pages":"4","tokens_est":49,"char_count":194,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0014","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 1. Mental health conditions and substance use disorders: background and rationale","content_type":"text","pages":"5","tokens_est":142,"char_count":568,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0015","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 1. Mental health conditions and substance use disorders: background and rationale","content_type":"text","pages":"5","tokens_est":249,"char_count":994,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0016","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 1. Mental health conditions and substance use disorders: background and rationale","content_type":"text","pages":"5","tokens_est":106,"char_count":423,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0017","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 1. Mental health conditions and substance use disorders: background and rationale","content_type":"text","pages":"5","tokens_est":132,"char_count":525,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0018","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 1. Mental health conditions and substance use disorders: background and rationale","content_type":"text","pages":"5-6","tokens_est":187,"char_count":748,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0019","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 1. Mental health conditions and substance use disorders: background and rationale","content_type":"text","pages":"5-6","tokens_est":241,"char_count":963,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0020","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 2. People- centred care for mental health conditions and substance use disorders in people affected by TB","content_type":"text","pages":"7-8","tokens_est":233,"char_count":932,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0021","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 2. People- centred care for mental health conditions and substance use disorders in people affected by TB","content_type":"text","pages":"7-8","tokens_est":71,"char_count":284,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0022","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB","content_type":"text","pages":"9","tokens_est":191,"char_count":762,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0023","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB","content_type":"text","pages":"9","tokens_est":156,"char_count":623,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0024","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB","content_type":"text","pages":"9","tokens_est":219,"char_count":876,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0025","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB","content_type":"text","pages":"9","tokens_est":193,"char_count":771,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0026","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB","content_type":"text","pages":"9","tokens_est":90,"char_count":358,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0027","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB","content_type":"text","pages":"9-10","tokens_est":216,"char_count":861,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0028","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB","content_type":"text","pages":"9-10","tokens_est":190,"char_count":759,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0029","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB","content_type":"text","pages":"10","tokens_est":223,"char_count":891,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0030","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB","content_type":"text","pages":"10","tokens_est":78,"char_count":312,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0031","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB | Table 1. Overview of priority mental health conditions","content_type":"table","pages":"10-11","caption":"Table 1. Overview of priority mental health conditions","tokens_est":27,"char_count":683,"has_attachment":true,"attachment_id":"Table 1.","attachment_path":"tables/WHO_TB_handbook_module6_comorbidities_2024/Table_1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0032","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB","content_type":"text","pages":"11","tokens_est":220,"char_count":878,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0033","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB","content_type":"text","pages":"11-12","tokens_est":222,"char_count":885,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0034","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB","content_type":"text","pages":"12","tokens_est":110,"char_count":439,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0035","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB | Fig. 1. Continuum of options in mental health care","content_type":"figure","pages":"12","caption":"Fig. 1. Continuum of options in mental health care","tokens_est":15,"char_count":60,"has_attachment":true,"attachment_id":"Fig. 1.","attachment_path":"figures/WHO_TB_handbook_module6_comorbidities_2024/Fig. 1..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0036","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB","content_type":"text","pages":"12","tokens_est":174,"char_count":696,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0037","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB","content_type":"text","pages":"12","tokens_est":220,"char_count":878,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0038","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB","content_type":"text","pages":"12","tokens_est":184,"char_count":733,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0039","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB | 3.1 Depression","content_type":"text","pages":"12-13","tokens_est":230,"char_count":918,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0040","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB | 3.1 Depression","content_type":"text","pages":"13","tokens_est":234,"char_count":936,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0041","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB | 3.1 Depression","content_type":"text","pages":"13","tokens_est":200,"char_count":797,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0042","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB | 3.1 Depression","content_type":"text","pages":"13","tokens_est":202,"char_count":808,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0043","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB | 3.1 Depression","content_type":"text","pages":"13","tokens_est":92,"char_count":365,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0044","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB | 3.1 Depression","content_type":"text","pages":"13-14","tokens_est":248,"char_count":990,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0045","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB | 3.1 Depression","content_type":"text","pages":"13-14","tokens_est":155,"char_count":620,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0046","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB | 3.2 Anxiety","content_type":"text","pages":"14","tokens_est":205,"char_count":817,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0047","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB | 3.2 Anxiety","content_type":"text","pages":"14","tokens_est":55,"char_count":217,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0048","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB | 3.2 Anxiety","content_type":"text","pages":"14","tokens_est":230,"char_count":920,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0049","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB | 3.2 Anxiety","content_type":"text","pages":"14","tokens_est":246,"char_count":984,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0050","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB | 3.2 Anxiety","content_type":"text","pages":"14-15","tokens_est":123,"char_count":490,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0051","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB | 3.3 Psychoses","content_type":"text","pages":"15","tokens_est":186,"char_count":743,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0052","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB | 3.3 Psychoses","content_type":"text","pages":"15","tokens_est":218,"char_count":870,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0053","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB | 3.3 Psychoses","content_type":"text","pages":"15","tokens_est":218,"char_count":870,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0054","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB | 3.3 Psychoses","content_type":"text","pages":"15","tokens_est":134,"char_count":533,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0055","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB | 3.4 Substance use disorders","content_type":"text","pages":"15-16","tokens_est":202,"char_count":808,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0056","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB | 3.4 Substance use disorders","content_type":"text","pages":"15-16","tokens_est":113,"char_count":452,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0057","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB | 3.4 Substance use disorders","content_type":"text","pages":"16","tokens_est":173,"char_count":692,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0058","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB | 3.4 Substance use disorders","content_type":"text","pages":"16","tokens_est":166,"char_count":662,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0059","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB | 3.4 Substance use disorders","content_type":"text","pages":"16","tokens_est":139,"char_count":553,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0060","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB | 3.4 Substance use disorders","content_type":"text","pages":"16","tokens_est":206,"char_count":824,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0061","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB | 3.4 Substance use disorders","content_type":"text","pages":"16-17","tokens_est":206,"char_count":824,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0062","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB | 3.4 Substance use disorders","content_type":"text","pages":"16-17","tokens_est":93,"char_count":371,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0063","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB | 3.5 Suicidal behaviours","content_type":"text","pages":"17","tokens_est":240,"char_count":959,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0064","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 3. Identifying and managing care for mental health conditions and substance use disorders in people affected by TB | 3.5 Suicidal behaviours","content_type":"text","pages":"17","tokens_est":46,"char_count":183,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0065","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 4. Special considerations | 4.1 Stigma","content_type":"text","pages":"18","tokens_est":207,"char_count":827,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0066","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 4. Special considerations | 4.1 Stigma","content_type":"text","pages":"18","tokens_est":113,"char_count":452,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0067","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 4. Special considerations | 4.2 Palliative care","content_type":"text","pages":"18","tokens_est":126,"char_count":503,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0068","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 4. Special considerations | 4.3 Homelessness","content_type":"text","pages":"18","tokens_est":212,"char_count":848,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0069","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Mental health conditions and substance use disorders | 4. Special considerations | 4.4 Multimorbidity and TB-associated disabilities","content_type":"text","pages":"18-19","tokens_est":174,"char_count":695,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0070","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Abbreviations and acronyms","content_type":"text","pages":"19-20","tokens_est":224,"char_count":893,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0071","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Abbreviations and acronyms","content_type":"text","pages":"20","tokens_est":171,"char_count":683,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0072","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Abbreviations and acronyms | HIV medicines","content_type":"text","pages":"20-21","tokens_est":77,"char_count":308,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0073","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Abbreviations and acronyms | Tuberculosis medicines","content_type":"text","pages":"21","tokens_est":42,"char_count":168,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0074","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Definitions","content_type":"text","pages":"22","tokens_est":213,"char_count":852,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0075","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Definitions","content_type":"text","pages":"22","tokens_est":231,"char_count":922,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0076","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Definitions","content_type":"text","pages":"22-23","tokens_est":224,"char_count":896,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0077","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Definitions","content_type":"text","pages":"23","tokens_est":157,"char_count":625,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0078","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Definitions","content_type":"text","pages":"23","tokens_est":225,"char_count":897,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0079","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Definitions","content_type":"text","pages":"23","tokens_est":212,"char_count":848,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0080","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Definitions","content_type":"text","pages":"23-24","tokens_est":235,"char_count":938,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0081","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Definitions","content_type":"text","pages":"24","tokens_est":229,"char_count":913,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0082","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 1. Background and rationale | 1.1 Background and burden of HIV-associated TB","content_type":"text","pages":"24","tokens_est":219,"char_count":874,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0083","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 1. Background and rationale | 1.1 Background and burden of HIV-associated TB","content_type":"text","pages":"24","tokens_est":207,"char_count":825,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0084","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 1. Background and rationale | 1.1 Background and burden of HIV-associated TB","content_type":"text","pages":"24-25","tokens_est":240,"char_count":958,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0085","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 1. Background and rationale | 1.1 Background and burden of HIV-associated TB","content_type":"text","pages":"24-25","tokens_est":207,"char_count":827,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0086","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 1. Background and rationale | 1.1 Background and burden of HIV-associated TB","content_type":"text","pages":"24-25","tokens_est":117,"char_count":466,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0087","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 1. Background and rationale | 1.1 Background and burden of HIV-associated TB","content_type":"text","pages":"25","tokens_est":125,"char_count":500,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0088","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 1. Background and rationale | 1.2 Development of the document","content_type":"text","pages":"25","tokens_est":196,"char_count":784,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0089","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 1. Background and rationale | 1.3 Summary of recommendations","content_type":"text","pages":"25","tokens_est":197,"char_count":786,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0090","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 1. Background and rationale | 1.3 Summary of recommendations","content_type":"text","pages":"25-26","tokens_est":229,"char_count":915,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0091","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 1. Background and rationale | 1.3 Summary of recommendations","content_type":"text","pages":"26","tokens_est":198,"char_count":790,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0092","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 1. Background and rationale | 1.3 Summary of recommendations","content_type":"text","pages":"26","tokens_est":172,"char_count":685,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0093","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 1. Background and rationale | 1.3 Summary of recommendations","content_type":"text","pages":"26","tokens_est":134,"char_count":533,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0094","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 1. Background and rationale | 1.3 Summary of recommendations","content_type":"text","pages":"26-27","tokens_est":225,"char_count":900,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0095","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 1. Background and rationale | 1.3 Summary of recommendations","content_type":"text","pages":"27","tokens_est":136,"char_count":544,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0096","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 1. Background and rationale | 1.3 Summary of recommendations","content_type":"text","pages":"27","tokens_est":241,"char_count":961,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0097","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 1. Background and rationale | 1.3 Summary of recommendations","content_type":"text","pages":"27","tokens_est":181,"char_count":723,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0098","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 1. Background and rationale | 1.3 Summary of recommendations","content_type":"text","pages":"27","tokens_est":145,"char_count":577,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0099","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 1. Background and rationale | 1.3 Summary of recommendations","content_type":"text","pages":"27-28","tokens_est":223,"char_count":889,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0100","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 1. Background and rationale | 1.3 Summary of recommendations","content_type":"text","pages":"28","tokens_est":203,"char_count":811,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0101","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 1. Background and rationale | 1.3 Summary of recommendations","content_type":"text","pages":"28","tokens_est":244,"char_count":976,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0102","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 1. Background and rationale | 1.3 Summary of recommendations","content_type":"text","pages":"28","tokens_est":120,"char_count":477,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0103","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB","content_type":"text","pages":"29","tokens_est":227,"char_count":906,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0104","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB","content_type":"text","pages":"29","tokens_est":215,"char_count":857,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0105","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | Summary of the Framework for collaborative action on TB and action on TB and comorbidities","content_type":"text","pages":"30","tokens_est":231,"char_count":924,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0106","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | Summary of the Framework for collaborative action on TB and action on TB and comorbidities","content_type":"text","pages":"30","tokens_est":228,"char_count":910,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0107","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | Summary of the Framework for collaborative action on TB and action on TB and comorbidities","content_type":"text","pages":"30-31","tokens_est":166,"char_count":661,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0108","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | Summary of the Framework for collaborative action on TB and action on TB and comorbidities","content_type":"text","pages":"31","tokens_est":150,"char_count":597,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0109","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.1 Strengthen governance and accountability for TB/HIV collaborative activities | 2.1.1 Strengthen political commitment, coordination and accountability for collaborative action on TB and HIV","content_type":"text","pages":"31","tokens_est":225,"char_count":897,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0110","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.1 Strengthen governance and accountability for TB/HIV collaborative activities | 2.1.1 Strengthen political commitment, coordination and accountability for collaborative action on TB and HIV","content_type":"text","pages":"31","tokens_est":212,"char_count":846,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0111","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.1 Strengthen governance and accountability for TB/HIV collaborative activities | 2.1.1 Strengthen political commitment, coordination and accountability for collaborative action on TB and HIV","content_type":"text","pages":"31","tokens_est":188,"char_count":749,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0112","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.1 Strengthen governance and accountability for TB/HIV collaborative activities | 2.1.1 Strengthen political commitment, coordination and accountability for collaborative action on TB and HIV","content_type":"text","pages":"31-32","tokens_est":234,"char_count":936,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0113","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.1 Strengthen governance and accountability for TB/HIV collaborative activities | 2.1.1 Strengthen political commitment, coordination and accountability for collaborative action on TB and HIV","content_type":"text","pages":"32","tokens_est":88,"char_count":349,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0114","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.1 Strengthen governance and accountability for TB/HIV collaborative activities | 2.1.2 Support financing and legislation that protect human rights and promote people- centred care","content_type":"text","pages":"32","tokens_est":192,"char_count":766,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0115","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.1 Strengthen governance and accountability for TB/HIV collaborative activities | 2.1.2 Support financing and legislation that protect human rights and promote people- centred care","content_type":"text","pages":"32","tokens_est":85,"char_count":338,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0116","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.1 Strengthen governance and accountability for TB/HIV collaborative activities | 2.1.2 Support financing and legislation that protect human rights and promote people- centred care","content_type":"text","pages":"32","tokens_est":201,"char_count":803,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0117","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.1 Strengthen governance and accountability for TB/HIV collaborative activities | 2.1.3 Ensure meaningful engagement of civil society and affected communities at all stages of planning, implementation, monitoring and evaluation","content_type":"text","pages":"32-33","tokens_est":218,"char_count":872,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0118","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.1 Strengthen governance and accountability for TB/HIV collaborative activities | 2.1.3 Ensure meaningful engagement of civil society and affected communities at all stages of planning, implementation, monitoring and evaluation","content_type":"text","pages":"32-33","tokens_est":229,"char_count":916,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0119","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.2 Conduct an analysis of access to quality services for TB and HIV | 2.2.1 Assess the joint burden of TB and HIV","content_type":"text","pages":"33","tokens_est":242,"char_count":966,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0120","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.2 Conduct an analysis of access to quality services for TB and HIV | 2.2.1 Assess the joint burden of TB and HIV","content_type":"text","pages":"33","tokens_est":185,"char_count":739,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0121","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.2 Conduct an analysis of access to quality services for TB and HIV | 2.2.1 Assess the joint burden of TB and HIV","content_type":"text","pages":"33","tokens_est":133,"char_count":531,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0122","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.2 Conduct an analysis of access to quality services for TB and HIV | 2.2.1 Assess the joint burden of TB and HIV","content_type":"text","pages":"33","tokens_est":182,"char_count":726,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0123","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.2 Conduct an analysis of access to quality services for TB and HIV | 2.2.1 Assess the joint burden of TB and HIV","content_type":"text","pages":"33-34","tokens_est":86,"char_count":341,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0124","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.2 Conduct an analysis of access to quality services for TB and HIV | 2.2.1 Assess the joint burden of TB and HIV | Box 2.1 Guidance for assessment of the joint burden of TB and HIV","content_type":"box","pages":"34","caption":"Box 2.1 Guidance for assessment of the joint burden of TB and HIV","tokens_est":245,"char_count":979,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0125","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.2 Conduct an analysis of access to quality services for TB and HIV | 2.2.1 Assess the joint burden of TB and HIV | Box 2.1 Guidance for assessment of the joint burden of TB and HIV","content_type":"box","pages":"34","caption":"Box 2.1 Guidance for assessment of the joint burden of TB and HIV","tokens_est":166,"char_count":661,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0126","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.2 Conduct an analysis of access to quality services for TB and HIV | 2.2.1 Assess the joint burden of TB and HIV | Box 2.1 Guidance for assessment of the joint burden of TB and HIV","content_type":"box","pages":"34","caption":"Box 2.1 Guidance for assessment of the joint burden of TB and HIV","tokens_est":104,"char_count":413,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0127","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.2 Conduct an analysis of access to quality services for TB and HIV | 2.2.1 Assess the joint burden of TB and HIV","content_type":"text","pages":"34","tokens_est":196,"char_count":782,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0128","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.2 Conduct an analysis of access to quality services for TB and HIV | 2.2.1 Assess the joint burden of TB and HIV","content_type":"text","pages":"34","tokens_est":171,"char_count":683,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0129","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.2 Conduct an analysis of access to quality services for TB and HIV | 2.2.2 Determine access to services and the financial burden for people with TB and HIV","content_type":"text","pages":"35","tokens_est":228,"char_count":910,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0130","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.2 Conduct an analysis of access to quality services for TB and HIV | 2.2.2 Determine access to services and the financial burden for people with TB and HIV","content_type":"text","pages":"35","tokens_est":84,"char_count":334,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0131","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.2 Conduct an analysis of access to quality services for TB and HIV | 2.2.3 Map health service delivery for TB and HIV","content_type":"text","pages":"35","tokens_est":231,"char_count":922,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0132","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.2 Conduct an analysis of access to quality services for TB and HIV | 2.2.3 Map health service delivery for TB and HIV","content_type":"text","pages":"35","tokens_est":130,"char_count":520,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0133","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.2 Conduct an analysis of access to quality services for TB and HIV | 2.2.4 Identify gaps in services and conduct root cause analysis","content_type":"text","pages":"35","tokens_est":96,"char_count":381,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0134","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.1 Identify priority comorbidities and interventions","content_type":"text","pages":"35","tokens_est":96,"char_count":384,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0135","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.1 Identify priority comorbidities and interventions","content_type":"text","pages":"35-36","tokens_est":227,"char_count":905,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0136","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.1 Identify priority comorbidities and interventions","content_type":"text","pages":"36","tokens_est":150,"char_count":600,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0137","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.2 Define and reorient models of care for HIV-associated TB and other comorbidities towards people- centred services, primary health care and universal health coverage","content_type":"text","pages":"36","tokens_est":238,"char_count":949,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0138","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.2 Define and reorient models of care for HIV-associated TB and other comorbidities towards people- centred services, primary health care and universal health coverage","content_type":"text","pages":"36","tokens_est":218,"char_count":872,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0139","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.2 Define and reorient models of care for HIV-associated TB and other comorbidities towards people- centred services, primary health care and universal health coverage","content_type":"text","pages":"36","tokens_est":233,"char_count":932,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0140","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.2 Define and reorient models of care for HIV-associated TB and other comorbidities towards people- centred services, primary health care and universal health coverage","content_type":"text","pages":"36","tokens_est":79,"char_count":316,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0141","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.2 Define and reorient models of care for HIV-associated TB and other comorbidities towards people- centred services, primary health care and universal health coverage | Box 2.2 Models of service delivery for HIV-associated TB","content_type":"box","pages":"37","caption":"Box 2.2 Models of service delivery for HIV-associated TB","tokens_est":175,"char_count":698,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0142","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.2 Define and reorient models of care for HIV-associated TB and other comorbidities towards people- centred services, primary health care and universal health coverage | Box 2.2 Models of service delivery for HIV-associated TB","content_type":"box","pages":"37","caption":"Box 2.2 Models of service delivery for HIV-associated TB","tokens_est":148,"char_count":591,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0143","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.2 Define and reorient models of care for HIV-associated TB and other comorbidities towards people- centred services, primary health care and universal health coverage | Box 2.2 Models of service delivery for HIV-associated TB","content_type":"box","pages":"37","caption":"Box 2.2 Models of service delivery for HIV-associated TB","tokens_est":140,"char_count":558,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0144","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.2 Define and reorient models of care for HIV-associated TB and other comorbidities towards people- centred services, primary health care and universal health coverage | Box 2.2 Models of service delivery for HIV-associated TB","content_type":"box","pages":"37","caption":"Box 2.2 Models of service delivery for HIV-associated TB","tokens_est":218,"char_count":870,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0145","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.2 Define and reorient models of care for HIV-associated TB and other comorbidities towards people- centred services, primary health care and universal health coverage | Box 2.2 Models of service delivery for HIV-associated TB","content_type":"box","pages":"37","caption":"Box 2.2 Models of service delivery for HIV-associated TB","tokens_est":187,"char_count":746,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0146","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.3 Conduct collaborative planning and budgeting to scale up people- centred services for TB and HIV","content_type":"text","pages":"37-38","tokens_est":220,"char_count":877,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0147","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.3 Conduct collaborative planning and budgeting to scale up people- centred services for TB and HIV","content_type":"text","pages":"37-38","tokens_est":122,"char_count":486,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0148","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.4 Align advocacy and communication across health programmes","content_type":"text","pages":"38","tokens_est":228,"char_count":912,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0149","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.4 Align advocacy and communication across health programmes","content_type":"text","pages":"38","tokens_est":61,"char_count":242,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0150","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.4 Implement and scale up people- centred services for HIV-associated TB | 2.4.1 Jointly develop policies, guidelines and procedures for collaborative TB/HIV activities","content_type":"text","pages":"38","tokens_est":150,"char_count":599,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0151","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.4 Implement and scale up people- centred services for HIV-associated TB | 2.4.2 Mobilize a qualified multidisciplinary workforce, including among private providers and non-health sectors for collaborative action","content_type":"text","pages":"38","tokens_est":202,"char_count":805,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0152","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.4 Implement and scale up people- centred services for HIV-associated TB | 2.4.3 Ensure access to essential medicines, vaccines, diagnostics and health technologies for TB and HIV","content_type":"text","pages":"39","tokens_est":171,"char_count":681,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0153","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.4 Implement and scale up people- centred services for HIV-associated TB | 2.4.3 Ensure access to essential medicines, vaccines, diagnostics and health technologies for TB and HIV | Box 2.3 Key actions to ensure access to essential medicines, vaccines, diagnostics and health technologies:","content_type":"box","pages":"39","caption":"Box 2.3 Key actions to ensure access to essential medicines, vaccines, diagnostics and health technologies:","tokens_est":226,"char_count":902,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0154","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.4 Implement and scale up people- centred services for HIV-associated TB | 2.4.3 Ensure access to essential medicines, vaccines, diagnostics and health technologies for TB and HIV | Box 2.3 Key actions to ensure access to essential medicines, vaccines, diagnostics and health technologies:","content_type":"box","pages":"39","caption":"Box 2.3 Key actions to ensure access to essential medicines, vaccines, diagnostics and health technologies:","tokens_est":103,"char_count":409,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0155","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.4 Implement and scale up people- centred services for HIV-associated TB | 2.4.4 Engage civil society and communities affected by TB and HIV in refining and delivering people- centred services","content_type":"text","pages":"39","tokens_est":235,"char_count":937,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0156","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.4 Implement and scale up people- centred services for HIV-associated TB | 2.4.4 Engage civil society and communities affected by TB and HIV in refining and delivering people- centred services","content_type":"text","pages":"39","tokens_est":87,"char_count":345,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0157","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.4 Implement and scale up people- centred services for HIV-associated TB | 2.4.4 Engage civil society and communities affected by TB and HIV in refining and delivering people- centred services","content_type":"text","pages":"39-40","tokens_est":240,"char_count":959,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0158","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.4 Implement and scale up people- centred services for HIV-associated TB | 2.4.5 Address the needs of key, vulnerable and at-risk populations | Box 2.4 Good practice and guidance statements on critical enablers for key populations","content_type":"box","pages":"40","caption":"Box 2.4 Good practice and guidance statements on critical enablers for key populations","tokens_est":197,"char_count":786,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0159","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.4 Implement and scale up people- centred services for HIV-associated TB | 2.4.5 Address the needs of key, vulnerable and at-risk populations | Box 2.4 Good practice and guidance statements on critical enablers for key populations","content_type":"box","pages":"40","caption":"Box 2.4 Good practice and guidance statements on critical enablers for key populations","tokens_est":243,"char_count":969,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0160","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.4 Implement and scale up people- centred services for HIV-associated TB | 2.4.5 Address the needs of key, vulnerable and at-risk populations | Box 2.4 Good practice and guidance statements on critical enablers for key populations","content_type":"box","pages":"40","caption":"Box 2.4 Good practice and guidance statements on critical enablers for key populations","tokens_est":129,"char_count":516,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0161","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.4 Implement and scale up people- centred services for HIV-associated TB | 2.4.5 Address the needs of key, vulnerable and at-risk populations","content_type":"text","pages":"40-41","tokens_est":230,"char_count":920,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0162","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.4 Implement and scale up people- centred services for HIV-associated TB | 2.4.5 Address the needs of key, vulnerable and at-risk populations","content_type":"text","pages":"40-41","tokens_est":41,"char_count":162,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0163","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.4 Implement and scale up people- centred services for HIV-associated TB | 2.4.5 Address the needs of key, vulnerable and at-risk populations","content_type":"text","pages":"41","tokens_est":215,"char_count":857,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0164","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.4 Implement and scale up people- centred services for HIV-associated TB | 2.4.5 Address the needs of key, vulnerable and at-risk populations | 2.4.6 Facilitate access to social protection to prevent financial hardship due to TB and HIV","content_type":"text","pages":"41","tokens_est":178,"char_count":709,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0165","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.4 Implement and scale up people- centred services for HIV-associated TB | 2.4.5 Address the needs of key, vulnerable and at-risk populations | 2.4.7 Facilitate uptake of digital technologies to deliver health and social protection services across programmes","content_type":"text","pages":"41","tokens_est":121,"char_count":482,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0166","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.4 Implement and scale up people- centred services for HIV-associated TB | 2.4.5 Address the needs of key, vulnerable and at-risk populations | 2.4.7 Facilitate uptake of digital technologies to deliver health and social protection services across programmes | Box 2.5 Prevent TB: a prototype mobile application to support programmatic management of TPT and screening","content_type":"box","pages":"41-42","caption":"Box 2.5 Prevent TB: a prototype mobile application to support programmatic management of TPT and screening","tokens_est":201,"char_count":801,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0167","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.4 Implement and scale up people- centred services for HIV-associated TB | 2.4.5 Address the needs of key, vulnerable and at-risk populations | 2.4.7 Facilitate uptake of digital technologies to deliver health and social protection services across programmes | Box 2.5 Prevent TB: a prototype mobile application to support programmatic management of TPT and screening","content_type":"box","pages":"41-42","caption":"Box 2.5 Prevent TB: a prototype mobile application to support programmatic management of TPT and screening","tokens_est":147,"char_count":587,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0168","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.4 Implement and scale up people- centred services for HIV-associated TB | 2.4.5 Address the needs of key, vulnerable and at-risk populations | 2.4.8 Scale up people- centred services for TB and HIV","content_type":"text","pages":"42","tokens_est":208,"char_count":832,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0169","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.5 Strengthen monitoring, evaluation and research | 2.5.1 Adopt indicators and set targets for collaborative TB/HIV activities","content_type":"text","pages":"42","tokens_est":243,"char_count":972,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0170","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.5 Strengthen monitoring, evaluation and research | 2.5.2 Strengthen surveillance for HIV among people with TB, and surveillance for TB among people with HIV in accordance with WHO recommendations","content_type":"text","pages":"42","tokens_est":212,"char_count":847,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0171","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.5 Strengthen monitoring, evaluation and research | 2.5.2 Strengthen surveillance for HIV among people with TB, and surveillance for TB among people with HIV in accordance with WHO recommendations | Box 2.6 Guidance for strengthening surveillance of HIV-associated TB","content_type":"box","pages":"42-43","caption":"Box 2.6 Guidance for strengthening surveillance of HIV-associated TB","tokens_est":196,"char_count":781,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0172","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.5 Strengthen monitoring, evaluation and research | 2.5.2 Strengthen surveillance for HIV among people with TB, and surveillance for TB among people with HIV in accordance with WHO recommendations | Box 2.6 Guidance for strengthening surveillance of HIV-associated TB","content_type":"box","pages":"43","caption":"Box 2.6 Guidance for strengthening surveillance of HIV-associated TB","tokens_est":238,"char_count":950,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0173","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.5 Strengthen monitoring, evaluation and research | 2.5.2 Strengthen surveillance for HIV among people with TB, and surveillance for TB among people with HIV in accordance with WHO recommendations | Box 2.6 Guidance for strengthening surveillance of HIV-associated TB","content_type":"box","pages":"43","caption":"Box 2.6 Guidance for strengthening surveillance of HIV-associated TB","tokens_est":37,"char_count":145,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0174","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.5 Strengthen monitoring, evaluation and research | 2.5.3 Introduce and scale up monitoring and evaluation of collaborative TB/HIV activities at all levels","content_type":"text","pages":"43","tokens_est":162,"char_count":648,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0175","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.5 Strengthen monitoring, evaluation and research | 2.5.3 Introduce and scale up monitoring and evaluation of collaborative TB/HIV activities at all levels","content_type":"text","pages":"43","tokens_est":237,"char_count":947,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0176","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.5 Strengthen monitoring, evaluation and research | 2.5.3 Introduce and scale up monitoring and evaluation of collaborative TB/HIV activities at all levels","content_type":"text","pages":"43","tokens_est":59,"char_count":235,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0177","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.5 Strengthen monitoring, evaluation and research | 2.5.4 Conduct joint reviews of quality and coverage of services to inform programming","content_type":"text","pages":"43","tokens_est":100,"char_count":398,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0178","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.5 Strengthen monitoring, evaluation and research | 2.5.4 Conduct joint reviews of quality and coverage of services to inform programming","content_type":"text","pages":"43-44","tokens_est":182,"char_count":725,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0179","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for HIV-associated TB | 2.5 Strengthen monitoring, evaluation and research | 2.5.5 Conduct operational and implementation research to inform policy, programming and service delivery","content_type":"text","pages":"44","tokens_est":214,"char_count":853,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0180","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV","content_type":"text","pages":"45","tokens_est":241,"char_count":962,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0181","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.1 TB screening","content_type":"text","pages":"45","tokens_est":213,"char_count":849,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0182","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.1 TB screening","content_type":"text","pages":"45","tokens_est":189,"char_count":753,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0183","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.1 TB screening","content_type":"text","pages":"45","tokens_est":75,"char_count":300,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0184","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.1 TB screening | 3.1.1 Frequency of screening","content_type":"text","pages":"45-46","tokens_est":181,"char_count":722,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0185","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.1 TB screening | 3.1.2 Screening tools","content_type":"text","pages":"46","tokens_est":76,"char_count":304,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0186","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.1 TB screening | 3.1.2 Screening tools | WHO-recommended four symptom screen","content_type":"text","pages":"46","tokens_est":246,"char_count":981,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0187","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.1 TB screening | 3.1.2 Screening tools | WHO-recommended four symptom screen","content_type":"text","pages":"46","tokens_est":198,"char_count":790,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0188","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.1 TB screening | 3.1.2 Screening tools | WHO-recommended four symptom screen","content_type":"text","pages":"46","tokens_est":178,"char_count":711,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0189","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.1 TB screening | 3.1.2 Screening tools | WHO-recommended four symptom screen","content_type":"text","pages":"46","tokens_est":185,"char_count":739,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0190","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.1 TB screening | 3.1.2 Screening tools | C-reactive protein","content_type":"text","pages":"47","tokens_est":247,"char_count":986,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0191","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.1 TB screening | 3.1.2 Screening tools | C-reactive protein","content_type":"text","pages":"47","tokens_est":219,"char_count":874,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0192","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.1 TB screening | 3.1.2 Screening tools | C-reactive protein","content_type":"text","pages":"47","tokens_est":79,"char_count":314,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0193","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.1 TB screening | 3.1.2 Screening tools | C-reactive protein","content_type":"text","pages":"47","tokens_est":242,"char_count":966,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0194","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.1 TB screening | 3.1.2 Screening tools | C-reactive protein","content_type":"text","pages":"47","tokens_est":159,"char_count":635,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0195","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.1 TB screening | 3.1.2 Screening tools | Chest radiography","content_type":"text","pages":"47-48","tokens_est":137,"char_count":548,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0196","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.1 TB screening | 3.1.2 Screening tools | Chest radiography","content_type":"text","pages":"48","tokens_est":142,"char_count":566,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0197","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.1 TB screening | 3.1.2 Screening tools | Chest radiography","content_type":"text","pages":"48","tokens_est":231,"char_count":924,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0198","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.1 TB screening | 3.1.2 Screening tools | Chest radiography","content_type":"text","pages":"48","tokens_est":197,"char_count":788,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0199","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.1 TB screening | 3.1.2 Screening tools | Chest radiography","content_type":"text","pages":"48","tokens_est":146,"char_count":581,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0200","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.1 TB screening | 3.1.2 Screening tools | Chest radiography","content_type":"text","pages":"48-49","tokens_est":242,"char_count":966,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0201","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.1 TB screening | 3.1.2 Screening tools | Chest radiography","content_type":"text","pages":"48-49","tokens_est":52,"char_count":206,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0202","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.1 TB screening | 3.1.2 Screening tools | Molecular WHO-recommended rapid TB diagnostic tests","content_type":"text","pages":"49","tokens_est":222,"char_count":888,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0203","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.1 TB screening | 3.1.2 Screening tools | Molecular WHO-recommended rapid TB diagnostic tests","content_type":"text","pages":"49","tokens_est":108,"char_count":429,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0204","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.1 TB screening | 3.1.2 Screening tools | Molecular WHO-recommended rapid TB diagnostic tests","content_type":"text","pages":"49","tokens_est":208,"char_count":829,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0205","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.1 TB screening | 3.1.2 Screening tools | Molecular WHO-recommended rapid TB diagnostic tests","content_type":"text","pages":"49","tokens_est":244,"char_count":975,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0206","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.1 TB screening | 3.1.2 Screening tools | Molecular WHO-recommended rapid TB diagnostic tests","content_type":"text","pages":"49","tokens_est":174,"char_count":694,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0207","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.1 TB screening | 3.1.2 Screening tools | Molecular WHO-recommended rapid TB diagnostic tests","content_type":"text","pages":"49-51","tokens_est":177,"char_count":706,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0208","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.2 TB diagnosis","content_type":"text","pages":"52","tokens_est":239,"char_count":956,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0209","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.2 TB diagnosis","content_type":"text","pages":"52","tokens_est":175,"char_count":698,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0210","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.2 TB diagnosis","content_type":"text","pages":"52","tokens_est":131,"char_count":522,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0211","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.2 TB diagnosis","content_type":"text","pages":"52-53","tokens_est":240,"char_count":957,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0212","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.2 TB diagnosis","content_type":"text","pages":"53","tokens_est":172,"char_count":685,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0213","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.2 TB diagnosis","content_type":"text","pages":"53","tokens_est":165,"char_count":660,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0214","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.2 TB diagnosis","content_type":"text","pages":"53","tokens_est":191,"char_count":763,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0215","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.2 TB diagnosis","content_type":"text","pages":"53","tokens_est":200,"char_count":798,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0216","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.2 TB diagnosis","content_type":"text","pages":"53","tokens_est":72,"char_count":288,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0217","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.2 TB diagnosis | Table 3.1. WHO-recommended rapid diagnostic tests as initial tests for TB diagnosis","content_type":"table","pages":"54","caption":"Table 1.1 summarizes all existing WHO recommendations2 that relate to HIV-associated TB in adults, as published in the WHO consolidated guidelines on tuberculosis. Module 6: tuberculosis and comorbidities. HIV-associated TB (in press). Some recommendations will however also be relevant for children and adolescents. A full summary of recommendations on HIV-associated TB for children and adolescents specifically, can be found in the WHO consolidated guidelines on tuberculosis. Module 5: management of TB in children and adolescents (8). Other recommendations for TB screening, diagnosis, treatment and care for people regardless of HIV status are also applicable and have been published in the respective modules of the WHO consolidated guidelines on tuberculosis (8-15).","tokens_est":206,"char_count":1466,"has_attachment":true,"attachment_id":"Table 1.1","attachment_path":"tables/WHO_TB_handbook_module6_comorbidities_2024/Table_1.1.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0218","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.2 TB diagnosis | 3.2.1 Initial diagnostic tests for diagnosis of TB with drug-resistance detection","content_type":"text","pages":"54-55","tokens_est":121,"char_count":481,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0219","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.2 TB diagnosis | 3.2.1 Initial diagnostic tests for diagnosis of TB with drug-resistance detection","content_type":"text","pages":"55","tokens_est":217,"char_count":867,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0220","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.2 TB diagnosis | 3.2.1 Initial diagnostic tests for diagnosis of TB with drug-resistance detection","content_type":"text","pages":"55","tokens_est":93,"char_count":369,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0221","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.2 TB diagnosis | 3.2.1 Initial diagnostic tests for diagnosis of TB with drug-resistance detection","content_type":"text","pages":"55","tokens_est":216,"char_count":861,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0222","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.2 TB diagnosis | 3.2.1 Initial diagnostic tests for diagnosis of TB with drug-resistance detection","content_type":"text","pages":"55","tokens_est":154,"char_count":616,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0223","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.2 TB diagnosis | 3.2.1 Initial diagnostic tests for diagnosis of TB with drug-resistance detection | Box 3.1 Extrapulmonary and disseminated TB","content_type":"box","pages":"55","caption":"Box 3.1 Extrapulmonary and disseminated TB","tokens_est":185,"char_count":738,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0224","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.2 TB diagnosis | 3.2.1 Initial diagnostic tests for diagnosis of TB with drug-resistance detection | Box 3.1 Extrapulmonary and disseminated TB","content_type":"box","pages":"55-56","caption":"Box 3.1 Extrapulmonary and disseminated TB","tokens_est":245,"char_count":980,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0225","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.2 TB diagnosis | 3.2.1 Initial diagnostic tests for diagnosis of TB with drug-resistance detection | Box 3.1 Extrapulmonary and disseminated TB","content_type":"box","pages":"55-56","caption":"Box 3.1 Extrapulmonary and disseminated TB","tokens_est":84,"char_count":333,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0226","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.2 TB diagnosis | 3.2.1 Initial diagnostic tests for diagnosis of TB with drug-resistance detection | Box 3.1 Extrapulmonary and disseminated TB","content_type":"box","pages":"56","caption":"Box 3.1 Extrapulmonary and disseminated TB","tokens_est":147,"char_count":586,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0227","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.2 TB diagnosis | 3.2.2 Urine LF-LAM","content_type":"text","pages":"56","tokens_est":177,"char_count":707,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0228","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.2 TB diagnosis | 3.2.2 Urine LF-LAM","content_type":"text","pages":"56","tokens_est":133,"char_count":531,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0229","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.2 TB diagnosis | 3.2.2 Urine LF-LAM","content_type":"text","pages":"56","tokens_est":250,"char_count":997,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0230","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.2 TB diagnosis | 3.2.2 Urine LF-LAM","content_type":"text","pages":"56","tokens_est":75,"char_count":297,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0231","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.2 TB diagnosis | 3.2.2 Urine LF-LAM | Box 3.2 Steps and processes for introducing and scaling up a new diagnostic test","content_type":"box","pages":"57","caption":"Box 3.2 Steps and processes for introducing and scaling up a new diagnostic test","tokens_est":232,"char_count":926,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0232","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.2 TB diagnosis | 3.2.3 Clinical diagnosis of TB","content_type":"text","pages":"57","tokens_est":180,"char_count":718,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0233","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.2 TB diagnosis | 3.2.3 Clinical diagnosis of TB","content_type":"text","pages":"57","tokens_est":177,"char_count":705,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0234","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.2 TB diagnosis | 3.2.3 Clinical diagnosis of TB","content_type":"text","pages":"57","tokens_est":76,"char_count":302,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0235","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.3 Algorithms for informing the decision to treat TB infection or TB disease among people living with HIV","content_type":"text","pages":"57-58","tokens_est":215,"char_count":857,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0236","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.3 Algorithms for informing the decision to treat TB infection or TB disease among people living with HIV","content_type":"text","pages":"58","tokens_est":198,"char_count":789,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0237","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.3 Algorithms for informing the decision to treat TB infection or TB disease among people living with HIV | Fig. 3.1. Placement of screening tools and initial diagnostic tests","content_type":"figure","pages":"58","caption":"Fig. 3.1. Placement of screening tools and initial diagnostic tests","tokens_est":79,"char_count":315,"has_attachment":true,"attachment_id":"Fig. 3.1.","attachment_path":"figures/WHO_TB_handbook_module6_comorbidities_2024/Fig. 3.1..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0238","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.3 Algorithms for informing the decision to treat TB infection or TB disease among people living with HIV","content_type":"text","pages":"58","tokens_est":226,"char_count":904,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0239","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.3 Algorithms for informing the decision to treat TB infection or TB disease among people living with HIV","content_type":"text","pages":"58","tokens_est":184,"char_count":736,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0240","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.3 Algorithms for informing the decision to treat TB infection or TB disease among people living with HIV | Table 3.2. Summary of algorithms for screening and diagnosing TB among people living with HIV","content_type":"table","pages":"58-70","caption":"Table 3.2. Summary of algorithms for screening and diagnosing TB among people living with HIV","tokens_est":36,"char_count":403,"has_attachment":true,"attachment_id":"Table 3.2.","attachment_path":"tables/WHO_TB_handbook_module6_comorbidities_2024/Table_3.2..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0241","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.3 Algorithms for informing the decision to treat TB infection or TB disease among people living with HIV","content_type":"text","pages":"70","tokens_est":235,"char_count":940,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0242","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.3 Algorithms for informing the decision to treat TB infection or TB disease among people living with HIV","content_type":"text","pages":"70","tokens_est":95,"char_count":377,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0243","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.3 Algorithms for informing the decision to treat TB infection or TB disease among people living with HIV | Algorithms for screening and diagnosis of TB among people living with HIV | Figure 3.2.1. Algorithm 1: W4SS followed by LF-LAM and mWRD","content_type":"figure","pages":"71","caption":"Figure 3.2.1. Algorithm 1: W4SS followed by LF-LAM and mWRD","tokens_est":104,"char_count":415,"has_attachment":true,"attachment_id":"Figure 3.2.1.","attachment_path":"figures/WHO_TB_handbook_module6_comorbidities_2024/Figure 3.2.1..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0244","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.3 Algorithms for informing the decision to treat TB infection or TB disease among people living with HIV | Algorithms for screening and diagnosis of TB among people living with HIV | Figure 3.2.2. W4SS and CXR followed by LF-LAM and mWRD","content_type":"figure","pages":"71","caption":"Figure 3.2.2. W4SS and CXR followed by LF-LAM and mWRD","tokens_est":109,"char_count":433,"has_attachment":true,"attachment_id":"Figure 3.2.2.","attachment_path":"figures/WHO_TB_handbook_module6_comorbidities_2024/Figure 3.2.2..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0245","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.3 Algorithms for informing the decision to treat TB infection or TB disease among people living with HIV | Algorithms for screening and diagnosis of TB among people living with HIV | Figure 3.2.3. Algorithm 3: W4SS followed by CRP followed by LF-LAM and mWRD","content_type":"figure","pages":"71","caption":"Figure 3.2.3. Algorithm 3: W4SS followed by CRP followed by LF-LAM and mWRD","tokens_est":110,"char_count":438,"has_attachment":true,"attachment_id":"Figure 3.2.3.","attachment_path":"figures/WHO_TB_handbook_module6_comorbidities_2024/Figure 3.2.3..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0246","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.3 Algorithms for informing the decision to treat TB infection or TB disease among people living with HIV | Algorithms for screening and diagnosis of TB among people living with HIV | Figure 3.2.4. Algorithm 4: LF-LAM and mWRD for medical inpatients living with HIV or people living with HIV who are seriously ill and require hospitalization in facilities where TB prevalence is >10%","content_type":"figure","pages":"71-72","caption":"Figure 3.2.4. Algorithm 4: LF-LAM and mWRD for medical inpatients living with HIV or people living with HIV who are seriously ill and require hospitalization in facilities where TB prevalence is >10%","tokens_est":271,"char_count":1081,"has_attachment":true,"attachment_id":"Figure 3.2.4.","attachment_path":"figures/WHO_TB_handbook_module6_comorbidities_2024/Figure 3.2.4..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0247","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.3 Algorithms for informing the decision to treat TB infection or TB disease among people living with HIV | Algorithms for screening and diagnosis of TB among people living with HIV | Figure 3.2.5. Algorithm 5: Clinical diagnosis of TB in people living with HIV who are seriously ill","content_type":"figure","pages":"72","caption":"Figure 3.2.5. Algorithm 5: Clinical diagnosis of TB in people living with HIV who are seriously ill","tokens_est":454,"char_count":1814,"has_attachment":true,"attachment_id":"Figure 3.2.5.","attachment_path":"figures/WHO_TB_handbook_module6_comorbidities_2024/Figure 3.2.5..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0248","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.4 TB treatment","content_type":"text","pages":"72","tokens_est":193,"char_count":771,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0249","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.4 TB treatment | 3.4.1 WHO-recommended treatment regimens for adults with drug-susceptible TB","content_type":"text","pages":"72","tokens_est":247,"char_count":986,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0250","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.4 TB treatment | 3.4.1 WHO-recommended treatment regimens for adults with drug-susceptible TB","content_type":"text","pages":"72","tokens_est":153,"char_count":609,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0251","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.4 TB treatment | 3.4.1 WHO-recommended treatment regimens for adults with drug-susceptible TB | 3.4.1.1 Six -month TB treatment regimen for adults living with HIV","content_type":"text","pages":"72","tokens_est":172,"char_count":685,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0252","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.4 TB treatment | 3.4.1 WHO-recommended treatment regimens for adults with drug-susceptible TB | 3.4.1.1 Six -month TB treatment regimen for adults living with HIV","content_type":"text","pages":"72","tokens_est":221,"char_count":882,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0253","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.4 TB treatment | 3.4.1 WHO-recommended treatment regimens for adults with drug-susceptible TB | 3.4.1.1 Six -month TB treatment regimen for adults living with HIV","content_type":"text","pages":"72","tokens_est":74,"char_count":294,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0254","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.4 TB treatment | 3.4.1 WHO-recommended treatment regimens for adults with drug-susceptible TB | 3.4.1.1 Six -month TB treatment regimen for adults living with HIV","content_type":"text","pages":"72","tokens_est":158,"char_count":630,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0255","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.4 TB treatment | 3.4.1 WHO-recommended treatment regimens for adults with drug-susceptible TB | 3.4.1.2 Four-month TB treatment regimen for adults living with HIV","content_type":"text","pages":"73","tokens_est":233,"char_count":932,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0256","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.4 TB treatment | 3.4.1 WHO-recommended treatment regimens for adults with drug-susceptible TB | 3.4.1.2 Four-month TB treatment regimen for adults living with HIV","content_type":"text","pages":"73","tokens_est":215,"char_count":858,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0257","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.4 TB treatment | 3.4.1 WHO-recommended treatment regimens for adults with drug-susceptible TB | Table 3.3. Treatment regimens for drug-susceptible TB","content_type":"table","pages":"73","caption":"Table 3.3. Treatment regimens for drug-susceptible TB","tokens_est":28,"char_count":570,"has_attachment":true,"attachment_id":"Table 3.3.","attachment_path":"tables/WHO_TB_handbook_module6_comorbidities_2024/Table_3.3..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0258","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.4 TB treatment | 3.4.1 WHO-recommended treatment regimens for adults with drug-susceptible TB | 3.4.2 WHO-recommended treatment regimens for drug-resistant TB","content_type":"text","pages":"74","tokens_est":132,"char_count":525,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0259","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.4 TB treatment | 3.4.1 WHO-recommended treatment regimens for adults with drug-susceptible TB | Table 3.4. Treatment regimens for drug-resistant TB","content_type":"table","pages":"74-78","caption":"Table 3.4 below provides a brief overview of treatment regimens for drug-resistant TB; detailed guidance is published in the WHO consolidated guidelines on tuberculosis. Module 4: treatment  drug-resistant tuberculosis treatment, 2022 update (10) and the accompanying operational handbook (104) . People living with HIV and drug-resistant TB are generally eligible for all the currently available TB treatment regimens, but due care should be taken to monitor for adverse events and drug drug interactions. Detailed guidance on caution when administering treatment for drug-resistant TB together with ART is available in the WHO consolidated guidelines on tuberculosis. Module 4: treatment  drug-resistant tuberculosis treatment, 2022 update (104) , and in the University of Liverpools HIV Drug Interactions resource ( www.hiv-druginteractions.org ) .","tokens_est":228,"char_count":1790,"has_attachment":true,"attachment_id":"Table 3.4","attachment_path":"tables/WHO_TB_handbook_module6_comorbidities_2024/Table_3.4.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0260","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.4 TB treatment | 3.4.1 WHO-recommended treatment regimens for adults with drug-susceptible TB | 3.4.3 TB treatment for people with HIV-associated TB and histoplasmosis","content_type":"text","pages":"78","tokens_est":226,"char_count":902,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0261","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.4 TB treatment | 3.4.1 WHO-recommended treatment regimens for adults with drug-susceptible TB | 3.4.4 TB care and support","content_type":"text","pages":"79","tokens_est":207,"char_count":827,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0262","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.4 TB treatment | 3.4.1 WHO-recommended treatment regimens for adults with drug-susceptible TB | 3.4.4 TB care and support","content_type":"text","pages":"79","tokens_est":230,"char_count":917,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0263","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.4 TB treatment | 3.4.1 WHO-recommended treatment regimens for adults with drug-susceptible TB | 3.4.4 TB care and support","content_type":"text","pages":"79","tokens_est":233,"char_count":931,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0264","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.4 TB treatment | 3.4.1 WHO-recommended treatment regimens for adults with drug-susceptible TB | 3.4.4 TB care and support","content_type":"text","pages":"79","tokens_est":118,"char_count":469,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0265","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment","content_type":"text","pages":"79-80","tokens_est":158,"char_count":630,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0266","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment","content_type":"text","pages":"80","tokens_est":215,"char_count":860,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0267","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment","content_type":"text","pages":"80","tokens_est":201,"char_count":804,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0268","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment","content_type":"text","pages":"80","tokens_est":158,"char_count":630,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0269","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment","content_type":"text","pages":"80","tokens_est":228,"char_count":912,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0270","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.1 Eligibility for TB preventive treatment","content_type":"text","pages":"81","tokens_est":191,"char_count":761,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0271","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.2 Ruling out TB disease prior to offering TB preventive treatment","content_type":"text","pages":"81","tokens_est":103,"char_count":412,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0272","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.2 Ruling out TB disease prior to offering TB preventive treatment","content_type":"text","pages":"81","tokens_est":188,"char_count":750,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0273","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.2 Ruling out TB disease prior to offering TB preventive treatment","content_type":"text","pages":"81","tokens_est":223,"char_count":890,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0274","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.2 Ruling out TB disease prior to offering TB preventive treatment","content_type":"text","pages":"81","tokens_est":123,"char_count":492,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0275","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.2 Ruling out TB disease prior to offering TB preventive treatment","content_type":"text","pages":"81","tokens_est":120,"char_count":480,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0276","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.2 Ruling out TB disease prior to offering TB preventive treatment | Figure 3.5.1: Algorithm 6: Algorithm to rule out TB disease in people living with HIV","content_type":"figure","pages":"81","caption":"Figure 3.5.1: Algorithm 6: Algorithm to rule out TB disease in people living with HIV","tokens_est":24,"char_count":95,"has_attachment":true,"attachment_id":"Figure 3.5.1","attachment_path":"figures/WHO_TB_handbook_module6_comorbidities_2024/Figure 3.5.1.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0277","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.2 Ruling out TB disease prior to offering TB preventive treatment | Table 3.5. Key considerations for assessment of eligibility for TPT in people living with HIV (113)","content_type":"table","pages":"82","caption":"Table 3.5. Key considerations for assessment of eligibility for TPT in people living with HIV (113)","tokens_est":56,"char_count":223,"has_attachment":true,"attachment_id":"Table 3.5.","attachment_path":"tables/WHO_TB_handbook_module6_comorbidities_2024/Table_3.5..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0278","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.3 Testing for TB infection","content_type":"text","pages":"82","tokens_est":199,"char_count":795,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0279","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.3 Testing for TB infection","content_type":"text","pages":"82-83","tokens_est":207,"char_count":826,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0280","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.3 Testing for TB infection","content_type":"text","pages":"83","tokens_est":240,"char_count":959,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0281","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.3 Testing for TB infection","content_type":"text","pages":"83","tokens_est":60,"char_count":239,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0282","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.4 TB preventive treatment regimens","content_type":"text","pages":"83","tokens_est":217,"char_count":866,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0283","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.4 TB preventive treatment regimens","content_type":"text","pages":"83","tokens_est":114,"char_count":456,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0284","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.4 TB preventive treatment regimens | Table 3.6. TB preventive treatment regimens","content_type":"table","pages":"84-91","caption":"Table 3.6. TB preventive treatment regimens","tokens_est":28,"char_count":1630,"has_attachment":true,"attachment_id":"Table 3.6.","attachment_path":"tables/WHO_TB_handbook_module6_comorbidities_2024/Table_3.6..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0285","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.4 TB preventive treatment regimens","content_type":"text","pages":"92","tokens_est":203,"char_count":809,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0286","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.4 TB preventive treatment regimens","content_type":"text","pages":"92","tokens_est":218,"char_count":869,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0287","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.4 TB preventive treatment regimens | TPT regimens and antiretrovirals","content_type":"text","pages":"93","tokens_est":212,"char_count":847,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0288","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.4 TB preventive treatment regimens | TPT regimens and antiretrovirals","content_type":"text","pages":"93","tokens_est":146,"char_count":582,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0289","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.4 TB preventive treatment regimens | Preventive treatment for MDR-TB","content_type":"text","pages":"93","tokens_est":206,"char_count":822,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0290","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.4 TB preventive treatment regimens | Liver function tests","content_type":"text","pages":"93","tokens_est":194,"char_count":776,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0291","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.4 TB preventive treatment regimens | Subpopulation considerations","content_type":"text","pages":"93-94","tokens_est":218,"char_count":871,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0292","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.4 TB preventive treatment regimens | Subpopulation considerations","content_type":"text","pages":"94","tokens_est":240,"char_count":959,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0293","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.4 TB preventive treatment regimens | Subpopulation considerations","content_type":"text","pages":"94","tokens_est":63,"char_count":250,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0294","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.4 TB preventive treatment regimens | Scale-up of TB preventive treatment","content_type":"text","pages":"94","tokens_est":223,"char_count":891,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0295","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.4 TB preventive treatment regimens | Fig. 3.2 Key enablers to scaling up TPT among people living with HIV","content_type":"figure","pages":"94","caption":"Fig. 3.2 Key enablers to scaling up TPT among people living with HIV","tokens_est":20,"char_count":78,"has_attachment":true,"attachment_id":"Fig. 3.2","attachment_path":"figures/WHO_TB_handbook_module6_comorbidities_2024/Fig. 3.2.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0296","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.4 TB preventive treatment regimens | 3.5.2 Infection prevention and control","content_type":"text","pages":"94","tokens_est":247,"char_count":986,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0297","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.4 TB preventive treatment regimens | 3.5.2 Infection prevention and control | Box 3.3 WHO recommendations on TB infection prevention and control","content_type":"box","pages":"94-95","caption":"Box 3.3 WHO recommendations on TB infection prevention and control","tokens_est":221,"char_count":882,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0298","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.4 TB preventive treatment regimens | 3.5.2 Infection prevention and control | Box 3.3 WHO recommendations on TB infection prevention and control","content_type":"box","pages":"95","caption":"Box 3.3 WHO recommendations on TB infection prevention and control","tokens_est":80,"char_count":319,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0299","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.4 TB preventive treatment regimens | 3.5.2 Infection prevention and control","content_type":"text","pages":"95","tokens_est":245,"char_count":977,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0300","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.4 TB preventive treatment regimens | 3.5.2 Infection prevention and control","content_type":"text","pages":"95","tokens_est":194,"char_count":774,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0301","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.4 TB preventive treatment regimens | 3.5.2 Infection prevention and control","content_type":"text","pages":"95-96","tokens_est":225,"char_count":897,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0302","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 3. Reduce the burden of TB among people living with HIV | 3.5 Prevention of TB | 3.5.1 TB preventive treatment | 3.5.1.4 TB preventive treatment regimens | 3.5.2 Infection prevention and control","content_type":"text","pages":"95-96","tokens_est":173,"char_count":690,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0303","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB","content_type":"text","pages":"97","tokens_est":234,"char_count":936,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0304","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB","content_type":"text","pages":"97","tokens_est":52,"char_count":206,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0305","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB","content_type":"text","pages":"97","tokens_est":185,"char_count":738,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0306","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB","content_type":"text","pages":"97","tokens_est":118,"char_count":472,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0307","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB","content_type":"text","pages":"97","tokens_est":154,"char_count":614,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0308","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB | Box 4.1 Summary of key considerations for scaling up HIV testing services among people with TB","content_type":"box","pages":"97-98","caption":"Box 4.1 Summary of key considerations for scaling up HIV testing services among people with TB","tokens_est":208,"char_count":830,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0309","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB | Box 4.1 Summary of key considerations for scaling up HIV testing services among people with TB","content_type":"box","pages":"98","caption":"Box 4.1 Summary of key considerations for scaling up HIV testing services among people with TB","tokens_est":92,"char_count":365,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0310","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB","content_type":"text","pages":"98","tokens_est":234,"char_count":936,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0311","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB","content_type":"text","pages":"98","tokens_est":65,"char_count":260,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0312","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB","content_type":"text","pages":"98","tokens_est":125,"char_count":497,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0313","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB | 4.1.1 HIV testing service delivery approaches","content_type":"text","pages":"98","tokens_est":224,"char_count":896,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0314","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB | 4.1.1 HIV testing service delivery approaches","content_type":"text","pages":"98","tokens_est":190,"char_count":759,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0315","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB | 4.1.1 HIV testing service delivery approaches | Box 4.2 WHO 5 Cs for HIV testing services:","content_type":"box","pages":"99","caption":"Box 4.2 WHO 5 Cs for HIV testing services:","tokens_est":197,"char_count":787,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0316","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB | 4.1.1 HIV testing service delivery approaches | Box 4.2 WHO 5 Cs for HIV testing services:","content_type":"box","pages":"99","caption":"Box 4.2 WHO 5 Cs for HIV testing services:","tokens_est":152,"char_count":606,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0317","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB | 4.1.1 HIV testing service delivery approaches | Box 4.2 WHO 5 Cs for HIV testing services:","content_type":"box","pages":"99","caption":"Box 4.2 WHO 5 Cs for HIV testing services:","tokens_est":190,"char_count":757,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0318","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB | 4.1.1 HIV testing service delivery approaches | Box 4.2 WHO 5 Cs for HIV testing services:","content_type":"box","pages":"99","caption":"Box 4.2 WHO 5 Cs for HIV testing services:","tokens_est":242,"char_count":967,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0319","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB | 4.1.1 HIV testing service delivery approaches","content_type":"text","pages":"99","tokens_est":133,"char_count":532,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0320","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB | 4.1.1 HIV testing service delivery approaches","content_type":"text","pages":"99-100","tokens_est":219,"char_count":873,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0321","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB | 4.1.1 HIV testing service delivery approaches","content_type":"text","pages":"99-100","tokens_est":116,"char_count":462,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0322","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB | 4.1.2 Algorithms for HIV testing","content_type":"text","pages":"100","tokens_est":208,"char_count":831,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0323","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB | 4.1.2 Algorithms for HIV testing","content_type":"text","pages":"100","tokens_est":82,"char_count":325,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0324","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB | 4.1.2 Algorithms for HIV testing","content_type":"text","pages":"100","tokens_est":242,"char_count":967,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0325","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB | 4.1.2 Algorithms for HIV testing | Fig. 4.1. WHO standard testing strategy for HIV-1 a diagnosis ( among children or adults 18 months of age)","content_type":"figure","pages":"100","caption":"Fig. 4.1. WHO standard testing strategy for HIV-1 a diagnosis ( among children or adults 18 months of age)","tokens_est":182,"char_count":727,"has_attachment":true,"attachment_id":"Fig. 4.1.","attachment_path":"figures/WHO_TB_handbook_module6_comorbidities_2024/Fig. 4.1..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0326","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB | 4.1.2 Algorithms for HIV testing","content_type":"text","pages":"100-101","tokens_est":237,"char_count":947,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0327","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB | 4.1.2 Algorithms for HIV testing","content_type":"text","pages":"100-101","tokens_est":54,"char_count":213,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0328","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB | 4.1.2 Algorithms for HIV testing | Fig. 4.2. Algorithm for self-testing for HIV","content_type":"figure","pages":"101","caption":"Fig. 4.2. Algorithm for self-testing for HIV","tokens_est":14,"char_count":54,"has_attachment":true,"attachment_id":"Fig. 4.2.","attachment_path":"figures/WHO_TB_handbook_module6_comorbidities_2024/Fig. 4.2..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0329","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB | 4.1.3 Retesting for HIV among people with TB","content_type":"text","pages":"101","tokens_est":30,"char_count":120,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0330","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB | 4.1.3 Retesting for HIV among people with TB","content_type":"text","pages":"101","tokens_est":233,"char_count":932,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0331","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB | 4.1.3 Retesting for HIV among people with TB","content_type":"text","pages":"101","tokens_est":237,"char_count":945,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0332","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB | 4.1.3 Retesting for HIV among people with TB","content_type":"text","pages":"101-102","tokens_est":223,"char_count":891,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0333","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB | 4.1.3 Retesting for HIV among people with TB","content_type":"text","pages":"101-102","tokens_est":103,"char_count":409,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0334","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB | 4.1.3 Retesting for HIV among people with TB","content_type":"text","pages":"102","tokens_est":144,"char_count":576,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0335","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB | 4.1.4 CD4 testing","content_type":"text","pages":"102","tokens_est":221,"char_count":883,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0336","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB | 4.1.4 CD4 testing","content_type":"text","pages":"102","tokens_est":219,"char_count":873,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0337","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.1 HIV testing services for people with presumptive and diagnosed TB | 4.1.4 CD4 testing","content_type":"text","pages":"102","tokens_est":98,"char_count":392,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0338","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB","content_type":"text","pages":"102-103","tokens_est":188,"char_count":749,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0339","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB","content_type":"text","pages":"103","tokens_est":217,"char_count":867,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0340","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB","content_type":"text","pages":"103","tokens_est":206,"char_count":824,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0341","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB","content_type":"text","pages":"103","tokens_est":178,"char_count":711,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0342","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.1 Rapid ART initiation, including among people with HIV and TB symptoms","content_type":"text","pages":"103","tokens_est":147,"char_count":588,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0343","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.1 Rapid ART initiation, including among people with HIV and TB symptoms","content_type":"text","pages":"103-104","tokens_est":248,"char_count":991,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0344","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.1 Rapid ART initiation, including among people with HIV and TB symptoms","content_type":"text","pages":"103-104","tokens_est":151,"char_count":603,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0345","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.2 ART initiation in people with HIV-associated TB","content_type":"text","pages":"104","tokens_est":217,"char_count":868,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0346","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.2 ART initiation in people with HIV-associated TB","content_type":"text","pages":"104","tokens_est":84,"char_count":334,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0347","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.2 ART initiation in people with HIV-associated TB | Box 4.3 ART initiation among people with signs and symptoms of meningitis","content_type":"box","pages":"104","caption":"Box 4.3 ART initiation among people with signs and symptoms of meningitis","tokens_est":205,"char_count":817,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0348","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.2 ART initiation in people with HIV-associated TB | Fig. 4.3. Time frame for ART initiation","content_type":"figure","pages":"104","caption":"Fig. 4.3. Time frame for ART initiation","tokens_est":127,"char_count":505,"has_attachment":true,"attachment_id":"Fig. 4.3.","attachment_path":"figures/WHO_TB_handbook_module6_comorbidities_2024/Fig. 4.3..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0349","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.2 ART initiation in people with HIV-associated TB","content_type":"text","pages":"104-105","tokens_est":93,"char_count":371,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0350","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.2 ART initiation in people with HIV-associated TB | Table 4.1. First-line ART regimens for adults and adolescents (17)","content_type":"table","pages":"105","caption":"Table 4.1. First-line ART regimens for adults and adolescents (17)","tokens_est":29,"char_count":960,"has_attachment":true,"attachment_id":"Table 4.1.","attachment_path":"tables/WHO_TB_handbook_module6_comorbidities_2024/Table_4.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0351","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.2 ART initiation in people with HIV-associated TB | Table 4.2. Second-line ART regimens for adults and adolescents (17)","content_type":"table","pages":"105","caption":"Table 4.2. Second-line ART regimens for adults and adolescents (17)","tokens_est":47,"char_count":1328,"has_attachment":true,"attachment_id":"Table 4.2.","attachment_path":"tables/WHO_TB_handbook_module6_comorbidities_2024/Table_4.2..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0352","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.2 ART initiation in people with HIV-associated TB","content_type":"text","pages":"106","tokens_est":141,"char_count":563,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0353","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.2 ART initiation in people with HIV-associated TB","content_type":"text","pages":"106","tokens_est":251,"char_count":1001,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0354","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.2 ART initiation in people with HIV-associated TB","content_type":"text","pages":"106","tokens_est":162,"char_count":645,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0355","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.2 ART initiation in people with HIV-associated TB","content_type":"text","pages":"106","tokens_est":159,"char_count":633,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0356","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.2 ART initiation in people with HIV-associated TB","content_type":"text","pages":"106-107","tokens_est":213,"char_count":850,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0357","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.2 ART initiation in people with HIV-associated TB","content_type":"text","pages":"106-107","tokens_est":76,"char_count":304,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0358","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.2 ART initiation in people with HIV-associated TB | 4.2.3 Co -trimoxazole prophylaxis","content_type":"text","pages":"107","tokens_est":232,"char_count":925,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0359","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.2 ART initiation in people with HIV-associated TB | 4.2.3 Co -trimoxazole prophylaxis","content_type":"text","pages":"107","tokens_est":39,"char_count":156,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0360","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.2 ART initiation in people with HIV-associated TB | 4.2.3 Co -trimoxazole prophylaxis","content_type":"text","pages":"107","tokens_est":217,"char_count":866,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0361","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.2 ART initiation in people with HIV-associated TB | 4.2.4 Other opportunistic infections: cryptococcal disease and histoplasmosis | 4.2.4.1 Cryptococcal disease","content_type":"text","pages":"107","tokens_est":155,"char_count":620,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0362","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.2 ART initiation in people with HIV-associated TB | 4.2.4 Other opportunistic infections: cryptococcal disease and histoplasmosis | 4.2.4.1 Cryptococcal disease | Table 4.3. Testing and treatment for cryptococcal disease","content_type":"table","pages":"107-108","caption":"Table 4.3. Testing and treatment for cryptococcal disease","tokens_est":26,"char_count":139,"has_attachment":true,"attachment_id":"Table 4.3.","attachment_path":"tables/WHO_TB_handbook_module6_comorbidities_2024/Table_4.3..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0363","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.2 ART initiation in people with HIV-associated TB | 4.2.4 Other opportunistic infections: cryptococcal disease and histoplasmosis | 4.2.4.1 Cryptococcal disease | Cryptococcal antigen screening","content_type":"text","pages":"108-109","tokens_est":228,"char_count":911,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0364","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.2 ART initiation in people with HIV-associated TB | 4.2.4 Other opportunistic infections: cryptococcal disease and histoplasmosis | 4.2.4.1 Cryptococcal disease | Cryptococcal antigen screening","content_type":"text","pages":"109","tokens_est":244,"char_count":975,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0365","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.2 ART initiation in people with HIV-associated TB | 4.2.4 Other opportunistic infections: cryptococcal disease and histoplasmosis | 4.2.4.1 Cryptococcal disease | Pre-emptive treatment of cryptococcal disease","content_type":"text","pages":"109","tokens_est":172,"char_count":687,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0366","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.2 ART initiation in people with HIV-associated TB | 4.2.4 Other opportunistic infections: cryptococcal disease and histoplasmosis | 4.2.4.1 Cryptococcal disease | Treatment of cryptococcal meningitis","content_type":"text","pages":"109","tokens_est":161,"char_count":641,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0367","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.2 ART initiation in people with HIV-associated TB | 4.2.4 Other opportunistic infections: cryptococcal disease and histoplasmosis | 4.2.4.1 Cryptococcal disease | Service delivery","content_type":"text","pages":"109","tokens_est":117,"char_count":467,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0368","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.2 ART initiation in people with HIV-associated TB | 4.2.4 Other opportunistic infections: cryptococcal disease and histoplasmosis | 4.2.4.1 Cryptococcal disease | Service delivery","content_type":"text","pages":"109-110","tokens_est":228,"char_count":912,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0369","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.2 ART initiation in people with HIV-associated TB | 4.2.4 Other opportunistic infections: cryptococcal disease and histoplasmosis | 4.2.4.2 Histoplasmosis","content_type":"text","pages":"110","tokens_est":187,"char_count":748,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0370","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.2 ART initiation in people with HIV-associated TB | 4.2.4 Other opportunistic infections: cryptococcal disease and histoplasmosis | 4.2.4.2 Histoplasmosis","content_type":"text","pages":"110","tokens_est":97,"char_count":388,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0371","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.2 ART initiation in people with HIV-associated TB | 4.2.4 Other opportunistic infections: cryptococcal disease and histoplasmosis | 4.2.4.2 Histoplasmosis","content_type":"text","pages":"110","tokens_est":234,"char_count":934,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0372","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.2 HIV treatment and care for people living with HIV diagnosed with TB | 4.2.2 ART initiation in people with HIV-associated TB | 4.2.4 Other opportunistic infections: cryptococcal disease and histoplasmosis | 4.2.4.2 Histoplasmosis","content_type":"text","pages":"110","tokens_est":93,"char_count":371,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0373","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.3 HIV prevention | 4.3.1 Combination HIV prevention for people with diagnosed or presumed TB","content_type":"text","pages":"110","tokens_est":108,"char_count":431,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0374","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.3 HIV prevention | 4.3.1 Combination HIV prevention for people with diagnosed or presumed TB","content_type":"text","pages":"110-111","tokens_est":194,"char_count":775,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0375","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.3 HIV prevention | 4.3.1 Combination HIV prevention for people with diagnosed or presumed TB","content_type":"text","pages":"110-111","tokens_est":167,"char_count":666,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0376","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.3 HIV prevention | 4.3.1 Combination HIV prevention for people with diagnosed or presumed TB","content_type":"text","pages":"111","tokens_est":70,"char_count":278,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0377","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.3 HIV prevention | 4.3.1 Combination HIV prevention for people with diagnosed or presumed TB | Box 4.4 Key considerations for expanding access to HIV prevention for people with TB and their partners:","content_type":"box","pages":"111","caption":"Box 4.4 Key considerations for expanding access to HIV prevention for people with TB and their partners:","tokens_est":198,"char_count":789,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0378","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.3 HIV prevention | 4.3.1 Combination HIV prevention for people with diagnosed or presumed TB | Box 4.4 Key considerations for expanding access to HIV prevention for people with TB and their partners:","content_type":"box","pages":"111","caption":"Box 4.4 Key considerations for expanding access to HIV prevention for people with TB and their partners:","tokens_est":206,"char_count":823,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0379","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.3 HIV prevention | 4.3.1 Combination HIV prevention for people with diagnosed or presumed TB | 4.3.1.1 Biomedical interventions for HIV prevention","content_type":"text","pages":"111","tokens_est":125,"char_count":497,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0380","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.3 HIV prevention | 4.3.1 Combination HIV prevention for people with diagnosed or presumed TB | 4.3.1.1 Biomedical interventions for HIV prevention","content_type":"text","pages":"111-112","tokens_est":243,"char_count":972,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0381","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.3 HIV prevention | 4.3.1 Combination HIV prevention for people with diagnosed or presumed TB | 4.3.1.1 Biomedical interventions for HIV prevention","content_type":"text","pages":"111-112","tokens_est":168,"char_count":672,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0382","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.3 HIV prevention | 4.3.1 Combination HIV prevention for people with diagnosed or presumed TB | 4.3.1.1 Biomedical interventions for HIV prevention","content_type":"text","pages":"112","tokens_est":148,"char_count":589,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0383","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.3 HIV prevention | 4.3.1 Combination HIV prevention for people with diagnosed or presumed TB | 4.3.1.2 Behavioural and structural interventions for HIV prevention","content_type":"text","pages":"112","tokens_est":164,"char_count":654,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0384","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.3 HIV prevention | 4.3.1 Combination HIV prevention for people with diagnosed or presumed TB | 4.3.1.2 Behavioural and structural interventions for HIV prevention","content_type":"text","pages":"112","tokens_est":209,"char_count":834,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0385","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | 4. Reduce the burden of HIV among people with TB | 4.3 HIV prevention | 4.3.1 Combination HIV prevention for people with diagnosed or presumed TB | 4.3.1.2 Behavioural and structural interventions for HIV prevention","content_type":"text","pages":"112","tokens_est":101,"char_count":402,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0386","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 1. Monitoring and evaluation of collaborative TB/HIV activities","content_type":"text","pages":"113","tokens_est":86,"char_count":343,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0387","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 1. Monitoring and evaluation of collaborative TB/HIV activities | Table A1.1 Summary of indicators for monitoring and evaluating collaborative TB/HIV activities","content_type":"table","pages":"113-114","caption":"Table A1.1 summarizes the core indicators recommended for monitoring and evaluating collaborative TB/HIV activities. The indicators are categorized as core indicators for global and national monitoring and reporting, and core indicators for national-level monitoring and reporting only.","tokens_est":84,"char_count":872,"has_attachment":true,"attachment_id":"Table A1.1","attachment_path":"tables/WHO_TB_handbook_module6_comorbidities_2024/Table_A1.1.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0388","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 1. Monitoring and evaluation of collaborative TB/HIV activities | Core indicators for global and national monitoring and reporting","content_type":"text","pages":"115","tokens_est":216,"char_count":863,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0389","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 1. Monitoring and evaluation of collaborative TB/HIV activities | Core indicators for global and national monitoring and reporting","content_type":"text","pages":"115","tokens_est":53,"char_count":211,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0390","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 1. Monitoring and evaluation of collaborative TB/HIV activities | Core indicators for national-level monitoring and reporting","content_type":"text","pages":"115","tokens_est":249,"char_count":993,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0391","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 1. Monitoring and evaluation of collaborative TB/HIV activities | Core indicators for national-level monitoring and reporting","content_type":"text","pages":"115","tokens_est":83,"char_count":331,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0392","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 1. Monitoring and evaluation of collaborative TB/HIV activities | Algorithms","content_type":"text","pages":"115","tokens_est":235,"char_count":939,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0393","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 1. Monitoring and evaluation of collaborative TB/HIV activities | Algorithms","content_type":"text","pages":"115-116","tokens_est":113,"char_count":449,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0394","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 1. Monitoring and evaluation of collaborative TB/HIV activities | Tuberculosis screening tools","content_type":"text","pages":"116","tokens_est":186,"char_count":743,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0395","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 1. Monitoring and evaluation of collaborative TB/HIV activities | Tuberculosis diagnostic tests","content_type":"text","pages":"116","tokens_est":183,"char_count":731,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0396","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 1. Monitoring and evaluation of collaborative TB/HIV activities | Accuracy of algorithms","content_type":"text","pages":"116","tokens_est":239,"char_count":954,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0397","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 1. Monitoring and evaluation of collaborative TB/HIV activities | Accuracy of algorithms","content_type":"text","pages":"116","tokens_est":39,"char_count":155,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0398","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 1. Monitoring and evaluation of collaborative TB/HIV activities | Costing of the algorithms","content_type":"text","pages":"117","tokens_est":225,"char_count":899,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0399","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 1. Monitoring and evaluation of collaborative TB/HIV activities | Costing of the algorithms","content_type":"text","pages":"117","tokens_est":190,"char_count":759,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0400","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 1. Monitoring and evaluation of collaborative TB/HIV activities | Limitations","content_type":"text","pages":"117","tokens_est":152,"char_count":606,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0401","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 1. Monitoring and evaluation of collaborative TB/HIV activities | Limitations","content_type":"text","pages":"117","tokens_est":222,"char_count":887,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0402","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 1. Monitoring and evaluation of collaborative TB/HIV activities | Limitations","content_type":"text","pages":"117","tokens_est":62,"char_count":248,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0403","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 1. Monitoring and evaluation of collaborative TB/HIV activities | Limitations","content_type":"text","pages":"117-118","tokens_est":177,"char_count":707,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0404","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 1. Monitoring and evaluation of collaborative TB/HIV activities | Conclusion","content_type":"text","pages":"118","tokens_est":220,"char_count":878,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0405","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 2. Methods for algorithms for diagnosis of TB in people living with HIV | RESULTS TABLES | Table A2.1. Algorithm 1","content_type":"table","pages":"119-120","caption":"Table A2.1. Algorithm 1","tokens_est":44,"char_count":413,"has_attachment":true,"attachment_id":"Table A2.1.","attachment_path":"tables/WHO_TB_handbook_module6_comorbidities_2024/Table_A2.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0406","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 2. Methods for algorithms for diagnosis of TB in people living with HIV | RESULTS TABLES | Table A2.2 . Algorithm 2","content_type":"table","pages":"120-121","caption":"Table A2.2 . Algorithm 2","tokens_est":45,"char_count":414,"has_attachment":true,"attachment_id":"Table A2.2","attachment_path":"tables/WHO_TB_handbook_module6_comorbidities_2024/Table_A2.2.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0407","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 2. Methods for algorithms for diagnosis of TB in people living with HIV | RESULTS TABLES | Table A2.3 . Algorithm 3","content_type":"table","pages":"121","caption":"Table A2.3 . Algorithm 3","tokens_est":45,"char_count":416,"has_attachment":true,"attachment_id":"Table A2.3","attachment_path":"tables/WHO_TB_handbook_module6_comorbidities_2024/Table_A2.3.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0408","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 2. Methods for algorithms for diagnosis of TB in people living with HIV | RESULTS TABLES | Table A2.4. Algorithm 4","content_type":"table","pages":"122","caption":"Table A2.4. Algorithm 4","tokens_est":35,"char_count":345,"has_attachment":true,"attachment_id":"Table A2.4.","attachment_path":"tables/WHO_TB_handbook_module6_comorbidities_2024/Table_A2.4..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0409","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 2. Methods for algorithms for diagnosis of TB in people living with HIV | RESULTS TABLES | Table A2.5. Cost estimates (median costs) : Costs associated with screening 1000 people with HIV (PTP 1%)","content_type":"table","pages":"122","caption":"Table A2.5. Cost estimates (median costs) : Costs associated with screening 1000 people with HIV (PTP 1%)","tokens_est":82,"char_count":400,"has_attachment":true,"attachment_id":"Table A2.5.","attachment_path":"tables/WHO_TB_handbook_module6_comorbidities_2024/Table_A2.5..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0410","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 2. Methods for algorithms for diagnosis of TB in people living with HIV | RESULTS TABLES | Table A2.6 Cost estimates (median costs) : Costs associated with screening 1000 people with HIV (PTP 10%)","content_type":"table","pages":"123-124","caption":"Table A2.6 Cost estimates (median costs) : Costs associated with screening 1000 people with HIV (PTP 10%)","tokens_est":80,"char_count":394,"has_attachment":true,"attachment_id":"Table A2.6","attachment_path":"tables/WHO_TB_handbook_module6_comorbidities_2024/Table_A2.6.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0411","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 3. Checklist for TB infection prevention and control","content_type":"text","pages":"126","tokens_est":226,"char_count":904,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0412","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 3. Checklist for TB infection prevention and control","content_type":"text","pages":"126-127","tokens_est":214,"char_count":856,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0413","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 3. Checklist for TB infection prevention and control","content_type":"text","pages":"127","tokens_est":228,"char_count":910,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0414","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 3. Checklist for TB infection prevention and control","content_type":"text","pages":"127-128","tokens_est":209,"char_count":833,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0415","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 3. Checklist for TB infection prevention and control","content_type":"text","pages":"128","tokens_est":233,"char_count":929,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0416","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 3. Checklist for TB infection prevention and control","content_type":"text","pages":"128","tokens_est":212,"char_count":847,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0417","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 3. Checklist for TB infection prevention and control","content_type":"text","pages":"128-129","tokens_est":232,"char_count":926,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0418","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 3. Checklist for TB infection prevention and control","content_type":"text","pages":"129","tokens_est":202,"char_count":805,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0419","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 3. Checklist for TB infection prevention and control","content_type":"text","pages":"129","tokens_est":194,"char_count":773,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0420","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 4. Package of care for advanced HIV disease | Table A4.1. Components of the package of care for people with advanced HIV disease","content_type":"table","pages":"130","caption":"Table A4.1 summarizes the specific components of the package of interventions that should be offered to people presenting with advancsed HIV disease. For detailed guidance on the package of interventions for advanced HIV disease, including for children, see Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy (1) and WHO consolidated guidelines on tuberculosis: Module 5. management of tuberculosis in children and adolescents (2).","tokens_est":140,"char_count":1065,"has_attachment":true,"attachment_id":"Table A4.1","attachment_path":"tables/WHO_TB_handbook_module6_comorbidities_2024/Table_A4.1.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0421","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"HIV | Annex 4. Package of care for advanced HIV disease","content_type":"text","pages":"130-131","tokens_est":14,"char_count":54,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0422","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | Abbreviations","content_type":"text","pages":"132","tokens_est":226,"char_count":903,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0423","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | Abbreviations","content_type":"text","pages":"132-133","tokens_est":54,"char_count":215,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0424","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | Definitions","content_type":"text","pages":"133","tokens_est":230,"char_count":918,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0425","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | Definitions","content_type":"text","pages":"133","tokens_est":192,"char_count":767,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0426","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | Definitions","content_type":"text","pages":"133-134","tokens_est":170,"char_count":680,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0427","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | Definitions","content_type":"text","pages":"134","tokens_est":152,"char_count":606,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0428","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | Definitions","content_type":"text","pages":"134","tokens_est":190,"char_count":760,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0429","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | Definitions","content_type":"text","pages":"134","tokens_est":192,"char_count":766,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0430","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | Definitions","content_type":"text","pages":"134","tokens_est":146,"char_count":582,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0431","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 1. Background and rationale | 1.1 Background and burden of TB and diabetes","content_type":"text","pages":"134","tokens_est":225,"char_count":897,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0432","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 1. Background and rationale | 1.1 Background and burden of TB and diabetes","content_type":"text","pages":"134","tokens_est":216,"char_count":864,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0433","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 1. Background and rationale | 1.1 Background and burden of TB and diabetes","content_type":"text","pages":"134","tokens_est":58,"char_count":231,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0434","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 1. Background and rationale | 1.1 Background and burden of TB and diabetes","content_type":"text","pages":"134-135","tokens_est":220,"char_count":878,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0435","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 1. Background and rationale | 1.1 Background and burden of TB and diabetes","content_type":"text","pages":"134-135","tokens_est":232,"char_count":927,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0436","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 1. Background and rationale | 1.1 Background and burden of TB and diabetes","content_type":"text","pages":"135","tokens_est":179,"char_count":715,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0437","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 1. Background and rationale | 1.1 Background and burden of TB and diabetes","content_type":"text","pages":"135","tokens_est":170,"char_count":679,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0438","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 1. Background and rationale | 1.1 Background and burden of TB and diabetes","content_type":"text","pages":"135","tokens_est":188,"char_count":750,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0439","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 1. Background and rationale | 1.1 Background and burden of TB and diabetes","content_type":"text","pages":"135","tokens_est":77,"char_count":305,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0440","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 1. Background and rationale | 1.2 Development of the document","content_type":"text","pages":"135","tokens_est":168,"char_count":670,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0441","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 1. Background and rationale | 1.2 Development of the document","content_type":"text","pages":"135-136","tokens_est":224,"char_count":893,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0442","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 1. Background and rationale | 1.2 Development of the document","content_type":"text","pages":"135-136","tokens_est":54,"char_count":214,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0443","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 1. Background and rationale | 1.3 Summary of recommendations","content_type":"text","pages":"136","tokens_est":109,"char_count":434,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0444","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 1. Background and rationale | 1.3 Summary of recommendations | Box 1. WHO recommendations to address TB and diabetes","content_type":"box","pages":"136","caption":"Box 1. WHO recommendations to address TB and diabetes","tokens_est":217,"char_count":865,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0445","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 1. Background and rationale | 1.3 Summary of recommendations | Box 1. WHO recommendations to address TB and diabetes","content_type":"box","pages":"136","caption":"Box 1. WHO recommendations to address TB and diabetes","tokens_est":157,"char_count":627,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0446","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 1. Background and rationale | 1.3 Summary of recommendations | Box 1. WHO recommendations to address TB and diabetes","content_type":"box","pages":"136","caption":"Box 1. WHO recommendations to address TB and diabetes","tokens_est":111,"char_count":443,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0447","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes","content_type":"text","pages":"136-137","tokens_est":220,"char_count":879,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0448","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes","content_type":"text","pages":"137-138","tokens_est":209,"char_count":836,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0449","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes","content_type":"text","pages":"138","tokens_est":183,"char_count":731,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0450","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes","content_type":"text","pages":"138-139","tokens_est":137,"char_count":548,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0451","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.1 Strengthen governance and accountability for collaborative TB/DM activities | 2.1.1 Strengthen political commitment, coordination and accountability for collaborative action on TB and diabetes","content_type":"text","pages":"140","tokens_est":178,"char_count":710,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0452","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.1 Strengthen governance and accountability for collaborative TB/DM activities | 2.1.1 Strengthen political commitment, coordination and accountability for collaborative action on TB and diabetes","content_type":"text","pages":"140","tokens_est":221,"char_count":882,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0453","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.1 Strengthen governance and accountability for collaborative TB/DM activities | 2.1.1 Strengthen political commitment, coordination and accountability for collaborative action on TB and diabetes","content_type":"text","pages":"140","tokens_est":151,"char_count":604,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0454","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.1 Strengthen governance and accountability for collaborative TB/DM activities | 2.1.1 Strengthen political commitment, coordination and accountability for collaborative action on TB and diabetes","content_type":"text","pages":"140","tokens_est":216,"char_count":862,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0455","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.1 Strengthen governance and accountability for collaborative TB/DM activities | 2.1.1 Strengthen political commitment, coordination and accountability for collaborative action on TB and diabetes","content_type":"text","pages":"140","tokens_est":234,"char_count":933,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0456","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.1 Strengthen governance and accountability for collaborative TB/DM activities | 2.1.1 Strengthen political commitment, coordination and accountability for collaborative action on TB and diabetes","content_type":"text","pages":"140-141","tokens_est":152,"char_count":607,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0457","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.1 Strengthen governance and accountability for collaborative TB/DM activities | 2.1.2 Support financing and legislation to promote people- centred care","content_type":"text","pages":"141","tokens_est":181,"char_count":723,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0458","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.1 Strengthen governance and accountability for collaborative TB/DM activities | 2.1.2 Support financing and legislation to promote people- centred care","content_type":"text","pages":"141","tokens_est":154,"char_count":616,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0459","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.1 Strengthen governance and accountability for collaborative TB/DM activities | 2.1.3 Ensure meaningful engagement of civil society and affected communities at all stages of planning, implementation, monitoring and evaluation","content_type":"text","pages":"141","tokens_est":127,"char_count":508,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0460","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.1 Strengthen governance and accountability for collaborative TB/DM activities | 2.1.3 Ensure meaningful engagement of civil society and affected communities at all stages of planning, implementation, monitoring and evaluation","content_type":"text","pages":"141-143","tokens_est":235,"char_count":937,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0461","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.1 Strengthen governance and accountability for collaborative TB/DM activities | 2.1.3 Ensure meaningful engagement of civil society and affected communities at all stages of planning, implementation, monitoring and evaluation","content_type":"text","pages":"141-143","tokens_est":237,"char_count":946,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0462","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.2 Conduct an analysis of access to quality services for TB and diabetes | 2.2.1 Assess the joint burden of TB and diabetes","content_type":"text","pages":"144","tokens_est":191,"char_count":761,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0463","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.2 Conduct an analysis of access to quality services for TB and diabetes | 2.2.1 Assess the joint burden of TB and diabetes","content_type":"text","pages":"144","tokens_est":173,"char_count":689,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0464","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.2 Conduct an analysis of access to quality services for TB and diabetes | 2.2.1 Assess the joint burden of TB and diabetes","content_type":"text","pages":"144","tokens_est":193,"char_count":770,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0465","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.2 Conduct an analysis of access to quality services for TB and diabetes | 2.2.2 Determine access to services and the financial burden for people with TB and diabetes","content_type":"text","pages":"144-145","tokens_est":232,"char_count":928,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0466","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.2 Conduct an analysis of access to quality services for TB and diabetes | 2.2.3 Map health service delivery for TB and diabetes","content_type":"text","pages":"145","tokens_est":199,"char_count":796,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0467","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.2 Conduct an analysis of access to quality services for TB and diabetes | 2.2.3 Map health service delivery for TB and diabetes","content_type":"text","pages":"145","tokens_est":136,"char_count":544,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0468","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.2 Conduct an analysis of access to quality services for TB and diabetes | 2.2.3 Map health service delivery for TB and diabetes","content_type":"text","pages":"145","tokens_est":194,"char_count":773,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0469","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.2 Conduct an analysis of access to quality services for TB and diabetes | 2.2.4 Identify gaps in services and conduct root cause analysis","content_type":"text","pages":"145","tokens_est":167,"char_count":665,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0470","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.1 Identify priority comorbidities and interventions","content_type":"text","pages":"145-146","tokens_est":241,"char_count":961,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0471","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.1 Identify priority comorbidities and interventions","content_type":"text","pages":"145-146","tokens_est":42,"char_count":167,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0472","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.1 Identify priority comorbidities and interventions","content_type":"text","pages":"146","tokens_est":179,"char_count":713,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0473","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.2 Define and reorient models of care for TB and diabetes and other comorbidities towards people- centred services, primary health care and universal health coverage","content_type":"text","pages":"146","tokens_est":238,"char_count":951,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0474","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.2 Define and reorient models of care for TB and diabetes and other comorbidities towards people- centred services, primary health care and universal health coverage","content_type":"text","pages":"146","tokens_est":93,"char_count":371,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0475","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.2 Define and reorient models of care for TB and diabetes and other comorbidities towards people- centred services, primary health care and universal health coverage","content_type":"text","pages":"146","tokens_est":145,"char_count":579,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0476","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.2 Define and reorient models of care for TB and diabetes and other comorbidities towards people- centred services, primary health care and universal health coverage","content_type":"text","pages":"146","tokens_est":220,"char_count":880,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0477","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.2 Define and reorient models of care for TB and diabetes and other comorbidities towards people- centred services, primary health care and universal health coverage","content_type":"text","pages":"146","tokens_est":115,"char_count":460,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0478","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.2 Define and reorient models of care for TB and diabetes and other comorbidities towards people- centred services, primary health care and universal health coverage","content_type":"text","pages":"146-147","tokens_est":205,"char_count":820,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0479","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.2 Define and reorient models of care for TB and diabetes and other comorbidities towards people- centred services, primary health care and universal health coverage","content_type":"text","pages":"146-147","tokens_est":95,"char_count":378,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0480","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.2 Define and reorient models of care for TB and diabetes and other comorbidities towards people- centred services, primary health care and universal health coverage | Box 2. Models of service delivery for TB and diabetes","content_type":"box","pages":"147","caption":"Box 2. Models of service delivery for TB and diabetes","tokens_est":240,"char_count":960,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0481","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.2 Define and reorient models of care for TB and diabetes and other comorbidities towards people- centred services, primary health care and universal health coverage | Box 2. Models of service delivery for TB and diabetes","content_type":"box","pages":"147","caption":"Box 2. Models of service delivery for TB and diabetes","tokens_est":141,"char_count":562,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0482","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.2 Define and reorient models of care for TB and diabetes and other comorbidities towards people- centred services, primary health care and universal health coverage | Box 2. Models of service delivery for TB and diabetes","content_type":"box","pages":"147","caption":"Box 2. Models of service delivery for TB and diabetes","tokens_est":166,"char_count":663,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0483","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.2 Define and reorient models of care for TB and diabetes and other comorbidities towards people- centred services, primary health care and universal health coverage | Box 2. Models of service delivery for TB and diabetes","content_type":"box","pages":"147-148","caption":"Box 2. Models of service delivery for TB and diabetes","tokens_est":207,"char_count":827,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0484","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.2 Define and reorient models of care for TB and diabetes and other comorbidities towards people- centred services, primary health care and universal health coverage | Box 2. Models of service delivery for TB and diabetes","content_type":"box","pages":"148","caption":"Box 2. Models of service delivery for TB and diabetes","tokens_est":208,"char_count":831,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0485","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.3 Conduct collaborative planning and budgeting to scale up people- centred services for TB and diabetes","content_type":"text","pages":"148","tokens_est":232,"char_count":927,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0486","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.3 Conduct collaborative planning and budgeting to scale up people- centred services for TB and diabetes","content_type":"text","pages":"148","tokens_est":218,"char_count":871,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0487","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.3 Conduct collaborative planning and budgeting to scale up people- centred services for TB and diabetes","content_type":"text","pages":"148","tokens_est":117,"char_count":466,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0488","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.3 Coordinate planning and resource mobilization for collaborative action | 2.3.4 Align advocacy and communication across health programmes","content_type":"text","pages":"148","tokens_est":149,"char_count":593,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0489","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.4 Implement and scale up people- centred services for TB and diabetes | 2.4.1 Jointly develop policies, guidelines and procedures for collaborative TB/DM activities","content_type":"text","pages":"149","tokens_est":224,"char_count":894,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0490","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.4 Implement and scale up people- centred services for TB and diabetes | 2.4.2 Mobilize a qualified multidisciplinary workforce, including private providers and non-health sectors, for collaborative action","content_type":"text","pages":"149","tokens_est":189,"char_count":756,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0491","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.4 Implement and scale up people- centred services for TB and diabetes | 2.4.2 Mobilize a qualified multidisciplinary workforce, including private providers and non-health sectors, for collaborative action","content_type":"text","pages":"149","tokens_est":220,"char_count":879,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0492","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.4 Implement and scale up people- centred services for TB and diabetes | 2.4.2 Mobilize a qualified multidisciplinary workforce, including private providers and non-health sectors, for collaborative action","content_type":"text","pages":"149","tokens_est":238,"char_count":952,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0493","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.4 Implement and scale up people- centred services for TB and diabetes | 2.4.3 Ensure access to essential medicines, vaccines, diagnostics and health technologies for TB and diabetes","content_type":"text","pages":"150","tokens_est":176,"char_count":703,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0494","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.4 Implement and scale up people- centred services for TB and diabetes | 2.4.3 Ensure access to essential medicines, vaccines, diagnostics and health technologies for TB and diabetes","content_type":"text","pages":"150","tokens_est":107,"char_count":427,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0495","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.4 Implement and scale up people- centred services for TB and diabetes | 2.4.3 Ensure access to essential medicines, vaccines, diagnostics and health technologies for TB and diabetes","content_type":"text","pages":"150","tokens_est":194,"char_count":773,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0496","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.4 Implement and scale up people- centred services for TB and diabetes | 2.4.3 Ensure access to essential medicines, vaccines, diagnostics and health technologies for TB and diabetes","content_type":"text","pages":"150","tokens_est":178,"char_count":711,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0497","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.4 Implement and scale up people- centred services for TB and diabetes | 2.4.3 Ensure access to essential medicines, vaccines, diagnostics and health technologies for TB and diabetes","content_type":"text","pages":"150","tokens_est":183,"char_count":732,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0498","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.4 Implement and scale up people- centred services for TB and diabetes | 2.4.4 Engage civil society and communities affected by TB and diabetes in refining and delivering people- centred services","content_type":"text","pages":"150-151","tokens_est":194,"char_count":773,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0499","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.4 Implement and scale up people- centred services for TB and diabetes | 2.4.4 Engage civil society and communities affected by TB and diabetes in refining and delivering people- centred services","content_type":"text","pages":"150-151","tokens_est":211,"char_count":842,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0500","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.4 Implement and scale up people- centred services for TB and diabetes | 2.4.4 Engage civil society and communities affected by TB and diabetes in refining and delivering people- centred services","content_type":"text","pages":"150-151","tokens_est":113,"char_count":450,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0501","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.4 Implement and scale up people- centred services for TB and diabetes | 2.4.4 Engage civil society and communities affected by TB and diabetes in refining and delivering people- centred services","content_type":"text","pages":"151","tokens_est":116,"char_count":461,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0502","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.4 Implement and scale up people- centred services for TB and diabetes | 2.4.5 Facilitate access to social protection to prevent financial hardship due to TB and diabetes","content_type":"text","pages":"151","tokens_est":230,"char_count":920,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0503","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.4 Implement and scale up people- centred services for TB and diabetes | 2.4.6 Facilitate uptake of digital technologies to deliver health and social protection services across programmes","content_type":"text","pages":"151","tokens_est":193,"char_count":772,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0504","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.4 Implement and scale up people- centred services for TB and diabetes | 2.4.7 Scale up people- centred services for TB and diabetes","content_type":"text","pages":"151-152","tokens_est":204,"char_count":813,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0505","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.4 Implement and scale up people- centred services for TB and diabetes | 2.4.7 Scale up people- centred services for TB and diabetes","content_type":"text","pages":"151-152","tokens_est":150,"char_count":599,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0506","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.5 Strengthen monitoring, evaluation and research | 2.5.1 Adopt indicators and set targets for collaborative TB/DM activities","content_type":"text","pages":"152","tokens_est":134,"char_count":533,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0507","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.5 Strengthen monitoring, evaluation and research | 2.5.1 Adopt indicators and set targets for collaborative TB/DM activities","content_type":"text","pages":"152","tokens_est":201,"char_count":802,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0508","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.5 Strengthen monitoring, evaluation and research | 2.5.1 Adopt indicators and set targets for collaborative TB/DM activities","content_type":"text","pages":"152","tokens_est":120,"char_count":477,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0509","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.5 Strengthen monitoring, evaluation and research | 2.5.2 Strengthen surveillance for diabetes among people with TB and surveillance for TB among people living with diabetes in accordance with WHO recommendations","content_type":"text","pages":"152","tokens_est":238,"char_count":949,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0510","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.5 Strengthen monitoring, evaluation and research | 2.5.2 Strengthen surveillance for diabetes among people with TB and surveillance for TB among people living with diabetes in accordance with WHO recommendations | Box 3. Actions for strengthening surveillance of the joint burden of TB and diabetes","content_type":"box","pages":"152-153","caption":"Box 3. Actions for strengthening surveillance of the joint burden of TB and diabetes","tokens_est":208,"char_count":831,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0511","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.5 Strengthen monitoring, evaluation and research | 2.5.2 Strengthen surveillance for diabetes among people with TB and surveillance for TB among people living with diabetes in accordance with WHO recommendations | Box 3. Actions for strengthening surveillance of the joint burden of TB and diabetes","content_type":"box","pages":"153","caption":"Box 3. Actions for strengthening surveillance of the joint burden of TB and diabetes","tokens_est":234,"char_count":936,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0512","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.5 Strengthen monitoring, evaluation and research | 2.5.2 Strengthen surveillance for diabetes among people with TB and surveillance for TB among people living with diabetes in accordance with WHO recommendations | Box 3. Actions for strengthening surveillance of the joint burden of TB and diabetes","content_type":"box","pages":"153","caption":"Box 3. Actions for strengthening surveillance of the joint burden of TB and diabetes","tokens_est":41,"char_count":162,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0513","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.5 Strengthen monitoring, evaluation and research | 2.5.3 Introduce and scale up monitoring and evaluation of collaborative TB/DM activities at all levels","content_type":"text","pages":"153","tokens_est":122,"char_count":487,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0514","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.5 Strengthen monitoring, evaluation and research | 2.5.3 Introduce and scale up monitoring and evaluation of collaborative TB/DM activities at all levels","content_type":"text","pages":"153","tokens_est":171,"char_count":681,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0515","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.5 Strengthen monitoring, evaluation and research | 2.5.3 Introduce and scale up monitoring and evaluation of collaborative TB/DM activities at all levels","content_type":"text","pages":"153","tokens_est":209,"char_count":833,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0516","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.5 Strengthen monitoring, evaluation and research | 2.5.4 Conduct joint review of quality and coverage of services to inform programming","content_type":"text","pages":"154","tokens_est":232,"char_count":928,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0517","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.5 Strengthen monitoring, evaluation and research | 2.5.5 Conduct operational and implementation research to inform policy, programming and service delivery","content_type":"text","pages":"154","tokens_est":182,"char_count":727,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0518","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 2. Establish and strengthen collaboration across health programmes and across sectors for delivering people- centred services for TB and diabetes | 2.5 Strengthen monitoring, evaluation and research | 2.5.5 Conduct operational and implementation research to inform policy, programming and service delivery","content_type":"text","pages":"154","tokens_est":184,"char_count":735,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0519","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes","content_type":"text","pages":"154","tokens_est":217,"char_count":866,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0520","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes","content_type":"text","pages":"154","tokens_est":117,"char_count":467,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0521","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.1 TB screening among people living with diabetes","content_type":"text","pages":"155","tokens_est":142,"char_count":567,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0522","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.1 TB screening among people living with diabetes | 3.1.1 Whom to screen for TB","content_type":"text","pages":"155","tokens_est":130,"char_count":517,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0523","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.1 TB screening among people living with diabetes | 3.1.2 When to screen for TB","content_type":"text","pages":"155","tokens_est":179,"char_count":713,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0524","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.1 TB screening among people living with diabetes | 3.1.3 How to screen for TB","content_type":"text","pages":"155","tokens_est":173,"char_count":692,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0525","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.1 TB screening among people living with diabetes | 3.1.3 How to screen for TB","content_type":"text","pages":"155-156","tokens_est":247,"char_count":988,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0526","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.1 TB screening among people living with diabetes | 3.1.3 How to screen for TB | Table 2. Diagnostic accuracy of symptoms, CXR and mWRDs for screening for TB disease among individuals aged  15 years with negative or unknown HIV status","content_type":"table","pages":"156","caption":"Table 2 shows the accuracy of these tools in studies of general populations with negative or unknown HIV status and with unknown diabetes status, from a systematic review conducted in 2020 for the update to the WHO TB screening guidelines, with bacteriologically confirmed pulmonary TB as the reference standard ( 102 ) . It should be noted that most data on the accuracy of screening tools derives from TB prevalence surveys in which the general population in high-TB burden settings are screened for TB.","tokens_est":142,"char_count":576,"has_attachment":true,"attachment_id":"Table 2","attachment_path":"tables/WHO_TB_handbook_module6_comorbidities_2024/Table_2.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0527","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.1 TB screening among people living with diabetes | 3.1.3 How to screen for TB","content_type":"text","pages":"156-157","tokens_est":242,"char_count":968,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0528","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.1 TB screening among people living with diabetes | 3.1.3 How to screen for TB","content_type":"text","pages":"156-157","tokens_est":99,"char_count":393,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0529","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.1 TB screening among people living with diabetes | 3.1.3 How to screen for TB","content_type":"text","pages":"157","tokens_est":157,"char_count":626,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0530","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.1 TB screening among people living with diabetes | 3.1.4 Increasing access to TB screening for people with diabetes","content_type":"text","pages":"157","tokens_est":204,"char_count":814,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0531","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.1 TB screening among people living with diabetes | 3.1.4 Increasing access to TB screening for people with diabetes","content_type":"text","pages":"157","tokens_est":72,"char_count":286,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0532","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.1 TB screening among people living with diabetes | 3.1.4 Increasing access to TB screening for people with diabetes","content_type":"text","pages":"157","tokens_est":209,"char_count":833,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0533","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.1 TB screening among people living with diabetes | 3.1.4 Increasing access to TB screening for people with diabetes | Box 4. Key considerations for scaling up TB screening in diabetes care","content_type":"box","pages":"157-158","caption":"Box 4. Key considerations for scaling up TB screening in diabetes care","tokens_est":231,"char_count":922,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0534","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.1 TB screening among people living with diabetes | 3.1.4 Increasing access to TB screening for people with diabetes | Box 4. Key considerations for scaling up TB screening in diabetes care","content_type":"box","pages":"158","caption":"Box 4. Key considerations for scaling up TB screening in diabetes care","tokens_est":204,"char_count":815,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0535","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.2 TB diagnosis among people living with diabetes","content_type":"text","pages":"158","tokens_est":140,"char_count":558,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0536","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.2 TB diagnosis among people living with diabetes | 3.2.1 How to diagnose TB","content_type":"text","pages":"158","tokens_est":76,"char_count":304,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0537","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.2 TB diagnosis among people living with diabetes | 3.2.1 How to diagnose TB","content_type":"text","pages":"158","tokens_est":185,"char_count":740,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0538","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.2 TB diagnosis among people living with diabetes | 3.2.2 Linkage to TB diagnostic networks","content_type":"text","pages":"158-159","tokens_est":232,"char_count":927,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0539","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.2 TB diagnosis among people living with diabetes | 3.2.2 Linkage to TB diagnostic networks","content_type":"text","pages":"158-159","tokens_est":59,"char_count":234,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0540","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.2 TB diagnosis among people living with diabetes | 3.2.2 Linkage to TB diagnostic networks","content_type":"text","pages":"159","tokens_est":125,"char_count":500,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0541","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.2 TB diagnosis among people living with diabetes | 3.2.3 Sample collection and transportation for TB diagnosis","content_type":"text","pages":"159","tokens_est":141,"char_count":564,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0542","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.2 TB diagnosis among people living with diabetes | 3.2.3 Sample collection and transportation for TB diagnosis","content_type":"text","pages":"159","tokens_est":184,"char_count":733,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0543","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.2 TB diagnosis among people living with diabetes | 3.2.4 Household contact investigation","content_type":"text","pages":"159","tokens_est":134,"char_count":535,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0544","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.3 TB treatment among people living with diabetes","content_type":"text","pages":"159","tokens_est":98,"char_count":389,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0545","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.3 TB treatment among people living with diabetes | 3.3.1 TB treatment regimens","content_type":"text","pages":"160","tokens_est":113,"char_count":452,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0546","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.3 TB treatment among people living with diabetes | 3.3.1 TB treatment regimens","content_type":"text","pages":"160","tokens_est":229,"char_count":913,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0547","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.3 TB treatment among people living with diabetes | 3.3.1 TB treatment regimens","content_type":"text","pages":"160","tokens_est":59,"char_count":235,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0548","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.3 TB treatment among people living with diabetes | 3.3.1 TB treatment regimens | Side-effects in people living with diabetes on TB treatment","content_type":"text","pages":"160","tokens_est":145,"char_count":579,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0549","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.3 TB treatment among people living with diabetes | 3.3.1 TB treatment regimens | Side-effects in people living with diabetes on TB treatment","content_type":"text","pages":"160","tokens_est":174,"char_count":693,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0550","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.3 TB treatment among people living with diabetes | 3.3.1 TB treatment regimens | Drug-drug interactions during co-management of TB and diabetes","content_type":"text","pages":"160","tokens_est":201,"char_count":802,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0551","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.3 TB treatment among people living with diabetes | 3.3.1 TB treatment regimens | Drug-drug interactions during co-management of TB and diabetes","content_type":"text","pages":"160-161","tokens_est":151,"char_count":601,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0552","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.3 TB treatment among people living with diabetes | 3.3.1 TB treatment regimens | Drug-drug interactions during co-management of TB and diabetes","content_type":"text","pages":"161","tokens_est":121,"char_count":484,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0553","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.3 TB treatment among people living with diabetes | 3.3.2 Integrated service delivery and ambulatory care","content_type":"text","pages":"161","tokens_est":172,"char_count":686,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0554","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.3 TB treatment among people living with diabetes | 3.3.2 Integrated service delivery and ambulatory care","content_type":"text","pages":"161","tokens_est":144,"char_count":575,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0555","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.3 TB treatment among people living with diabetes | 3.3.3 Treatment support and social protection","content_type":"text","pages":"161","tokens_est":235,"char_count":938,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0556","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.3 TB treatment among people living with diabetes | 3.3.3 Treatment support and social protection","content_type":"text","pages":"161","tokens_est":184,"char_count":735,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0557","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.4 Glycaemic control to prevent TB among people living with diabetes","content_type":"text","pages":"162","tokens_est":94,"char_count":376,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0558","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.4 Glycaemic control to prevent TB among people living with diabetes","content_type":"text","pages":"162","tokens_est":244,"char_count":975,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0559","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.4 Glycaemic control to prevent TB among people living with diabetes","content_type":"text","pages":"162","tokens_est":71,"char_count":282,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0560","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.4 Glycaemic control to prevent TB among people living with diabetes","content_type":"text","pages":"162","tokens_est":152,"char_count":605,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0561","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.5 TPT for people living with diabetes | 3.5.1 Eligibility for TPT","content_type":"text","pages":"162","tokens_est":222,"char_count":886,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0562","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.5 TPT for people living with diabetes | 3.5.1 Eligibility for TPT | Box 5. Populations for which WHO recommends systematic assessment of eligibility and provision of TB preventive treatment","content_type":"box","pages":"162-163","caption":"Box 5. Populations for which WHO recommends systematic assessment of eligibility and provision of TB preventive treatment","tokens_est":208,"char_count":832,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0563","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.5 TPT for people living with diabetes | 3.5.1 Eligibility for TPT | Box 5. Populations for which WHO recommends systematic assessment of eligibility and provision of TB preventive treatment","content_type":"box","pages":"163","caption":"Box 5. Populations for which WHO recommends systematic assessment of eligibility and provision of TB preventive treatment","tokens_est":82,"char_count":326,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0564","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.5 TPT for people living with diabetes | 3.5.2 Tests for TB infection","content_type":"text","pages":"163","tokens_est":210,"char_count":840,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0565","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.5 TPT for people living with diabetes | 3.5.3 TPT regimens","content_type":"text","pages":"163","tokens_est":200,"char_count":798,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0566","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.5 TPT for people living with diabetes | 3.5.3 TPT regimens","content_type":"text","pages":"163","tokens_est":157,"char_count":626,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0567","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.6 TB IPC in clinics that provide diabetes care","content_type":"text","pages":"164","tokens_est":206,"char_count":822,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0568","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.6 TB IPC in clinics that provide diabetes care","content_type":"text","pages":"164","tokens_est":59,"char_count":236,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0569","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.6 TB IPC in clinics that provide diabetes care","content_type":"text","pages":"164","tokens_est":142,"char_count":568,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0570","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.6 TB IPC in clinics that provide diabetes care","content_type":"text","pages":"164","tokens_est":145,"char_count":578,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0571","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.6 TB IPC in clinics that provide diabetes care | Box 6. WHO recommendations on TB IPC","content_type":"box","pages":"164","caption":"Box 6. WHO recommendations on TB IPC","tokens_est":234,"char_count":934,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0572","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.6 TB IPC in clinics that provide diabetes care","content_type":"text","pages":"164","tokens_est":215,"char_count":858,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0573","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.6 TB IPC in clinics that provide diabetes care","content_type":"text","pages":"164","tokens_est":124,"char_count":494,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0574","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.6 TB IPC in clinics that provide diabetes care","content_type":"text","pages":"164","tokens_est":217,"char_count":866,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0575","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 3. Reduce the burden of TB among people living with diabetes | 3.6 TB IPC in clinics that provide diabetes care","content_type":"text","pages":"164","tokens_est":223,"char_count":892,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0576","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 4. Reduce the burden of diabetes among people with TB","content_type":"text","pages":"164-165","tokens_est":247,"char_count":986,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0577","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 4. Reduce the burden of diabetes among people with TB","content_type":"text","pages":"164-165","tokens_est":75,"char_count":300,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0578","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 4. Reduce the burden of diabetes among people with TB","content_type":"text","pages":"165","tokens_est":221,"char_count":883,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0579","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 4. Reduce the burden of diabetes among people with TB | 4.1 Diabetes screening and diagnosis","content_type":"text","pages":"165","tokens_est":189,"char_count":755,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0580","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 4. Reduce the burden of diabetes among people with TB | 4.1 Diabetes screening and diagnosis","content_type":"text","pages":"165-166","tokens_est":75,"char_count":300,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0581","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 4. Reduce the burden of diabetes among people with TB | 4.1 Diabetes screening and diagnosis | 4.1.1 Diabetes screening strategies for people with TB","content_type":"text","pages":"166","tokens_est":245,"char_count":979,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0582","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 4. Reduce the burden of diabetes among people with TB | 4.1 Diabetes screening and diagnosis | 4.1.1 Diabetes screening strategies for people with TB","content_type":"text","pages":"166","tokens_est":122,"char_count":488,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0583","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 4. Reduce the burden of diabetes among people with TB | 4.1 Diabetes screening and diagnosis | 4.1.1 Diabetes screening strategies for people with TB","content_type":"text","pages":"166","tokens_est":213,"char_count":850,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0584","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 4. Reduce the burden of diabetes among people with TB | 4.1 Diabetes screening and diagnosis | 4.1.1 Diabetes screening strategies for people with TB","content_type":"text","pages":"166","tokens_est":246,"char_count":981,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0585","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 4. Reduce the burden of diabetes among people with TB | 4.1 Diabetes screening and diagnosis | 4.1.1 Diabetes screening strategies for people with TB","content_type":"text","pages":"166-167","tokens_est":123,"char_count":491,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0586","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 4. Reduce the burden of diabetes among people with TB | 4.1 Diabetes screening and diagnosis | 4.1.1 Diabetes screening strategies for people with TB | Fig. 2. Assessment of signs and symptoms before testing for diabetes","content_type":"figure","pages":"167","caption":"Fig. 2. Assessment of signs and symptoms before testing for diabetes","tokens_est":20,"char_count":78,"has_attachment":true,"attachment_id":"Fig. 2.","attachment_path":"figures/WHO_TB_handbook_module6_comorbidities_2024/Fig. 2..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0587","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 4. Reduce the burden of diabetes among people with TB | 4.1 Diabetes screening and diagnosis | 4.1.2 How to diagnose diabetes in people with TB","content_type":"text","pages":"167","tokens_est":136,"char_count":544,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0588","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 4. Reduce the burden of diabetes among people with TB | 4.1 Diabetes screening and diagnosis | 4.1.2 How to diagnose diabetes in people with TB","content_type":"text","pages":"167","tokens_est":229,"char_count":914,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0589","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 4. Reduce the burden of diabetes among people with TB | 4.1 Diabetes screening and diagnosis | 4.1.2 How to diagnose diabetes in people with TB","content_type":"text","pages":"167","tokens_est":111,"char_count":441,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0590","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 4. Reduce the burden of diabetes among people with TB | 4.1 Diabetes screening and diagnosis | 4.1.2 How to diagnose diabetes in people with TB | Fig. 3. Diagnostic thresholds and strengths and weaknesses of diagnostic tests","content_type":"figure","pages":"167","caption":"Fig. 3. Diagnostic thresholds and strengths and weaknesses of diagnostic tests","tokens_est":22,"char_count":88,"has_attachment":true,"attachment_id":"Fig. 3.","attachment_path":"figures/WHO_TB_handbook_module6_comorbidities_2024/Fig. 3..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0591","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 4. Reduce the burden of diabetes among people with TB | 4.1 Diabetes screening and diagnosis | 4.1.2 How to diagnose diabetes in people with TB","content_type":"text","pages":"167","tokens_est":206,"char_count":822,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0592","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 4. Reduce the burden of diabetes among people with TB | 4.1 Diabetes screening and diagnosis | 4.1.2 How to diagnose diabetes in people with TB","content_type":"text","pages":"167","tokens_est":91,"char_count":362,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0593","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 4. Reduce the burden of diabetes among people with TB | 4.2 Management of diabetes | 4.2.1 Management of type 2 diabetes","content_type":"text","pages":"168","tokens_est":191,"char_count":764,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0594","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 4. Reduce the burden of diabetes among people with TB | 4.2 Management of diabetes | 4.2.1 Management of type 2 diabetes","content_type":"text","pages":"168","tokens_est":106,"char_count":424,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0595","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 4. Reduce the burden of diabetes among people with TB | 4.2 Management of diabetes | 4.2.1 Management of type 2 diabetes","content_type":"text","pages":"168","tokens_est":190,"char_count":757,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0596","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 4. Reduce the burden of diabetes among people with TB | 4.2 Management of diabetes | 4.2.1 Management of type 2 diabetes","content_type":"text","pages":"168","tokens_est":244,"char_count":975,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0597","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 4. Reduce the burden of diabetes among people with TB | 4.2 Management of diabetes | 4.2.1 Management of type 2 diabetes | Fig. 4. Protocol for control of blood glucose in people with type 2 diabetes","content_type":"figure","pages":"168","caption":"Fig. 4. Protocol for control of blood glucose in people with type 2 diabetes","tokens_est":22,"char_count":86,"has_attachment":true,"attachment_id":"Fig. 4.","attachment_path":"figures/WHO_TB_handbook_module6_comorbidities_2024/Fig. 4..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0598","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 4. Reduce the burden of diabetes among people with TB | 4.2 Management of diabetes | 4.2.1 Management of type 2 diabetes","content_type":"text","pages":"168-169","tokens_est":219,"char_count":876,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0599","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 4. Reduce the burden of diabetes among people with TB | 4.2 Management of diabetes | 4.2.2 Management of type 1 diabetes","content_type":"text","pages":"169","tokens_est":229,"char_count":913,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0600","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 4. Reduce the burden of diabetes among people with TB | 4.2 Management of diabetes | 4.2.2 Management of type 1 diabetes","content_type":"text","pages":"169","tokens_est":108,"char_count":432,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0601","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 4. Reduce the burden of diabetes among people with TB | 4.2 Management of diabetes | 4.2.3 Management of complications of diabetes","content_type":"text","pages":"169","tokens_est":246,"char_count":982,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0602","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 4. Reduce the burden of diabetes among people with TB | 4.2 Management of diabetes | 4.2.3 Management of complications of diabetes","content_type":"text","pages":"169","tokens_est":81,"char_count":324,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0603","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 4. Reduce the burden of diabetes among people with TB | 4.2 Management of diabetes | 4.2.4 Side -effects and drugdrug interactions of glucose-lowering medication","content_type":"text","pages":"169","tokens_est":172,"char_count":687,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0604","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 4. Reduce the burden of diabetes among people with TB | 4.2 Management of diabetes | 4.2.5 Considerations for integrated care and linkage to care after completion of TB treatment","content_type":"text","pages":"169-170","tokens_est":209,"char_count":836,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0605","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | 4. Reduce the burden of diabetes among people with TB | 4.2 Management of diabetes | 4.2.5 Considerations for integrated care and linkage to care after completion of TB treatment","content_type":"text","pages":"170","tokens_est":169,"char_count":674,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0606","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | Annex 2. Research gaps in the response to TB and diabetes | Screening people with diabetes for TB","content_type":"text","pages":"171","tokens_est":231,"char_count":924,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0607","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | Annex 2. Research gaps in the response to TB and diabetes | Prevention of TB among people with diabetes","content_type":"text","pages":"171","tokens_est":247,"char_count":986,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0608","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | Annex 2. Research gaps in the response to TB and diabetes | Prevention of TB among people with diabetes","content_type":"text","pages":"171","tokens_est":161,"char_count":644,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0609","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | Annex 2. Research gaps in the response to TB and diabetes | TB treatment in people with diabetes","content_type":"text","pages":"171","tokens_est":138,"char_count":549,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0610","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | Annex 2. Research gaps in the response to TB and diabetes | Screening people with TB for diabetes","content_type":"text","pages":"171-172","tokens_est":108,"char_count":432,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0611","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | Annex 2. Research gaps in the response to TB and diabetes | Diabetes treatment for people with TB","content_type":"text","pages":"172-173","tokens_est":51,"char_count":201,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0612","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | Annex 3. Criteria for referral to higher levels of care (1)","content_type":"text","pages":"174","tokens_est":228,"char_count":909,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0613","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | Annex 3. Criteria for referral to higher levels of care (1)","content_type":"text","pages":"174","tokens_est":137,"char_count":547,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0614","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | Annex 4. Monitoring and evaluation of collaborative TB/DM activities","content_type":"text","pages":"174","tokens_est":109,"char_count":435,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0615","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | Annex 4. Monitoring and evaluation of collaborative TB/DM activities | Summary of indicators for monitoring and evaluating collaborative TB/DM activities | Reduce the burden of TB among people living with diabetes (reported by the diabetic care provider).","content_type":"text","pages":"174-175","tokens_est":216,"char_count":862,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0616","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | Annex 4. Monitoring and evaluation of collaborative TB/DM activities | Summary of indicators for monitoring and evaluating collaborative TB/DM activities | Reduce the burden of TB among people living with diabetes (reported by the diabetic care provider).","content_type":"text","pages":"175","tokens_est":90,"char_count":359,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0617","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | Annex 4. Monitoring and evaluation of collaborative TB/DM activities | Summary of indicators for monitoring and evaluating collaborative TB/DM activities | Reduce the burden of diabetes among people with TB (reported by the TB care provider).","content_type":"text","pages":"175","tokens_est":233,"char_count":931,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module6_comorbidities_2024|0618","doc_id":"WHO_TB_handbook_module6_comorbidities_2024","section_path":"Diabetes | Annex 4. Monitoring and evaluation of collaborative TB/DM activities | Summary of indicators for monitoring and evaluating collaborative TB/DM activities | Reduce the burden of diabetes among people with TB (reported by the TB care provider).","content_type":"text","pages":"175","tokens_est":108,"char_count":430,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module6_comorbidities_2024_manifest.xlsx"}
